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General introduction 
1.1. Background 
1.1.1 Toxicological risk assessment 
Toxicology investigates adverse effects on organisms, induced by substances in their 
environment. To assess whether a substance forms a health risk, the potential hazards of the 
substance have to be identified. This involves empirical toxicity studies and investigation of 
the mechanism of toxic action (figure 1.1) Substances in a mixture may cause unexpected 
effects (interactions). Extrapolations are needed to interpret short-term and high dose studies 
to real-life long term exposures to low doses, /nfraspecies extrapolation accounts for 
differences in response between individuals, /nferspecies extrapolation is required to 
translate the results obtained in animal toxicity studies to the human situation. The factors 
are taken into account to determine an uncertainty factor, which is applied in combination 
with exposure levels to assess human health risk. 
Human health risk assessment 
t Exposure levels Uncertainty factor 
Chronic studies 
Low doses 
Acute studies 
High doses 
Mixtures studies 
interactions 
/interspecies 
extrapolation 
/ntraspecies 
extrapolation 
Mechanism of action 
Figure 1.1 Schematic overview of human health risk assessment. 
The identification of hazard involves empirical testing in acute and chronic toxicity studies, and 
assessment of (unexpected) effects of mixtures. Mechanism of toxic action of the compound may 
be investigated, to enable intra- and /nferepecies extrapolations. The factors are taken into account 
to determine an uncertainty factor, which is applied in combination with exposure levels to assess 
human health risk. 
1.1.2 Current toxicological methods for hazard identification 
To determine potential hazards of a substance, a set of toxicity studies has to be performed 
according to international standards (EC, OECD, FDA). In these studies, the acute and 
chronic toxicity of the compound will be established, based on a number of parameters, such 
as (histo)pathology, clinical chemistry and hematology. Pathology and histopathology form 
the basis of routine toxicity studies. Pathological examination may reveal changes in body 
and organ weights and macroscopic abnormalities. Histopathological techniques enable the 
microscopic examination of tissues, to detect toxic effects at the cellular level. Clinical 
chemistry, and hematology are used to determine changes in blood that correlate with 
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certain types of toxicity. Most of these parameters were established empirically. They are the 
result of aberrant cellular processes and late effects of toxicity, rather than components of 
mechanisms leading to toxicity. For instance, leakage of enzymes through disrupted cell 
membranes is observed in blood by clinical chemistry, and is clearly a secondary process in 
a late stage of cell death. Dependent on the complexity of the study, biochemical analyses of 
tissue samples and urine analysis may be required to provide complementary information 
about the compound under study. However, most of the routine toxicity studies determine 
adverse effects empirically and provide few insights in mechanisms of toxicity. 
The development of small-scale molecular biological techniques enabled to determine the 
composition and expression of specific genes and proteins, relevant to mechanisms of 
toxicity. These methods (eg. RT-PCR, Northern and Western blotting, ELISA, see table 1.1) 
are intended to study mechanisms of toxicity and interindividual or interspecies differences, 
at the molecular level. Specific molecular markers can distinguish different forms of toxicity 
within an organism or even within a tissue. Also, specific molecular endpoints may be 
detected early and at lower exposure levels compared to histopathology, clinical chemistry or 
hematology. However, these small-scale methods are applied only if a preconceived notion 
exists on the possible mode of action of the substance. Moreover, they will only reveal 
effects on single molecules. 
1.1.3 New functional genomics technologies in toxicology 
New technologies are being developed that could enable cell-wide and detailed analysis of 
mechanisms of toxicity, without the need of a priori knowledge on the mode of toxic action. 
As a result of the recent elucidation of complete genome sequences, functional genomics 
disciplines have emerged. These disciplines study the functions of the (complete) genome in 
relation to its composition, and measure gene expression (transcriptomics), protein levels 
(proteomics) or metabolite contents (metabolomics). Toxicogenomics can be defined as the 
application of the functional genomics technologies in toxicology. Toxicogenomics studies 
the adverse effects of xenobiotic substances in relation to the structure and activity of the 
genome [9]. The different disciplines and technologies are described in detail at the end of 
this chapter. First, applications of the functional genomics technologies in toxicology will be 
discussed. 
1.2 Applications of functional genomics technologies in toxicology 
Toxicology is likely to benefit from the new functional genomics technologies, as discussed in 
various publications [10-20]. Toxicogenomics methods may enhance health risk assessment 
in various ways. Detailed investigation of mechanisms of toxicity may enable to identify 
critical effects and the sequence of events at the molecular level (section 1.2.1). Adverse 
effects in (animal) toxicity studies could be detected earlier and more sensitively than with 
the current methods (section 1.2.2). Toxicogenomics results may enable more accurate 
extrapolations and the identification or even prediction of interactions upon exposure to 
mixtures (sections 1.2.3, 1.2.4). Eventually, toxicogenomics could enable to determine or 
predict the implications of the (individual's) genome composition for the toxic effects caused 
by substances. In vitro models in combination with toxicogenomics methods might allow to 
reduce, refine and possibly even replace in vivo testing (section 1.2.5 ,1.2.6). 
1.2.1 Studying mechanisms of toxic action 
Changes in protein and gene expression play a role in signal transduction mechanisms, 
metabolic pathways and protective responses in a cell. In reaction to an insult, the changes 
at the protein and gene expression level in the cell precede the response at the tissue or 
even organism level. Thus, mechanisms leading to pathologically observed endpoints may 
be recognised through observation of changes in expression of genes and proteins. The 
functional genomics technologies could be useful to elucidate the critical steps and the 
sequence of events in the development of toxicity after exposure to toxic substances. 
A toxic compound, by itself, or via reactive metabolites after bioactivation, elicits a cellular 
response upon interaction with a target molecule. This target may be a receptor molecule 
that initiates a response that involves many other molecules. The primary target of the 
toxicant might not always be identified directly through changes in gene or protein 
expression. However, the downstream cascade of effects may help to find the initial targets 
at the origin of the response. As thousands of molecules are investigated simultaneously, the 
chance of identifying (unexpected) molecules affected by the xenobiotic is greatly improved. 
This might also enable to recognise adverse side-effects of pharmaceutical compounds. 
Pathological endpoints such as hepatic necrosis result from a spectrum of events, often non-
specific processes like membrane damage, ATP depletion and apoptosis. These processes 
could be associated with characteristic gene expression changes. Model compounds known 
to specifically elicit one of these events could be helpful to identify molecular changes 
corresponding to these events. To this date, several toxicogenomics studies were performed 
with model compounds that induced different effects in liver, such as hepatic necrosis, 
biotransformation enzyme induction and peroxisome proliferation [12]; [21-27]. Metabolomics 
was used, for instance, to analyse toxicity through metabolites in liver, plasma and urine of 
rats treated with model hepatotoxicants and nephrotoxicants [18]; [28-33]. 
1.2.2. Identification of toxicity markers 
Toxicogenomics methods measure thousands of genes, proteins or metabolites. Therefore, it 
is expected that sensitive and specific markers will be identified that can detect or even 
predict pathological abnormalities at early stages, and after exposure to low dose levels. 
Toxicogenomics patterns of changes will be more efficient than single molecule markers to 
discern slightly different mechanisms that lead to similar adverse effects. Subtle changes in 
levels of many molecules are likely to precede the conventional symptoms of toxicity. A cell-
wide pattern of gene or protein expression, in analogy to a fingerprint, can be used to early 
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discern a healthy cell from a cell with slight abnormalities. Gene expression profiles have 
been applied successfully to discriminate samples exposed to different classes of toxicants 
[22];[34];[35]. Transcriptomics was also used to classify blind-coded liver samples, according 
to the class of toxicant to which the rats were exposed [36]. Proteomics methods with 2D-
gelelectrophoresis were applied a.o., to identify biomarkers of acute nephrotoxicity induced 
by puromycin aminonucleoside [37]. Metabolomics has been used to classify urine samples 
of rats treated with either a liver or a kidney toxicant [31];[18]. Urine profiles were analyzed in 
time upon single dosage of ANIT, galactosamine and butylated hydroxytoluene [32]. Time-
related differences in metabolite contents were related to the stage of the lesions, and 
specific changes in metabolite levels were identified for each compound. 
Metabolite profiling can also be used to assess levels of exposure or confirm successful 
dosing by measuring the (metabolites of) toxicants or drugs in blood plasma or urine. A great 
advantage is that samples obtained by non-invasive methods (urine, blood, saliva) can be 
used for measurements. All functional genomics methods can be applied to identify new 
molecules as markers of toxicity, while also the complete patterns of changes may be 
characteristic and robust markers of adverse effects. 
1.2.3 Interspecies and intraspecies extrapolation 
The extrapolation of results from toxicity studies to account for /nferepecies and //rtraspecies 
differences increases the uncertainties for human health risk assessment. Toxicogenomics 
methods may reduce the uncertainty by providing detailed insight in molecular mechanisms 
underlying the toxic endpoints. While these (physiological) endpoints might differ, the 
underlying molecular mechanisms may be conserved to a much higher extent between 
species. Laboratory animals and humans, are highly similar at the molecular level. The 
majority of the genes found in humans are also present in organisms like rat or mouse, and 
genomes of man and rodents exhibit more than 90% similarity. This is of great benefit for the 
extrapolation of results of toxicity studies at the molecular level. Thus, so-called bridging 
effect markers may be developed, that can be used in extrapolation to humans of effects 
found in animals. Furthermore, the identification of critical steps in molecular mechanisms 
that to explain empirically observed intra- and /nterspecies differences in response to 
toxicants might be feasible with toxicogenomics methods. Because less than 0.1% of the 
genome differs between individual persons, it should be possible to characterise many of the 
small differences ("SNP mapping") with toxicogenomics (or toxicogenetics) methods, and 
identify genetic differences responsible for susceptibility to toxicants [38]. In summary, 
toxicogenomics has the potential to improve extrapolations by providing more insight in 
mechanisms at the molecular level. 
1.2.4 Exposure to mixtures of compounds 
Harmful effects can be expected to be caused by more than one substance in complex 
mixtures, such as environmental pollutants or even nutrition. A thorough analysis of the 
toxicity of mixtures is technically difficult. In general, toxicity data of studies with single 
compound exposures are used to predict effects of exposure to mixtures of compounds. 
However, sometimes effects are observed that deviate from the predictions. These 
interaction effects may be synergistic, or antagonistic. In order to assess interaction effects of 
compounds, large studies have to be designed including exposures to individual chemicals 
as well as to combinations at different dose levels. Currently, the identification of toxic 
interaction effects is limited by the capacity of the available markers of toxicity to distinguish 
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and quantify effects after treatment with mixtures in comparison with single compounds. 
Functional genomics technologies allow the monitoring of thousands of effects and will 
enhance the discrimination of exposure groups based on observed effects. Mechanisms of 
the combinatorial effects can be studied and possibly predicted at the molecular level. When 
different substances in the mixture affect similar molecules or pathways, enhanced effects 
might be expected. When changes are provoked in different biological pathways, 
interference by the compounds in the mixture would not be expected. Because of the 
complexity of an organism, secondary effects of one substance could interfere with the 
mechanism of toxicity of another substance. For instance, a depletion of the intracellular 
antioxidant defense system by reactive metabolites of a compound could lower the threshold 
for damage by another xenobiotic. In conclusion, toxicogenomics methods will facilitate the 
assessment and prediction of putative harmful interaction effects upon exposure to mixtures 
of substances. 
1.2.5. Toxicogenomics in combination with in vitro testing 
Toxicogenomics might be able to support the use of in vitro models for various reasons. 
Although pathological endpoints of toxicity can not be identified in vitro, the preceding or 
underlying molecular mechanisms eventually leading to these effects can be analysed. Both 
in vitro and in vivo, the same sets of thousands of genes, or proteins can be measured and 
directly compared. Thus, toxicogenomics could enhance extrapolations of results from in 
vitro experiments to in vivo circumstances Toxicogenomics may enable better identification 
and discrimination of responses in the in vitro models, compared to the currently available 
methods. In in vitro experiments, the circumstances, such as exposure conditions, can be 
defined much better than in the in vivo situation. Metabolism of parent compounds to reactive 
metabolites can be followed, and metabolites are accessible for analysis, eg. with a 
metabolomics approach. Toxicogenomics methods make it possible to evaluate and 
compare multiple aspects of the in vitro models with the in vivo situation. This will drive the 
development of models that better mimic the real situation. 
Toxicogenomics has great potential to facilitate the recognition of toxic properties in the early 
stages of screening of candidate drugs. Few of the many newly synthesised candidate drugs 
are evaluated in time and cost intensive assessments of efficacy and toxicity. Potential signs 
of toxicity in in vitro models may therefore provide a useful criterion for early selection or 
prioritising of drug candidates. The gene or protein expression profiles induced by the 
compounds could, like a fingerprint, be used to classify compounds according to toxic 
potency, mechanism of action and target organ. A novel compound could be classified as 
putatively toxic if it induces the same transcriptional changes as known toxicants ("guilt by 
association"). Several studies have shown the feasibility of this concept in animal 
experiments [39] [22], while a few also applied this to in vitro model systems with cultured 
hepatocytes [34]; [40-42]. Concluding, toxicogenomics can support the use and the further 
development of in vitro models, and could save resources when applied for early in vitro 
screening of toxicity. 
1.2.6 Reduction, refinement and replacement of animals testing 
The recognition of toxicity with toxicogenomics-based markers after short-term exposure 
could reduce long-term animal exposures. In particular for assessment of carcinogenic 
properties of compounds, a considerable amelioration is expected. If toxicogenomics 
methods enable to test toxicity of compounds at lower dose levels, this will reduce the 
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discomfort of the animals. Possibly, less animals are needed to determine mechanisms of 
toxicity of a compound when functional genomics technologies are fully exploited. Detailed 
insights in mechanisms can be used to refine toxicity tests and select appropriate models for 
further studies. As described earlier, toxicogenomics might enhance identification of toxicity 
in alternative in vitro models rather than in live animals. It may enhance the extrapolation of 
test results for human health risk assessment. Thus, toxicogenomics facilitates the reduction 
and refinement and perhaps eventually the replacement of animal testing, especially when 
applied in combination with predictive in vitro models. 
1.3 Functional genomics technologies 
Functional genomics technologies measure molecular responses in an organism in a 
cell-wide manner. The description of the full genome sequence of human and model 
organisms became available recently, and knowledge about proteins and metabolites in cells 
is increasing rapidly. Genomics is the sub-discipline of biology that studies the genome 
through analysis of the nucleotide sequence, the genome structure and its composition. 
Transcriptomics, proteomics and metabolomics determine the levels of gene transcripts, 
proteins or metabolites, respectively. Figure 1.2 displays the relation between DNA, gene 
expression, protein production and activity (towards metabolites) in the cell. A schematic 
representation of the different cellular molecules and the novel technologies to study these is 
provided in table 1.1. The disciplines and the corresponding technologies, as well as the 
bioinformatics methods for data interpretation are discussed in detail in the following 
sections. 
Biochemical reactions in the ceil 
Functional proteins 
Protein modifications 
interactions,complexes 
Protein x 
metabolite b 
+ 
metabolite c 
metabolite a 
Translation 
amino acids 
L k 
•A o 
Transcription mRNA 
(gene expression) 
DNA 
Chromosomes Genex Geney 
Figure I.2 DNA, gene expression, protein production and activity 
Chromosomes contain the (>30000) genes. When genes are expressed, complementary mRNA is 
transcribed from DNA. Messengers (mRNA) transfer the information for correct synthesis of proteins 
from free amino acids (translation). Chains of amino acids (peptides) are shaped into proteins, which 
may require post-translational modifications to be functional in (biochemical) processes in the cell. 
Functional proteins, for example, are enzymes that catalyse conversions of metabolites. 
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Table 1.1 Functional genomics technologies 
The functional genomics disciplines and (small and large-scale) technologies that are currently 
used to study DNA, gene expression, proteins, and metabolites. 
Subject of study Discipline Technologies 
DNA 
composition of genome, 
chromosomes and genes 
Gene expression 
through levels of mRNAs 
(transcripts) 
Proteins 
protein contents of tissues, 
cells, and body fluids 
Metabolites 
(small molecules) 
Genomics 
Transcriptomics 
Proteomics 
Metabolomics 
Automated sequencing, 
SNP detection, array CGH, FISH, 
Southern blotting, AFLP 
DNA microarrays (cDNA or 
oligonucleotides) 
branched DNA assay, 
RT-PCR, SAGE, Northern blotting 
2D-gel electrophoresis, 
Mass spectrometry, SELDI, 
ICAT, protein arrays, ELISA, 
Western blotting, immunodetection 
NMR spectrometry, GC-MS, MS-MS, 
1.3.1 Genomics 
The genetic material contains the basic information needed for the production of all cellular 
proteins. Knowing the composition of this genetic material is a major step towards the 
elucidation of molecular mechanisms. Information about the organisation of genes and 
transcriptional regulatory elements on chromosomes contributes to the understanding of 
gene-functions and their role in specific processes. In comparative genomics, complete 
genomes from different organisms are compared to investigate shared as well as unique 
cellular mechanisms and physiological properties of different species. 
Genotyping involves the identification of (small) modifications in individual genomes. Single 
nucleotide polymorphisms (SNPs) are responsible for many /nferindividual differences and 
for genetic diseases, and may be of great importance for toxicology. Less than 0.1% of the 
genome differs between individual persons, but these small genetic differences may account 
for large effects. Inherited diseases, but also large differences in susceptibility to xenobiotic 
toxicants may result from these small polymorphisms [38]. For example, if a drug 
metabolising enzyme is slightly altered, its activity could be highly compromised. Therefore, 
metabolism of a xenobiotic substance will be altered, with consequences for the toxicity 
found in the organism. Genetic differences may also influence gene expression levels. 
Analysis of the composition of the genome and /nferindividual differences will facilitate 
assessment of susceptibility to toxic substances, valuable for health risk assessment. 
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1.3.2. Transcriptomics 
Many cellular processes are controlled at the level of gene expression. Determination of 
changes in gene expression, by measurement of the mRNA levels, is used to predict 
changes in protein levels and activity. Single-strand DNA or RNA has the capacity to 
specifically hybridise to its complementary strand. This capacity is used in several methods 
that determine mRNA levels of gene of interest. Specific detection with radiolabelled 
nucleotides is called Northern blotting. The development of the reverse transcription 
polymerase chain reaction (RT-PCR) enabled extremely sensitive, semi-quantitative 
detection of specific mRNA in a sample. Specific mRNA levels can be quantified in 
comparison to a constitutively expressed, "housekeeping" gene with quantitative real time 
PCR. Northern blotting and PCR techniques are very labour-intensive and not suitable for 
scale-up. Serial analysis of gene expression (SAGE) is a scaled-up method that determines 
the sequence of hundreds of mRNA fragments, and counts the specific mRNAs in the 
sample. Recently, DNA microarrays [43] or DNA chips [44] were developed as a large-scale 
method for gene expression measurement, and the technologies have been described 
extensively [45-50]. Like in Northern blots, the capacity of single-strand DNA and RNA to 
specifically hybridise is used to sort the mRNAs and determine gene expression levels. 
However, instead of one gene at the time, single-strand cDNA or oligonucleotide molecules 
for thousands of different genes are deposited in a fixed spot on a surface (e.g. glass slide, 
plastic, nylon membrane). The microarrays can be custom-made in the laboratory, or 
obtained from commercial providers (eg. affymetrix, agilent, incyte, sigma, clonetech). 
Microarrays take advantage of the availability of collections (libraries) of gene fragments with 
a known sequence and with annotation concerning their (putative) function in the cell. 
Microarrays can contain DNA fragments for which a function has yet to be determined. The 
process of microarray-based measurement of gene expression is depicted in figure 1.3a, and 
an image of a section of a hybridised microarray is shown in figure 1.3b. 
By hybridisation of the cDNA micorarray with a pool of isolated mRNAs, each specific mRNA 
will only hybridise with the cDNA in the spot containing the complementary cDNA for this 
specific gene. The amount of cDNA hybridised in each spot can be detected by 
measurement of fluorescence that was incorporated in the sample. In practice, two samples 
are hybridised together on the cDNA microarray, where the test sample is labelled with one 
type of fluorophore (e.g. green) and the reference or control sample is labelled with another 
type (e.g. red). Quantification of both types of fluorescence enables the determination of a 
ratio of expression for each gene in the test sample with respect to the control sample. Data 
analysis of DNA microarray experiments will be described in detail in section 1.3.5 and figure 
1.6. The majority of the thousands of genes will not show differences in expression levels 
when diseased or treated samples are compared to controls. The gene expression levels 
that are induced or reduced provide a wealth of information on cellular mechanisms that are 
affected at the gene expression level by the disease or treatment. 
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mRNA -»cDNA with 
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Tester cDNA Control cDNA 
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binding mRNAs to microarray 
Wash away unbound cDNAs 
Measurements 
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Figure l.3.a Transcriptomics method using DNA microarrays 
The process of transcriptomics using DNA microarrays to measure differential gene expression in 
a test compared to a control sample. Isolated mRNA of a test and control sample is labelled with 
different fluorescent labels and hybridised to the microarray. Thus, expression levels can be 
quantified from the fluorescence in each spot representing a different gene. Ratios of intensities of 
the two types of fluorescence can be used to determine relative gene expression levels in test and 
control samples. 
Figure l.3.b Fragment of a DNA microarray 
Fragment of a scanned rat oligonucleotide DNA microarray containing around 5000 different gene 
fragments, spotted in duplicate. This DNA microarray was hybridised with RNA from a control rat 
liver and a sample from a rat treated with a liver toxicant. 
Chapter I 
1.3.3 Proteomics 
Not all changes in cellular mechanisms can be measured at the gene expression level. 
Protein modification or sub-cellular redistribution of proteins provide an organism with rapid 
mechanisms to respond to stimuli, without the need for gene expression. Proteomics 
technologies measure the thousands of proteins in a cell or body fluid. Posttranslational 
modifications and protein complexes can be visualised. Because proteins are the actors in 
cellular reactions, rather than gene transcripts, proteomics is likely more relevant than 
transcriptomics. However, the measurement of the proteome is more complex, because the 
separation of the proteins in a cell or sample is a difficult task, as all the proteins have 
different properties (mass, iso-electric point, solubility, stability, etc.). 
Initial proteomics methods combined two-dimensional gel electrophoresis with automated 
image analysis software and mass spectrometry [51-55]. This process is schematically 
drawn in figure 1.4. The proteins in a sample are first separated according to their iso-electric 
point using a pH gradient and secondly separated based on mass by standard 
electrophoresis. Separated protein spots are visualised with fluorescent or silver staining. 
Gels are scanned and dedicated software quantifies the spot volumes. Sometimes, protein 
spots can be putatively identified by matching to a reference gel in (internet) databases. 
Spots of interest can be isolated, and identified by mass spectrometry after fragmentation 
(e.g. digestion with trypsin). The pattern of peptide fragment with very specific masses is 
determined by (matrix assisted laser desorption ionisation time-of flight) mass spectrometry 
(MALDI-TOF-MS)[56-57]. The protein is identified by matching the pattern to predicted 
patterns of all known proteins in a database. Peptide sequencing by MS/MS techniques can 
further confirm identities. 
More recent proteomics methods applied protein antibody arrays, comparable to DNA 
microarrays [58];[59]. A major drawback is that binding affinity varies largely between 
proteins. Optimised conditions for binding are only applicable for part of the proteins and 
suboptimal binding will bias the results. Methods that exploit these differences in binding 
affinity to sort proteins include ICAT (isotope-encoded affinity tags, [60]) and SELDI (surface-
enhanced laser desorption / ionisation [61], [62]). Different surface chemistries are used to 
selectively isolate proteins and analyse them by mass spectrometry. 
In summary, proteomics techniques provide a wealth of detailed information about protein 
contents and protein modifications in cells, tissues or body fluids, that may help to better 
understand molecular processes, for instance in response to toxic compounds. 
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Figure I.4. The proteomics method with 2D-gel electrophoresis 
Protein samples are separated using a two step 2D-gelelectrophoresis. Spots are quantified 
using automated gel analysis. After excision of the protein spot from the gel, tha material can 
be analysed with mass spectrometry for protein identification, using a reference database. 
1.3.4 Metabolomics (metabolite profiling) 
Metabolomics methods measure the levels of metabolite (small molecules) in the cell and in 
extracellular fluids, which may reflect changes in cellular processes. The dynamics of 
biochemical reactions in the cell can be studied by monitoring the (dis)appearance of 
reaction products. Processes like metabolism and biotransformation of xenobiotics can be 
followed in cells or plasma, and excreted metabolites can be determined in the urine. Various 
applications of metabolomics in toxicology have been reported and reviewed [18]; [63]; [64]; 
[65]. Metabolomics methods include gas chromatography and mass spectrometry (GC/MS), 
that allow the measurement of low concentrations of individual components. Proton nuclear 
magnetic resonance (1H-NMR) spectroscopy is an attractive approach to simultaneously 
quantify a wide range of metabolites without extensive sample preparation. A spectrum is 
obtained with resonance signals characteristic for all small biomolecules. Thus, a metabolic 
fingerprint may be used to characterise biological samples. Individual signals can be 
quantified and identified in using reference spectra, if available in databases. NMR spectra of 
biological fluids are very complex due to the mixture of numerous metabolites. Variations 
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between spectra can often not be recognised by eye. In order to compare NMR spectra and 
thereby maximise the power of the subsequent data analysis, a partial linear fit algorithm 
adjusts minor shifts in the spectra while maintaining the resolution. To find significant 
differences in the spectra, multivariate statistical data analysis is applied. This enables to 
explore recurrent patterns in multiple NMR spectra. A factor spectrum can be used to identify 
metabolite NMR peaks that differ between samples. An illustrative factor spectrum of NMR 
profiles of plasma of vehicle controls and rats after exposure to a hepatotoxicant is shown in 
figure 1.5. Signals (metabolites) in the complex and large data sets can be correlated to a 
variable of interest, such as toxicity status. A combination of analytical techniques is 
desirable for an exhaustive analysis of a complex mixture of metabolites. A major advantage 
of metabolomics (for toxicology) is that non-invasive methods can be used to collect samples 
from blood (plasma), urine or other body fluids, which allows applications in human and 
animal experiments. 
Regression 
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Figure 1.5 NMR Factor spectrum of urine metabolomics analysis 
Factor spectrum constructed using multivariate statistical analysis that compares average 
NMR spectra of blood plasma of rats. In this case, spectra obtained 6 hours after treatment 
with a high dose of liver toxicant are compared to vehicle controls. 
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1.3.5 Data processing and bioinformatics 
The handling of raw data from large-scale functional genomics experiments requires 
powerful data processing equipment and algorithms (bioinformatics). The steps in pre-
processing of raw data to clean data and the options for data mining and interpretation are 
depicted in figure 1.6. Information that describes the experimental conditions should be 
automatically stored (e.g. in a Laboratory Information Management System (LIMS)) and 
organised in a searchable manner. Systematic bias originating from various technical 
sources should be corrected. A signal-to-noise threshold should exclude weak and unreliable 
signals from further interpretation. Standardisation, normalisation or scaling are methods that 
are applied to transform data sets in order to be able to compare the measurements within 
studies, but also between studies. After raw data processing, secondary results files are 
obtained that should be stored along with the description of the method of data analysis, 
preferably according to internationally established MIAME requirements (Minimal Information 
About Microarray Experiments). The clean data files are the basis for the interpretation of the 
results, described in the next section. 
Measurements Raw data: fluorescence intensities 
Tester: s - b 
Experiment info 
(LIMS, protocols, 
samples, 
QA: spot filtering (intensity, shape, homogeneity, 
ratio Tester / Reference 
Pre-processing 
normalisation between spots 
option scaling between slides 
average duplicate spots 
logarithm transformation 
QA: slide filtering (eg. homogeneity) 
QA: gene filtering (presence per 
experiment) 
impute/replace missings 
Data min ing & interpretat ion 
"Clean data" 
Univariate statistics 
•ANOVA 
• Students T-test 
•SAM 
Multivariate statistics 
• PCA. PCDA 
• Clustering 
•PLS 
Hypothesis generation 
Bio-knowledge 
• Gene ontology 
• Pathway organisation 
• Transcription factors 
• Literature mining 
Figure 1.6 Transcriptomics data pre-processing and interpretation 
The steps in pre-processing of raw data to clean data and the options for data mining and 
interpretation are depicted schematically (according to in-house procedures at TNO). 
QA indicates quality assessments at various stages in the analysis. After the raw data 
(fluorescence intensities) pre-processing into "clean data" these are linked to experimental 
and biological information. At this stage, the results are ready for data mining, biological 
interpretation and hypothesis generation. 
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1.3.6 Biological interpretation and hypothesis generation 
The challenge of functional genomics methods is to turn the large data sets with relatively 
high amounts of noise and without obvious biological meaning into relevant findings. It is not 
feasible to analyse data per gene, protein or metabolite. Moreover, this would result in a 
great loss of the information that resides in the coherence of the data. The relationships 
between genes or proteins, and their changes under specific conditions, are probably the 
most valuable insights obtained in functional genomics studies. To assess relationships 
between molecules, the large datasets have to be structured and organised, also called data 
mining. Multivariate statistical techniques and the (automated) integration of measurements 
with pre-existing knowledge can facilitate data-mining. 
Statistical techniques for data mining 
Toxicogenomics data may be analysed with univariate and/or multivariate statistical 
techniques. Univariate statistical methods (eg. ANOVA, Student's T-tests) are efficient and 
typically used to determine significance of changes in a single parameter under study. A 
variety of multivariate statistical techniques can be applied to structure large datasets. 
Different methods of functional genomics data analysis and interpretation are reviewed in 
detail [66]; [67]; [68]. Mathematical clustering algorithms like hierarchical clustering, K-means 
clustering and self-organising maps calculate a measure of similarity between levels of gene 
or proteins in profiles. Clustering creates subsets of molecules that behave similar to each 
other and enables to select molecules with biologically relevant characteristics, out of the 
thousands of genes, proteins or metabolites. Unsupervised methods such as principal 
component analysis (PCA) determine intrinsic structure within data sets, without prior 
knowledge. PCA can be used to calculate a measure of similarity between large datasets, 
such as NMR spectra or DNA microarray measurements. Supervised methods such as 
partial least squares (PLS) and principal component discriminant analysis (PCDA) use 
additional information such as biochemical, histopathological or clinical data to optimise the 
discrimination between samples. These methods allow to identify the molecules in the large 
datasets that most contribute to differences between the samples, for instance induced by a 
toxic treatment. 
Pre-existing knowledge for data mining 
Structuring of large datasets can be achieved with the use of pre-existing knowledge about 
biological processes. The vast expansion of the world-wide web proved to be crucial for the 
rapid developments of functional genomics and bioinformatics. Global sharing of biological 
data and information enabled to link previously scattered and isolated information. Relying 
and building on the complete DNA sequence of the human genome, many sources of 
biological information on genes and proteins and interaction with the environment have 
become available. These sources each provide information concerning annotation of genes 
and proteins, gene functions, structures and other properties of proteins, biochemical 
processes and relations of genes and proteins with physiological changes, eg. a diseases 
(table 1.2). Uniform and standardised names and functional categories are assigned to each 
gene, protein and metabolite. This process, called ontology, is essential for correct exchange 
of results. 
The development of methods for automated literature searching and interpretation holds 
great promise. This would allow to more easily utilise the data gathered in the past. 
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By categorising the molecules according to biological processes, rather than finding changes 
in one enzyme, changes in entire biochemical pathway can be identified in response to 
applied conditions. Textbooks and schematic drawings of pathways can be used to explain 
individual changes in the context of pathways. This is facilitated by conversion of pathway 
schemes into electronic versions, with extensive annotation and flexibility. Computer 
software is being developed to visualise effects, for instance changes in gene expression, in 
the context of the biological process of interest. Thus applied, genomics experiments can 
provide insights in entire changes in pathways and processes, besides changes in individual 
molecules. 
After identification of the molecules involved in the response to the environmental conditions, 
only these molecules can be analysed in further, dedicated, studies. It is important to realise 
that changes at the molecular level are biologically relevant only if they are associated with 
changes in the physiology of the organism. In toxicology, for instance, reversible changes are 
referred to as adaptations, while only irreversible effects are considered to be adverse and, 
therefore, pose a putative health risk. The effects observed with the functional genomics 
methods most often generate new hypotheses that have to be confirmed with other 
techniques, and fitted into the context of physiological effects. In toxicology, this means that 
results from toxicogenomics studies have to be integrated with effects seen with 
histopathology or other conventional methods. The many possible applications of functional 
genomics methods will only be fully deployed when these methods are integrated with 
conventional techniques, to allow an iterative process of hypothesis generation and 
confirmation. 
Table 1.2 Selection of worldwide web sources of biological information 
Provider Information type U.R.L. 
EBI: European Bioinformatics 
Institute 
NCBI: National Centre for 
Biotechnology Information 
Swissprot + Boehringer maps 
BioASP, The Netherlands 
Gene ontology consortium 
RGD: Rat Genome database 
MGD: Mouse genome 
database 
Source (Stanford university) 
GeneCards 
KEGG pathway maps 
GenMapp 
Biocarta 
various services 
various services 
various services (proteins) 
various services 
Gene ontology (annotation) 
rat gene database 
mouse gene database 
gene information 
gene information 
biochemical pathways 
visualisation of pathways 
biochemical pathways 
www.ebi.ac.uk 
www.ncbi.nlm.nih.gov 
www.expasy.org 
www.bioasp.com 
www.geneontology.org 
rgd.mcw.edu 
www.informatics.jax.org 
source.stanford.edu 
bioinfo.weizmann.ac.il/cards 
www.genome.ad.jp/kegg 
www.genmapp.org 
www.biocarta.com 
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1.4 Objectives of this thesis 
The studies described in this thesis were performed to demonstrate the potential value of 
toxicogenomics, the integration of functional genomics methods in toxicology. Many possible 
applications of toxicogenomics were described earlier in this introduction, and this thesis 
primarily demonstrated the use of toxicogenomics to: 
a) investigate mechanisms of toxicity (see 1.2.1) 
The aim was to characterise gene and protein expression changes in relation to pathological 
abnormalities, after exposure to (potentially) toxic compounds. The studies concentrated on 
analysis of toxicity in rat liver, which is probably the most critical and best studied target 
organ of toxicity. Also, the liver plays an important role in detoxification, metabolic activation 
and systemic distribution of many (xenobiotic) substances. 
b) obtain new markers of toxicity (see I.2.2) 
The studies aimed to discover new markers of hepatotoxicity with transcriptomics, 
proteomics and metabolomics methods. These markers should enable early identification of 
adverse effects, at exposure to lower dose levels in comparison to the current toxicity 
markers. 
c) assess effects of mixtures of toxic compounds (see 1.2.4) 
The objective was to use gene expression profiles to assess and explain putative joint effects 
and interactions upon exposure to mixtures of chemicals. 
Furthermore, technical aspects of toxicogenomics methods were evaluated. The 
reproducibility and sensitivity were determined for transcriptomics, proteomics and 
metabolomics methods, in relation to conventional methods in toxicology. The relationship 
between transcriptomics, proteomics and metabolomics was investigated in toxicological 
applications. The integration of these different methods in toxicogenomics could be crucial 
for the understanding of the sequence of events and the critical steps in the mechanisms of 
toxicity at the molecular level. 
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1.5 Outline of this thesis 
This thesis describes the toxicogenomics analyses of the response in rats after exposure to 
bromobenzene, benzene and trichloroethylene and mixtures of benzene and 
trichloroethylene. Chapter I introduces possible applications and the different technologies 
used in toxicogenomics. Chapter II describes the analysis of toxicity at the level of gene and 
protein expression in liver. The effects of bromobenzene, a well-known model 
hepatotoxicant, were studied in rat liver with transcriptomics and proteomics, 24 hours after 
single dosage. The methods were evaluated and compared and toxicological interpretation of 
the results corroborated existing, and raised new hypotheses regarding the mechanisms of 
hepatotoxicity of bromobenzene. The toxicity principle that the dose of a compound 
determines its effects, prompted us to establish how the bromobenzene-induced changes at 
the gene expression level were dependent on the dose. Chapter III describes hepatotoxicity 
induced by different doses of bromobenzene at the transcriptome level. The time 
dependency of gene expression changes was determined 6, 24 and 48 hours after dosage. 
The results were related to routine toxicity parameters. The transcriptomics data from this 
study were analysed in combination with nuclear magnetic resonance (NMR) measurements 
of metabolite profiles in urine and blood plasma samples of the same study, as described in 
chapter IV. The aim was to determine whether a combined analysis of the patterns of 
hepatic gene expression and urine or plasma metabolite profiles would improve the detection 
of toxicity. We also investigated whether new insights could be obtained in the molecular 
mechanisms leading to chemically induced hepatic necrosis. Multivariate statistical methods 
were applied in order to fully exploit the large amounts of data and facilitate biological 
interpretations. 
Previous chapters describe the effects of a model toxicant that induces obvious signs of liver 
damage within days. In chapter V and VI, effects at the liver gene expression level are 
reported after exposure for 28 days to different concentrations of widely used chemicals, 
benzene and trichloroethylene (TCE). The metabolism of both TCE and benzene primarily 
takes place in liver and determines the toxic effects in the target organs. For benzene, these 
are the blood and bone marrow, and exposure can ultimately provoke leukemia. TCE is 
nephrotoxic and a suspected carcinogen. Both compounds are not known as 
hepatotoxicants, although exposure can lead to increased liver weights. Analysis of hepatic 
gene expression changes in response to benzene and TCE aimed to delineate the specificity 
of the effects induced by (potentially) hepatotoxic chemicals. Therefore, effects of benzene 
and TCE were compared to earlier effects of the well-known hepatotoxicants bromobenzene, 
described earlier in this thesis, and published data on acetaminophen [69]. In Chapter VII, 
toxic effects of mixtures of benzene and trichloroethylene in liver are analysed using 
transcriptomics. To our knowledge, this thesis presents the first approach to investigate 
combined action of mixtures of (toxic) compounds at the gene expression level. For this 
analysis, rats were exposed to benzene, trichloroethylene or to mixtures of these chemicals 
at different dose-levels. Gene expression profile changes were used in a multivariate 
statistical model to assess putative interaction effects. Expression changes relevant to the 
mechanisms of toxicity of both benzene and TCE were analysed in more detail. In chapter 
VIII, the findings of all studies are summarised. Technical aspects of the technologies, and 
possible applications of toxicogenomics are discussed using the results of the studies 
described in chapters II VII, and lastly future challenges are mentioned. 
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Abstract 
Toxicogenomics is a novel approach integrating the expression analysis of 
thousands of genes (transcriptomics) or proteins (proteomics) with classical 
methods in toxicology. Effects at the molecular level are related to 
pathophysiological changes of the organisms, enabling detailed comparison 
of mechanisms and early detection and prediction of toxicity. This report 
addresses the value of the combined use of transcriptomics and proteomics 
technologies in toxicology. Acute hepatotoxicity was induced in rats by 
bromobenzene administration resulting in depleted glutathione levels and 
reduced average body weights, 24 hours after dosage. These physiological 
symptoms coincided with many changes of hepatic mRNA and protein 
content. Gene induction confirmed involvement of glutathione-S-transferase 
isozymes and epoxide hydrolase in bromobenzene metabolism and identified 
many genes possibly relevant in bromobenzene toxicity. Observed 
glutathione depletion coincided with induction of the key enzyme in 
glutathione biosynthesis, y-glutamylcysteine synthetase. Oxidative stress was 
apparent from strong upregulation of heme oxygenase, peroxiredoxin 1 and 
other genes. Bromobenzene-induced protein degradation was suggested 
from 2-dimensional gelelectrophoresis, upregulated mRNA levels for 
proteasome subunits and lysosomal cathepsin L, whereas also genes were 
upregulated with a role in protein synthesis. Both protein and gene expression 
profiles from treated rats were clearly distinct from controls as shown by 
principal component analysis, and several proteins found to significantly 
change upon bromobenzene treatment were identified by mass spectrometry. 
A modest overlap in results from proteomics and transcriptomics was found. 
This work indicates that transcriptomics and proteomics technologies are 
complementary to each other and provide new possibilities in molecular 
toxicology. 
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11.1 Introduction 
Toxicology aims to detect adverse effects of a compound on an organism based on observed 
symptoms or toxicity markers. However, a wide variety of mechanisms underlie the different 
types of toxicity at the cellular level. To discriminate between these various types of toxicity, 
an extension of the methods and markers currently used in toxicology is required. 
Technologies based on the progression in functional genomics research enable the 
determination of the expression of thousands of genes (transcriptomics) or proteins 
(proteomics) in a single experiment. In the novel research discipline toxicogenomics, 
functional genomics technologies are integrated with classical methods to study toxicity at 
the molecular level in relation to the patho-physiological changes of the organism. This 
holistic approach enables detailed comparison of mechanisms and early detection and 
prediction of toxicity. Primary effects of toxicants on gene expression are triggered upon 
binding to receptors, whereas secondary effects on gene expression are to be expected as a 
result of changes in various cellular processes. 
cDNA-microarray based multiple gene expression measurement (transcriptomics) was 
shown to be a powerful tool in the niechanistic assessment of toxic responses 
[34];[21];[22];[40];[27]The determination of thousands of gene expression levels 
simultaneously in a given sample provides an insight in the molecular processes that 
together determine the specific status of that sample. Gene expression profiles can be used 
to discriminate samples exposed to different classes of toxicants, to predict toxicity of (yet) 
unknown compounds and to study cellular mechanisms that lead to or result from toxicity. In 
analogy to this, the simultaneous measurement of the thousands of proteins in a cell will be 
of great benefit for toxicology, or even of more importance, while the proteins predominantly 
act in the cellular reactions rather than the gene transcripts. As all proteins have different 
properties (mass, iso-electric point, solubility, stability, etc), the accurate measurement of 
thousands of proteins in a sample is a very complicated task. In this respect, the great 
advantage of measuring transcripts is that only one type of biomolecule, the mRNA (with all 
its different sequences), has to be extracted and quantified. Whether all cellular mechanisms 
can be identified at the mRNA level is still uncertain. For instance, the process of apoptosis is 
primarily executed through proteolytic (self)activation of the caspase cascade. Especially 
cell-protective responses might be orchestrated through fast modification or subcellular 
redistribution of proteins already present in the cell. Proteomics technologies may have a 
better chance to visualise processes that do not involve active biosynthesis, or at least they 
will be complementary to gene expression analysis. Although relationships between single 
gene expression and corresponding protein levels have been widely studied, to this date, not 
much has been published on the relation between large scale transcriptomics and 
proteomics assessments. Scarce examples are provided in literature, for instance describing 
changes in Bacillus subtilis [71];[72]. Ruepp et al. [73] describe gene and protein expression 
in rat liver after acetaminophen (paracetamol) administration, and identified several proteins 
that changed in acetaminophen hepatotoxicity. It is important to realise that the relationship 
between mRNA and protein content is heavily dependent on time, cellular localisation as well 
as stability of the molecules. Transcription of DNA into mRNA is an earlier and more rapid 
response than the translation from mRNA to proteins. An advantage of the proteomics 
approach is that it allows the finding of previously unknown molecules, in contrast to the 
cDNA microarray technology, which only regards known DNA sequences. 
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This study addresses the value of the functional genomics technologies using cDNA 
microarrays and 2-dimensional gelelectrophoresis-based proteomics in toxicology. For this 
evaluation, the well-studied toxicant bromobenzene (BB) was used to induce hepatotoxicity 
in rats. Bromobenzene is an industrial solvent that elicits toxicity predominantly in the liver, 
where it causes centrilobular necrosis. Like many xenobiotics, it is a hydrophobic molecule 
that is subjected to biotransformation in order to enable excretion in the urine. The 
metabolism and toxicity of bromobenzene in (rat) liver have been described in detail [74,75], 
[76-79]; Bromobenzene is subjected to cytochrome P450-mediated epoxidation, followed by 
either conjugation with glutathione, enzymatic hydrolysis or further oxidation of the phenols, 
leading to hydroquinone-quinone redox cycling. At high BB doses, primarily due to 
conjugation to the epoxides or bromoquinones, hepatic cellular glutathione is depleted. This 
triggers a number of secondary reactions like lipid peroxidation, altered intracellular calcium 
levels, and mitochondrial dysfunction, ultimately leading to cell death. Housekeeping 
functions such as energy production, (protein) biosynthesis and cytoskeleton organisation 
might be disrupted. An important process in bromobenzene toxicity is the covalent binding of 
reactive BB metabolites to (specific) endogenous proteins, especially containing sulfhydryl 
groups [80]. Necrotic cells elicit responses from neighbouring cells like recruitment or 
induction of proteases. If the BB-induced damage does not lead to cell death, many genes 
and proteins involved in recovery and regeneration will be regulated to restore homeostasis. 
In the liver, the toxic effects are primarily observed at the centrilobular region, due to the high 
oxygen concentration and cytochrome P450 activity. After transport to the kidneys, 
bromobenzene induces nephrotoxicity mainly through BB-metabolites conjugated to 
glutathione that elicit oxidative stress. 
A simple study design assesses the molecular toxicity of an intraperitoneal dose of 
bromobenzene, 24 hours after administration. cDNA Microarray measurements were 
duplicated and 2-dimensional electrophoresis gels were performed in triplicate for each 
individual animal, while control groups of both untreated and vehicle treated rats were 
included. In-depth toxicological discussion of the results is beyond the scope of this 
evaluation of transcriptomics and proteomics in toxicology, and will be reported elsewhere 
[3]. Although toxicological interpretations are restricted by the limited design of the studies 
reported here, a comprehensive set of genes and proteins in rat liver is presented that 
change upon bromobenzene treatment and that may play a role in the mechanism of toxicity 
leading to hepatocellular necrosis. Using transcriptomics and proteomics techniques we were 
able to confirm previously reported effects and identify genes and proteins that were not 
recognised before in bromobenzene toxicity, involved in processes like drug metabolism, 
oxidative stress, GSH depletion, the acute phase response and many more yet to be 
resolved. 
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11.2 Materials and Methods 
Unless otherwise indicated, all reagents were obtained from Sigma. Bromobenzene 99% was from 
Sigma-Aldrich Chemie GmbH. Corn oil was from obtained from Remia. 
In vivo rat study 
Male Wistar outbred rats (Charles River Deutschland), (10-12 weeks, body weight 225 ± 8 grams ) 
were injected intraperitoneally with bromobenzene (5.0 mmol/kg body weight, dissolved in corn oil, 
40% v/v) or corn oil only, as vehicle control. Rats (3-4 per group) were treated with BB or with corn oil 
only, and an additional group contained the untreated controls. Rats had free access to food and 
drinking water and were treated according to Good Laboratory Practice (GLP) guidelines and 
protocols approved by the laboratory animal ethical committee. Rats were sacrificed by decapitation 
24 hours after BB or CO administration. Livers were immediately dissected, quickly weighed, snap-
frozen in liquid nitrogen, and stored at -80°C until further processing. Livers were homogenised with a 
mortar and pestle in liquid nitrogen before preparing the total RNA and total protein extracts. Livers 
were isolated and processed in a random order to exclude biased results originating from sample 
preparation. 
GSH determination 
GSH + GSSG and GSSG levels in liver homogenate were determined using 5,5'dithiobis-2-
nitrobenzoic acid (DTNB) to oxidise GSH and form 5-thio-2-nitrobenzoic acid (TNB) which was 
measured spectrophotometrically at 405 nm. GSSG was measured after derivatisation of GSH with 2-
vinyl-pyridine [81,81]. 
Cytosolic glutathione-S-Transferase activity 
Microsomal and cytosolic fractions were isolated by ultracentrifugation from homogenised liver. The 
activity of glutathione-S-transferase in the cytosol of rat liver was determined using the model 
substrate CDNB (1-chloro-2,4-dinitrobenzene) according to [82]. Total protein concentration was 
determined according to the standard Bradford method using Biorad solution [83]. 
RNA extraction 
Total RNA was extracted from liver homogenate using Trizol (Life Technologies S.A) according to the 
manufacturer's protocol. Total RNA was further purified using the RNEasy RNA purification kit 
(Qiagen). RNA was checked for purity and stability by gel electrophoresis and the concentration was 
calculated from the extinction at 260 nm as determined spectrophotometrically. 
Reference RNA 
To allow comparison of all individual expression patterns, reference RNA was prepared. Dissected 
organs (liver (-50% w/w of total), kidneys, lungs, brains, thymus, testes, spleen, heart, and muscle 
tissues) of several untreated male Wistar rats were flash-frozen in liquid nitrogen and stored at -80 °C. 
All tissues were homogenised together in liquid nitrogen before RNA isolation. 
cDNA Microarray preparation 
About 3000 different sequence verified rat cDNA clones from the I.M.A.G.E. consortium were 
purchased (Research Genetics.), and cDNA was amplified by PCR using forward (5' -
CTGCAAGGCGATTAAGTTGGGTAAC-3) and reverse (5'-
GTGAGCGGATAACAATTTCACACAGGAAACAGC-3') primers containing a 5'- C6-aminolinker 
(Isogen Bioscience) to facilitate cross-linking to the aldehyde coated glass microscope slides. PCR 
products were purified by ethanol precipitation and checked for purity and fragment size by 
electrophoresis on a 1% agarose gel. Purified PCR products were dissolved in 3x SSC and clones 
were arrayed in a controlled atmosphere on CSS-100 silylated aldehyde glass slides (TeleChem) 
(modified from DeRisi et al., [48]). In total, about 3800 cDNAs, including 3000 different rat genes, 
some in duplicate, and various control clones were deposited on the slides. After drying, slides were 
blocked with borohydrideand stored in a dark and dust-free cabinet until further use. Prior to 
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hybridisation, slides were prehybridised in buffer (5x SSC, 0.1 % SDS, and Bovine Serum Albumin (10 
mg/ml)) for 2 hours at 42°C , washed in milliQ water, dipped in isopropanol and dried. 
cDNA synthesis and labelling 
A typical labelling reaction was performed using 50 \ig of total RNA using an indirect procedure. In 
vitro transcription reactions were performed using reverse transcriptase according to the protocol with 
the Cyscribe Reagent Kit (Amersham Biosciences). In this reaction, amino allyl dUTP linkers were 
incorporated, after which the reaction mixture was divided over two portions for coupling with Cy3 or 
Cy5 fluorophores respectively.RNA was degraded by hydrolysis in NaOH (30 min. at 37°C and the 
mixture was neutralised with an equimolar amount of acetic acid. The cDNA was purified using the 
QIAquick spin columns (Qiagen) and water was evaporated. Pelleted cDNA was resuspended in 0.3 
M sodium bicarbonate buffer, pH 9.0 and Cy3 or Cy5 fluorophores (freshly dissolved in DMSO) were 
chemically attached to the aminoallyl linkers. The reaction mixture was quenched with hydroxylamine 
(0.3 volumes, 4 M) for 1 min. at room temperature to avoid non-specific fluorescence by free 
fluorophores. Labelled cDNA was purified from unincorporated fluorophores using an AutoseqG-50 
(Amersham Biosciences) sephadex chromatography column. The amount of cDNA obtained and the 
incorporation rate of the fluorophore were determined spectrophotometrically. Prior to hybridisation, 
labelled cDNAs of both sample and reference were mixed and dissolved in 30 nl EasyHyb 
hybridisation buffer (Roche Diagnostics). Yeast tRNA (100 ug, Life Technologies S.A) and Poly dAdT 
(20 jig, Amersham Biosciences) were added to avoid non-specific binding. The hybridisation mixture 
was denatured for 1.5 minutes at 100 °C and pipetted onto a pre-hybridised microarray slide.covered 
with a plastic coverslip and, embedded in a slide incubation chamber (Corning, Life Sciences), 
submerged in a water bath for16 hours at 42°C. After hybridisation, slides were washed by firm 
shaking in 0.5x SSC buffer in a 50ml tube and two times 10 minutes in 0.2x SSC on a mechanical 
shaking platform. Slides were dried quickly by centrifugation at 700 rpm. 
Scanning 
Slides were scanned immediately after drying using the ArrayWorxs CCD scanner (Applied Precision). 
The ArrayWorxs software processes the acquired images into results files, text files containing signal 
and local background intensity for both channels. Excel (Microsoft Corporation) was used to further 
process the data. 
Transcriptomics experimental design 
In order to compare many samples, individuals, or samples from different studies, an external 
reference was introduced. Each individual rat sample was co-hybridised with the reference RNA, 
prepared from untreated rat tissues. For each gene fragment, the amount of mRNA in the sample 
relative to the amount in the reference was determined. The complete set of hybridisations was 
duplicated with swapping of the two fluorophores incorporated in the sample and reference RNA. As a 
consequence of the introduction of the reference sample, comparisons are indirect, as the ratios 
'treated / reference' and 'control / reference' are compared to obtain the desired 'treated/control' 
values. To assess whether different results are obtained using the indirect comparison, three direct co-
hybridisations of one BB rat liver and one CO rat liver were performed and compared to the results 
obtained through indirect comparison of all the BB and CO samples relative to the reference. 
Data Analysis 
For each spot, the local background intensity was subtracted from the signal intensity. Technical 
variations introduced during labelling of RNA samples with the two different fluorophores or by 
scanning have to be taken into account. It is assumed that the large part of the transcripts is equally 
present in both samples and the total fluorescence should be equal in both channels. Therefore, the 
sum of all background subtracted signals (if >0) of each channel was normalised to an arbitrary value 
of 1,000,000 to enable comparison between the channels but also between the microarrays. 
Background intensities outside the cDNA spots were very low and homogeneous. To account for non-
specific hybridisation and background fluorescence of the cDNA on the slide, control spots were 
included on the microarrays containing cDNAs of fungal or yeast origin, with no significant homology 
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to (known) rat cDNAs. Fluorescence intensity in these spots was used to determine a signal intensity 
threshold value. If background-corrected signal intensities were below a threshold value of 100 for any 
of the two channels, measurements were excluded from analysis. After doing so, one complete 
microarray, co-hybridised with RNA from BB-treated rat liver and reference RNA, was excluded from 
further analysis since too many spots did not meet the threshold value. Background-corrected and 
normalised signal intensities were used to calculate the ratio of gene expression of the sample over 
the reference. The group average fold change in gene expression relative to reference was calculated 
for the untreated, corn oil control, and bromobenzene groups (up to 8 values per group). Statistical 
significance of the difference in expression between these groups was analysed with a two-tailed 
Student's T-test for each gene, and differences were considered significant if the p-value did not 
exceed 0.01. The average fold changes of CO versus UT and of BB versus CO were calculated from 
the group average fold changes. 
Proteomics 
Sample preparation 
Homogenised frozen liver was diluted 1:15 (w/v) with sample lysine buffer consisting of 8M urea, 2% 
(v/v) CHAPS, 1% (w/v) DTT, 0.8% (v/v) Pharmalyte. Samples werefurther homogenised through a 25 
inch gauge needle using a 10 ml syringe. Samples were centrifuged for 30 minutes at 100,000 g at 
15°C. Supernatant was stored in aliquotsat -80°C until further use. Protein was determined in 
homogenised liver using a dye-binding procedure [83,83]. 
Two dimensional gel electrophoresis, analytical gels 
13 umol of homogenised liver sample (50 ug of protein) was overnight rehydrated in a volume of 350 
umol in a Reswelling Tray on Immobiline DryStrip (IPG) pH 4-7 in 0.5% (v/v) CHAPS, 15 mM DTT, 
0.5% (v/v) IPG buffer pH 4-7L. Isoelectric focussing of samples was performed on a Multiphor II 
Electrophoresis Unit for 45000 VH using the following program: 30 min at 150 V; 1 h at 300 V; 1 h at 
1500 V and 12 h and 20 min at 3500 V. Subsequently, IPG strips were equilibrated for 15 min in 
Equilibration Buffer (6M urea, 30% (w/v) glycerol, 2% SDS in 0.05 M Tris-HCI buffer, pH 8.8) 
containing 1% (w/v) tributylphospine) and 0.001% (w/v) bromophenol blue. Next, IPG strips were 
equilibrated for 15 min in Equilibration Buffer containing 250 mM iodoacetamide. Second dimension 
electrophoresis was performed on custom made 12-15% polyacrylamide gels, using the Hoefer DALT 
Multiple Casting Chamber (Amersham Biosciences). Gels were prepared according to procedures 
recommended by the manufacturer. Gels were silver stained without glutaraldehyde, according to the 
method described by Shevchenko [51]. Scanning of gels was performed on a BioRad GS-710 
Calibrated Imaging Densitometer (Bio-Rad). 
Gel Image and Data analysis 
Scanned TIFF images were analysed using Phoretix 2D Gel Analysis Software version 5.01 
(Nonlinear Dynamics). For one of the bromobenzene treated rats, repeated attempts to obtain an 
analysable gels image were made, but the quality criteria were not met and no proteome data were 
analysed for this rat. For all other gels, spots were automatically detected and analysed images were 
scrutinised by eye for undetected or incorrectly detected spots. The total staining intensity within each 
detected spot, that is the amount of protein present, is defined as 'spot volume'. To compare spot 
volumes across different gels, the protein spots detected in each experimental gel were matched to 
the corresponding protein spots within a digitised reference spot pattern. Background intensity was 
subtracted from the spot volumes. To correct for differences in staining intensity between gels, spot 
volumes were divided by the volume of all spots and multiplied by the summarised total area of all 
spots. The resulting values represent the 'normalised spot volumes'.Differences in spot volumes from 
different treatment groups were analysed for statistical significance by two-tailed Student T-tests 
(assuming normal distributions and equal variance) using Excel. 
Two dimensional gel electrophoresis, preparative gels 
Preparative gels for mass spectrometric identification of differentially expressed proteins spots were 
prepared similar to the analytical gels, except that at least 1 mg of protein was loaded per gel. 
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Mass spectrometry 
For identification, protein spots were manually cut from the gel in a dust free cabinet to prevent 
contamination with keratin. Gel plugs were processed for mass spectrometry essentially according to 
Shevchenko [51]. Silver stained gel pieces were destained with 30 mM potassium ferricyanide and 
100 mM sodium thiosulphate (Merck), washed with water (MillQ, Milllipore) and twice with acetonitrile 
(Biosolved B.V.) The liquid was substituted with reduction buffer ( 6.5 mM DTT in 50 mM NH4HC03 pH 
8.5) followed by a 60minutes incubation at room tempurature. The buffer was then replaced with 
acetonitrile which in turn was replaced with alkylation buffer (55 mM iodoacetamide in 50mM 
NH4HCO3) and gel plugs were incubated for 30 minutes at room temperature in the dark.The gel 
pieces were dehydrated with acetonitrile and rehydrated with 50 mM NH4HCO3 pH 8.5 twice. Finally 
the gel pieces were dehydrated with acetonitrile and rehydrated in digestion buffer at 4°C (50 mM 
NH4HCO3,) containing 10ng/ul trypsin, and then incubated overnight at 37 °C. Samples were 
centrifuged and the supernatant was transferred to micro ZipTip C18 pipette tips (Milllipore), and 
further processed according to the manufacturer's protocol. For MALDI-TOF-MS, the peptides were 
eluted directly from the ZipTip onto the MALDI target in 1-2 pi matrix solution (10 mg/ml a-cyano-4-
hydroxycinnamic acid in 50% (v/v) acetonitrile, 0.1% trifluoroacetic acid). The peptide mixture for 
nano-electrospray MS/MS (NANO-ESI-MS/MS) was eluted from the ZipTip in 1-2 pi 50% (v/v) 
acetonitrile containing 0.1 % (v/v) formic acid and transferred into a custom made nano-electrospray 
needle. The entire desalted digest from the silver stained spots was used for peptide mapping by 
MALDI-TOF-MS. When peptide extracts obtained from coomassie blue stained spots were used, the 
digest was split 1:4 for MALDI-TOF-MS peptide mapping and nano-electrospray MS/MS, respectively. 
MALDI-TOF-MS peptide mass spectra were recorded on an Applied Biosystems voyager DE-STR 
mass spectrometerin reflector and delayed extraction mode. The data were sampled with 4 GHz (0.5-
ns channel width). All further processing including spectrum calibration based on the trypsin 
autodigest was performed using the software package DataExplorer 4.0 provided by the manufacturer. 
For further protein identification, a Micromass Q-tof mass spectrometer with a nanospray source was 
used for partial sequencing of the ZipTip desalted peptide mixture. A full scan was acquired over a 
wide mass range and precursor ions of interest were selected for MS/MS ion scan. This technique is 
well suited to high-sensitivity sequencing because there is no need for further chromatographic 
separation of the peptide mixture. 
Database search mass spectrometry 
Proteins were tentatively identified using the Mascot Search software (Matrix Science Ltd) to search 
the OWL (http://bioinf.man.ac.uk/dbbrowser/OWL/) protein database. The parameters were set to 
allow 1 miss cleavage with the enzyme trypsin and a peptide mass tolerance of 50-150 ppm. 
Additional protein information and calculation of theoretical pi and molecular mass were obtained from 
SwissPROT (http://www.expasy.ch). 
Principal component analyses 
To discern between transcriptome or protein profiles obtained from rats exposed to bromobenzene 
and controls, principal component analyses were performed. Principal component analysis (PCA) is a 
mathematical technique that reduces the many dimensions of a large dataset to a few dimensions that 
actually describe the large part of the variation in the samples without a priori knowledge. PCA was 
performed using EAGLES, an in house developed software package. The dataset consisted of all 
expression ratios of sample versus reference of all genes left after quality filtering. Ratios were log 
transformed (base 10) for PCA analysis, and excluded values were replaced by a value of 0 . A two-
dimensional plot of the most relevant principal components is used to visualise the difference in gene 
or protein expression profile from the different rat livers, displayed as the objects in the plot. The larger 
the separation between two objects in the plot, the higher the degree of difference is between the 
expression profiles.AII spot volumes from the three protein gels obtained from each animal were 
included in the analysis. For each animal, triplicate scores (representing gels) are interconnected by 
lines resulting in triangles. By comparison of the distances between the centre of each triangles of 
different animals conclusions can be drawn with respect to the difference in proteomes. 
26 
Bromobenzene transcriptomics & proteomics 
11.3 Results 
Rats received a single intraperitoneal dose of bromobenzene and the effect on expression of 
proteins and genes in the liver was determined using proteomics and transcriptomics 
technologies. The bromobenzene dose was chosen based on previous studies to be 
hepatotoxic, and this was confirmed by the finding of a nearly complete glutathione depletion 
at 24 hours after bromobenzene administration (Figure 11.1). Glutathione (GSH + GSSG) 
levels were lowered 27-fold from nearly 21 umol/g in the corn oil controls to 0.8 umol/g in the 
livers of bromobenzene treated animals. The low level of oxidised (GSSG) relative to 
reduced glutathione (GSH) indicates that the depletion is primarily due to conjugation and to 
a much lesser extent due to oxidation of glutathione. No changes in GSH levels were 
induced by corn oil administration. The bromobenzene administration resulted in on average 
7 % decrease in body weight of after 24 hours, whereas vehicle control rats gained on 
average 6 % of weight. The relative liver weights did not change significantly. A significant 
average 1.4-fold increase ( p < 0.04) in activity of glutathione-S-transferase towards CDNB 
was observed in the cytosolic liver fractions of rats treated with bromobenzene compared to 
vehicle controls, which showed activities similar to untreated controls. 
GSH + GSSG (|jmol/ml) • GSSG ([jmol/ml) 
Untreated Corn oil control Bromobenzene 
Figure 11.1. Intracellular (GSH + GSSG) and (GSSG) levels 
Intracellular (GSH + GSSG) and (GSSG) levels were determined of rat liver homogenate of 
untreated, corn oil controls and bromobenzene treated rats. An almost complete depletion of 
intracellular GSH levels occurred 24 hours after bromobenzene intraperitoneal administration. 
Transcriptomics 
Using cDNA microarrays, we determined the transcript levels of about 3000 different genes 
in rat liver, relative to the expression in a reference sample, in duplicated microarray 
hybridisation experiments for all rats individually. About 10-20% of the rat cDNA spots of 
each array contained no or very weak fluorescent signal, corresponding to genes that are not 
expressed or only below detection limits of the technology. After the quality filtering 
procedure as described in the methods section, the remaining elements were subjected to 
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extensive analysis. The majority of the genes represented on our microarray was comparably 
expressed throughout all the samples. However, the bromobenzene treatment distinctly 
elicited alterations in the expression pattern of a number of genes in rat liver. The average 
fold changes in expression were calculated between BB treated versus corn oil control (CO) 
rat livers, and between CO and untreated rat livers. Using the quality criteria described in the 
Methods section, 32 genes were found to be significantly upregulated, and 17 were 
repressed more than twofold by bromobenzene treatment relative to the vehicle control, 
while respectively 63 and 35 genes were up- or downregulated when considering a more 
subtle ( > 1.5 ) fold change. Genes that changed expression significantly upon 
bromobenzene treatment were functionally grouped and listed in Table 11.1. (drug 
metabolism, glutathione metabolism and oxidative stress), Table II.2. (acute phase 
response), Table II.3. (protein synthesis and proteolysis, Table II.4. (others, > 1.5-fold 
change). 
Table 11.1. Genes related to drug metabolism, glutathione metabolism and oxidative 
stress 
The columns describe the Genbank accession numbers (AC#) of the cDNA fragments present 
on the microarray, the name of the gene, the average fold change (FC) in expression of both 
CO versus UT and BB versus CO, as well as the p-value of the Student's T-test.b: duplicate 
cDNA fragment printed on the microarray 
CO/UT BB/CO 
Acc# Gene name FC FC p 
AA900551 Epoxide hydrolase (microsomal) (Ephxl) 
AA923966 Aflatoxin B1 aldehyde reductase (Afar) 
AA955106 Aldehyde dehydrogenase (Aldh) 
AA956507 NADPH-cytochrome P-450 oxidoreductase 
AA818917 similar to NADH-ubiquinone dehydrogenase 
AA818339 Glutathione S-transferase Ya (Gsta) 
AA998734 Glutathione-S-transferase, mu type 2 (Gstm2) 
AA965220 gamma-glutamylcysteine synthetase (Gclc) 
AA818339 b Glutathione S-transferase Ya (Gsta) 
AA955668 Glutathione S-transferase P (Gstp) 
AA819810 Weakly similar to glutathione S-transferase P 
AA819810 " Weakly similar to glutathione S-transferase P 
AA964788 Glutathione peroxidase (Gpx1) 
AA874884 heme oxygenase gene (HO-1) 
AA817693 ferritin light chain subunit 
AA874884 heme oxygenase (HO-1) 
AA875245 Peroxiredoxin 1 (Heme-binding protein 23) 
AA875245 b Peroxiredoxin 1 (Heme-binding protein 23) 
AA818441 ferritin-H subunit 
AA957593 Tissue inhibitor of metalloproteinase-1 (Timpl) 
Table 11.1 lists the enzymes involved in drug metabolism that are responding upon BB 
treatment. Bromobenzene strongly induces the levels of mRNA encoding the liver 
glutathione-S-transferase Alpha and Mu subunits, the microsomal epoxide hydrolase (Ephxl) 
and the aflatoxin B1 aldehyde reductase (Afar). Aldehyde dehydrogenase gene expression 
increased more than twofold upon bromobenzene treatment. Concurrently, the NADPH-
cytochrome P-450 oxidoreductase was significantly upregulated. In contrast to the Gst Alpha, 
Mu and Pi subunits' upregulation, the 'EST weakly similar to (rat) Gst Pi subunit' decreased 
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over twofold. Sequence analysis of this cDNA fragment (ACC# AA819810) revealed 
similarity to the rat Gst class Pi 7-7 (gi:121749) at the amino acid sequence level.Also genes 
involved in the metabolism of intracellular glutathione that changed upon BB treatment are 
listed in Table 11.1. Besides the induction of glutathione-S-transferases, a 2.5 fold 
upregulation of y-GCS (Gclc), the key enzyme in GSH biosynthesis was observed. GSH 
peroxidase, an enzyme also implicated in oxidative stress was found to be downregulated. 
Genes typically responding to oxidative stress such as heme oxygenase-1, peroxiredoxin 1 
(heme binding protein 23), metallothioneins, ferritin, TIMP1 were found to be induced. 
Bromobenzene treatment elicits changes in transcript levels of many of the so-called acute 
phase proteins. Ferritin, apolipoprotein M and metallothionein are induced in the acute phase 
response (APR) and were found to be strongly induced by the BB treatment. Moreover, 
negative APPs including alpha-1-inhibitor 3, alpha-1-macroglobulin, transferrin, complement 
components, liver fatty acid binding protein 1 and fibrinogen are downregulated 24 hours 
after bromobenzene treatment (Table II.2.) 
Interestingly, many ribosomal subunits and other factors involved in protein synthesis 
(Initiation factor, elongation factor) were induced upon BB treatment (Table II.3). 
Furthermore, table II.3 lists the induction of several components of the proteasome and of 
the proteolytic enzyme Cathepsin L from the lysosome. Many genes with interesting 
implications in other cellular processes (Table II.4 ) were found to be upregulated such as 
beta actin, glucose-6-phosphate dehydrogenase, thyrotropin receptor, cytochrome c, 
cytochrome b5, cysteine sulfinic acid decarboxylase and clathrin. Genes downregulated by 
BB include a mitochondrial ATPase inhibitor, thymosin beta 10, betaine homocysteine methyl 
transferase (Bhmt), cysteine dioxygenase, hemoglobin, insulin-like growth factor and 
mitochondrial HMG-CoA synthase. 
Table II.2. Genes related to the hepatic acute phase response 
The columns describe the Genbank accession numbers (AC#) of the cDNA fragments present 
on the microarray, the name of the gene, the average fold change (FC) in expression of both 
CO versus UT and BB versus CO, as well as the p-value of the Student's T-test.b: duplicate 
cDNA fragment printed on the microarray 
Acc# 
AA874884 
AA900218 
AA859399 
AA858741 
AA818441 
AA819204 
AA926277 
AA817963 
AI072074 
AA817963b 
AA998796 
AA956238 
AA900592 
AA901379 
AA819267 
AI044677 
AA963164 
AA819043 
Gene name 
ferritin light chain subunit, 
heme oxygenase (HO-1) 
metallothionein-i (mt-1) 
Metallothionein 
apolipoprotein M 
ferritin-H subunit 
Weakly similar to rat Metallothionein-I 
CELF/ C/EBP delta transcription factor 
alpha-1-inhibitor 3 
Fatty acid binding protein 1, liver 
alpha-1-inhibitor 3 
Complement component C9 precursor 
Vitronectin 
Similar to human complement component 
Inter-alpha-inhibitor H4P heavy chain 
Fibrinogen gamma chain-a 
Weakly similar to rat gamma-fibrinogen 
Synaptojanin II 
Fibronectin 1 
CO/UT 
FC 
0.83 
1.06 
1.46** 
1.86" 
1.21 
0.89 
1.14 
0.93 
0.62** 
0.85 
0.66 
1.21 
1.29 
1.23 
1.52* 
0.98 
1.84** 
1.00 
0.88 
BB/CO 
FC 
4.29 
2.70 
2.76 
2.71 
2.05 
2.01 
1.66 
0.83 
0.64 
0.56 
0.55 
0.54 
0.54 
0.53 
0.52 
0.52 
0.51 
0.49 
0.47 
P 
0.005 
0.002 
0.002 
0.002 
0.001 
0.004 
0.007 
0.007 
0.008 
0.001 
0.005 
0.001 
0.002 
0.000 
0.009 
0.007 
0.004 
0.004 
0.000 
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Ah 37907 
AA858975 
AA819465 
AI072074 
AA963445 
Alpha-1 -macroglobulin 
Transferrin 
apolipoprotein C-lll 
Fatty acid binding protein 1, liver 
selenoprotein P 
1.22 
0.92 
0.96 
1.09 
1.10 
0.46 
0.46 
0.44 
0.42 
0.39 
0.006 
0.006 
0.000 
0.006 
0.002 
Table II.3 Genes related to protein synthesis and proteolysis 
The columns describe the Genbank accession numbers (AC#) of the cDNA fragments present 
on the microarray, the name of the gene, the average fold change (FC) in expression of both CO 
versus UT and BB versus CO, as well as the p-value of the Student's T-test.b: duplicate cDNA 
fragment printed on the microarray 
Acc# Gene name 
CO/UT 
FC 
BB 
FC 
/CO 
AI045792 Highly similar to rat 60S ribosomal protein L9 
AA819544 ribosomal protein S2 
AA900657 60S ribosomal protein L7A 
AA874997 ribosomal protein S8 
AA924912 ribosomal protein L6 
AA899448 ribosomal protein S3a 
AA818640 Highly similar to human 40S ribosomal prot S18 
AA925200 60S ribosomal subunit protein L35 
AA866268 Highly similar to RL860S ribosomal protein L8 
AA818442 Ribosomal protein S11 
AA900527 ribosomal protein S26 
AA924882 ribosomal protein L15 
AA998895 Nucleophosmin (nucleolar protein B23) 
AA819244 Nuclear-encoded mitochondrial elongation factor G 
AA874949 Similar to human initiation factor elF-5A gene 
AA875102 Highly sim. to mouse/human small nuclear 
ribonucleoprotein E 
AA964651 Highly similar to mouse prefoldin subunit 2 
AA899472 Highly similar to eukaryotic translation initiation factor 
3. Subunit 8 
AA859498 cathepsin L 
NA cathepsin L 
AA859484 Proteasome subunit beta type. 3 
AA859300 Proteasome subunit alpha type 1 
AI030596 Similar to human 26S proteasome subunit S5B 
AA859582 Proteasome subunit beta type 5 (epsilon chain) 
AI043800 ESTs, Highly similar to 26S proteasome-associated 
padl homolog 
AA964414 proteasome component C8 
AA925795 proteasomal ATPase (SUG1) 
1.14 
1.04 
0.96 
1.04 
0.86 
0.78 
0.88 
0.93 
1.10 
0.89 
0.92 
0.98 
0.95 
0.51 
0.88 
0.85 
0.77 
0.89 
0.83 
0.94 
0.96 
1.00 
1.15 
1.30 
0.86 
0.92 
0.96 
2.47 
2.33 
2.25 
1.97 
1.94 
1.89 
1.88 
1.85 
1.71 
1.70 
1.52 
1.41 
3.02 
2.31 
1.95 
1.62 
1.60 
1.58 
3.53 
3.21 
2.27 
1.73 
1.60 
1.57 
1.47 
1.40 
1.30 
0.010 
0.001 
0.000 
0.001 
0.000 
0.006 
0.006 
0.007 
0.002 
0.001 
0.009 
0.005 
0.000 
0.004 
0.001 
0.001 
0.010 
0.000 
0.037 
0.007 
0.000 
0.014 
0.054 
0.057 
0.043 
0.089 
0.054 
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Table 11.4 Genes related to other functions 
The columns describe the Genbank accession numbers (AC#) of the cDNA fragments 
present on the microarray, the name of the gene, the average fold change (FC) in expression 
of both CO versus UT and BB versus CO, as well as the p-value of the Student's T-test.b: 
duplicate cDNA fragment printed on the microarray 
CO/UT BB/CO 
Acc# Gene name FC FC P-value 
AI059976 Vesl-2 
AA964496 Highly similar to actin beta 
AA858998 RAN. member RAS oncogene family 
AI030685 nestin 
AI060085 Thyrotropin receptor 
AA964725 Highly similar to mouse Flightless I homolog 
AA965078 mitochondrial 3-2 trans-enoyl-CoA isomerase 
AI045953 Cysteine sulfinic acid decarboxylase 
AI059951 Neuronal cell death related gene in neuron -7 
AA818887 MHC class I 
AA956323 membrane bound cytochrome b5 
AI058620 Bax inhibitor-1 (BI-1) (Testis enhanced gene transcript) 
AI058566 Peptide/histidine transporter 
AA874955 Clathrin light chain (LCB3) 
AA900595 Anti-silencing protein ASF1 homolog 
AA964548 Highly similar to rat tubulin beta chain 
AA866442 Somatic cytochrome c 
AA900102 Mitochondrial import inner membrane translocase 
AA899102 Glucose-6-phosphate dehydrogenase 
AA874837 Phosphoglycerate mutase B isozyme PGAM 
AA819314 Initiation factor 2 associated 67 kDa protein; methionine 
aminopeptidase 
AA859476 Cofilin 
AI453996 Heat shock 70kD protein 5 
AA964657 EST. unknown 
AA964651 Highly similar to mouse prefoldin subunit 2 
AA875070 alpha-prothymosin 
AI043642 potassium channel (KCNQ2) 
AA957012 Highly similar to human RNA polymerase II 
AA866264 similar 20-alpha-hydroxysteroid dehydrogenase 
AI070597 Highly similar to human CGI-97 protein 
AA925346 Cytochrome P450 51, lanosterol 14-alpha-demethylase 
AA818579 cysteine dioxygenase 
AA963258 insulin-like growth factor I (IGF-I) 
AA819034 alpha interferon inducible protein 
AI136048 mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 
AA819784 Hemoglobin, alpha 1 
AA926010 long-chain acyl-CoA synthetase 
AA901407 betaine homocysteine methyltransferase (BHMT) 
AA924288 thymosin beta-10 gene 
AA858662 tryptophan 5-monooxygenase activation protein (Ywhaz) 
AA819164 Mitochondrial IF1 ATPase inhibitor 
AA926359 receptor-linked protein tyrosine phosphatase 
0.94 
1.14 
0.91 
0.98 
1.10 
1.18 
1.01 
1.02 
1.10 
0.92 
0.78 
1.09 
1.06 
0.78 
1.10 
0.99 
0.64 
1.00 
0.98 
0.82 
0.78 
0.81 
0.96 
0.96 
0.77 
0.94 
1.00 
1.00 
0.92 
1.60** 
1.10 
0.76 
1.12 
1.31 
1.45 
1.39 
1.12 
0.67 
0.77 
0.82 
0.96 
1.18 
3.77 
3.48 
2.88 
2.44 
2.36 
2.35 
2.22 
2.17 
2.01 
1.96 
1.90 
1.89 
1.82 
1.80 
1.80 
1.79 
1.77 
1.74 
1.73 
1.73 
1.72 
1.69 
1.68 
1.64 
1.60 
1.58 
1.53 
0.68 
0.66 
0.65 
0.61 
0.58 
0.55 
0.54 
0.53 
0.52 
0.46 
0.45 
0.42 
0.41 
0.41 
0.39 
0.001 
0.005 
0.004 
0.007 
0.002 
0.008 
0.006 
0.004 
0.001 
0.004 
0.000 
0.002 
0.001 
0.001 
0.000 
0.000 
0.006 
0.005 
0.003 
0.007 
0.010 
0.006 
0.004 
0.005 
0.010 
0.006 
0.003 
0.001 
0.010 
0.009 
0.000 
0.009 
0.009 
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0.008 
0.010 
0.002 
0.003 
0.005 
0.000 
0.005 
0.000 
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Table 11.5. Genes that change significantly (p s 0.01) changed more than 1.5 fold by 
corn oil administration as compared to untreated. 
Acc# 
AA964554 
AA859399 
AI044677 
AI070597 
AA900218 
AA957923 
AA818896 
AA817963 
Gene name 
Highly similar to human U3 snoRNP-
associated 55-kDa protein 
Metallothionein 
Weakly similar to rat gamma-fibrinogen 
Highly similar to human CGI-97 
Metallothionein-i (mt-1) 
mast cell protease II gene 
Cytochrome P-450J (Cyp2e1) 
alpha-1-inhibitor 3 
CO/UT 
FC 
2.54 
1.86 
1.84 
1.60 
1.46 
0.68 
0.63 
0.62 
P 
0.009 
0.008 
0.010 
0.002 
0.006 
0.001 
0.010 
0.007 
BB/CO 
FC 
0.59 
2.71 
0.51 
0.65 
2.76 
1.25 
1.39 
0.64 
P 
0.164 
0.002 
0.004 
0.009 
0.002 
0.108 
0.128 
0.008 
Only a few liver transcripts markedly changed in expression caused by corn oil injection. 
(Table II.8.) Metallothionein, the "EST weakly similar to (rat) fibrinogen gamma", and C4 
complement protein were significantly upregulated by CO. These are proteins modulated in 
the acute phase response and interestingly, the latter two were downregulated by BB. (Table 
II.4.) The negative acute phase protein alpha-1-inhibitor was significantly downregulated in 
the CO controls, and levels decreased further in the BB treated rats. The mRNA for 
cytochrome P450 oxygenase 2E1 (Cyp2e1) was downregulated on average 1.6 fold by corn 
oil. 
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Figure II.2. Principal component analysis of transcriptome data. 
Objects in the plot represent expression profiles from individual rat livers. The two principal 
components explaining the majority of the variation in the dataset are plotted. Clearly, the 
expression profiles of rat liver after BB treatment are distinct from the controls. The injection 
of corn oil only as the vehicle control did not result in aberrant gene expression profiles 
compared to the untreated samples. UT = untreated (squares); CO = corn oil vehicle control 
(circles); BB = bromobenzene treated (triangles) ; Directly compared BB vs. CO samples 
(inverted triangles) Individual rat numbers are indicated, followed by 'Cy5'when the liver RNA 
sample was labeled with Cy5 fluorophore (and the reference with Cy3). In the other samples, 
the fluorophore incorporation was swapped. 
Principal component analysis (PCA) was applied to visualise the differences in the 
expression profiles from treated and non-treated rats (Figure II.2.). The expression profiles of 
rat liver after BB treatment are clearly distinct from the controls. In the plot, the horizontal 
distance (principal component # 1) between the groups of BB treated and control liver 
expression profiles is larger than the distance between samples within one group. The 
injection of corn oil only as the vehicle control did not result in aberrant gene expression 
profiles compared to the untreated samples. The vertical distance (PC#2) between samples 
in the plot does not reflect relevant biological effects but technical variation. The distance 
between two expression profiles obtained from the same rat indicates that the technical 
variation introduced by the RNA labelling and hybridisation procedures provides the main 
source of variation within a treatment group. The interindividual biological variation within the 
treatment groups did not exceed the technical variation. Additionally, the principal component 
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values were calculated per gene and genes were ranked according to the PC#1 values. The 
genes with the largest PC#1 values are differentially expressed after treatment. Genes with 
positive PC#1 values proved to be upregulated by bromobenzene, whereas genes with 
negative values were downregulated by BB compared to controls. The genes that account 
for most of the differences in the expression profiles of BB-treated compared to controls in 
the PC-analysis were found to be the identical genes that were identified by fold-change 
calculations (Tables 11.1- II.4). 
PC-analysis indicated a cluster of genes which most pronouncedly contributed to 
bromobenzene induced hepatotoxicity. This cluster contained several drug metabolising 
enzymes like the microsomal epoxide hydrolase 1 (Ephxl), glutathione-S-transferase Alpha 
(Gsta), Mu (Gstm) and Pi subunits and aflatoxin B1 aldehyde reductase (Afar). Moreover, 
proteins related to oxidative stress response like ferritin (both heavy and light subunit), heme 
oxygenase-1 (HO-1), peroxiredoxin 1 and NADPH cytochrome P450 oxidoreductase were 
elevated in concordance. Most of the genes considerably downregulated were identified as 
acute phase proteins. 
To test whether similar results are obtained using direct or indirect hybridisations including a 
general reference sample, three co-hybridisations of one BB rat liver and one CO rat liver 
mRNA sample were performed and compared to the results obtained through indirect 
comparison of all the BB and CO samples. Relative expression levels should correlate well 
for all genes, but especially the differential expression of genes should be identified similarly 
using both approaches. Therefore, the BB/CO fold change of 165 genes identified in the 
indirect approach to be differentially expressed with > 1.5 fold change (T-test p < 0.02) was 
compared to the average fold change as measured in three replicated BB vs. CO co-
hybridisations, resulting in a correlation coefficient of 0.879. 
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Proteomics 
At least three 2-dimensional gels were prepared from each liver extract. A reference protein 
pattern was constructed from rat liver, containing 1124 protein spots. In Figure II.3, the 
protein pattern obtained from an untreated animal is shown. Spot numbers and identities -
whenever available - of 24 proteins that were differentially expressed in bromobenzene or 
corn oil treated animals are indicated. 
14.4 
Mass 
Figure 11.3. Two-dimensional electrophoresis gel of liver from untreated rat 
A two-dimensional electrophoresis gel obtained from an untreated animal is shown. Spot 
numbers and identities - whenever available - of 24 proteins that were differentially expressed in 
bromobenzene-treated animals are indicated. The method of identification is indicated: M: 
MALDI-TOF-MS; N: ESI-MS/MS. 
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UT CO 
UT CO BB 
364: 
4-hydroxyphenylpyruvic acid 
dioxygenase 
UT CO 
287 
420 _ 
112: 
ATP synthase beta subunit. 
157: 
HSP60 protein 
UT CO 
308: 
Carbamoyl-phosphate 
synthase 
UT CO 
358: 
4-hydroxyphenylpyruvic acid 
dioxygenase 
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Figure II.4. Protein spots that changed statistically significant upon corn oil (CO), or 
bromobenzene (BB) treatment. 
Average spot volume + standard deviation obtained from all gels within a group is shown. 
(UT: untreated; CO: corn oil vehicle control; BB: bromobenzene). a: significant difference 
(two-tailed Student's T-test) between untreated and corn oil vehicle control treated animals, b: 
significant difference (two-tailed Student's T-test) between bromobenzene and corn oil 
treated animals. *: P < 0.05; **: P < 0.005; ***: P < 0.001. Protein names of identified spots 
are indicated. 
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Figure 11.4 displays the volumes for all spots identified as statistically significantly changed 
upon bromobenzene or corn oil treatment. The bars represent normalised spot volumes, 
averaged for all (9-12) gels within one treatment group (untreated, vehicle control or 
bromobenzene treated). Hence, the depicted standard deviation reflects both the interanimal 
variation, as well as technical variation between gels. Part of the spots marked as 
significantly changing were identified by MALDI-TOF or nano-electrospray mass 
spectrometry. Spot 112 was identified as the ATP synthase beta subunit (gi:1374715). The 
level of ATP synthase beta subunit decreased ~3.5 fold upon bromobenzene treatment. 
Peptide fragments from spot 925, which also decreased by bromobenzene were found to 
match the mitochondrial ATP synthase alpha subunit (liver isoform) (gi:114523). Remarkably, 
other peptide fragments isolated from this same spot matched the glutathione S-transferase 
Y subunit (gi:204503). The peptide fragment pattern obtained from protein spot 157 was 
found to match a protein sequence from the murine Heath Shock Protein 60 (gi:51452). 
Sequence alignment (BLAST at NCBI) indicated that the amino acid sequence is more than 
99% identical to the Rattus norvegicus Hsp60 (gi: 1334284). The expression of Hsp60 
decreased about 3-fold upon bromobenzene treatment as compared to control groups. 
Peptide fragments from both spot 358 and spot 364 were identified as 4-
hydroxyphenylpyruvic acid dioxygenase (Hpd, gi:8393557), using MALDI-TOF-MS and ESI-
MS-MS respectively. Hpd converts 4-hydroxyphenylpyruvate dioxygenase to homogentisate 
and is involved in tyrosine catabolism. Hpd decreased -5.5 fold upon treatment with 
bromobenzene, part of which could be explained by an effect of corn oil. Both spots 
represent proteins with similar molecular mass, however, a slight difference in pi was found. 
Additional peptide fragment analyses, using ESI-MS-MS, of spot 358 isolated from two new 
gels, twice revealed a mixture of fragments that matched Hpd and peptide fragments that 
matched hydroxymethylglutaryl-CoA synthase (HMG-CoA synthase, gi: 123330). Spot 687 
was identified as mitochondrial aldehyde dehydrogenase 2 (gi:14192933). Aldehyde 
dehydrogenase 2 increased -2.5 fold upon bromobenzene exposure, whereas 
intraperitoneal administration of corn oil did not induce changes in the protein content. 
Peptide fragments derived from spot 934 matched with fragments from the D-dopachrome 
tautomerase gene (Dopa, gi: 13162287). Dopa is an enzyme catalysing the tautomerisation of 
D-dopachrome to 5,6-dihydroxyindole. D-Dopachrome tautomerase decreased upon corn oil 
treatment, but not statistically significant. However, a significant further decrease in 
expression level was caused by bromobenzene treatment. Spots 308 and 697 both were 
identified as carbamoyl-phosphate synthase (CPSI, gi:117492), an enzyme involved in the 
urea cycle (E.C. 6.3.4.16). Spot 308, corresponding with a high molecular mass protein (-40 
kDa), decreases upon BB treatment, whereas spot 697 corresponds with a smaller (-25 kDa) 
protein which amount increases upon BB. One bright spot, 262, was found to be induced by 
BB 1.5 fold compared to corn oil and 2-fold compared to UT, but no statistical significance 
could be shown due to one outlier intensity value in the CO group, resulting in standard 
deviation of over 50% for the CO group. Mass spectrometry identified peptide fragments of 
this spot matching to glutathione synthetase (gi:1170038), an enzyme involved in the GSH 
synthesis. Besides the few proteins found to statistically significantly change with corn oil and 
bromobenzene treatment, a decrease in the average size of the proteins in the 
bromobenzene livers as compared to the corn oil livers is observed in figure II.5. 
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A: Corn oil control Mass 
B: Bromobenzene treated Mass 
Figure 11.5. Representative gel images from livers of control (A) and 
bromobenzene-treated rats (B). 
These images show a shift towards proteins with lower molecular mass after 
bromobenzene treatment. 
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In ail gels from BB-treated livers, less spots are present in the upper (large mass proteins) 
region of the gels and more spots appear in the lower region compared to both CO and UT 
controls. Principal component analysis on the proteomics data (Figure 11.6) also illustrates a 
clear difference between liver protein patterns of bromobenzene-treated animals and 
controls. Each object in the plot represents all normalised spot volumes from one gel. There 
is a relatively large distance between objects of the BB treatment group to the objects of both 
control groups. The distance between the three objects from the same rat is generally larger 
than distance between samples from different animals, indicating that technical variations 
exceed the interindividual variations within treatments groups. 
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Figure II.6. Principal component analysis ofproteomes. 
PCA was applied using spot volume data obtained from untreated, corn oil control and 
bromobenzene-treated animals. The two principal components explaining the majority of the 
variation in the dataset are plotted. Individual gels of bromobenzene treatment samples are 
displayed by triangles, circles indicate the corn oil controls and squares the untreated 
samples. The three gels from the same animal are connected by lines. Protein patterns from 
bromobenzene treated animals are clearly distinct from corn oil and untreated controls. A 
slight difference in the pattern of corn oil treated animals as compared to untreated rats could 
be concluded from this image. 
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11.4 Discussion 
Novel functional genomics technologies are applied to toxicology to aid the study of cellular 
mechanisms of toxicity. The combined application of transcriptomics and proteomics 
methods was evaluated in a toxicological experiment in rats with a typical hepatotoxicant, 
bromobenzene. Acute toxicity by intraperitoneal bromobenzene administration is known to 
lead to centrilobular necrosis in the liver. In elaborate studies of the effects on rat liver gene 
expression with multiple doses of bromobenzene and time points of analysis, we determined 
expression profiles that correspond well with the results presented here; a comparable oral 
dose (5 mmol / kg BW) of bromobenzene elicited distinct responses at 24 hours, while 6 
hours after dosage, responses were not yet pronounced. Administration of lower doses of 
bromobenzene induced fewer changes in the transcriptome. Changes at the expression level 
are related to other toxicity parameters [3]. 
The observed glutathione depletion and body weight decrease 24 hours after dosage are 
physiological symptoms that concur with many changes at the mRNA and protein level in the 
liver, presented in this report. The depletion of cellular GSH content can not be explained by 
the formation of GSSG from oxidation of two GSH molecules, since the GSSG content does 
not increase. Rather, GSH depletion reflects the exhaustive use of GSH in conjugation to 
reactive BB metabolites catalysed by Gsts, or through spontaneously conjugation. The 
strong induction of Gst Alpha, Mu and Pi subunit mRNAs that was found (Table 11.1) 
corroborates the importance of GSH conjugation by these enzymes in the biotransformation 
of bromobenzene. The significant 1.4-fold increase in cytosolic Gst activity towards CDNB, 
24 hours after BB dosage, confirms the functional implications of the observed induction of 
Gst isozymes at the mRNA level. Catalysis of CDNB turnover is effected by several cytosolic 
Gst isozymes, while Gst Alpha is the most abundant enzyme in rat liver and presumably 
responsible for the large part of activity towards CDNB. The pivotal role of the depletion of 
intracellular GSH levels in the process of bromobenzene toxicity was strengthened by the 
finding of the induced gene expression of y-glutamylcysteine synthetase, which is the rate-
limiting enzyme in GSH synthesis. Induction has been reported under conditions where 
cellular GSH was depleted, and provides the cell with the ability to reconstitute GSH levels. 
The other enzyme important in the GSH synthesis, GSH synthase, was not found to change 
significantly at the mRNA level. However, at the protein level, a bromobenzene-induced 
increase in GSH synthase (spot 262) was found although one outlier value in the control 
prevented statistical corroboration of this change. Additionally, the downregulation of GSH 
peroxidase is probably directly related to GSH depletion and has been shown in 
acetaminophen toxicity as well [84]. Thus, both transcriptomics and proteomics results 
provide complementary information to the changes in biochemically determined cellular GSH 
levels and specific enzyme activity of Gst in the cytosol. 
The induction of mRNA for microsomal epoxide hydrolase is coherent with its role in 
bromobenzene metabolism; the hydrolysis of the toxic epoxide BB intermediates. Microsomal 
epoxide hydrolase is expressed strongly in liver, but also foundin many other organs. It is 
induced by xenobiotics like phenobarbital, trans-stilbene oxide and Aroclor 1254 [85]. The 
cytosolic epoxide hydrolase gene expression was not significantly changed upon 
bromobenzene treatment. The co-ordinate response of a cluster of genes upregulated by BB 
consisting of genes like Gsta, Gstm, y-GCS (Gclc), HO-1 and ferritin, peroxiredoxinl and 
NADPH-cytochrome P450 oxidoreductase might reflect a common regulatory mechanism. 
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Indeed, many of the genes in this cluster have been shown to be under transcriptional control 
of the Electrophile Response Element (EpRE, formerly named antioxidant response element, 
ARE). [86,87]. We speculate that more genes in this cluster could be under transcriptional 
control of the EpRE, probably activated by the BB epoxide metabolites, which are very strong 
electrophilic species. Heme oxygenase upregulation is a characteristic response to hepatic 
oxidative stress. Hypoxia, endotoxins, and xenobiotics that induce oxidative stress (e.g. 
cadmium chloride [88], acetaminophen[84] were all found to induce heme oxygenase. The 
upregulation of hepatic heme oxygenase 1 by bromobenzene has been described long ago 
[89]. HO-1 is the enzyme that catalyses the degradation of heme into biliverdin, and induction 
could be functional against oxidative stress [90]. Bilirubin, produced from biliverdin by 
biliverdin reductase is an antioxidant, which would provide the cell with a defence 
mechanism against reactive oxygen species. The co-induction of HO-1 and peroxiredoxinl 
was described before after exposure to heme or heavy metals CdCI2 and CoCI2 [91]. 
The intraperitoneal administration of a high dose of bromobenzene clearly elicits a response 
well-known as the Acute Phase Response (APR), as can be concluded from the differential 
expression of the genes listed in Table II.4. The APR is a response of the organism to 
various types of stress like mechanical damage (liver regeneration after partial hepatectomy), 
systemic inflammation (endotoxins like lipopolysaccharides) or local inflammation [92,93]. 
Especially in the liver, the APR coincides with dramatic changes in a wide variety of proteins 
with the general purpose to provide a protective response and re-establish cellular 
homeostasis. A major function of the liver, the production of secreted proteins like plasma 
proteins, is heavily disturbed. The so-called negative acute phase proteins are 
downregulated in the APR, and comprise plasma transport proteins like albumin, hemopexin, 
ceruloplasmin and alphal-acid glycoprotein. The expression of genes that encode for 
proteins with protective effects, for instance sequestering of reactive oxygen species, is 
upregulated in APR. Proteins like Ferritin, metallothioneins, and alpha-fetoprotein are 
regarded as positive acute phase proteins. The injection of corn oil as a control elicits the 
downregulation of the alpha-1-inhibitor and the upregulation of one metallothionein species. 
Remarkably, fibrinogen is upregulated by corn oil, in contrast to the downregulation by BB. 
The expression of 260 genes in liver and kidney of mice exposed to bromobenzene has been 
measured and compared to treatment with various chemicals by Bartosiewicz et al. [94]. A 
very high dose of BB (2.5 g / kg BW) was given, causing all mice to die within 48 hours post-
dosage. Indeed, the approximate lethal dose in mice was reported to be 0.9 g / kg [95],The 
authors compared BB toxicity to CCI4-induced toxicity and reported 15 genes to be regulated 
24 hours after administration, both in BB as well as in CCI4-treated mice, including strong 
upregulation of hsp25, c-jun, gadd45, y-GCS and downregulation of Cyp2e. Also, some 
genes were found to be regulated by BB but not by CCI4, including Gst Yc, Cyp2b9, myeloid 
differentiation and P450 reductase. Several genes were identified to change in concordance 
with our findings, (eg. y-GCS and glutathione-S-transferases), however, patterns of gene 
expression also showed marked differences. Bartosiewicz ef al. found more genes related to 
general stress pathways to be induced, possibly because a very high dose of bromobenzene 
was given. Moreover, mice were used whereas rats were studied in our work, which could 
account for species-specific differences in response. 
A correlation was found for the gene and protein expression changes in aldehyde 
dehydrogenase...At the protein level, bromobenzene induced a 2.5-fold increase in the 
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mitochondrial aldehyde dehydrogenase 2. Using cDNA microarrays, significant (over twofold) 
changes in the expression level of aldehyde dehydrogenase and also of aflatoxin B1 
aldehyde reductase were found. The induction of aldehyde dehydrogenase and reductase 
may be an adaptation both at the gene and protein level to increased levels of 4-hydroxy-2-
nonenal that could result from bromobenzene induced lipid peroxidation [96];[97]. 
The 3.5 fold decrease in ATPase beta subunit protein concentration upon bromobenzene 
treatment probably indicates mitochondrial toxicity and a loss of cellular energy production in 
line with mitochondrial damage. Previous studies indicated the ability of bromobenzene to 
deplete ATP-levels in vitro and in vivo [98];[99]. The protein decrease could not be related to 
changes in mRNA levels, as the cDNA microarray measurements for the ATPasesubunits 
were inconclusive. Along with the ATPase decrease, the gene expression of the 
mitochondrial IF1 ATPase inhibitor was strongly inhibited. Recently, it was shown that 
acetaminophen-induced hepatotoxicity also resulted in decreased ATP-synthase subunit and 
Hsp60 levels in mice [100]. 
Upon BB treatment, the amount of Heat shock protein 60 (Hsp60), 4-hydroxyphenylpyruvic 
acid dioxygenase (Hpd) and D-dopachrome tautomerase (Dopa) decreased. Remarkably, 
two spots represent Hpd protein with similar molecular mass but different pi, suggesting that 
Hpd exists in more than one state, possibly through post-translational protein modification. 
ESI-MS-MS analyses of spot 358 cut from two new gels revealed both fragments that 
matched Hpd as well as peptide fragments that matched hydroxymethylglutaryl-CoA 
synthase. The decrease in intensity of this spot can not be directly related to decreased 
expression of either Hpd or HMG-CoA synthase as both might contribute to the decrease. 
Downregulation of Hpd was concluded from analysis of protein spot 364, whereas 1.9 fold 
downregulated gene expression was found for HMG-CoA synthase. Dopa is catalysing the 
tautomerisation of D-dopachrome to 5,6-dihydroxyindole, which is a melanin precursor. Dopa 
is related to macrophage migration inhibitory factor (MIF) both by sequence and by enzyme 
activity. Moreover, MIF acts as a phenylpyruvate tautomerase, and is expressed at sites of 
inflammation, with a suggested role in regulating macrophages in host defence. Whether the 
change in Dopa levels has any toxicological implications related to MIF functions is unclear. 
A putative toxicological explanation for the observed decrease in Hsp60 and Hpd has yet to 
be determined. The decrease in the carbamoyl-phosphate synthase (CPSI) of -40 kDa and 
the concordant increase in the smaller (-25 kDa) protein upon BB treatment propose a 
degrading activity towards this protein and provide an example of the capability to visualise 
protein processing with 2-dimensional gelelectrophoresis. No statistically significant changes 
were observed in the gene expression levels of Dopa and Hpd (clones AA924020 and 
AA900788, respectively, on the cDNA microarray) upon bromobenzene treatment. 
Unfortunately, cDNAs representing Hsp60 and CPSI were not present on the microarray. 
Proteomics data indicated that bromobenzene induced a shift in the protein pattern from high 
molecular mass proteins towards more lower molecular mass species (Figure II.5), which 
could indicate bromobenzene-induced degradation of proteins. All samples were processed 
randomly and the shift was only observed in the treated samples. The mRNA level for the 
lysosomal proteolytic enzyme cathepsin L significantly increased 3.5 fold upon BB injection, 
and many subunits of the proteasome complex were also found to be induced, although 
statistical probabilities were lower (Table II.6). The bromobenzene-specific degradation of 
proteins through induced proteasome and cathepsin L activity might provide an explanation 
for the protein pattern shift observed in the gels. Besides, bromobenzene metabolites are 
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known to covalently interact with protein sulfhydryl groups [80]. This protein adduction may 
target proteins for ubiquitinylation, resulting in activation of an ATP/ubiquitin-dependent 
proteolytic pathway mediated by the proteasome complex. Induced transcription of many 
factors involved in protein synthesis such as ribosomal proteins, translation initiation and 
elongation factors, could be an indication of increased protein synthesis (Table 11.5). 
Together with increased degradation, a higher protein turnover rate is suggested. 
Alternatively, the mechanism of protein synthesis could be affected in bromobenzene toxicity 
resulting in premature termination of protein translation explaining the shift in observed 
protein mass. Further investigations are required to identify the presence of premature 
proteins. 
The fact that only 24 proteins were found to significantly change in all animals upon 
bromobenzene treatment seems to contradict the massive shift in the proteome pattern 
observed in the gel images (figure 11.3). The application of strict quality criteria provides the 
main explanation for the limited identification of significantly changing spots. The low number 
of proteins that were found to significantly change using the proteomics approach, is also in 
contrast to the many genes that were found to be differentially expressed. This is partly 
explained by known non-linearity between mRNA synthesis and protein concentration and 
the temporal difference in responses. Moreover, technical limitations of the 2-dimensional 
gelelectrophoresis in terms of protein abundance, solubility and physico-chemical properties 
apparently prevented the detection of many proteins for which corresponding mRNA level 
changes were observed using transcriptomics. For about half of the proteins that were found 
to significantly change, the identification by mass spectrometry was not successful, either 
because we could not recover protein spots from the preparative gels or because an 
interpretable mass spectrum was not obtained. Indications for post-translational protein 
modifications were obtained from the detection of two forms of 4-hydroxyphenylpyruvic acid 
dioxygenase with similar mass but slightly different pi, and the carbamoyl phosphate 
synthase that was identified twice with differing pi and molecular mass. 
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11.5 Conclusions 
The results presented here acknowledge the possibilities to study toxicology at the 
molecular level using transcriptomics and proteomics technologies. The confirmation 
of previously identified effects as well as the finding of genes and proteins not yet 
know to be involved in BB induced liver toxicity indicates that these technologies 
have the capability to expand insights in toxicology. Secondly, this evaluation 
stresses the difficulties and limitations in combining transcriptomics and proteomics 
results. While functional genomics technologies result in thousands of gene and 
protein measurements, many results can not be established with high confidence. 
Therefore, these methods require the application of strict quality filtering procedures, 
which we believe are of crucial importance for the outcome of the experiments. Due 
to the strict quality criteria, only a few proteins were identified as changing upon 
bromobenzene treatment, frustrating the finding of matching results from 
transcriptomics and proteomics analyses. Especially the proteomics technique using 
two-dimensional gelelectrophoresis and mass spectrometry for protein identification, 
does not easily allow the large scale identification of proteins involved in BB toxicity. 
Hnwpver, new high throughput proteomics technologies (e.g. protein arrays) arc-
being developed at high speed. While transcriptomics methods rapidly provide brow! 
insights in cellular mechanisms, the determination of actual cellular protein rind 
metabolite levels is required for the detailed elucidation of cellular processus in 
toxicity. 
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Abstract 
Rats were exposed to three levels of bromobenzene, sampled at 6, 24 and 48 
hours, and liver gene expression profiles were determined to identify dose 
and time-related changes. Expression of many genes changed transiently, 
and dependent on the dose. Few changes were identified after 6h, but many 
genes were differentially expressed after 24 h, while after 48 h, only the high 
dose elicited large effects. Differentially expressed genes were involved in 
drug metabolism (upregulated GSTs, Ephxl, Nqo1, Mrps, downregulated 
Cyps, sulfotransferases), oxidative stress (induced HO-1, peroxiredoxin, 
ferritin). GSH depletion (induced Gclcl, Gsta, Gstm) the acute phase 
response, and in processes like cholesterol, fatty acid and protein 
metabolism, and intracellular signalling. Transcriptional regulation via the 
electrophile and sterol response elements seemed to mediate part of the 
response to bromobenzene. Recovery of the liver was suggested in response 
to BB by the altered expression of genes involved in protein synthesis and 
cytoskeleton rearrangement. Furthermore, after 48 h, rats in the mid dose 
group showed no toxicity, and gene expression patterns resembled the 
normal situation. For certain genes (e.g. Cyp4a. metallothioneins), intraday 
variation in expression levels was found, regardless of the treatment. 
Selected cDNA microarray measurements were confirmed using the specific 
and sensitive branched DIMA signal amplification assay. 
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111.1 Introduction 
Bromobenzene, an industrial solvent and an additive in motor oils, causes necrosis in the 
liver and kidney. The metabolism and toxicity of BB in (rat) liver have been studied in detail 
[74-78]. To enable excretion in urine, BB is subjected to biotransformation in the liver, and 
metabolites of BB are highly hepatotoxic while secondary metabolites of BB are highly 
nephrotoxic. Figure 111.1 schematically depicts the biotransformation of BB in the liver. Upon 
entrance in the liver, BB is hydrolysed by Cyps, and inhibitors of Cyps were found to 
decrease the hepatotoxicity [101]. Cyp mediated epoxidation yields the highly electrophilic 
BB 3,4-epoxide. The irreversible binding of this very reactive metabolite to proteins like GST, 
L-FABP and carbonic anhydrase, is highly correlated to pathological effects [80]. The 
alternative, more stable, BB 2,3-epoxide was found to covalently bind soluble proteins like 
hemoglobin [102]. Phase II drug metabolising GSTs catalyse the sequestration of the 
reactive epoxides through conjugation to glutathione. The levels of GSH conjugates excreted 
in the bile correlated with the BB-dosage and the hepatotoxic effects [101]. The epoxides are 
also hydrolysed by the microsomal epoxide hydrolase and Cyps. The resulting bromophenols 
can be oxidised to hydroquinones, and conjugated to GSH. At high doses, conjugation to the 
metabolites depletes the hepatic GSH pool, and the intracellular protection against reactive 
oxygen species (ROS) and hazardous xenobiotic metabolites is lost. This may lead to a 
number of secondary events that damage the cell, like lipid peroxidation [97], ATP depletion, 
[98], [99], mitochondrial dysfunction, energy imbalance and altered intracellular calcium 
levels. 
Recently, we reported a study where transcriptomics and proteomics were used to 
investigate BB-induced hepatotoxicity [2]. We explored the application of transcriptomics and 
proteomics in toxicology, and identified proteins that changed specifically 24 h after a single 
injection of BB. An increased abundance of proteins with lower molecular mass was 
observed, possibly indicating specific protein degradation. At the same time, a wide spectrum 
of genes in rat liver was differentially expressed. However, extensive toxicological 
examinations were omitted and only limited conclusions could be drawn on the mechanism 
of hepatotoxicity. 
A new transcriptomics study was designed to investigate the sequence of events in time in 
hepatotoxicity, after oral exposure to BB, and to show the dose dependency of the observed 
effects at the transcriptome level. Measuring the expression of thousands of genes allowed 
more in-depth investigations in the hepatic changes at the molecular level in response to BB 
administration. Moreover, we expected to detect changes in gene expression at lower dose 
levels and earlier time points compared to the routine toxicity examinations. 
Rats were given BB by oral gavage, at three dose levels and liver gene expression profiles 
were determined 6, 24 and 48 h later. Histopathology and clinical chemistry parameters in 
plasma were determined, as well as glutathione contents of the liver. Expression of several 
genes, selected based on the cDNA microarray results, was analysed in more detail using 
the bDNA assay. 
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III.2 Materials and Methods 
Animal treatment and sample preparation 
Bromobenzene, 99%, was obtained from Sigma-Aldrich Chemie, GmbH (Steinheim, Germany). The 
LD50 of BB was reported to be approximately 20 mmol/kg body weight for male CrhCd rats (Haskell 
Laboratory for Toxicology and Industrial Medicine, 1981, unreviewed). Three doses of BB (0.5, 2.0 and 
5.0 mmol/kg body weight, dissolved in corn oil, 40% v/v) were administered by oral gavage to male 
Wistar rats (Charles River Deutschland, Sulzfeld, Germany), 10-12 weeks, body weight approximately 
200 grams. Non-fasted rats were assigned to the groups by randomisation, and nine rats per dose 
group were treated with BB or corn oil, while an additional group contained the untreated controls 
(UT). Animals were kept under controlled conditions according to international guidelines and national 
legislation, regarding proper care and ethical use of animals. After dosage, rats received water and 
food ad libitum, but no food during the 6 or 16 hours before sacrifice. The rats were dosed at 9 a.m. on 
day 1. Three rats from each group were sacrificed after 6, 24 and 48 h, blood was collected in heparin 
tubes and livers were immediately dissected, frozen in liquid nitrogen, and stored at -80CC until further 
processing. A section of the liver was kept aside in formaline for pathological examination. Blood 
plasma was isolated for clinical chemistry. Livers were pulverised by mortar and pestle in liquid 
nitrogen. 
GSH and clinical chemistry parameters 
Glutathione ([GSH + GSSG] and [GSSG]) levels in liver homogenate were determined 
spectrophotometrically according to [81], and from these values, reduced glutathione, ([GSH]), levels 
were calculated. LDH, ALP, AST, ALT, bilirubin, cholesterol, phospholipids, triglycerides, glucose, 
GGT, creatin, albumin, urea and albumin to globulin (A/G) ratio in plasma were determined using a 
Hitachi-911 Bioanalyser, using Boehringer reagents, according to the manufacturer's protocols. One-
way Analysis Of Variance (ANOVA) was used to assess the level of statistical significance of the 
changes. 
RNA extraction 
Total RNA was extracted from liver homogenate using Trizol (Life Technologies S.A., Merelbeke, 
Belgium) according to the manufacturer's protocol, and further purified using the RNEasy kit (Qiagen, 
Westburg B.V., Leusden, Netherlands), including a DNA digestion by RNAse-free DNAsel incubation. 
RNA was checked for purity and integrity by agarose gel electrophoresis and the concentration was 
determined spectrophotometrically. 
cDNA Microarray preparation and labelling 
cDNA microarray preparation was described previously, [2]. Briefly, about 3000 different sequence-
verified rat cDNA fragments were arrayed on glass slides, and control spots were included. A typical 
labelling reaction was performed using 25 micrograms of total RNA, using the Cyscribe (Amersham 
Biosciences, Freiburg, Germany) fluorescence labelling kit. Cy3 or Cy5 fluorophore dUTP nucleotides 
were directly incorporated in the cDNA during the in vitro transcription reaction. RNA was degraded by 
hydrolysis in NaOH (30 min. at 37°C). Labelled cDNA was purified using an Autoseq G-50 (Amersham 
Biosciences, Freiburg, Germany) chromatography column. Hybridisation of labelled cDNA to the slides 
was performed as described before [2]. 
Image capture and analysis 
Slides were scanned using a (Packard Biosciences) ScanArray Express confocal laser scanner, at 
wavelength 550nm (cy3 signal) and 650nm (cy5). TIFF images were analysed using Imagene 
(Biodiscovery Inc., USA.), and settings were applied to automatically flag weak or negative signals and 
spots with a non-homogenous signal. Excel (Microsoft Corporation, USA) and SAS (SAS, Cary, USA) 
were used to further process and analyse the data. 
Transcriptomics experimental design 
In order to compare all samples of individual rats to each other, and to other studies, an external 
reference sample was used. Thus, for each gene fragment, the amount of mRNA in the sample 
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relative to the amount in the reference was determined. The complete set of hybridisations was 
duplicated with swapping of the fluorophore incorporation in the sample and reference RNA. The value 
of this reference RNA has been described before [2]. A good correlation was found between the 
changes in gene expression determined in direct hybridisations and in indirect hybridisations using the 
reference. 
DAM Microarray data preprocessing 
After image analysis, the local background intensity was subtracted from the signal for each spot. 
Background intensities outside the cDNA spots were very low and homogeneous. Control spots and 
background fluorescence were used to determine a minimal signal to noise ratio threshold value of 1.5 
for the two channels. Flagged spots and controls were excluded from further interpretation, as well as 
genes for which less than 75% of the microarrays yielded an acceptable signal. To account for 
technical variations introduced during labelling or hybridisation, data were normalised assuming that 
the majority of the transcripts was equally present in both samples. Since a relationship was found 
between the intensity of the signals and the variation in the ratio of gene, the lowess normalisation 
algorithm, according to [103], was applied in SAS software. This procedure fits the expression ratios to 
an intensity-dependent curve by locally weighted regression. After normalisation and logarithm 
transformation of the ratios tester/reference, a set of about 2700 rat cDNAs was used for further 
analysis. Excluded values were replaced by 0, and averages were calculated of the logarithms of fold 
changes between treatment groups. 
DNA Microarray data analysis 
Pair-wise comparisons of the expression ratios were made between samples of the different time and 
dose groups and controls. In these comparisons, untreated and corn oil control samples were 
considered as one control group, since preliminary analyses revealed only minor changes induced by 
single oral corn oil dosage. Statistics (two-sided, unpaired t-tests) was applied assuming unequal 
variance and changes were considered significant if the tests resulted in a p-value less than 0.01. In 
the tables, p-values were denoted as follows: *** : p < 0.001; ** : p < 0.01. The genes significantly 
differentially expressed upon treatment were explored in the context of biological mechanisms and 
pathways. Genes were categorised based on biological processes using literature and gene 
information databases. 
Gene expression measurement by branched DNA signal amplification assay 
mRNA levels of Ephxl, HO-1, Nqo1, Mt-1, Gclc, Cyp2b1/2, Cyp4a2/3, Mrp1, Mrp2 and Mrp3 and 
Gapdh were analysed for all samples individually by the bDNA assay using probes specific to each 
transcript (Quantigene HV10 kits, Genospectra, www.genospectra.com) as described in [104]; [105], 
Oligonucleotide probe sets that detect Nqo1, Cyp2b1/2, Cyp4a2/3, Mt-1, Mrp1, Mrp2, and Mrp3 were 
previously described [106]; [104] ; [107] Oligonucleotide probe sets for Ephxl, HO-1 and Gclc are 
described in Table III. 5 (supplementary material) 
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111.3 Results 
Changes in the liver transcriptome were related to classical toxicological parameters, which 
showed toxicity only after the highest of three dose levels of BB. Dose-dependent effects of 
BB at the transcriptome level were analysed per time point. Additionally, we report intraday 
variation in gene expression regardless of the treatment. The bDNA assay was used to 
further investigate changes highlighted by the DNA microarrays. 
(Histo)pathology 
No significant changes in body weights or macroscopic changes were seen. Neither the 
livers of the controls nor of the low or mid dose groups displayed pathological aberrations. 
The livers isolated 24 h after a high dose of BB revealed a patchy appearance and gross 
lesions, while the livers of rats sacrificed 48 h after a high dose had focal discoloration. Six h 
after dosing of mid and high levels of BB, relative liver weights were around 10% lower than 
the controls (ANOVA + Dunnett's test, p < 0.05 for high and p < 0.01 for mid). At 24 or 48 h, 
controls as well as low dosed rats had relative liver weights of 75-85% of the rats sacrificed 
after 6 h. In all the high BB treated rats, a significant increase to around 130% of vehicle 
controls (p < 0.01) was observed. Microscopic examination of the livers showed slight 
presence of mononuclear cell aggregates and/or necrotic hepatocytes in several rats 
regardless of the treatment. After 24 and 48 h, pronounced centrilobular necrosis was found 
in all rats of the high dose groups, with interindividual variation from very slight to very severe 
necrosis. 
Clinical chemistry 
Clinical chemistry parameters in plasma are represented in Figure III.2. Bilirubin levels (panel 
A) in the mid dose group were increased after 24 h, but not after 48 h. In the high dose 
group, bilirubin levels were slightly up at 6 h, and highly elevated after 24 h and 48 h. Only 
upon high dose, the rats showed highly elevated ALAT and ASAT levels after 24 h and 48 h 
(panels B and C). Plasma lactate dehydrogenase (LDH, not shown) activity was increased 
100 fold 24 h after the high dose, but showed normal levels at 48 h. Alkaline phosphatase 
(ALP, panel D) activity in plasma gradually increased with dose at 24 h (not significant), and 
was elevated 48 h after the high dose. Plasma glucose (panel E) decreased equally by mid 
and high dose after 24 and 48 h. Cholesterol (n.s.) and phospholipids levels (panel F) in the 
high dose group were increased at 6 h and remained elevated. The creatin content 
decreased upon the high dose after 6 h (n.s.). Regardless of the treatment, urea levels were 
higher and triglyceride levels lower at 24 and 48 h compared to 6 h. No significant changes 
were observed in plasma levels of gamma-glutamyl transpeptidase, total protein, albumin, 
and the albumin to globulin ratio (A/G). 
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Figure III.2. Clinical chemistry parameters in blood plasma 
Measurements of clinical chemistry parameters in plasma. Levels are depicted of bilirubin 
(panel A), ASAT (panel B) and ALAT (panel C), alkaline phosphatase (ALP, panel D), 
glucose (panel E), phospholipids (F). Average levels of the treatment groups ± SD are 
represented. Statistical significance is denoted with ** p-value < 0.01; *** p-value < 0.001. 
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Figure III.3. Hepatic intracellular glutathione levels 
Intracellular reduced glutathione, [GSH], levels were determined in rat liver homogenate 6, 
24 and 48 hours after a single dosage of bromobenzene at low, mid or high dose. Average 
levels of the treatment groups ± SD are represented. Statistical significance is denoted with * 
for a p-value < 0.005 
52 
Bromobenzene transcriptomics 
Glutathione depletion 
Hepatic reduced GSH levels, after correction for oxidised disulfide of glutathione (GSSG), 
are shown in Figure III.3. An intraday variation in the concentration of GSH was observed in 
control rats. More GSH was present at 6 h compared to the 24 h or 48 h time point, The low 
dose of BB caused a slight decrease of GSH levels after 6 h, whereas both the mid and high 
BB doses depleted GSH to -25% of control levels. After 24 h, GSH levels in the mid dose 
group increased significantly to -125% of controls, and remained elevated 48 h after dosage. 
Gene expression 
Pair-wise comparisons of the gene expression levels were made between treated and control 
groups. After 6 h, only few changes could be identified, whereas many genes changed in 
expression 24 and 48 h after dosage. Overlap of the genes differentially expressed upon BB 
treatment at all time points was observed, although many genes were altered with statistical 
significance only at one time point. The individual gene expression profiles of all the BB-
treated rats sacrificed after 24 h were recorded in duplicate. Many genes were regulated 
after a high (176 genes) or mid dose of BB (41 genes), whereas a low dose induced changes 
that were significant in only 6 genes ( p < 0.01). The majority of the genes significantly 
regulated 24 h after the mid dose were also regulated after the high dose, whereas most of 
the genes that were changed upon the low dose were altered uniquely in this group. 
6 hours 
Table 111.1 lists the genes that were significantly differentially expressed after 6 h in the BB 
dosed rats. A marked ( 2 - 8 fold ) increase in gene expression was observed for several 
metallothioneins (Mt). Both the flavin-containing mono-oxygenases Fmo1 and Fmo3 were 
upregulated by the high dose, as well as cathepsin L and ASAT. The enzymes cysteine 
dioxygenase 1 and betaine homocysteine methyltransferase were upregulated. A twofold 
upregulation was found for mRNA encoding Rho-interacting protein 3. Genes downregulated 
by the high dose include LDH B, tubulin, and cholesterol metabolism enzymes farnesyl 
diphosphate synthase and farnesyl diphosphate farnesyl transferase 1, 'sterol-C4-methyl 
oxidase-like', HMG-CoA synthase 1. Several genes, HO-1, Timpl, Afar and serine protease 
15, changed significantly with the mid or the low dose after 6 h but not with the high dose. 
Three genes were down regulated by both the mid and high dose, namely the 'EST similar to 
GSTP', Hsp70 and calpain. 
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Table 111.1 Genes differentially expressed by bromobenzene after 6 hours 
Category 
Ox. stress 
Ox. stress 
Ox.stress 
Ox.stress 
Ox.stress 
Ox.stress 
Gene name 
Heme oxygenase (Ho-1) 
tissue inhibitor of metalloproteinase 1 
Metallothionein (Mt) 
Metallothionein (Mt) 
High sim to Metallothionein-ll 
Weak sim to Metallothionein-I 
AcutePhase? nuclear protein 1 
Aminoacid 
Cholest. 
Cholest. 
Cholest. 
Cholest? 
Cysteine 
Cysteine 
Biotransf 
Biotransf 
Biotransf 
Biotransf 
Biotransf 
Biotransf; 
Biotransf; 
Biotransf 
Heat shock 
Immuno 
Immuno 
LDH 
Proteolysis 
Proteolysis 
Proteolysis 
Proteolysis 
Proteolysis 
Proteolysis? 
Ribosome 
Ribosome 
Ribosome 
Structure 
Structure 
Structure 
Structure 
Transcr. 
factor 
Transport 
signal transc 
Other 
Other 
Aspartate aminotransferase (Asat) 
farnesyl diphosphate farnesyl 
transferase 1 
3-HMG-CoA synthase 1 
farensyl diphosphate synthase 
sterol-C4-methyl oxidase-like 
cytosolic cysteine dioxygenase 1 
betaine-homocysteine 
methyltransferase (Bhmt) 
flavin-containing monooxygenase 3 
Flavin-containing monooxygenase 1 
cytochrome P450 4A3 (Cyp4A3) 
cytochrome P450, 2b19 (Cyp2B19) 
sulfotransferase family, 2A1 
Glutathione S-transferase 1 (Gsttl) 
Weak sim to GST P (Gst 7-7) 
aflatoxin B1 aldehyde reductase (Afar 
heat shock 70kD protein 5 (Hsp70) 
ig delta heavy chain constant region 
MHC class I 
lactate dehydrogenase B (Ldh) 
cathepsin L 
protease, serine, 15 
sim to ubiquitin conjugating enzyme 
High sim to leucine aminopeptidase 
calpain 1 
ubiquitin D 
ribosomal protein L22 
ribosomal protein L28 
ribosomal protein L35 
Rho interacting protein 3 
Unconventional myosin from rat 3 
actinin alpha 4 
beta-tubulin T betal 5 
Transforming growth factor beta 
stimulated clone 22 
vitamin D-binding protein 
. 14-3-3- protein Ywhaq 
S6 kinase 
sim to Suc-CoA:3-ketoacid-coA transf 
Acc# 
AA874884 
AA957593 
AA859399 
AA900218 
AA924281 
AA819204 
AI070183 
AA900928 
AA818927 
AA924800 
AA859192 
AA859607 
AA818579 
AA901407 
AA964011 
AA860001 
AA924591 
AA818412 
AA819605 
AI044236 
AA819810 
AA923966 
AI453996 
AA964201 
AA818887 
AA819821 
NA 
AI070052 
AA818770 
AA858780 
AA901002 
AI030354 
AA924274 
NA 
AA925200 
AA924848 
AA818082 
AI712704 
AA899219 
AH 37902 
AA818706 
AA858957 
AA900032 
AA819087 
low 
0.76 
1.14 
0.98 
0.71 
0.91 
0.43 
0.22 
-0.28 
-0.34 
-0.26 
-0.30 
-0.21 ** 
-0.30 
0.08 
-0.03 
-0.03 
0.33 
-0.63 ** 
-0.87 ** 
-0.13 
-0.40 
1.09 
-0.27 
0.09 
-0.28 
-0.32 
-0.18 
0.53 ** 
0.28 ** 
-0.35 
0.06 
-0.32 
-0.16 
0.30 
-0.05 
-0.13 
-0.77 ** 
-0.21 
-0.31 
0.10 
0.24 
-0.02 
0.10 
-0.46 
mid 
2.32 ** 
1.92 ** 
3.52 
3.06 
1.88 
1.04 
-0.42 
-0.32 
-0.40 
-0.21 
-0.79 
-0.08 
0.13 
-0.07 
-0.18 
0.14 
0.38 ** 
-0.21 
-0.43 
-0.26 ** 
-0.64 ** 
1.23 " 
-0.86 ** 
0.15 
-0.22 
-0.27 
-0.08 
0.39 
0.10 
-0.41 
-0.56 ** 
-0.34 
-0.18 
0.44 ** 
0.38 
0.09 
-0.27 
-0.21 ** 
-0.20 
** 
-0.64 
0.35 " 
-0.33 
-0.12 
-0.23 
high 
0.57 
0.51 
3.01 
2.42 
2.15 
1.19 
-0.58 
0.82 
-0.71 
-0.83 
-0.87 
-0.31 
0.67 
0.61 
0.87 
0.46 
0.19 
0.08 
-0.33 
-0.03 
-0.56 
0.07 
-0.70 
0.26 
-0.53 
-0.59 
0.59 
0.24 
-0.01 
-0.48 
-0.34 
-0.44 
0.64 
0.13 
-0.30 
1.01 
0.10 
-0.11 
-0.56 
-0.30 
-0.03 
-0.34 
0.36 
-0.72 
*** 
*** 
*** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
** 
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24 hours 
Table III.2, in supplementary material, lists the subset of genes that changed significantly 24 
h after BB, in the high dosed rats. Genes were categorised according to biological 
processes. Amongst many others, Gsta and Gstm, Ephxl, Afar, ferritins, peroxiredoxin, 
transketolasel, Gapdh, Nqo1, proteasome subunit alpha"), and ALP were markedly elevated 
upon mid and high dose. The genes encoding 'EST similar to human phosphodiesterase 
(cAMP specific)' and the alpha(1)-inhibitor 3 were markedly down regulated by all doses of 
BB, while the glucocorticoid receptor was mildly but significantly downregulated by all doses 
(not shown). Decreased upon mid and high dose were the genes encoding cysteine 
dioxygenase, asialoglycoprotein receptor 2, 14-3-3 protein (Ywhaz), 'EST similar to GSTP', 
sulfotransferase 2 and the transcription factor 'core promoter element binding 
protein'(C/EBP). 
48 hours 
The differential expression of genes 48 h after the high concentration of BB was similar to the 
expression pattern after 24 h (Table III. 3) Many of these 175 genes were also differentially 
expressed after 24 h, although frequently the difference was less marked and not statistically 
significant. Only two genes, interferon-inducible transmembrane protein and steroid sulfatase 
were found to be subtly but significantly differentially expressed at the low BB dose. The mid 
dose slightly induced three genes, also induced by the high dose. 
Intraday variation 
The control rats were used to analyse the intraday variation in liver gene expression as well 
as in other parameters. Intraday differences were observed in GSH content and relative liver 
weights as well as in levels of parameters in plasma. Triglyceride levels were lower at 24 h 
(and 48 h) than at 6 h. This was also the case for ALP, phospholipids, cholesterol and urea 
Also at the gene expression level, the 6 h time point was found to be clearly distinct from the 
24 and 48 h time points. Profiles obtained from untreated rats were very similar to those 
obtained from corn oil treated rats. No genes were recognised with a marked change in 
expression between 24 and 48 h in the controls. Table III. 4 shows genes which' expression 
changed significantly from 6 h to 24 h in controls. The most distinctly higher expressed genes 
were metallothioneins. Moreover, various Cyp isozymes (Cyp4A1 and Cyp4A2/3), 
arginosuccinate lyase, cathepsin L and various genes involved in fatty acid metabolism were 
higher expressed at 24 h than at the 6 h time point. Genes which' expression was lower after 
24 h compared to 6 h included several GSTs, transferrin, tubulin, lysyl hydroxylase and GSH 
peroxidase. 
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Table III. 4. Gene expression changes comparing 6 and 24 h time points 
The subset of genes that were significantly ( p < 0.01) differentially expressed between the 6 h 
and 24 h time point in control rats. Genes were categorised according to biological mechanism 
or pathways. The log (base 2) average fold change and the p-value for the three dose levels 
are listed. A treshold was chosen for display reasons which was a log (base2) fold change > 
0.5 or < -0.5 in any of the dose groups compared to the controls. Statistical level of 
significance: **: p < 0.01, ***: p < 0.001. ACC#: Genbank Accession number, metab: 
metabolism 
Category 
Acute Phase 
Acute phase 
Acute phase 
Aminoacid 
Cholesterol 
Drug metab 
Drug metab 
Drug metab; 
Drug metab; 
Drug metab; 
Drug metab; 
Drug metab; 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Proteolysis 
Proteolysis 
Structure 
Other 
Other 
Other 
Other 
; Ox.stress 
Ox. stress 
Ox.stress 
GSH 
GSH 
GSH 
GSH 
GSH 
Gene name 
Metallothionein (Mt) 
Metallothionein (Mt) 
Transferrin 
argininosuccinate lyase 
farnesyl diphosphate synthase 
cytochrome P450, 4a10 (Cyp4a10) 
cytochrome P450 4A3 (Cyp4a3) 
GST, soluble.class Mu ?; Gst Y(b) 
Weak sim to GST P (Gst 7-7) (pi) 
Weak sim to GST P (Gst 7-7) (pi) 
glutathione S-transferase, alpha 1 Gsta 
Glutathione peroxidase 1 (Gpx1) 
dodecenoyl-coenzyme A delta isomerase 
Dei 
delta3, delta2-enoyl-CoA isomerase Dei 
2,4-dienoyl CoA reductase 1, mit. 
cytosolic acyl-CoA thioesterase 1 
cathepsin L 
Cathepsin L 
beta-tubulin T beta15 
enoyl coenzyme A hydratase 1 
isocitrate dehydrogenase 1 
cytochrome c oxidase subunit Vb 
lysine hydroxylase 
ACC# 
AA859399 
AA900218 
AA858975 
AA818673 
AA859192 
AA956787 
AA924591 
AA998734 
AA819810 
AA819810 
AA818339 
AA964788 
AA965078 
AA997009 
AA875267 
AA925003 
NA 
AA859498 
AA899219 
AA926032 
AA925731 
AA955550 
AI045272 
24h - 6h 
3.24 
2.65 
-0.69 
1.05 
-1.06 
1.50 
1.32 
-0.73 
-1.08 
-1.14 
-1.21 
-1.32 
1.69 
1.30 
0.64 
0.50 
0.90 
0.77 
-0.65 
1.05 
-0.51 
-0.64 
-1.32 
*** 
** 
** 
** 
** 
** 
*** 
** 
** 
*** 
** 
** 
** 
*** 
** 
** 
*** 
** 
*** 
** 
** 
** 
** 
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Confirmation of gene expression changes 
cDNA microarrays results for selected genes were analysed for all rat samples using the 
bDNA assay (Figure 111.4). This method was shown to very specifically determine mRNA 
levels in a wide concentration range. The gene expression levels for Ephxl, Gapdh, HO-1, 
Mt-1, Nqo1 and Cyps in the bDNA assay largely overlapped with the cDNA microarray 
results. For example, between both methods, a coefficient of correlation of 0.94, 0.89 and 
0.86 was found for the individual rats' levels of Ephxl, HO-1 and Mt-1, respectively. Also, 
genes were analysed that were not (conclusively) measured in the microarrays. We 
hypothesised these genes (Mrp1, Mrp2 or Mrp3, Gclc) could be modulated based on other 
changes observed using the microarrays, for instance indicating EpRE-mediated 
transcriptional regulation. Gapdh, which is frequently regarded as a so-called housekeeping 
gene with stable expression levels, was measured using both the microarrays and the bDNA 
assay. By both methods, Gapdh was found to be upregulated more than two-fold at high 
dose levels after 24 h. 
Ephxl Ho-1 Mt-1 
24h 48h 
Nqo1 
6h 
• * » . 
24h 
Gclc 
48h 
_ ***H 
3500 
2500 
2000 
1500 
1000 
0 
24h 48h 
Gapdh 
6h 24h 48h 6h 
|~~| Untreated Q Vehicle control 
24h 48h 
1 Low BB 1 Mid BB • HighBB 
Figure 111.4. Hepatic gene expression levels as measured by the Branched DNA 
signal amplification assay. 
Average levels of the treatment groups ± SD are represented. White bars represent samples 
taken 6 h after dosage, grey bars 24 h and black bars represent samples taken 48 h after 
dosage. UT: untreated; CO: corn oil controls; L, M and H denote the low, mid and high dose 
of bromobenzene. Statistical significance : ** :p-value < 0.01; ***: p-value < 0.001. 
57 
Chapter III 
111.4 Discussion 
The dose and time related effects of acute hepatotoxicity induced by BB were analysed at 
the gene expression level. Hepatic centrilobular necrosis was found after 24 h in rats at the 
high dose, but not at lower doses. Also clinical chemistry parameters detected hepatocellular 
damage only after 24 h in the high dose group. Significant changes in expression of genes 
upon the high, mid and even the low dose were identified, especially after 24 h. The large 
part of the genes identified to change significantly upon the high dose also responded to the 
mid dose, although frequently not as pronounced or not with the same statistical significance. 
Thus, a dose-relationship can be observed in transcriptomics experiments, both in the 
number of genes that change and the magnitude of the changes. In time, the mid dose 
elicited most effects after 24 h, while after 48 h, hardly any change persisted. In contrast, in 
the high dose group, those effects identified after 24 h persisted after 48 h. 
Paradoxically, several genes including Ephxl, Afar, HO-1, Timpl were markedly upregulated 
by the low and mid dose at 6 h, but not by the high dose. At later stages, these genes were 
highly upregulated by BB in a dose-dependent manner. The effects measured by cDNA 
microarrays were confirmed using the bDNA assay. The initial lack of response with the high 
dose contradicts the dose-dependency usually assumed in toxicology. No explanation was 
found for this phenomenon, and no such observations were found in literature. 
Pathways and mechanisms 
Genes with statistically significant differential expression upon BB administration were 
categorised according to biological processes in the cell, putatively relevant in BB-induced 
hepatotoxicity. The most relevant changes in BB-induced hepatotoxicity were schematically 
displayed in Figure III.5. 
Drug metabolism 
The strong induction of transcripts encoding Gsta and Gstm stresses the importance of GSH 
conjugation in the biotransformation of BB. The upregulation of Ephxl mRNA levels by BB is 
coherent with its role; the hydrolysis of epoxide BB intermediates, enabling their excretion. 
The epoxides are amongst the most reactive BB-metabolites and their hydrolysis is crucial in 
the hepatic detoxification. The Ephxl is also induced by xenobiotics like phenobarbital, trans-
stilbene oxide and Aroclor 1254 [85]. BDNA assays revealed about two-fold increased 
expression levels as early as 6 h after the low dose. Mid or high doses elevated Ephxl 
expression after 24 h, while after 48 h, Ephxl was pronouncedly upregulated only in the high 
dose rats. Similar to Ephxl, induction of Nqo1 was identified using the bDNA assays. Nqo1 
is an enzyme with a role in protection of cells from oxidative stress, cytotoxicity, and 
mutagenicity of quinones, which are also formed in the biotransformation of BB. The induced 
Afar, and aldo-ketoreductases exert putative roles in metabolism of xenobiotics and products 
from lipid peroxidation like 4-hydroxy-2-nonenal. The early induction of Fmos has possible 
implications in the biotransformation of BB as well. Fmos have a broad substrate specificity 
and their functions partly overlap with Cyps. Induction of Fmo1 was found in rat liver by the 
polycyclic aromatic hydrocarbon, 3-methylcholanthrene [108]. Different Cyp (2B1/2, 2E1, 
2A2C39, 4A2/3, 4A10, 2C12, 2C23) and sulfotransferases were down regulated and 
remained lower after 24 h. The bDNA assay confirmed specific changes in expression levels 
of the Cyp2B 1/2 and Cyp4A 2/3 isoforms. At 6 h, BB slightly increased Cyp2B and Cyp4A 
expression, while after 24 and 48 h, expression was reduced upon high BB treatment. 
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Moreover, intraday variation in expression was observed in the controls. The decreased 
gene expression of Cyps could diminish the bioactivation of BB to harmful metabolites. 
Expression of the multidrug resistance proteins Mrp1, Mrp2 and Mrp3 was measured with the 
bDNA assay. The change in expression of Mrp1, Mrp2 or Mrp3 was not measured in the 
microarrays, but Mrp3 induction was hypothesised from the suggested EpRE-mediated 
induction of several genes. A pronounced induction of Mrp3 gene expression was observed 
24 h after high BB treatment, whereas the Mrp2 expression did not change. Mrp1 expression 
levels were very low in the liver, but an induction was observed by high BB after 24 h. 
Substrates for Mrp-facilitated export across the membranes include glucuronide, sulfate and 
GSH conjuates. The induction of Mrps by BB could enhance the biliary excretion of 
conjugated BB metabolites, as found for acetaminophen metabolites [105] ; [109]. The 
concurrent increased hydrolysis of the epoxides, GSH conjugation and clearance of the 
harmful BB metabolites may provide the liver with an effective mechanism of detoxification. 
GSH metabolism 
GSH is believed to be of crucial importance in the detoxification of xenobiotics like BB. A 
dose-dependent lowering of the liver GSH levels was observed 6 h after BB administration. 
Compared to our previous study with intraperitoneal injection of BB [2], total GSH depletion 
was not observed in this study, 24 h after an oral administration. On the contrary, after 24 h 
GSH concentration was higher upon BB administration than in the controls. The increased 
level of GSH after the initial depletion has been suggested as a recovery mechanism [110]. 
Also, a significant upregulation of Gsta and Gstm was found after 24 h even by the low dose. 
The rate-limiting enzyme in GSH synthesis is Gclc, transcriptionally regulated by EpRE. 
Using the bDNA assay, we detected a pronounced upregulation of Gclc as early as 6 h after 
the low dose (Figure III.6). Recently, we also found GSH synthase protein to be induced by 
BB [2]. The upregulation of the enzymes in GSH metabolism can be explained as an 
adaptive response to restore the depleted GSH levels in liver. 
Oxidative stress 
Highly reactive metabolites such as formed from BB can induce oxidative stress. Additionally, 
the depletion of GSH diminishes the intracellular protective mechanism against ROS and 
electrophilic metabolites The early induction of key markers, the mRNA levels of HO-1 and 
Timpl suggests the induction of oxidative stress by BB After 24 h, HO-1 mRNA levels were 
elevated only in the high dose group, while returned to normal in the mid dose group. HO-1 
catalyses the degradation of heme to C02 and biliverdin, which is subsequently catabolised 
to bilirubin. Bilirubin may serve as an intracellular antioxidant. In line with this, we observed 
bilirubin levels in plasma to be slightly increased in the high dose group at 6 h, while largely 
increased after 24 h. Also peroxiredoxin 1 and the ferritin light and heavy subunit transcripts 
were elevated significantly by BB. Ferritins sequester free iron molecules thus preventing 
formation of ROS, hydroxyl radicals, through the Fenton reaction. Peroxiredoxins are 
antioxidant enzymes with a role in signal transduction. Metallothionein transcripts were highly 
induced at 6 h after all doses of BB. At 24 and 48 h an elevation of the Mt mRNA levels was 
observed independent of the treatment. Metallothioneins are cysteine-rich proteins that 
function in the sequestration of the metals Cu2+, Cd2+, Zn2+' while also ROS can be 
scavenged. The BB-induced rapid increase of Mt mRNA corresponds with reported 40% 
increased protein concentrations in the liver and kidneys 6 h after BB. [111] and [112]. The 
protein Vdupl was induced and has been reported to interact with thioredoxin and to be 
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associated with oxidative stress. [113]. GSH peroxidase, selenoprotein P and synaptojanin 2, 
genes possibly related to oxidative stress, were down regulated. Gapdh was induced more 
than two-fold 24 after the high dose of BB. Gapdh has been reported to be regulated by 
hypoxia and induced by insulin and glutamine. Responsive elements for hypoxia-inducible 
factor, and C/EBP have been identified in the Gapdh gene promotor [114,115]; [116] The 
induction of Gapdh might be in concordance with its function in glycolysis, upregulated to 
meet the energy requirements of the regenerating liver. 
Acute phase response 
The acute phase response is elicited by various types of stress like mechanical damage and 
inflammation [92]; [93]. Especially in the liver, changes in many genes and proteins provide a 
protective response and re-establish cellular homeostasis. We previously identified that the 
acute phase response was elicited upon an intraperitoneal administration of BB [2]. Present 
experiments showed that also upon oral gavage, BB was able to elicit changes in transcript 
levels of many acute phase proteins in liver. Orosomucoid 1 (former AGP), cytokeratin-18, 
apolipoprotein A1 were induced. Negative acute phase transcripts including alpha-1-inhibitor 
3 and pre-alpha-inhibitor heavy chain 3, serine protease inhibitor, complement component 1 
and 4, L-FABP 1 and fibrinogen B were down regulated by BB. 
Fatty acid & cholesterol metabolism 
Plasma levels of cholesterol increased upon high dose after 6 h and remained elevated at 24 
and 48 h. Several enzymes involved in cholesterol metabolism were significantly and dose-
dependently down regulated after 6 h by BB. Cholesterol is biosynthesised from acetyl-CoA, 
the product of fatty acid degradation, and enzymes in both pathways are down regulated by 
BB, including HMG-CoA synthase, Acetyl-CoA acetyltransferase 1, hydroxylacyl-CoA 
dehydrogenase, acyl-coA oxidase, trifunctional protein. Many of the genes coordinately 
downregulated are transcriptionally induced through binding of the sterol responsive element 
binding protein (SREBP) to a sterol-responsive element in the upstream DNA sequence of 
those genes. [117], [118]. Cholesterol levels play a role in the regulation of the SREBP 
pathway. The downregulation of the fatty acid and cholesterol metabolism could be due to 
the requirement of energy for these processes. In this situation of distress, the cell might 
have to dedicate all energy supplies to cope with the toxicity induced by BB, and restore 
homeostasis. Energy-requiring processes should be down regulated, while energy-
generating processes are upregulated. In line with this, the decrease of plasma glucose 
levels could be ascribed to increased catabolism of glucose in the glycolysis. 
Protein synthesis & proteolysis 
Genes involved in protein synthesis, including many ribosomal subunits, eukaryotic initiation 
factors and elongation factor, were over-expressed one day after dosage. Furthermore, an 
induction was observed for several components of the proteasome and the proteolytic 
enzyme cathepsin L. Dose and time related changes in gene expression were observed for 
serine protease, dipeptidyl peptidase, polyubiquitin and calpain. The histopathologically 
observed slight nucleolar enlargement and the mitotic increase in the BB-treated livers 
correspond with the induction of proteins required for transcription and translation. 
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Structure & cytoskeleton 
Genes encoding cell-structure proteins increased upon the high dose of BB. Stongly 
upregulated were actin and 'weakly similar to pervin', a protein with high homology to a 
human cytoskeleton-interacting protein. Also actinin, cortactin, 'EST highly similar to actin', 
keratin, dynein, tubulins and others were differentially expressed. Thymosin beta-4 is an 
actin binding protein and is upregulated 48 h after a high dose of BB. Rho-interacting protein 
is involved in cytoskeleton rearrangement, and increases after 6 h. Oxidative modifications of 
the microfilaments are suggested to cause cytotoxicity in the form of blebs on plasma 
membranes, when polymerised actin is disrupted by oxidation of its sulfhydryl groups. Upon 
rupture of the blebs, cellular ion gradients and intracellular components are lost, leading to 
necrotic cell death. The change of cellular calcium (Ca2+) levels may play a role in the 
cytotoxicity. Increasing Ca2+ levels promote dissociation of actin from a-actinin, and 
activation of the calpain protease, which cleaves actin-binding proteins. When the anchoring 
of the cytoskeleton to the plasma membrane is disturbed, membrane blebbing may occur 
[119]; [120]. BB caused down regulation of calpain gene expression after 6 h. The induction 
of both the protein synthesis and the cell-structure genes suggests that enhanced protein 
synthesis and/or proliferation occur, which aids in hepatic tissue remodelling and recovery 
after BB-induced hepatocellular injury. Corroborating evidence is found in the 
histopathological observation of a mitotic increase and nucleolar enlargement in the 
hepatocytes upon high BB dosage. 
Recovery 
The gene expression profiles obtained from livers isolated 48 h after a mid BB dose 
resembled the profiles of the controls and the low dose livers. We suggest that the mid dose 
still effectuates a marked response, especially detectable 24 h after oral ingestion of BB, but 
is not high enough to induce irreversible damage detectable by histopathology or clinical 
chemistry. This suggests that the rats in the mid dose group did not suffer, or recovered from 
the toxic stimulus. From the time-series, it was clear that most pronounced changes in gene 
expression were observed 24 h after BB administration. Previously, [121] suggested that 
irreversible changes occurred after 24 h, when the limited centrilobular lesions progressed to 
a more widespread pattern, and DMSO could no longer attenuate the BB-induced necrosis. 
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Figure III.5. Schematic representation of the most prominent changes in bromobenzene-
induced hepatotoxicity. 
The biotransformation of BB in rat liver, and biological processes relevant to the hepatic response 
to BB are shown. Blue rectangular boxes represent the metabolites formed from BB in 
biotransformation. Filled circular boxes represent genes, grey rectangular boxes represent 
metabolites or small molecules. A red arrow is pointing up when the gene is upregulated by BB 
and a green arrow is pointing down when a gene is downregulated by BB. Circular boxes with 
dashed lines are shown for the genes known to be transcriptionally regulated by an electrophile 
response element (EpRE). Oxidative stress induced by the reactive metabolites of BB plays a 
central role in the response at the gene expression level. 
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Coordinate expression mediated by the electrophile response element 
The coordinate induction of HO-1, ferritins as well as Gsta, and Nqo1 by BB is consistent 
with the reported presence of an electrophile response element (EpRE), formerly named 
antioxidant response element (ARE), in those genes [122]; [86]; [87]. Rat Gsta, Nqo1 and 
ferritin were known to be transcriptionally regulated by binding of Nrf2 to this EpRE. More 
Nrf2-regulated genes were identified in mice upon induction by the isothiocyanate 
sulforaphane [123]. These included Afar, glucose-6-phosphate dehydrogenase, 
carboxylesterase, transketolase, and aldehyde dehydrogenase. In our studies in rats, BB 
induced HO-1, ferritins, Gsta, Gstm, and Nqo1, concurrently with Timpl, Afar, Gstm, 
peroxiredoxinl, aldo-keto reductase, transketolase, and also Mrp3. The rat Mrp3 was 
recently found to be induced by CAR and EpRE activators in liver. [104] The presence of the 
EpRE in rat Afar, as suggested by our data, was confirmed recently [124]. 
Intraday variation in gene expression 
Control rats sacrificed 6 h after the start of the study had higher relative liver weights and 
also the levels of GSH differed. Urea, triglycerides and phospholipids levels in plasma varied 
on an intraday basis. These changes were accompanied by altered liver gene expression. 
Intraday variation of GSH levels (and of other plasma parameters) might not be a negligible 
effect on the outcome of pharmacology and toxicity studies. Our results show that also 
expression levels of certain genes change considerably during the day. 
Inter-study comparison and route of administration 
Previously, we reported rat liver genes and proteins with altered expression upon 
intraperitoneal administration of BB [2]. The majority of the genes that changed in the 
previous study with i.p administration of BB again was identified to change in the present 
study with oral administration of BB. The overlap between the two, independent, studies 
demonstrates the robustness of the methods and confirms that our data analysis approach 
did not allow the introduction of many false positives, frequently raised as a point of concern 
for cDNA microarray experiments. We conclude that with both routes of administration, i.p. 
and oral, the same hepatic response was induced at the transcriptome level. The i.p. 
injection of corn oil induced some subtle effects, while changes induced by the oral 
administration of corn oil were not readily detected. 
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Concluding remarks 
In summary, gene expression measurements in liver, 6, 24 and 48 h after dosage of 
several doses of BB yielded a more comprehensive insight into different cellular 
pathways that are activated when rats are given BB, leading to hepatotoxicity. 
Results expanded the findings of our earlier experiments [2]. Many changes were in 
line with the observations from routine toxicological assessments, while also new 
hypotheses on mechanisms of BB-induced hepatotoxicity were postulated. Recovery 
of the liver was suggested in response to BB with the altered expression of genes 
involved in protein synthesis and cytoskeleton rearrangement. After 48 h, the rats in 
the mid dose group showed no signs of toxicity, concurrent with a gene expression 
patterns that largely resembled the controls. We identified genes responding to dose 
levels below 5.0 mmol/kg BW, with some genes responding to oral administration of 
as low as 0.5 mmol/kg. Thus, we were able to detect significant effects at 2 to 10-fold 
lower doses with transcriptomics compared to clinical chemistry or histopathology. 
Genes that could serve as early biomarkers of hepatotoxicity at lower BB exposure 
were revealed, such as Ho-1, Ephxl, Afar, Mt1. A sample of results from the cDNA 
microarrays were confirmed by the bDNA assay. Future research will have to 
establish further whether the changes in gene expression are adverse or protective, 
and whether they are reversible or irreversible effects. 
Acknowledgements 
The authors wish to thank Dr. T. van der Lende, E. Wesseling, M. Havekes, R.van de 
Kerkhof and Dr. F. Schuren for excellent expertise and setting up of the microarray facility. H. 
Aten and M. van den Wijngaard for assistance in sample isolation. 
64 
Chapter IV 
Profiles of metabolites and gene expression in 
rats with chemically induced 
hepatic necrosis 
Wilbert H.M. Heijne 1 \ Robert-Jan A.N. Lamers \ Peter J. van Bladeren 2, John P. Groten 
1
'
2
, Joop H.J. van Nesselrooij1 and Ben van Ommen 1 
Submitted to Tox. Pathology, 2004 
1TNO Nutrition and Food Research, Zeist, The Netherlands 
2
 Department of Toxicology, Wageningen University, The Netherlands 
Chapter IV 
Abstract 
This study analysed changes in gone expression patterns and metabolite 
levels in plasma or urine in parallel. The aim was to more sensitively detect 
hepatotoxicity and provide new insights in molecular mechanisms of hepatic 
necrosis. Rats received the model hepatotoxicant bromobenzene at three 
dose levels, the highest dose inducing acute centrilobular necrosis. The 
hepatic transcriptome and plasma and urine metabolite profiles were 
analysed after 6, 24 and 48 hours, using multivariate statistics. 
Principal component analysis showed that molecular profiles from rats with 
hepatic necrosis differed largely from controls. Changes in levels of genes 
and metabolites were identified in correlation with the degree of necrosis, 
providing putative novel markers of hepatotoxicity. Moreover, samples from 
treated rats were distinguished from controls after exposure to 
bromobenzene below the concentration that induced hepatotoxicity markers 
or histopathological changes. Genes with altered expression were involved 
in oxidative stress, the acute phase response, cytoskeleton structure, 
apoptosis, biotransformation, glycolysis, cholesterol and fatty acid 
metabolism. Levels of endogenous metabolites like alanine, lactate, tyrosine 
and dimethylglycine distinguished plasma from treated and control rats. 
Complementary, NMR metabolite profiling enabled to distinguish the urine 
samples based on the exposure levels, primarily through presence of a 
multitude of bromobenzene-derived metabolites. 
Concluding, this parallel analysis of the liver transcriptome and metabolite 
profiles in plasma enabled to more sensitively detect changes related to 
hepatotoxicity and discover novel putative markers. Detailed insights in the 
role of various biological pathways in bromobenzene-induced hepatic 
necrosis were obtained. 
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IV.1 Introduction 
Previous toxicogenomics studies have shown that both large-scale measurement of gene 
expression (transcriptomics) and metabolite profiling complement the current methods to 
identify and discriminate different types of toxicity. Moreover, the new technologies enable to 
investigate the mechanisms that lead to toxicity. To this date, most studies concentrated on 
hepatic toxicity. Transcriptomics using DNA-microarrays enabled the discrimination of 
responses by different classes of hepatotoxicants in vivo, as shown by [34],[21],[22]. 
Hamadeh and co-workers distinguished samples treated with two classes of toxins, and 
provided more details on the mechanisms of action [27]. 
In parallel, metabolomics, i.e. metabolite profiling by NMR combined with pattern recognition 
techniques, has been used to classify urine samples of rats treated with either a liver or a 
kidney toxicant [31]. Others analysed metabolites in liver, plasma and urine of rats treated 
with the model hepatotoxicant alpha-naphthylisothiocynanate (ANIT) [33] Urine profiles were 
analysed in time upon single dosage of ANIT, galactosamine and butylated hydroxytoluene 
[32]. Time-related differences in metabolite contents were related to the stage of the lesions, 
and specific changes in metabolite levels were identified for each compound. 
While gene expression changes influence biochemical reactions, metabolite levels are 
determined by those biochemical reactions. Therefore, complementary information is 
expected from so-called systems toxicology approaches, where transcriptomics, proteomics 
and/or metabolomics are combined to analyse toxicity in a systematic and holistic manner. 
Only few experiments integrating results from transcriptomics and metabolite profiling have 
been described. Very recently, Coen and colleagues reported transcriptomics and 
metabolomics analyses in mice treated with acetaminophen (paracetamol) [125]. This study 
demonstrated that analysis of gene expression and metabolite profiles provided 
complementary insights in APAP-induced hepatic effects. In earlier studies in our laboratory, 
we evaluated the combined use of transcriptomics and proteomics analyses of hepatotoxicity 
induced by bromobenzene (BB). Bromobenzene is a well studied model toxicant that causes 
necrosis in the liver (centrilobular) and kidney. Hepatic biotransformation and toxicity of BB in 
rat have been reported in detail [74-78]. Because the liver is the target for toxicity induced by 
many compounds including bulk chemicals, drugs and food ingredients, the characteristics of 
the response induced by BB could be helpful in understanding hepatotoxicity induced by a 
variety of xenobiotics. 
Transcriptomics and proteomics analyses of hepatotoxicity were evaluated 24 hours after a 
single i.p. dose of BB [2]. A new study was designed to determine the acute hepatotoxic 
effects at the gene expression level in time, after oral dosage of various concentrations of 
BB. Hepatic necrosis was observed only at the high dose level after 24 h, though gene 
expression changes characteristic for BB exposure were observed at 2.5 times lower dose 
level. A few genes changed at 10 times lower dose levels, expression of several genes was 
found to change 6 h after dosage. Genes that were statistically significant differentially 
expressed upon BB dosage were involved in processes like drug metabolism, oxidative 
stress, GSH synthesis and the acute phase response [3]. 
Aim of the study 
In the present study, the aim was to investigate whether integrated analysis of the data from 
transcriptomics and metabolite profiling further increased the sensitivity of detection of 
hepatotoxicity. Our second question was how the combined analysis may expand current 
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knowledge about the mechanism of chemically-induced hepatotoxicity. Moreover, 
relationships between gene expression changes and altered metabolite levels were 
assessed. Thus, NMR-based metabolite profiles of plasma and urine samples, collected from 
the study described by Heijne and colleagues [3] were combined with the transcriptomics 
data of this same study. The metabolite profiling aimed at detecting changed concentrations 
of endogenous metabolites as a result of hepatotoxicity (biomarkers of effect) and of BB-
derived metabolites in urine and plasma (biomarkers of exposure). Results from parallel 
gene expression and metabolite analysis were combined with pre-existing biochemical 
knowledge in an overall interpretation of the mechanisms of action and effects of BB, a 
necrosis-inducing chemical, on liver physiology. 
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IV.2 Materials and methods 
Urine and plasma samples were collected from the study by Heijne and colleagues [3], which was also 
the source of the transcriptomics and toxicity data. Briefly, three doses of bromobenzene (0.5, 2.0 and 
5.0 mmol/kg body weight, dissolved in corn oil, 40% v/v) were administered to male Wistar rats by oral 
gavage. Animals were kept under controlled conditions, and the welfare of the animals was 
maintained in accordance with the general principles governing the use of animals in toxicity 
experiments of the European Communities (Directive 86/609/EEC) and Dutch legislation (The 
Experiments on Animals Act, 1997). Nine rats per dose group were treated BB or corn oil, while an 
additional group was not treated. Three rats per group were sacrificed after 6, 24 and 48 h and blood 
and livers were collected. Urine was collected for metabolomics between dosing and sacrifice for the 6 
h group, and during the last 16 h before sacrifice for the 24 and 48 h groups. During the time urine 
was collected, rats received water ad libitum, but no food. 
Transcriptomics 
cDNA microarray preparation and hybridization was described previously, [3];[2], A reference RNA 
was used, and hybridizations were replicated with swapped fluorophore incorporation (Cy3 and Cy5) 
in the sample and reference RNA. After quality filtering, lowess normalization and log(base 2) 
transformation, a set of about 2700 cDNAs was obtained. In present study, we required a correlation 
higher than 0.6 between the duplicate sets of dye-swap measurements, keeping about 400 genes in 
the dataset. 
NMR analysis 
NMR spectra of urine of individual animals were recorded in triplicate, according to (Lamers et al., 
2003). Plasma samples were deproteinised by filtration. Filters with a cut-off of 10 kDa (Microcon YM-
10, Millipore) were spin-rinsed with 0.5 ml of 0.05 M NaOH followed by 2 x 0.5 ml de-ionised water to 
avoid contamination of the ultrafiltrate with glycerin. Centrifugation (1h at 10000 rpm) of 0.5 ml plasma 
over a filter was followed by the centrifugation (1h at 10000 rpm) of 0.5 ml de-ionised water. Filtrates 
were freeze-dried and reconstituted in 750 \i\ sodium phosphate buffer (pH 6.0, made up with D20) 
containing 1mM sodium trimethylsilyl-[2,2,3,3,-2H4]-1 -propionate (TMSP) as an internal standard. 
NMR spectra were recorded in a fully automated manner on a Varian UNITY 400 MHz spectrometer 
(Palo Alto, CA, USA) according to [126]. 
Dara preprocessing and multivariate data analysis 
The NMR data file was imported into Winlin (V1.12, TNO, Zeist, The Netherlands). Minor variations 
from comparable signals in different NMR spectra were adjusted and aligned without loss of 
resolution. The intensities of signals present in each NMR spectrum were normalised, so that the sum 
of all intensities was equal to 1. This data set was imported into Matlab (Version 6.5, The MathWorks 
Inc., Natick, MA, USA) together with the transcriptomics data for preprocessing and multivariate data 
analysis. The data matrix was centred across time and dose. The sum of squares per variable over 
time and dose was scaled to 1, and PCA was performed. PCA is a multivariate statistical analysis that 
reduces the many dimensions of a dataset to few dimensions that describe the majority of the 
variance. PCA was performed with the PLS toolbox (Version 3.0, Eigenvector Research Inc., Manson, 
WA, USA), and a score plot visualised differences in gene expression and metabolite profiles. The 
contribution of each variable to the trend observed in the plot was determined. PCA was also 
performed on plasma and urine NMR data separately. When score plots revealed differences between 
groups, the contributions of the original NMR signals to these difference between treated and control 
were displayed in a factor spectrum. Metabolites were identified using an in-house reference 
database, and chemical shifts of characteristic metabolites in the NMR spectra are listed in table IV.3. 
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IV.3 Results 
Rats were exposed to the chemical compound bromobenzene and developed hepatic 
necrosis 24 h after dosing with the high concentration. In parallel, hepatic gene transcription 
and profiles of plasma and urine metabolites were analysed. 
Toxicological examinations 
No macroscopic aberrancies of the liver or other organs were observed in any of the rats 
sacrificed 6 hours after dosage. Histopathology of liver tissue showed no abnormalities in the 
controls and low dose rats. In some livers a slight presence of mononuclear cell aggregates 
and/or necrotic hepatocytes was observed. Only in rats that received high concentration of 
BB, livers had a patchy appearance and gross lesions after 24 hours and focal discoloration 
after 48 hours. Centrilobular necrosis was found in livers of all those rats, with inter-individual 
variation in the degree of response (table IV.1). Plasma levels of ASAT, ALAT and bilirubin 
were markedly elevated, also with inter-individual variation. To correlate the conventional 
markers of hepatotoxicity with the degree of necrosis in the individual rats, a semi-
quantitative score was defined for the hepatocellular necrosis ranging from 0 (no effects) to 
10 (very severe centrilobular necrosis) (table IV.1). This score was also used to correlate 
gene expression levels to necrosis. Figure IV.1 depicts the correlation of ASAT, ALAT, 
bilirubin, and the relative liver weight with the observed degree of hepatocellular damage. 
Apart from the signs of hepatotoxicity, BB significantly decreased plasma levels of glucose at 
the mid and high dose, after 24 and 48 hours. Cholesterol (n.s.) and phospholipids levels 
increased by high BB treatment at all time points. Hepatic GSH levels, which play a pivotal 
role in the hepatotoxicity induced by BB, were slightly decreased six hours after 
administration of BB. The mid and high dose depleted GSH levels to - 2 5 % of control levels. 
After 24 hours, GSH levels were nearly restored. 
ALAT,ASAT(x1000U/l) 
0 10 
30 -, 
25-
20 
15-
10 -
5 -
0 ' 
Bilirubin (mmol/l) 
A 
*S 1 
~ ^ * * ^ ' 
+-+^ , , 
Relative liver weight 
• ^ 
> ^ 
0>^* 
^ ^ 
r , , 
Degree of hepatic necrosis 
0 5 10 
Degree of hepatic necrosis 
0 5 10 
Degree of hepatic necrosis 
Figure IV.1. Relation of conventional markers to hepatotoxicity 
Correlation of toxicity markers ALAT, ASAT, bilirubin and relative liver weight with the 
observed degree of hepatic necrosis in individual rats. 
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Table IV.1. Histopathological and clinical chemistry 
Histopathological and clinical chemistry findings in rats, 24 and 48 hours after exposure to mid 
and high dose of bromobenzene. The degree of hepatic necrosis was expressed with a score 
(S) between 0-10. 
BW Gross pathology Liver histopathology § 
g of the liver 
Dose T 
mmol / h 
kg 
BW 
Rat Rel. 
liver 
%of 
CO 
2.0 24 Mean 109% 187 No gross lesions (Very) Slight mononuclear cell 
aggregates/ necrotic hepatocytes 
62 108% 188 
64 108% 178 
66 110% 194 
Slight mononuclear cell aggregates/ 
necrotic hepatocytes 
Slight mononuclear cell aggregates/ 
necrotic hepatocytes 
Very slight mononuclear cell 
aggregates/ necrotic hepatocytes 
2.0 48 Mean 108% 184 No gross lesions 
Very slight mononuclear cell 
aggregates/ necrotic hepatocytes 
(1/3} 
0.5 
68 
70 
72 
5.0 24 Mean 
80 
82 
84 
5.0 48 Mean 
86 
88 
90 
114% 
105% 
104% 
131% 
120% 
125% 
149% 
142% 
129% 
136% 
161% 
191 
186 
175 
177 
183 
173 
174 
181 
187 
186 
170 
-
-
Patchy 
appearance 
Patchy 
appearance 
Patchy 
appearance 
Patchy 
appearance 
Pale appearance 
others (2/3) 
No gross lesions 
Pale appearance 
Pronounced 
lobular pattern 
Pale appearance 
Red areas 
Firm tissue 
Very slight mononuclear cell 
aggregates/ necrotic hepatocytes 
No abnormalities 
No abnormalities 
Centrilobular necrosis 
Nucleolar enlargement (2/3) 
Very slight centrilobular necrosis 
Nucleolar enlargement 
Severe centrilobular necrosis 
Nucleolar enlargement 
Very severe centrilobular necrosis 
Centrilobular necrosis 
Slight centrilobular fatty change 
(2/3) 
Mitotic increase (2/3) 
Nucleolar enlargement 
Slight centrilobular necrosis 
Nucleolar enlargement 
Moderate centrilobular necrosis 
Slight centrilobular fatty change 
Slight mitotic increase 
Nucleolar enlargement 
Severe centrilobular necrosis 
Slight centrilobular fatty change 
Slight mitotic increase 
Nucleolar enlargement 
0.5 
0 
0 
3 
8 
10 
4 
6 
8 
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Transcriptomics analysis and parallel metabolite profiling 
BB elicited specific changes in gene expression of many rat liver genes, as reported before 
[3]. In this study, the profiles of the transcriptomics measurements were combined with the 
profiles obtained by NMR, describing the metabolite contents of plasma. Consensus PCA 
[127] was performed using both types of data in one integrated analysis, and results are 
shown in figure IV.2. This plot indicates that the samples from the high and mid dose groups, 
collected after 24 and 48 hours were distant from the others, having lower PC1 scores. Most 
distinct from all the other samples were the samples from rats #84, #82, and #90, that 
received a high dose of BB. Microscopic examination revealed (very) severe hepatic 
centrilobular necrosis in those rats. Profiles of rats #80, #86 and #88 were less distant from 
the controls. Correspondingly, moderate centrilobular necrosis was observed in rat #88, and 
(very) slight necrosis in rats #86 and #80. The profiles of the rats treated with a mid dose of 
BB were distinct from the controls after 24 hours. Routine markers were not able to indicate 
hepatotoxicity in those rats. After 48 hours, rats treated with the mid dose were not distinct 
from controls. Samples from rats treated with the low dose of BB could not readily be 
separated from the controls, after 24 or 48 hours. All samples collected after 6 hours were 
distinct from the other time points in the down right corner of the plot. Treatment with BB 
resulted in patterns distinct from the controls. 
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Figure IV.2 Score plot of consensus PCA 
Consensus PCA was performed using both hepatic transcriptomics and plasma metabolite 
profiling data in one integrated analysis. The percentage of the total variance explained by the 
individual PCs is indicated in the plots. Time points: Boxes: 6 h samples, circles: 24 h samples; 
triangles: 48 h samples. Dose levels: white: controls, light grey: low BB; dark grey: mid BB; 
black: high BB 
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Genes and metabolites were sorted according to their contribution to the observed trend, 
reflecting the degree of hepatic necrosis. Tables IV. 2 A and B list the genes and metabolites 
with the highest and lowest scores, that therefore putatively correlate with the degree of 
hepatotoxicity. The levels of gene expression and metabolites listed in are present at either 
high or low levels in correlation with the necrosis. Many genes with a significant contribution 
to pattern differences in the PCA were identified to be up- or down regulated by BB with high 
significance in univariate statistical tests, and the rationale of these changes in terms of 
toxicology was discussed before [3]. 
Genes with high scores in the parallel analysis include structure and cytoskeleton-related 
genes (beta actin, weakly similar to pervin, tubulin), many ribosomal subunits, and other 
factors involved in protein synthesis (eg. nucleophosmin). Also oxidative stress induced 
genes (Ho-1, Timpl, peroxiredoxinl, ferritins), hepatic acute phase response genes 
(orosomucoid 1, fibrinogen gamma) and enzymes involved in glucose metabolism (Gapdh, 
phosphoglycerate mutase 1, aldolase A) have high rankings. Drug metabolising enzymes like 
Ephxl, Afar, Gsta and aldo-keto reductases, likely involved in the hepatic biotransformation 
of bromobenzene, appeared in the upper part of the ranking. Several cell cycle and 
apoptosis related genes (Bcl2-related protein A1, Pcna, p53, p21 (Waf), EST, highly similar 
to p53-regulated PA29-T2, cyclin G1) were co-ordinately upregulated. High ranked genes 
with others functions include casein kinase II, VL30 element and RAN. Plasma metabolites 
with a high score in the analysis include acetate, choline, phenylalanine and some 
uncharacterised metabolites. 
Genes with low scores include hepatic acute phase response genes like alpha-1-inhibitor, 
serine protease inhibitor, fibrinogen beta, complement components, drug metabolising 
enzymes like Cyps, aldehyde dehydrogenases, Fmo3, enzymes involved in fatty acid and 
cholesterol metabolism (HMG-CoA synthase, Lcat, Star, fatty acid CoA ligase, acyl CoA 
dehydrogenases) and glucose metabolism (G6pt1, alanine-glyoxylate aminotransferase) 
Many genes with other functions, like asialoglycoprotein receptor 2, Cathepsin S, and 
dimethylglycine dehydrogenase had a low score, indicating that they were down regulated 
compared to the controls. Plasma metabolites with a low score in the analysis include 
dimethylglycine, tyrosine and glucose. 
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Table IV.2a: Genes from consensus principal component analysis 
Highest and lowest ranked genes from consensus principal component analysis. Rank, gene 
name and Genbank accession number, category, and the correlation to the degree of hepatic 
necrosis are indicated. Expression of high ranked genes is upregulated, while low ranked genes 
are downregulated in the samples with a high degree of hepatic necrosis. 
Rank Gb Ace. Category Gene name Correl 
1 
2 
3 
4 
5 
6 
8 
10 
552 
553 
554 
555 
556 
557 
558 
559 
560 
561 
AA859846 Structure 
AA964725 Structure 
AA964496 Structure 
AA957078 Structure 
AA924111 glycolysis 
AI029162 APR 
AA997175 Signal transd. 
AA900726 Signal transd. 
AI070895 Fatty acid 
AA866389 other 
AA964340 other 
AA955402 Cysteine 
AA925933 Proteolysis 
AA819756 Drug metab 
AH 36048 Cholesterol 
AI071033 acute phase 
AA997322 Cholesterol 
AA997920 Signal transd. 
actin, beta 
Weak sim to pervin 
High sim to S11222 actin gamma, cytoskeletal 
alpha-tubulin 
Glyceraldehyde-3-phosphate 
(GAPDH) 
Orosomucoid 1 
casein kinase II beta subunit 
GTP-binding protein (ral A) 
Weakly sim. to acyl-CoA dehydrog., 
epoxide hydrolase [C.el] 
lumican 
syndecan 2 
S-adenosylhomocysteine hydrolase 
cathepsin S 
0.881 
0.842 
0.853 
0.842 
dehydrogenase 
arachidonic acid epoxygenase;Cyp2C23 
3-hydroxy-3-methylglutaryl-Coenzyme 
Fibrinogen, B beta polypeptide 
Lecithin-cholesterol acyltransferase (L 
asialoglycoprotein receptor 2 
A synthase 2 
cat) 
0.811 
0.885 
0.835 
0.789 
-0.735 
-0.865 
-0.747 
-0.776 
-0.801 
-0.888 
-0.821 
-0.820 
-0.745 
-0.900 
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Table IV. 2b. Metabolites from consensus principal component analysis 
Highest and lowest ranked metabolites from consensus principal component analysis. The rank 
and chemical shift in the NMR analysis of the (putatively) identified metabolites is indicated. 
High ranked metabolites are more abundant in treated compared to control plasma samples, 
and metabolites with a low rank are more abundant in controls. 
High rank 
Rank 
7 
9 
51 
61 
70 
73 
82 
100 
109 
110 
111 
114 
119 
124 
126 
129 
130 
Shift 
1.475 
1.4925 
8.4575 
7.83 
1.9275 
3.2075 
3.0075 
7.4325 
3.5975 
5.3875 
3.0275 
7.8475 
7.4125 
7.3375 
7.375 
1.005 
3.0525 
Metabolite 
alanine 
alanine 
formate 
unidentified metabolite 
acetate 
choline? 
unidentified metabolite 
phenylalanine? 
choline? 
unsaturated lipid? 
cysteine? 
histidine? 
phenylalanine? 
phenylalanine? 
phenylalanine? 
isoleucine? 
unidentified metabolite 
Low rank 
Rank 
430 
391 
390 
389 
383 
379 
378 
376 
375 
374 
373 
372 
369 
368 
367 
366 
365 
Shift 
2.935 
6.91 
6.89 
7.185 
7.2075 
3.4925 
3.245 
3.3775 
3.7325 
3.4225 
4.64 
3.715 
5.23 
3.09 
3.7475 
3.2225 
3.4375 
Metabolite 
dimethylglycine? 
tyrosine 
tyrosine 
tyrosine 
tyrosine 
glucose 
glucose 
glucose 
glucose 
glucose 
glucose 
glucose 
glucose 
unidentified metabolite 
unidentified metabolite 
unidentified metabolite 
unidentified metabolite 
Table IV.3. Chemical shifts of characteristic metabolites in NMR spectra 
Metabolite Chemical shift (ppm) 
Diverse BB-metabolites 
Lipids 
Lactate 
Alanine 
Glutathione (and conjugates) 
Cysteine (and conjugates) 
Methionine 
Dimethylglycine 
Taurine 
Creatine (and creatinine) 
Glucose 
Tyrosine 
Nicotinamide/nicotinate 
Formate 
Choline 
4.27-4.40 and 5.95-6.35 (region) 
0.84-1.32 (region) 
1.33 doublet 
1.48 doublet 
2.8-3.1 (region) 
3.02 multiplet 
3.80 triplet 
2.74 singlet and 2.94 singlet 
3.25 triplet and 3.42 triplet 
3.04 singlet and 3.93 singlet 
4.64 doublet, 5.25 doublet and 3.7-3.9 (region) 
6.91 doublet and 7.2 doublet 
above 8 
8.46 singlet 
3.21 singlet, 3.52 multiplet and 4.07 multiplet 
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Gene expression markers 
The correlation between the level of gene expression and the degree of necrosis in the 
individual rats was calculated (Table IV.2). Figure IV.3 illustrates expression of ESTs highly 
similar to actin and pervin, and orosomucoid 1 in relation to hepatic necrosis. Expression 
levels of asialoglycoprotein receptor 2 and lecithin-cholesterol acyltransferase (Lcat) 
decreased in concordance with the degree of hepatic damage. In total, 14 genes were found 
with a positive correlation between 0.80 and 0.89, the highest coefficient. The correlation of 
the average expression level of these 14 genes with necrosis was 0.969. In parallel, 20 
negatively correlated genes were found with an individual correlation to necrosis varying from 
-0.80 to -0.90. The correlation of the average gene expression of these 20 genes with 
necrosis was -0.959. This suggests that valuable markers of hepatocellular necrosis consist 
of combination of gene expressions. 
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Figure IV.3 Putative gene expression markers for hepatic necrosis 
Levels of expression of genes that correlate with the observed degree of hepatic necrosis in 
individual rats. 
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Factor Spectrum Plasma 6 Hours Vehicle vs. High Dose 
High Dose Dimethylglycine Creatine 
Tyrosine 
Vehicle 
.Lipids 
Lactate 
Choline Alanine 
—r 
0 
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Regression 
Factor Spectrum Plasma 24 Hours Vehicle vs. High Dose 
ppm 
Figure IV.Plasma metabolite profiling 
Factor Spectra of NMR measurements after principal component analysis. 
Upper panel: plasma after 6 hours, Lower panel: plasma after 24 hours 
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Time and dose-dependent changes in plasma metabolites 
Besides the parallel analysis of transcriptomics and metabolite profiling, the plasma NMR 
data were analysed separately by PCA, and time and dose specific changes in metabolite 
levels between treated and control samples were visualised in factor spectra, (figure IV.4 
a,b). After both high and mid dose of BB, lipid levels were higher than in controls. Clinical 
chemistry indicated an increase in plasma phospholipids levels upon high but not mid dose 
treatment. The levels of glucose were higher 6 hours after a high dose of BB, but lower after 
24 and 48 hours. These observations were identical to the clinical chemistry measurements. 
NMR of plasma showed higher levels of creatine and/or creatinine in BB-treated rats, though 
clinical chemistry did not reveal significant changes in creatinine. The levels of tyrosine were 
lower 6 and 24 hours after BB, while higher after 48 hours. Methionine, alanine and lactate 
levels in plasma of BB-treated rats were lower 6 hours after dosage but higher 24 and 48 
hours after dosage. Dimethylglycine and taurin levels were increased compared to controls 6 
hours after the BB treatment, and decreased after 24 hours. Choline levels were decreased 
after treatment to mid or high dose of BB. 
Profiles of urine metabolites 
Also in urine, metabolite NMR profiles were discerned using PCA. Analysis per time point 
showed that BB treatment changed urine profiles (data not shown). All rat urines collected 
during the first 6 hours could be distinguished by levels of exposure. By 48 hours after 
dosage, rats treated with the high concentration of BB could still be recognised from controls 
by their urine profiles. In order to determine the NMR signals that most significantly differed 
between the high dose and control group, factor spectra were constructed. Figure IV.5 shows 
the factor spectrum for rat urine collected during the 6 hours after dosage. Using reference 
databases, the identity of several peaks was established. Factor spectra revealed the 
marked presence of BB-derived metabolites like bromphenols, bromcatechols, and quinones 
in urine. It was not possible to discriminate and identify these various metabolites. Markedly 
elevated levels of mercapturic acids, derived from GSH-conjugates, were observed after 
treatment. Methionine levels in urine were higher in the treated rats compared to controls. 
Formate levels increased after 24 hours in the treated rats, and elevated levels were 
observed of urocanate and (methyl)histidine, as well as decreased levels of nicotinate, 
hippurate, phenylalanine/tyrosine and glucose/fructose. 
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Factor Spectrum Urine 6 hours Vehicle vs. High Dose 
Urocanate 
Regression (Methyl)Histidine 
1 
BB-metabolites Succinate 
GSH and cysteine conjugates^ 
1 
(Hydroxy)Butyrate 
Lipids 
Hippurate Phenylalanine/Tyrosine Malate ppm 
Figure IV.5 Urine metabolite profiling 
Factor Spectra after principal component of NMR analysis of urine, 6 hours after dosage with 
bromobenzene, compared to vehicle control. 
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IV.4 Discussion 
This study presents one of the first integrated toxicogenomics studies, where acute 
hepatotoxicity was analysed at the transcriptome and metabolite level in a time- and dose-
dependent manner. An integration of the (raw) datasets of the transcriptomics and 
metabolomics experiments could increase the sensitivity of detection of hepatotoxicity. 
Moreover, this could enhance the assessment of relationships between gene expression and 
metabolite level changes. 
When rats were treated with BB, hepatic centrilobular necrosis was observed after 24 hat the 
high, but not at lower doses. The inter-individual response varied from very slight to very 
severe hepatic centrilobular necrosis. Individual plasma ALAT, ASAT and bilirubin levels and 
the increase in relative liver weight correlated with the severity of the necrosis. 
Complementary to these toxicological observations, the molecular profiles of hepatic gene 
expression and plasma metabolites were analysed in parallel. Differences between 
molecular profiles were dependent on the dose and time after dosage. Profiles from the 6 
hours time point were distinguishable from other time points. BB treatment at the high dose 
resulted in highly distinct profiles, while the mid dose altered the profiles up to 24 hours after 
dosage. At this dose level, conventional signs of hepatotoxicity were not observed. 
Combining transcriptomics and metabolite profiling did not allow to discriminate samples 
treated with the low dose from controls. 
Markers of gene expression 
Gene expression changes were identified in correlation with the degree of hepatic necrosis, 
providing comprehensive means to diagnose the degree of necrosis. Moreover, if these 
markers prove to be predictive at earlier time points or lower dose levels, they will improve 
detection of hepatotoxicity. Changes in these marker gene expression levels could be 
explained from a mechanistic point of view. The upregulation of cytoskeleton constituents 
(actin and pervin ao.) with the degree of necrosis indicates remodelling of the cytoskeleton. 
Presumably, necrosis and repair occur simultaneously in different liver cells, but our 
experiments using whole liver do not allow to localise the events. The negative correlation of 
genes like alpha-1-inhibitor and serine protease inhibitor is probably related to the acute 
phase response, involving altered hepatic synthesis of proteins. When expression levels 
were averaged for sets of genes, the correlation with the degree of necrosis increased. A 
further suggestion would be to construct a model of combined sets of positively and 
negatively correlated genes and metabolites to further increase the relation with 
hepatocellular necrosis. 
Metabolite profiles 
Xenobiotic compounds like BB are degraded into many metabolites, and ultimately excreted 
in urine. BB-derived metabolites could be suitable to monitor exposure and to elucidate 
routes of biotransformation. Levels of endogenous metabolites that changed after treatment 
form putative biomarkers of toxicity, and could help to identify the mechanism of 
hepatotoxicity. 
Urine collected from rats exposed to different doses of BB varied in metabolite contents, in 
agreement with the levels of exposure. Especially shortly after dosage, many water-soluble 
BB-metabolites were found, like bromphenols, -catechols and -quinones, and mercapturic 
acids. The lack of reference spectra and insufficient resolution of the separation frustrated 
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the identification of all corresponding metabolites. Peaks around 6 p.p.m. in the spectra could 
result from bromphenols, bromcatechols and/or BB-dihydrodiols. Therefore, the precise 
biotransformation of BB could not be determined. Further efforts to elucidate this based on 
urine metabolite profiles require techniques like liquid chromatography and mass 
spectrometry (LC-MS) for identification of the compounds. Few endogenous metabolites, 
putative markers of hepatotoxicity, were discovered in urine. Levels of methionine were 
higher 24 hours after BB dosage. Urocanate, related to histidine metabolism, and histidine 
itself displayed elevated levels. Notably, elevated urocanate levels were also found with 
galactosamine-induced hepatotoxicity [32]. 
Contrary to urine, in plasma, distinct signals of BB-derived metabolites were not found. On 
the other hand, endogenous metabolites in plasma, or combinations of them, could be 
effective biomarkers of toxicity. Decreased glucose and increased lipid levels measured by 
NMR were corroborated by clinical chemistry. The levels of formate in plasma, and urine, 
were increased after 24 and 48 hours. Formate could be produced from dimethylglycine 
through sarcosine and formaldehyde. Formate is also a product of oxalate in the glyoxylate 
catabolism, and possibly related to folate synthesis in the one-carbon metabolism. 
Biochemical pathways 
The most significant effects determined in the parallel analysis of transcriptomics and plasma 
metabolite profiling were categorised according to biochemical pathways. Changes in gene 
expression in several pathways were described previously [3]. Other changes, eg. in 
apoptosis and cell cycle were not noted before. Pathways like glycolysis, GSH and amino 
acid metabolism were disturbed both at the gene expression and metabolite level, and are 
described below. Figure IV.6 presents a proposed schematic overview of changes in GSH 
and amino acid metabolism, associated to bromobenzene-induced hepatic necrosis. 
Glycolysis 
Glucose levels in plasma decreased in time after BB treatment. This could be ascribed to 
increased glycolysis, in order to increase the production of energy to restore homeostasis 
after the toxic insult. Decreasing glucose levels are corresponding with increasing plasma 
levels of alanine and lactate, products that may be formed by breakdown of glucose when 
the oxidation of pyruvate is incomplete. Expression of many genes involved in glycolysis, 
gluconeogenesis and glucose transport was altered. Expression of a glucose transport 
protein was decreased by BB. From the changes, we conclude that glycolysis enzymes were 
induced (GAPDH, aldolase A, pyruvate kinase, G6PD and PGAM), and gluconeogenesis 
was reduced through down regulation of G-6-phosphatase, transport protein 1 (G6pt1), 
alanine-glyoxylate aminotransferase and pyruvate carboxylase. It is known that the 
hepatotoxic effects of high doses of APAP are similar to the effects of bromobenzene. In 
agreement with our findings, APAP was found to decrease glucose levels and was 
suggested to induce glycolysis based on gene expression and metabolite profile changes, 
suggestively as a reaction to decreased ATP availability from beta oxidation of fatty acids 
[125]. 
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Figure IV.6 Gene expression and plasma metabolite changes in bromobenzene-induced 
hepatic necrosis 
Simplified, schematic representation of gene expression and plasma metabolite changes in 
bromobenzene-induced hepatic necrosis, related to GSH and amino acid metabolism. Ovals 
represent genes, boxes represent metabolites in plasma. When measured, changes in gene 
expression or plasma metabolite levels are indicated schematically to the right of each object. 
GSH and amino acid metabolism 
A central process in the chemically-induced hepatic necrosis is the depletion of GSH levels, 
which normally protect cells by scavenging of hazardous, reactive molecules. GSH levels 
decreased to around 25% of controls, 6 hours after oral BB dosage, [3], while total depletion 
of hepatic GSH was observed 24 h after i.p. administration of BB [2]. GSH is used in 
conjugation reactions to BB-derived metabolites, catalysed by GSTs. The reduction of GSH 
levels was accompanied by a decrease of plasma methionine, according to NMR 
measurements. The GSH depletion was countered through induction of GSH synthase 
protein [2] and Gclc gene expression [3]. Along with the changes in GSH and methionine 
levels, related enzymes and metabolites were found to change. GSH and methionine levels 
are connected via cysteine and homocysteine levels, involving enzyme activity of BHMT. 
Gene expression of BHMT was found to initially increase, and later decrease upon BB 
treatment. The expression of S-adenosyl homocysteine hydrolase was decreased. Plasma 
levels of dimethylglycine, produced in the reaction catalysed by BHMT were found to 
correlate with the BHMT mRNA levels in time, and also the hepatic dimethylglycine 
dehydrogenase gene expression levels followed this pattern. Dimethylglycine can be 
catalysed in a multi-step reaction to formate, which levels were increased both in plasma and 
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urine after treatment. Induced levels of cysteine in plasma were observed after BB treatment, 
along with increased gene expression of cysteine dioxygenase, while increased levels of 
cysteine sulfinic acid decarboxylase were observed before [2]. Plasma tyrosine levels show a 
characteristic pattern, decreasing drastically 24 hours after high BB, while 48 hours after high 
BB, levels were highly increased compared to controls. Protein levels of HPD, an enzyme 
involved in tyrosine metabolism, were found to decrease 24 hours after BB [2]. The level of 
phenylalanine is related to tyrosine and seems to decrease in plasma due to the treatment. 
Conclusion 
In summary, this study presents one of the first integrated analyses of transcriptomics 
and metabolite profiling. r ival ing additional information in the process of chemically-
induced hepatic necrosis. A full merge between the methods awaits technical 
optimization, especially for the identification of metabolites. Nevertheless, 
corroborating findings from liver transcriptomics and plasma metabolite profiling aided 
in the generation of new hypotheses concerning cellular mechanisms putatively related 
to necrosis, such as changes in cyloskeleton remodelling and acute phase response, 
apoptosis, glycolysis, amino acid, fatty acid and cholesterol metabolism. Through 
integration of the datasets, changes were observed before histopathology or clinical 
chemistry indicated necrosis. Both liver gene and plasma metabolite markers were 
discovered in correlation with the degree of hepatocellular necrosis in individual 
animals. Through measurement of urine metabolite profiles, exposure was rapidly 
recognised. 
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Abstract 
The number of published toxicogenomics studies is rapidly increasing. Most of the 
studies so far have analysed hepatic gene expression changes upon exposure to 
well-known hepatotoxic compounds. To delineate the specificity of gene expression 
changes induced by (potentially) hepatotoxic compounds, the present study 
analysed the effects of the industrial chemical benzene, also found in automobile 
exhaust and cigarette smoke. Benzene is not typically toxic in liver, and critical 
organs are bone marrow and blood, after bioactivation in the liver. Benzene 
increased liver weight and possibly other adverse effects in liver. 
This toxicogenomics study assessed hepatic gene expression in relation to subacute 
toxicity in rats repeatedly exposed to benzene. A metabolomics approach using NMR 
and pattern recognition was used to assess exposure to benzene through 
characteristic metabolite profiles in urine. 
Oral exposure to 200 and 800 mg/kg/day, but not 10 mg/kg/day, for 28-days, induced 
hematotoxicity in male F344 rats. It slightly reduced body weights, increased relative 
liver weights and elevated hepatic glutathione levels, but no histopathological 
abnormalities were found in liver. Using oligonucleotide microarrays, changes in 
gene expression were identified, even at exposure to 10 mg/kg/day. A marked dos-
dependency in the hepatic effects was not seen, probably because hematotoxicity 
was the critical effect. Specific gene expression changes were observed, while some 
effects were also seen with model hepatotoxicants bromobenzene and 
acetaminophen. Modulated genes were involved in biotransformation, glutathione 
synthesis, fatty acid and cholesterol metabolism and other pathways. Induction of 
cytochrome P450 2e1 and epoxide hydrolase suggested enhanced bioactivation. 
while induction of various (conjugation) enzymes could enhance detoxification. In 
conclusion, this study identified and characterised hepatic gene expression changes 
upon repeated exposure to benzene, in relation to the subacute toxicity. 
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V.I Introduction 
Toxicogenomics studies 
Gene expression changes in livers of rats exposed to model hepatotoxicants were analysed 
in detail in several toxicogenomics studies. The effects of enzyme inducers (eg. 
phenobarbital) and agents that induce peroxisome proliferation (eg. Wy14,643) were 
distinguished and mechanisms of hepatic toxicity were studied [27], [34],[21],[22]. Our 
laboratory identified characteristic changes at the gene and protein expression level, 
concurring with acute hepatic necrosis induced by bromobenzene (BB) [2], [3]. Heinloth and 
colleagues [69] analysed effects of high doses of acetaminophen (APAP, or paracetamol), 
which also induced acute hepatic centrilobular necrosis. Changes in gene expression were 
identified in various biological pathways, such as biotransformation, glycolysis and 
metabolism of proteins, fatty acids and glutathione. Nevertheless, the relation between 
hepatotoxicity and (specific) changes in gene expression profiles, is still unclear. 
Aim of this study 
To shed light on the specificity of gene expression changes in liver, the present study 
analysed the response to benzene, which is not a typical hepatotoxicant. Benzene is a widely 
used chemical that is bioactivated in liver and ultimately induces hematotoxicity and 
myelotoxicity. Benzene induced relative liver weight, and reactive metabolites might induce 
other adverse effects in liver. Therefore, hepatic gene expression changes in rats exposed to 
benzene were analysed and compared with effects of model hepatotoxicants. 
Benzene toxicity 
Benzene is an industrial chemical widely used in the production of paints, resins, rubber, inks 
and dyes. Common sources of environmental exposure include gasoline fumes, automobile 
exhaust and cigarette smoke. Benzene is genotoxic in animals and possibly in humans 
[128,129]. The most important effect of benzene is hematopoietic toxicity, depleting white 
blood cells [130]. Chronic exposure induced bone marrow toxicity (myelotoxicity) in humans 
and animals, and increased the risk of acute myelogenous leukaemia [119],[128],[131]. 
Hydroquinone metabolites of benzene accumulate in the bone marrow. There, 
myeloperoxidases produce p-benzoquinones, which are protein-reactive and possibly 
responsible for myelotoxicity by damaging the stem cells and progenitor cells [132-135]. 
Benzoquinones can be detoxified by Nqo1, though this enzyme is expressed at low levels in 
the bone marrow, making this tissue especially prone to damage by these metabolites. It was 
shown that exposure to benzene reduced the number of lymphocytes, and increased the 
number of granulocytes in the bone marrow [136]. Benzene metabolites formed covalent 
adducts with proteins (eg. hemoglobin) in human blood [137], and also with nucleic acids in 
rats [138-140], in correlation with decreased RNA synthesis [141]. 
Metabolism of benzene 
Toxicity of benzene depends on bioactivation, primarily by Cyp2e1 in the liver. Subsequently 
formed benzene oxide is nonenzymatically rearranged to phenol, catalysed by Ephxl to 
dihydrodiol and to catechols [142]. Detoxification involves conjugation by GSTs, UGTs and 
sulfotransferases. Benzene oxide can also be metabolised to the (hemato)toxic metabolite 
f,f-muconaldehyde [143], and ultimately excreted in urine as f,f-muconic acid [130]; [144], 
[131]; [145] Benene biotransformation was dependent on the dose, and the relative amount 
of muconic acid and other toxic metabolites decreased as the dose increased (eg. [146]}. 
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Urine metabolomics 
Many different metabolites of benzene are ultimately excreted in urine. Therefore, the highly 
characteristic metabolite profile could be suitable to assess exposure to benzene in urine. A 
metabolomics approach combining NMR spectroscopy and mathematical pattern recognition 
was followed, comparable to previous applications of this technology [65] [33],[126],[4]. 
In summary, the hepatic response to benzene at the gene expression level assessed in 
relation to conventional toxicological observations, and to gene expression changes found 
with model hepatotoxicants. This study also investigated whether changes in gene 
expression could provide insight in the mechanisms of hepatic bioactivation and toxicity of 
benzene. 
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V.2 Materials and methods 
Benzene (> 99% purity) was obtained from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Corn 
oil was obtained from Remia (Den Dolder, The Netherlands). 
Male F344 rats (CDFF® (F344)/CrlBR) were obtained from Charles River Wiga GmbH (Sulzfeld, 
Germany). The animals were maintained in accordance with the general principles governing the use 
of animals in toxicity experiments of the European Communities (Directive 86/609/EEC) and Dutch 
legislation (The Experiments on Animals Act, 1997). The rats were housed conventionally, in macrolon 
cages with stainless steel grid covers and wood shavings as bedding material, five rats per cage, in a 
room maintained at 22 ± 2°C with a relative humidity of 30-70% and a 12-h light/dark cycle. 
Throughout the study, feed (a powdered, cereal-based, closed-formula rodent diet (Rat and mouse 
No. 3 Breeding diet; RM3) from Special Diets Services (Witham, England)) and tap water were freely 
available. Following an acclimatisation period of 8 days, the 5-week old rats were allocated randomly 
to the groups, in such a way that the mean body weights were about the same in all groups. 
Benzene was dissolved in corn oil and administered by oral gavage in a volume of 5 ml per kg body 
weight at dose levels of 10, 200 and 800 mg/kg/day, once daily, for 28 consecutive days. The last 
dose was given on the day before scheduled sacrifice. The highest dose level was intended to induce 
toxic effects but no severe suffering, death or marked growth retardation. The low and mid dose levels 
were selected to demonstrate dose-effect relationships, and no toxic effects at the lowest dose level, 
based on routine toxicity studies, reviewed in [128] Controls were dosed with corn oil (5 ml/kg body 
weight) only. The dose volumes were adjusted twice per week to changes in body weight. Fresh 
benzene solutions were prepared once per week and stored at 2-10°C in portions sufficient for one 
day. 
Observations and toxicological analyses 
General clinical observations were made daily before and after dosing. The rats were weighed twice 
per week and at final necropsy. Food consumption was measured per cage, over successive periods 
of 7 days (wk 1-3) or 4 days (wk 4). Water consumption was measured per cage, on three consecutive 
days in wk 1-3. In addition, water consumption of individual animals was measured during the 24 h 
urine collection period in wk 4. Neurobehavioural functioning was evaluated on day 22 before the daily 
dosing. During one minute, the animal was observed in an open arena for gait characteristics, arousal 
and the occurrence of clonic and/or tonic convulsions. Next, sensorimotor reflex testing (aerial righting, 
responses to the approach of a pencil, touch of a pencil to the rump, click stimulus and tail pinch), 
gripstrength (forelimb and hindlimb) measurements and landing foot splay were performed. 
Organ weights and pathology 
At the end of the treatment period, the rats were killed by exsanguination from the abdominal aorta 
under C02 /02 anaesthesia and examined grossly for pathological changes. The kidneys, liver, 
prostate, spleen, testes and thymus were weighed. After fixation in a 4% neutral buffered solution of 
formaldehyde, the kidneys, liver, spleen and thymus were processed, embedded in paraffin, sectioned 
at 5 urn, stained with haematoxylin and eosin, and examined by light microscopy. Parts of these 
organs were snap-frozen in liquid nitrogen and stored at < -70°C. 
Urine analysis and metabolomics 
Urine was collected towards the end of the fourth week of treatment. The rats were kept in metabolism 
cages (one rat/cage) for two consecutive days, with food and water freely available. After one day of 
acclimatisation, 24 h urine samples were collected, in ice-cooled containers. Each sample was 
characterised with respect to appearance, volume, density (Bellingham and Stanley refractometer), 
total protein (Cobas-Bio centrifugal analyser), glucose, creatinine, alkaline phosphatase (ALP), 
gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH) and N-acetyl-fi-glucosaminidase 
(NAG) (Automatic analyser model 911 from Hitachi, Japan). Protein, glucose, creatinine and the 
enzyme activities were expressed as units excreted per 24 h by multiplying the concentrations 
measured by the volume of the urine produced. 
The urine samples were also analysed with a metabolomics approach, by NMR spectroscopy 
according to Lamers et al. [126] and Heijne ef al. [A]. The multivariate statistical technique PCDA was 
used to determine differences in the NMR profiles of the metabolites in urine. PCDA [147] is a semi-
supervised method based on principal component analysis that uses the dose levels as a discriminant 
to optimise the contrast between the treatment groups. After calculations, the differences between the 
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individual profiles were visualised in a score plot. Along the axis of the score plot, the D#1 and D#2 
values were plotted. The score plot displayed every individual profile (in this case NMR spectrum) as 
one dot, and the distance between the dots reflects the degree of similarity between the individual 
profiles. 
Haematology 
At final necropsy, blood samples were collected from the abdominal aorta using K2-EDTA as 
anticoagulant. Each sample was analysed for haemoglobin, packed cell volume, red blood cell count 
(RBC), total white blood cell count (WBC), thrombocyte count (Sysmex K-1000 Haematology Analyser 
from Toa Medical Electronics Co., Ltd, Japan), differential white blood cell counts (microscopic 
examination of stained blood smears), and prothrombin time (Normotest, Nyegaard and Co. A/S, 
Norway). Mean corpuscular volume, mean corpuscular haemoglobin concentration and absolute white 
blood cell counts were calculated. 
Clinical chemistry 
At final necropsy, blood samples were collected from the abdominal aorta in heparinised tubes. The 
samples were centrifuged and the plasma was analysed for aspartate aminotransferase (ASAT), 
alanine aminotransferase (ALAT), ALP, GGT, LDH, total protein, albumin, glucose (non-fasting), urea, 
creatinine, total bilirubin, total cholesterol, triglycerides and phospholipids (Automatic analyser model 
911 from Hitachi, Japan). The albumin/globulin ratio was calculated. 
Hepatic GSH and CYP 
Frozen liver tissue was homogenised in 0.01 M Tris-HCI/0.14 M KCI, pH 7.4 buffer (1:3 w/w) using a 
Potter-Elvejhem tissue homogeniser. Post-mitochondrial supernatant (S9-mix) was prepared by 
centrifugation at 10 000 g for 20 min. An aliquot of the S9-mix was stored at <-20°C until analysed for 
GSH. Microsomes for Cyp analysis were prepared by ultracentrifugation (100 000 g for 75 min) of S9-
mix. The microsomal pellet was resuspended in homogenisation buffer and centrifuged for 60 min at 
100 000 g. The washed microsomes were suspended in homogenisation buffer and stored at <-70°C 
until analysis. The S9-mix and microsomes were analysed for protein content using the Bradford 
method. Total glutathione (GSH) was measured according to [81] Total hepatic Cyp protein contents 
were determined according to [148]. 
Statistical analysis of toxicity parameters 
Body weights were evaluated by one-way analysis of covariance (covariate: body weight on day 0) 
followed by Dunnett's multiple comparison tests. The continuous neurobehavioral parameters (grip 
strength, landing foot splay), water consumption measured per animal, red blood cell and clotting 
potential variables, total white blood cell counts, absolute differential white blood cell counts, clinical 
chemistry values, routine urinary parameters (except for appearance), organ weights and hepatic 
levels of Cyps and glutathione were evaluated by one-way analysis of variance followed by Dunnett's 
multiple comparison tests. Rank order neurobehavioral data (gait score, arousal, reflexes), relative 
differential white blood cell counts, and urinary appearance were evaluated by Kruskal-Wallis non-
parametric analysis of variance followed by Mann-Whitney U-tests. Histopathological findings were 
analysed by Fisher's exact probability test. All analyses were two-sided. 
Liver RNA extraction 
Frozen liver samples were pulverised with mortar and pestle in liquid nitrogen before isolation of total 
RNA. Total RNA was extracted using Trizol according to the manufacturer's protocol (Invitrogen, 
Breda, The Netherlands) Total RNA was further purified using the RNEasy RNA purification kit, 
including a DNA digestion by RNAse-free DNAsel incubation (Qiagen, Westburg B.V., Leusden, 
Netherlands). RNA was checked for purity and stability by gel electrophoresis and the concentration 
was calculated from the OD2eo as determined spectrophotometrically. The yield of total RNA was 
calculated per g of frozen, pulverised liver. 
DNA microarray-based gene expression measurement (transcriptomics) 
A referenced design was used for microarray hybridisation, to account for dye-dependent effects, 
which are generally recognised to influence the outcome of dual-channel microarray experiments. 
Tester samples, equal amounts of RNA of each rat liver pooled per dose group, were fluorescently 
labelled with Cy5, while reference material, obtained from pooled RNA of the livers of the control rats, 
was labelled with Cy3. 
90 
Benzene 
Oligonucleotide microarray preparation 
Oligonucleotide microarrays were produced in collaboration with the University Medical Center Utrecht 
Genomics Laboratory [149]. The method according to [48], was described before, [2]. Briefly, about 
5000 different oligonucleotide fragments (Qiagen Operon, Westburg B.V., Leusden, The Netherlands) 
were arrayed in duplicate on glass slides. Additionally, spots with only buffer and control DNAs were 
included with no significant homology to rat DNAs. 
RNA labeling, hybridisation and scanning 
In vitro transcription reactions with indirect fluorescence labelling were performed according to Heijne 
et al. [2]. Hybridisation was performed for 16 hours at 42°C. Slides were washed and scanned, using a 
Packard Scanarray confocal laser scanner, using different lasers for the cy3 (wavelength 550nm) and 
cy5 (wavelength 650nm) channel. Two TIFF images per slide were saved for analysis using Imagene 
5.0 (Biodiscovery Inc., El Segundo.CA, USA). Settings were applied to automatically flag weak or 
negative signals and spots with a non-homogenous signal. Excel (Microsoft Corporation, Redmond, 
WA.USA) and SAS (SAS, Cary, USA) were used to further process and analyse the data. 
Microarray quality criteria 
Technical replicate hybridisations of the samples were performed until 4 microarrays were obtained 
that met our quality criteria. These criteria consider the homogeneity of the spot signal intensities, the 
effect of bleaching of the fluorescence, the number of manually flagged (excluded) spots, the spatial 
distribution of the signals over the slide surface, the balance between cy3 and cy5 signal intensity, the 
number of saturated spots and the quality of the slide with respect to other slides of the experiment. 
Data processing 
After image analysis, the local background intensity was subtracted from the signal intensity for each 
spot. Background intensities outside the cDNA spots were very low and homogeneous. Fluorescence 
intensity in control spots that account for non-specific hybridisation and background fluorescence were 
used to determine a minimal signal intensity threshold value of 1.5 for the two channels. Flagged spots 
and controls were excluded from further interpretation. Genes for which less than 70 % of the 
microarrays delivered a reliable signal were excluded from further interpretation. Ratios of the 
background-corrected intensities of tester over reference were calculated for each slide and, to 
account for technical variations introduced during labeling or hybridisation, data were normalised using 
the lowess algorithm [103] in SAS. Data were log-transformed, with base 2, and excluded values were 
replaced by 0. Statistical analysis of the changes was performed using One-way ANOVA in SAS. 
Genes with an ANOVA p-value < 0.01 were considered to have changed statistically significantly. 
Student's t-tests were performed to determine at which dose significant changes occurred. For 
presentation in the tables, the average log(2) gene expression levels were corrected for the 
expression levels in the controls. The ANOVA was performed with, and repeated without, the three 
slides identified by PCA as aberrant from the others, and similar results were obtained. PCA and 
PCDA were performed on the filtered, normalised and log(2) transformed data. Excluded values were 
replaced by 0. 
An unsupervised PCA was used, according to Heijne et al., (2003) [2], to assess the differences 
between the individual microarray profiles (not shown). This analysis indicated that, though meeting 
the quality criteria, several microarray slides (s26, s91, s93) were aberrant from the others, 
independent of the treatment. These slides were excluded in the subsequent PCDA. The PCDA was 
performed as described above for the urine metabolomics data, and a score plot was drawn. The 
genes with the largest significance for the differences between samples treated with benzene and 
controls were found by ranking of the genes according to D#1. 
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V.3 Results 
Rats were exposed to benzene for 28 days and hepatic gene expression was determined, 
complementary to conventional toxicity parameters and metabolomics analysis of the urine. 
No chemical-related mortality occurred, and the daily clinical observations and the 
neurobehavioral assessment showed no treatment-related changes. After dosing, animals 
given benzene at 800 mg/kg/day showed the following, transient symptoms: (facial) tremors 
on at least 11 days, walking with hunched back, excited, lethargy, ataxia, blepharospasm, 
flattened ears, increased respiratory frequency on one or a few days in weeks 1 and 2. Body 
weight (Table V.1) and food consumption were dose-dependently decreased from 200 
mg/kg/day. The terminal body weight was decreased by about 10% at 200 mg/kg/day and 
about 20% at 800 mg/kg/day. Water consumption was not affected. 
Organ weights and pathology 
Animals given benzene showed statistically significant increased relative liver weights at 800 
mg/kg/day, and decreased weights of spleen and thymus (table V.1). Studies have shown 
that in subacute studies, an increase in relative liver weight should be considered as a liver-
specific change that can not be ascribed to reduction of body weight only [150],[151]. Various 
mechanisms that could explain the increased relative liver weight were described [151]. In 
the case of benzene, the increased expression of drug metabolism enzymes in the liver 
might be the most important reason for the relative increase of the liver weight. Concurring 
histopathological effects were not observed, though at higher dose levels, induction or rough 
endoplasmatic reticulum (RER) and hypertrophy might be found. Macroscopic examination 
revealed no changes which could be ascribed to the administration of benzene. 
Histopathological examination showed a treatment-related decrease in the number of B-
lymphocytes in the marginal zone of the spleen at 800 mg/kg/day (incidences: 0/5 at 0, 10 
and 200 mg/kg/day , 4/5 at 800 mg/kg/day). 
Table V.1. Body weights and relative organ weights. 
Values represent group means (n=5) and standard deviations. 
Benzene 
(mg/kg/day) 
0 
10 
200 
800 
body 
(g) 
210.7 ±7.2 
205.6 ± 4.6 
194.0 ±7.6 
169.8 ±1.7** 
rel. liver 
(g/kg BW) 
40.1 ±0.6 
39.7 ±0.5 
41.1 ±0.6 
44.3 ±1.7* 
rel. kidney 
(g/kg BW) 
7.15 ±0.07 
7.08 ± 0.03 
7.19 ±0.09 
7.47 ±0.14 
rel. spleen 
(g/kg BW) 
2.31 ± 0.04 
2.35 ± 0.04 
1.99 ±0.04** 
1.71 ±0.06** 
rel. thymus 
(g/kg BW) 
1.80 ±0.05 
1.74 ±0.04 
1.74 ±0.07 
1.56 ± 0.04* 
Statistical analysis: ANOVA + Dunnetts tests: significance *: p< 0.05, **: p< 0.01 
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Urine analyses and metabolomics 
Conventional urine analysis showed statistically significant decreases in the amount of 
creatinine excreted per 24 h and in the concentrations of glucose and protein at 800 
mg/kg/day (data not shown). The lower concentrations of glucose and protein were not 
considered to be of toxicological significance because the excretion of these analytes per 24 
hr was not altered significantly. 
Metabolomics analysis of urine samples of the rats determined the metabolite contents by 
NMR spectroscopy. PCDA was used to discern the NMR patterns of the samples from the 
different exposure levels. Results of the PCDA are visualised in figure V.1. This score plot 
reveals the differences between the urine samples, based on the treatments. The pattern of 
the metabolite contents in urine changed in a dose-dependent manner. While the low dose 
exposure samples closely resembled the controls, the high dose samples were very different. 
The interanimal variation within the groups (triplicate measurements of 5 rat urines) was 
smaller than the difference between the treatment groups. 
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Figure V.1. Urine metabolomics: PCDA Score plot 
Score plot of principal component analysis with discriminant (PCDA) of NMR spectra, 
reflecting the metabolite profiles of urine. Each symbol in the score plot represents an 
individual NMR spectrum. Per group, samples of 5 rats were measured in triplicate. The 
symbols represent: 0: controls; x: exposure to low dose of benzene (10mg/kg/day); + : mid 
dose of benzene (200mg/kg/day); and *': high dose of benzene (800 mg/kg/day). 
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Figure V.2. Hematology 
Analysis of blood of rats exposed for 28 days to 0, 10, 200 or 800 mg/kg/day of benzene. 
Group average values and s.e.m. are represented, panel A. White blood cell counts (WBC), 
panel B. Numbers of lymphocytes, panel C. Red blood cell counts (RBC), panel D. 
Hemoglobin levels in blood. Statistical significance is denoted with **: p < 0.01, *: p< 0.05. 
Hepatic Total GSH 
Figure V.3. Hepatic glutathione (GSH) levels. 
Group average values and standard deviations are represented. Statistical significance (p 
0.01) is denoted with **. 
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Analysis of blood and liver 
Haematology revealed that total white blood cell count (Figure V.2A) and lymphocyte count 
(Figure V.2B) were dose-dependently decreased from 200 mg/kg/day . Red blood cell count 
and hemoglobin levels slightly increased (n.s.) (Figure V.2C and 2D). Clinical chemistry 
values showed no statistically significant differences in plasma of animals given benzene and 
controls (data not shown). The levels of total glutathione in liver were dose-dependently 
increased from 200 mg/kg/day (p < 0.01) (Figure V.3). The total hepatic Cyp contents 
showed no significant differences between animals given benzene and controls. The yield of 
the RNA isolation from pulverised and frozen liver tissue was lower in the samples of the 
benzene-treated rats (data not shown). The yield in the high dose group was 66 % of the 
yield in the controls (n=5, Student's T-test p = 0.01). 
Gene expression analysis 
Liver gene expression was measured in quadruplo per treatment group. Statistical analysis 
of variance (ANOVA) was used to identify which genes were significantly altered by benzene 
at one or more dose levels. Table V.2 lists the genes for which expression was statistically 
significantly modulated by benzene. Exposure to benzene did not elicit changes in mRNA 
levels larger than four fold, though many small changes were statistically significant at one or 
more dose levels. Genes with altered expression upon benzene treatment were categorised 
according to biological processes including drug metabolism, GSH metabolism and oxidative 
stress, fatty acid and cholesterol metabolism, glycolysis and protein synthesis. For a 
selection of relevant genes, the expression levels were shown in figure V.5. 
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Figure V. 5. Benzene-induced expression changes for a selection of genes. 
Average expression levels (log(2)) and standard deviation (n = 4) are shown. Statistical 
significance is denoted as: *** p < 0.001; ** p < 0.01, * p < 0.02 for T-tests above the bars 
and for ANOVA next to the titles. Dose levels: CO: control, low: 10 mg/kg/day, mid: 200 
mg/kg/day, high: 800 mg/kg/day. Abbreviations: Aldhl: aldehyde dehydrogenase 1; Ah: 
Aryl hydrocarbon; Cyp2e1: Cytochrome P450 enzyme 2E1; G6pc:glucose-6-phosphatase; 
G6pd:glucose-6-phosphate dehydrogenase; Gclc: gamma-glutamylcysteine synthetase; 
mEH (=Ephx1): microsomal epoxide hydrolase; Nqo1: NAD(P)H dehydrogenase, quinone 1 
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Figure V.4. Score plot ofPCDA of hepatic gene expression changes 
Score plot of the principal component analysis with discriminant (PCDA) of trancriptomics 
measurements of hepatic gene expression. Each symbol in the score plot represents an 
individual DNA microarray measurement. Per group, pooled samples of 5 rats were 
measured in triplicate. For each symbol, the slide identification number of the DNA 
microarrays is provided (s#). CO: controls; B: benzene; low: benzene 10 mg/kg/day of 
benzene; mid: 200 mg/kg/day of benzene and high 800 mg/kg/day of benzene. 
Table V. 3a PCDA: Genes with highest D#1 score (most reduced by benzene) 
D#1 GeneName Acc# 
1.95 Similar to SON protein (LOC304092) 
1.47 ribosomal protein L35 
1.33 ATP synthase, H+ transporting, mit.F1 F0 complex 
1.27 Large subunit ribosomal protein L36a 
1.23 NADH ubiquinone oxidoreductase subunit B13 
1.21 Ribosomal protein L37 
1.21 Ribosomal protein S24 
1.18 Glucose-6-phosphatase 
1.15 Ribosomal protein L35a 
1.13 Fatty acid synthase 
AW 144637 
X51705 
D13121 
NM_031105 
NM_012985 
NM_031106 
NM_031112 
NM_013098 
NM_021264 
NM 017332 
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In addition to ANOVA, the multivariate statistical technique PCDA was performed to identify 
significantly modulated genes upon benzene exposure. Figure V.4 shows the score plot of 
the PCDA analysis. It demonstrates that independent of the dose, the benzene treatment 
altered the pattern of liver gene expression. Along the horizontal axis (D#1), the gene 
expression profiles from the benzene-treated rats were distinct from the controls. Thus, 
genes were sorted according to the scores on D#1, to reflecting their individual contribution 
to the differences in the gene expression profiles. Genes with the highest positive or negative 
contribution are listed in tables 3 a, b. 
Table V.3b PCDA: Genes with lowest score on D#1 (most induced by benzene) 
D#1 GeneName Acc# 
-2.45 apolipoprotein B (apoB) X55969 
-1.88 Retinoid X receptor alpha NM012805 
-1.75 Apobec-1 complementation factor, APOBEC-1 stimulating protein NM_133400 
-1.49 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65) BU671201 
-1.44 fatty acid elongase 1 NM_134382 
-1.44 Hepatic nuclear factor 4 (alpha transcription factor 4) NM_022180 
-1.42 D-amino acid oxidase BF545995 
-1.4 Similar to Eif4g2 protein (LOC361628) BU671233 
-1.39 Similar to Polymerase delta interacting protein 38 (LOC287544) BF543017 
-1.37 Similar to transmembrane protein TM9SF3 (LOC309475) AA800019 
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V.4 Discussion 
A subacute, 28-day oral exposure study examined the toxicity of benzene in rats, and the 
expression of 5000 different liver genes was determined by oligonucleotide microarrays. The 
critical toxic effects of benzene were the decrease of white blood cells, and lower spleen and 
thymus weights. In addition, benzene caused a slight decrease in body weight probably 
caused by growth retardation through reduced food intake [150]. Benzene slightly induced 
the relative liver weight and hepatic GSH content, but no other hepatic effects observed with 
histopathology or clinical chemistry. 
Urine analysis and metabolomics 
Analytical methods exist to monitor benzene levels in expired breath and blood [152]; 
[153],[154],[155],[156]. However, the current biomarkers of exposure are not specific 
Because metabolites of benzene excreted in the urine could provide a characteristic profile, 
NMR and pattern recognition techniques were used to assess exposure to benzene in urine 
samples. This approach enabled to specifically and robustly distinguish urines from the 
different exposure levels based on metabolite profiles. 
Benzene-induced gene expression changes 
Many liver genes were found to be differentially expressed after exposure to benzene (table 
V.2A). Pattern recognition techniques enabled to distinguish treated from control samples by 
the hepatic gene expression profile and to identify the genes that were most significantly 
affected by benzene. Most likely due to the critical hematotoxic effects of benzene at the doe 
levels tested, a marked dose-dependency of the hepatic changes was not observed. 
Nevertheless, significant changes in liver gene expression were identified at all dose levels 
and these were categorised according to biological processes. 
Biotransformation 
Many biotransformation enzymes were affected by benzene. Most pronouncedly induced 
were several Aldhs and Adhs, Afar, and several conjugation enzymes like GSTs, UGTs and 
SULTs (all 2 to 2.5 fold induced). The induction of these enzymes could enhance benzene 
detoxification. The induction of Aldhs (figure V.5) might be a functional response to (toxic) 
muconaldehyde metabolites. Also enzyme inducing agents like phenobarbital induced Aldh 1 
expression, via the constitutive androstane receptor (CAR) [157];[158]. Enzymes known to 
be crucial for benzene bioactivation, Cyp2e1 and microsomal epoxide hydrolase (Ephxl) 
were induced (figure V.5). This was in agreement with recently observed, 2.2-fold, induction 
of Cyp2e1 gene expression and protein upon 14-day benzene exposure in rats [159]. 
Furthermore, the absence of Cyp2e1, in knock-out mice, impaired benzene-induced toxicity 
[160].The present induction of Cyp2e1 might aggravate toxic effects. The importance of the 
Ephxl for development of toxicity was shown in male but not in female mice [144]. 
Upregulation of Ephxl could enhance bioactivation of benzene, thereby increasing the toxic 
effects. Hepatic Nqo1, which plays a role in detoxification of benzene metabolites was 
upregulated by benzene (figure V.5). Polymorphisms in Nqo1 in humans were reported to 
affected susceptibility to benzene poisoning [161],[162]. Nqo1 deficient mice were more 
susceptible to benzene-induced (hemato)toxicity [144]. Previously, the Aryl hydrocarbon (Ah) 
receptor was reported to be involved in benzene toxicity [163], and to induce (human) 
Cyp1a1, Cyp1a2 and phase II enzymes [164]. In agreement, a dose-dependent upregulation 
of the Ah receptor was observed, though changes were not established with statistical 
significance. 
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Oxidative stress and GSH metabolism 
Because benzene metabolites are highly reactive they might induce oxidative stress 
Characteristic induction of heme oxygenase and ferritins, nor of other gene expression 
markers of oxidative stress was observed. Expression of metallothioneins was slightly 
reduced. Enhanced protection from reactive metabolites might come from increased hepatic 
GSH levels, probably a results from induction of gamma glutamylcysteine synthetase light 
chain (Gclc), the rate-limiting enzyme in GSH biosynthesis. Also G6pd, involved in GSH 
synthesis, was induced at high doses (figure V.5). 
Hemoglobin metabolism 
The hepatic gene expression of both hemoglobin alpha and beta subunits was induced upon 
exposure to 10 or 200 mg/kg/day. Concurrently, slight induction of a key enzyme in 
hemoglobin biosynthesis, aminolevulinate synthase 2 was observed. NADPH diaphorase 
(Dial) can increase hemoglobin levels when NADPH is provided by G6pd [130]. Dial was 
slightly induced, and also G6pd was induced at high dose levels. In agreement with the gene 
expression changes, plasma levels of hemoglobin were elevated after exposure to benzene 
(figure V.2). 
Glycolysis and gluconeogenesis 
Enzymes important in glycolysis and gluconeogenesis were differentially expressed by 
benzene. G6pd was induced more than 2.5-fold by the high dose of benzene. G6pc was 
repressed two-fold and expression of Hnf4, which regulates G6pc and glucokinase gene 
expression [165]; [166] was increased by benzene. The PCDA identified Hnf4 as one of the 
most pronouncedly differentially expressed genes between controls and benzene-treated 
samples. Also the transcription factor Hnf6, with a reported role in glucokinase induction 
[167],[168],[169], seemed to be induced. The enzyme 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase 1 involved in regulation of glycolysis was downregulated. The data suggest 
enhanced glycolysis and/or attenuated gluconeogenesis. 
Fatty acid, cholesterol and lipid metabolism 
Inductions of gene expression for many enzymes involved in cholesterol and fatty acid 
metabolism were measured (Table V.2B.). These were visualised using Genmapp 
(www.genmapp.org) in figures V.6 and V.7. Expression of a key enzyme in cholesterol 
metabolism, HMG-CoA reductase, was dose-dependently upregulated (figure V.5). In 
agreement, levels of plasma cholesterol (and phospholipids) were found to be slightly 
elevated in benzene-treated groups (n.s.). Both with ANOVA and PCDA, apolipoprotein B 
(ApoB) was identified as one of the most pronouncedly induced genes, along with Acf, the 
Apobec-1 complementation factor, involved in ApoB mRNA cytidine to uridine editing [170] 
[171]. Also noteworthy was the increased expression of the sterol regulatory element binding 
protein (Srebfl) at all dose levels. Srebfl binds to regulatory element in genes involved in 
fatty acid metabolism, like acetyl-CoA carboxylase beta. Remarkably, expression of acetyl-
CoA carboxylase beta was slightly increased at high dose exposure, but slightly decreased 
at mid or low dose. 
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Possibly associated to lipid metabolism was the slight reduction of expression of the liver-
specific transcription factor Lisch7. Lisch7 binds to lipoproteins including ApoB and ApoE (rat 
genome database: rgd.mcw.edu). Yen and colleagues [172] speculate that Lisch7 is a rate-
limiting step for the clearance of dietary triglycerides and plays a role in determining their 
partitioning between the liver and peripheral tissues. Lastly, an important molecular receptor, 
retinoid X receptor alpha, was upregulated at all dose levels. The RXR forms dimers with 
other nuclear receptors (eg. PPAR) and regulates expression of many genes, related to ao. 
fatty acid metabolism [164] including acyl CoA oxidase, which was also induced by benzene. 
In conclusion, the elevated plasma levels of phospholipids and cholesterol may result from 
enzyme induction upon benzene treatment. 
Protein and RNA synthesis 
Expression of various ribosome subunits and several translation factors was reduced. While, 
according to statistical analysis, few ribosomal subunits were significantly downregulated 
(table V.2), PCDA showed reduced expression of 18 ribosomal subunits amongst the 100 
genes most significantly affected by benzene treatment (see table V.3). Possibly in 
agreement with this, less total RNA was isolated from treated compared to control liver 
samples. 
Hematopoiesis 
Benzene exposure affected the lymphocytes. Possibly in relation to this, hepatic expression 
of the transcription factor Hnf6, was characteristically modulated by benzene. The low and 
mid dose reduced its expression, while the high dose induced Hnf6. Besides its role in 
glycolysis, Hnf6 is involved in B lymphopoiesis in (fetal) liver [169]. Further studies will have 
to determine whether induction of this transcription factor is related to hematotoxicity by 
benzene. A gene encoding the "hematopoietically expressed homeobox" was downregulated 
at all dose levels. This homeobox is suggested to have a regulatory function in 
hematopoiesis, though its precise function has yet to be resolved. 
Chromosomal aberrations 
Chromosome aberrations might be reflected in expression changes of genes located on 
specific chromosomes. In humans, chromosomes 5 and 7 were found susceptible to 
aneuploidy upon benzene exposure [173]. Furthermore, the hydroquinone metabolite of 
benzene in vitro, increased trisomy and monosomy of chromosomes 7 and 8. [174]. Analysis 
of the chromosomal location of the genes affected by benzene (Table V.2), revealed no 
indications for chromosome-specificity of changes. 
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Table V.4 Specificity of gene expression changes in rat 
Comparison of hepatic gene expression changes induced by bromobenzene (BB), 
acetaminophen (A) and benzene (B). BB and APAP were given as a single dose, and gene 
expression changes were followed 1-2 days after exposure (Heijne et a/., 2004) and (Heinloth et 
a/., 2004). Benzene (present study) was given repeatedly for 28 days. 
Symbol 
Ephxl 
Afar 
Gsta 
Nqo1 
Cyp2c12 
Cyp2e1 
Aldh 
Ugt 
G6pc 
G6pd 
Gclcl 
Mt 
Timpl 
Prdxl 
HO-1 
Ftl.Fth 
Orm 
Mug 
Gene 
microsomal epoxide hydrolase 
Aflatoxin B1 aldehyde reductase 
Glutathione-S-transferase Alpha 
NADPH dehydrogenase.quinonel 
Cytochrome P450 15-beta 
Cytochrome P450, 2e1 
Aldehyde dehydrogenases 
UDP-glucuronosyltransferases 
Glucose-6-phosphatase 
Glucose-6-phosphate dehydrogenase 
Glutamylcysteine gamma synthetase light 
chain 
Metallothioneins 
Tissue inhibitor of metalloproteinase 1 
peroxiredoxinl 
heme oxygenase 1 
Ferritin light and heavy chain 
orosomucoid 
alpha(1)-inhibitor 3 
AccJ1 
NM_012844 
NM_013215 
NM_031509 
NM_017000 
NM_031572 
NM_031543 
div 
div 
NM_013098 
NM_012942 
J05181 
div 
ND 
D30035 
NM_012580 
J00696 
NM_017351 
Acc.#2 
AA900551 
AA923966 
AA818339 
AA899180 
AA818124 
AA818896 
div 
div 
AA964628 
AA923963 
AA965220 
div 
AA957593 
AA875245 
AA874884 
AI029162 
AA817965 
8B 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
A 
+ 
-
0/+ 
+ 
-
-
0 
0/+ 
-
0 
? 
+ 
+ 
+ 
+ 
0/+ 
+? 
-
B 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
-
+ 
+ 
0 
? 
0 
0 
0 
ns 
ns 
various ribosomal subunits 
various proteasome subunits 
Hbbeta hemoglobin beta 
Hbalpha hemoglobin alpha 
various fatty acid metabolism genes 
Bhmt Betaine-homocysteine methyltransferase 
Beta actin 
div div + + 
div div + 0 0/-
X05080 AA818084 + ND + .. 
NM_013096 AA819784 + - + .. • 
+ 
NM_030850 AA901407 - + + 
NM 031144 AA859846 + ? + 
1
 Accession number of the DNA fragment used on the 
study. 
oligonucleotide microarrays in the B 
Accession number of the DNA fragment used on the cDNA microarrays in the BB and APAP 
studies 
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Gene expression changes in bone marrow 
Recently, two reports described gene expression in bone marrow of mice exposed to 
benzene [175] and [176]. Faiola and co-workers tentatively concluded that upon 2-weeks of 
inhalatory benzene exposure, hematopoietic stem cells were not actively proliferating and the 
DNA repair genes were not significantly altered. Yoon and co-workers analysed exposure to 
benzene in wildtype and p53-knockout mice [175]. The authors suggested that benzene 
induced apoptosis through p53-mediated caspase 11 activation. A slight induction of Cyp2e1 
and Mpo was observed in bone marrow, though the statistical significance of the changes 
was not indicated. Further studies are needed to assess the relation between gene 
expression changes in liver, blood and bone marrow, in relation to the toxic effects of 
benzene. 
Specificity of gene expression changes: benzene compared with hepatotoxicants 
Benzene induced changes in hepatic gene expression after 28-day exposure, though it 
remains unclear whether these are reversible or irreversible effects, leading to toxicity. To 
determine the specificity of the effects, they were compared to acute hepatic gene 
expression changes in recent studies with the known hepatotoxicants BB[2] and [3] and 
APAP [69]. Both BB and APAP provoked hepatic centrilobular necrosis within two days, and 
both dose-dependently elicited hepatic gene expression changes in common biological 
pathways. Also, a dose-dependent increase in relative liver weight was observed [3]. Despite 
of technical variation between the studies, concordance was found between many gene 
expression changes by BB and APAP. BB as well as APAP deregulated general processes 
like drug metabolism, the acute phase response, fatty acid and cholesterol metabolism, 
protein synthesis and glycolysis. Likewise, 28-days exposure to benzene elicited changes in 
most of these processes, though the effects were less pronounced, both in the number and 
the magnitude of the changes, and often not dependent on the dose level. Therefore, a direct 
comparison of hepatic gene expression changes was hampered, and the gene-by-gene 
comparison was limited to the most pronounced effects at the high dose levels, between 
effects of BB, APAP and benzene (Table V.4). Benzene and BB commonly induced the 
biotransformation enzymes Ephxl, Gsta, Afar and aldehyde dehydrogenases. For APAP, 
this response was not as pronounced. The pattern of gene induction suggests the 
involvement of the electrophile response element (EpRE or ARE) in the transcriptional 
regulation. This element was found to mediate expression of genes like Afar, Gsta, Gclc, and 
ferritin, peroxiredoxinl and Nqo1 [86,177]; [124]; [87]. Oxidative stress-induced expression of 
HO-1, Timpl and metallothioneins was found rapidly after single dosage of BB and APAP, 
but not after 28-days exposure to benzene, though this might also depend on the duration of 
the treatment. Six hours after BB dosage, hepatic GSH levels were largely depleted, but they 
were restored after 24 hours, most likely through the induction of the Gclc enzyme. Also 
benzene induced Gclc and, in agreement, GSH levels were elevated after 28 days of 
exposure. G6pd was induced and G6pc repressed in common by BB, APAP and benzene. 
The Cyp2c12 gene was commonly decreased by all compounds, and Cyp2e1, decreased by 
BB and APAP, was induced by benzene. In summary, benzene, which induced liver 
enlargement but no histopathological effects, elicited several gene expression changes in 
common with known hepatotoxicants. However, there was a clear difference in the number, 
the magnitude of the hepatic gene expression changes and the dose-dependency. 
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Conclusion 
In summary, without provoking overt hepatotoxicity, benzene changed expression of 
many liver genes in rats. In addition to gene expression profiling, urine metabolite 
profiling (metabolomics) proved useful to specifically and robustly assess benzene 
exposure. Benzene altered expression of genes with putative implications for (its own) 
biotransformation, fatty acid, cholesterol and hemoglobin metabolism, and other 
processes. Hepatic gene expression changes were related to observed increases in 
relative liver weight and GSH levels, and possibly also to toxic properties of benzene. 
The specificity of liver gene expression changes was determined in a comparison of 
the benzene-induced effects with those of hepatotoxicants BB and APAP. Several 
genes were transcriptionally regulated in common by the chemicals, such as through 
suggested involvement of the electrophile response element. However, there was a 
clear difference between benzene and the model hepatotoxicants in the number, the 
magnitude of the hepatic gene expression changes and the dose-dependency of the 
effects. 
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Abstract 
This study analysed hepatic gene expression changes and subacute toxicity 
markers in rats after 28-day exposure to trichloroethylene (TCE). TCE is a 
widely used chemical, nephrotoxic and putatively hepatotoxic. Hepatic 
metabolism determines the toxicity of TCE. The aim was to characterise the 
hepatic gene expression changes in relation to hepato-pathological changes 
induced by TCE. Gene expression changes were determined with DNA 
microarrays in livers of male F344 rats treated for 28 days with TCE. and 
subacute toxicity was assessed after exposure to 50. 500 and 2000 
mg/kg/day. Metabolite profiles of urine were analysed in a metabolomics 
approach, to specifically and robustly assess exposure to TCE. even at 50 
mg/kg/day. 
Conventional toxicology revealed nephrotoxicity, but no hepatotoxicity 
besides increased relative liver weight from 500 mg/kg/day. Transcriptomics 
revealed dose-dependent hepatic gene expression changes, from 50 
mg/kdg/day. TCE markedly induced expression of biotransformation (ao. 
Cyp2e1. Gsta. Aldhl) and beta oxidation enzymes, and many others. The 
changes were related to bioactivation and detoxification of TCE. with possible 
consequences for nephrotoxicity and carcinogenicity. For example, elevated 
hepatic glutathione biosynthesis and induction of glutathione-S-transferases 
could enhance formation of nephrotoxic metabolites. Decreased Fiepatic 
expression of alpha 2u-globulin explained why TCE did not cause hyalin 
nephropathy. TCE modulated several genes in common with hepatotoxicants 
that caused liver necrosis or peroxisome proliferation, and with benzene, 
though many transcriptome changes were characteristic for TCE exposure. In 
conclusion, this study characterised TCE-induced hepatic gene expression 
changes at doses that induced weight increase but no other hepatotoxic 
effects. 
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VI.1 Introduction 
Transcriptomics methods, that measure gene expression with DNA microarrays, enabled to 
study cellular mechanisms in great detail. A variety of applications of these methods in 
toxicology (toxicogenomics) has been reported [34],[21],[22],[27]. In our laboratory, gene 
expression changes in liver were characterised in detail after exposure to the hepatotoxicant 
bromobenzene (BB) [2];[3]. Simultaneously, Heinloth and colleagues have analysed gene 
expression changes after a high dose of acetaminophen (APAP) [69]. BB and APAP are 
well-known hepatotoxicants that caused hepatic necrosis, increased the relative liver weight 
and, in parallel, changed the expression of many hepatic genes. These changes in gene 
expression were related to, a.o., biotransformation, glutathione metabolism, protein synthesis 
and proteolysis, fatty acid and cholesterol metabolism, oxidative stress and the acute phase 
response. 
To further investigate the specificity of hepatic gene expression changes in relation to 
hepato-pathological changes, we used transcriptomics to study the effects of benzene [5]and 
trichloroethylene (TCE) (this paper), and compared the effects with those of the model 
hepatotoxicants. The liver plays a central role in the biotransformation, ultimately leading to 
bioactivation and detoxification of benzene as well as TCE. TCE is a solvent applied in large 
quantities to produce other chemicals, and consumer products such as paint removers, 
adhesives, degreasers and typewriter correction fluid contain TCE. Human exposure may 
occur through contaminated water or ambient air. The metabolism and toxicity of TCE have 
been reviewed in detailed [178];[179];[180]. TCE is not considered a (model) hepatotoxicant. 
Nevertheless, in parallel to nephrotoxicity, TCE induced effects in liver such as weight 
increase [181];[128] and increased peroxisomal B-oxidation activity [182];[183]. TCE induced 
tumours in rats and mice, but there is an ongoing debate about its (nephro)carcinogenicity in 
humans [184-186]. 
The purpose of the present study was to investigate the specificity of changes in hepatic 
gene expression, upon exposure to the industrial chemical TCE. For this purpose, rats were 
exposed to trichloroethylene for 28 days, and subacute toxicity was determined with 
conventional toxicological methods, while transcriptome changes in the liver were 
determined with oligonucleotide DNA microarrays. In parallel with conventional urine 
analysis, a metabolomics approach with NMR and pattern recognition was used to analyse 
the urine, to specifically and robustly demonstrate exposure to TCE in urine samples. The 
effects of TCE at the hepatic transcriptome level were compared with gene expression 
changes elicited by model hepatotoxicants that cause hepatic necrosis, and with effects of 
benzene [5]. Because earlier studies showed peroxisome proliferation upon exposure to TCE 
[182], the data were also compared to effects of compounds inducing peroxisome 
proliferation. 
113 
Chapter VI 
VI.2 Materials and Methods 
TCE was obtained from Aldrich Chemical Co. (Milwaukee, USA), and corn oil from Remia (Den 
Dolder, The Netherlands). Male F344 rats (CDFF® (F344)/CrlBR) from Charles River Wiga GmbH 
(Sulzfeld, Germany). Were kept in accordance with the general principles governing the use of 
animals in toxicity experiments of the European Communities (Directive 86/609/EEC) and Dutch 
legislation (The Experiments on Animals Act, 1997). The rats were housed in macrolon cages with 
stainless steel grid covers and wood shavings as bedding material, five rats per cage, in a room 
maintained at 22 ± 2°C with a relative humidity of 30-70% and a 12 h light/dark cycle. Throughout the 
study, feed (a powdered, cereal-based, closed-formula rodent diet (Rat and mouse No. 3 Breeding 
diet; RM3) from Special Diets Services (Witham, England)) and tap water were freely available. 
Following an acclimatization period of 8 days, the 5-week old rats were allocated randomly to groups 
of five, in such a way that the mean body weights were about the same in all groups. 
Administration route, duration and dose levels 
TCE was dissolved in com oil and administered by oral gavage in a volume of 5 ml per kg body weight 
at dose levels of 50, 500 and 2000 mg/kg/day, once daily for 28 consecutive days, for the last time on 
the day before scheduled sacrifice. The highest dose level was intended to induce toxic effects but no 
severe suffering, death or marked growth retardation. The low- and mid-dose levels were selected to 
demonstrate dose-effect relationships, and no toxic effects at the lowest dose level [178] Controls 
were dosed with corn oil only. The dose volumes were adjusted twice per week for changes in body 
weight. Fresh TCE solutions were prepared once per week and stored at 2-10°C in portions sufficient 
for one day. 
Observations and analyses 
General clinical observations were made daily before and after dosing. The rats were weighed twice 
per week and at final necropsy. Food consumption was measured per cage, over successive periods 
of 7 days (wk 1-3) or 4 days (wk 4). Water consumption was measured per cage, on three consecutive 
days in wk 1-3. Water consumption of individual animals was measured during the 24 h urine 
collection period in wk 4. Routine neurobehavioral functioning was evaluated on day 22 before the 
daily dosing, according to Heijne ef a/.[5]. 
Urine analysis and metabolomics 
Urine was collected at the end of the fourth week of treatment. The rats were kept separately in 
metabolism cages for two consecutive days. After one day of acclimatisation, 24 h urine samples were 
collected, in ice-cooled containers. Each sample was characterised with respect to appearance, 
volume, density (Bellingham and Stanley refractometer), total protein (Cobas-Bio centrifugal analyser), 
glucose, creatinine, alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), lactate 
dehydrogenase (LDH) and N-acetyl-ft-glucosaminidase (NAG) (Automatic analyser model 911 from 
Hitachi, Japan). Protein, glucose, creatinine and the enzyme activities were expressed as units 
excreted per 24 h by multiplying the concentrations measured by the volume of the urine produced. 
The urine samples were also analysed with a metabolomics approach, by NMR spectroscopy 
according to Lamers ef al. [126] and Heijne ef al. [4]. The multivariate statistical technique PCDA was 
used to determine differences in the NMR profiles of the metabolites in urine. PCDA [147] is a semi-
supervised method based on principal component analysis that uses the dose levels as a discriminant 
to optimise the contrast between the treatment groups. After calculations, the differences between the 
individual profiles were visualised in a score plot. Along the axis of the score plot, the D#1 and D#2 
values were plotted. The score plot displayed every individual profile (in this case NMR spectrum) as 
one dot, and the distance between the dots reflects the degree of similarity between the individual 
profiles. 
Haematology 
At final necropsy, blood samples were collected from the abdominal aorta using K2-EDTA as 
anticoagulant. Each sample was analysed for haemoglobin, packed cell volume, red blood cell count, 
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total white blood cell count, thrombocyte count (Sysmex K-1000 Haematology Analyser from Toa 
Medical Electronics Co., Ltd, Japan), differential white blood cell counts (microscopic examination of 
stained blood smears), and prothrombin time (Normotest, Nyegaard and Co. A/S, Norway). Mean 
corpuscular volume, mean corpuscular haemoglobin and mean corpuscular haemoglobin 
concentration were calculated. 
Clinical chemistry 
At final necropsy, blood samples were collected from the abdominal aorta in heparinised tubes. The 
samples were centrifuged and the plasma was analysed for ASAT, ALAT, ALP, GGT, LDH, total 
protein, albumin, glucose (non-fasting), urea, creatinine, total bilirubin, total cholesterol, triglycerides 
and phospholipids (Automatic analyser model 911 from Hitachi, Japan). The albumin/globulin ratio 
was calculated. 
Hepatic GSH and Cyp 
Frozen liver tissue was homogenised in 0.01 M Tris-HCI/0.14 M KCI, pH 7.4 buffer (1:3 w/w) using a 
Potter-Elvejhem tissue homogeniser. Post-mitochondrial supernatant (S9-mix) was prepared by 
centrifugation at 10 000 g for 20 min. An aliquot of the S9-mix was stored at <-20°C until analysed for 
GSH. Microsomes for Cyp analysis were prepared by ultracentrifugation (100 000 g for 75 min) of S9-
mix. The microsomal pellet was resuspended in homogenization buffer and centrifuged for 60 min at 
100 000 g. The washed microsomes were suspended in homogenization buffer and stored at <-70°C 
until analysis. The S9-mix and microsomes were analysed for protein content using the Bradford 
method. Total glutathione (GSH) was measured according to Anderson ef al. [81] Total hepatic Cyp 
protein contents determined according to Rutten era/., [148]. 
Organ weights and pathology 
At the end of the treatment period, the rats were killed by exsanguination from the abdominal aorta 
under C02 /02 anaesthesia and examined grossly for pathological changes. The kidneys, liver, 
prostate, spleen, testes and thymus were weighed. After fixation in a 4% neutral buffered solution of 
formaldehyde, the kidneys, liver, spleen and thymus were processed, embedded in paraffin, sectioned 
at 5 urn, stained with haematoxylin and eosin, and examined by light microscopy. In addition, parts of 
these organs were snap-frozen in liquid nitrogen and stored at < -70°C. 
Statistical analysis of conventional toxicity parameters 
Body weights were evaluated by one-way analysis of covariance (covariate: body weight on day 0) 
followed by Dunnett's multiple comparison tests. The continuous neurobehavioral parameters (grip 
strength, landing foot splay), water consumption measured per animal, red blood cell and clotting 
potential variables, total white blood cell counts, absolute differential white blood cell counts, clinical 
chemistry values, routine urinary parameters (except for appearance), organ weights and hepatic 
levels of Cyps and GSH were evaluated by one-way analysis of variance followed by Dunnett's 
multiple comparison tests. Rank order neurobehavioral data (gait score, arousal, reflexes), relative 
differential white blood cell counts, and urinary appearance were evaluated by Kruskal-Wallis non-
parametric analysis of variance followed by Mann-Whitney U-tests. Histopathological findings were 
analysed by Fisher's exact probability test. All analyses were two-sided. 
Transcriptome analysis: liver RNA extraction 
Liver samples were pulverised with mortar and pestle in liquid nitrogen before isolation of total RNA. 
Total RNA was extracted from liver homogenate using Trizol according to the manufacturer's protocol 
(Invitrogen, Breda, The Netherlands) and further purified using the RNEasy RNA purification kit, 
including a DNA digestion by RNAse-free DNAsel (Qiagen, Westburg B.V., Leusden, Netherlands). 
RNA was checked for purity and stability by gel electrophoresis and the concentration was calculated 
from the OD260 as determined spectrophotometrically. 
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Transcriptome analysis: design 
A referenced design was used for microarray hybridisation, to account for dye-dependent effects. 
Tester samples contained equivalent amounts of total RNA of the treated rat livers, pooled per dose 
group. These were fluorescently labelled with Cy5, while reference material, obtained from pooled 
RNA of the livers of the control rats, was labelled with Cy3. 
Transcriptome analysis: oligonucleotide microarrays 
Oligonucleotide microarrays were produced in collaboration with the University Medical Center Utrecht 
Genomics Laboratory [149]. The method adapted form DeRisi [48], was described before, [2]. Briefly, 
about 5000 different oligonucleotide fragments (Qiagen Operon, Westburg B.V., Leusden, The 
Netherlands) were arrayed in duplicate on glass slides. Control cDNAs were included with no 
significant homology to (known) rat cDNAs as well as spots with only buffer. In vitro transcription 
reactions with indirect fluorescence labelling were performed according to [2]. After hybridisation (16 
hours at 42°C), slides were washed and scanned with a Packard Scanarray confocal laserscanner, 
using different lasers for both the cy3 (wavelength 550nm) and cy5 (wavelength 650nm) channel. Two 
TIFF images per slide were saved for analysis using Imagene 5.0 (Biodiscovery Inc., El Segundo.CA, 
USA) Settings were applied to automatically flag weak or negative signals and spots with a non-
homogenous signal. Excel (Microsoft Corporation, Redmond,USA) and SAS (SAS, Cary, USA) were 
used to further process and analyse the data. 
Transcriptome analysis: DNA microarray quality criteria 
Technical replicate hybridisations of the samples were performed to obtain, 4 microarrays per sample 
according to our stringent quality criteria. These criteria consider the homogeneity of the spot signal 
intensities, the effect of bleaching of the fluorescence, the number of manually flagged (excluded) 
spots, the spatial distribution of the signals over the slide surface, the balance between cy3 and cy5 
signal intensity, the number of saturated spots and the quality of the hybdridised microarray with 
respect to others of the experiment. 
Transcriptome analysis: DNA microarray data processing and statistical analysis 
After image analysis, the local background intensity value was subtracted from the signal intensity for 
each spot. Background intensities outside the cDNA spots were very low and homogeneous. 
Fluorescence intensity in control spots was used to determine a minimal signal intensity threshold 
value of 1.5 for the two channels. Flagged spots and controls were excluded from further 
interpretation, as well as genes for which less than 70 % of the microarrays delivered a reliable signal. 
After this stringent selection, around 40% of the genes on the microarray were kept. Ratios of the 
background-corrected intensities of tester over reference were calculated and, to account for technical 
variations introduced during labelling or hybridization, data were normalised using the lowess 
normalization algorithm [103] in the SAS program. Data were log(2) transformed, and excluded values 
were replaced by 0. Statistical analysis of the differences between the treatment groups was 
performed with ANOVA in SAS. Changes with an ANOVA p-value < 0.01 were considered statistically 
significant. 
In parallel with ANOVA, multivariate statistical techniques for pattern recognition were applied to the 
log(2) ratios. Unsupervised PCA was used, as described before [2], to discern transcript profiles from 
rats exposed to the different concentrations of TCE and controls. PCA indicated that, independent of 
the treatment, two microarrays were aberrant from the others, even though the technical quality criteria 
were met. These slides, s91 and s92 were rejected from PCDA. The PCDA was performed as 
described above for the urine metabolomics data, and a score plot was drawn. The genes with the 
largest significance for the differences between samples treated with TCE and controls were found by 
ranking of the genes according to D#1. 
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VI.3 Results 
This study analysed subacute toxicity in rats exposed to TCE and related the results of 
hepatic transcriptomics analysis to the outcome of conventional toxicity tests. 
Subacute toxicity of TCE 
No TCE-related mortality occurred. The daily general clinical observations before dosing and 
the neurobehavioral assessment showed no treatment-related changes. After dosing, 
animals given TCE at 50 mg/kg/day showed no abnormalities. Rats given 500 or 2000 
mg/kg/day showed on many days the following, transient symptoms: walking with hunched 
back, excited, lethargy and ataxia. Blepharospasm, salivation or smacking movements were 
observed incidentally. Rats treated with 500 and 2000 mg/kg/day consumed slightly more 
water (n.s.) and food consumption was decreased in the rats given 2000 mg/kg/day. These 
rats had reduced growth rate and terminal body weights (table VI. 1). 
Table VI.1 . Terminal body weights (g) and relative liver and kidney weights. 
Mean values (mg/kg BW) ± s.e.m. are shown per group, n = 5. 
Treatment Dose Body weight Rel. liver Rel. kidney 
Control 
TCE 
TCE 
TCE 
0 
50 
500 
2000 
210.7 ±7.2 
198.7 ±4.3 
206.3 ± 3.0 
177.3 ±4.2** 
40.1 ±0.6 
40.8 ±0.8 
45.6 ±1.6** 
49.9 ± 0.5** 
7.15 ±0.07 
7.19 ±0.21 
7.63 ±0.14 
7.55 ±0.16 
Statistical significance: One-way ANOVA + Dunnetts tests: *: p< 0.05; **: p< 0.01 
Organ weights and pathology 
Animals given TCE had increased relative liver weights at 500 and 2000 mg/kg/day (Table 
VI.1). At 2000 mg/kg/day, statistically significantly lower absolute kidney, spleen and thymus 
weights and increased relative testes weights were found, though these effects were 
considered secondary to the lower body weights in this group. Histopathological examination 
showed karyomegaly in the kidneys of all rats treated with 2000 mg/kg/day of TCE. 
Increased hyaline droplet nephropathy was observed in the controls (incidence 3/5) and low 
dose group (4/5) but not in the mid and high dose group. The other organs showed no TCE-
related histopathological changes. 
Haematology 
Haematology revealed no significant changes related to treatment with TCE. Differential 
white blood cell counts showed a slight shift from lymphocytes to neutrophils after 500 and 
2000 mg/kg/day (n.s.). 
Clinical chemistry and hepatic GSH and Cyp measurements 
TCE significantly decreased plasma glucose and increased phospholipids at 2000 mg/kg/day 
(Figure VI.1A and B). Albumin was increased at 500 mg/kg/day, and the albumin/globulin 
ratio was dose-dependently increased at 500 and 2000 mg/kg/day (Figure VI. 1C). Total 
hepatic glutathione (GSH) was dose-dependently increased at 500 and 2000 mg/kg/day 
(Figure VI.1D). Hepatic Cyp contents showed no significant differences between animals 
given TCE and controls. 
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Figure VI.1. Plasma and liver parameters determined in controls and in rats exposed to 
TCE at dose levels of 50, 500 and 2000 mg/kg/day. 
Panel A. Mean glucose levels ± s.e.m. in plasma (mmol/l), Panel C. Mean phospholipids levels ± 
s.e.m. in plasma (mmol/l), Panel C. Mean albumin to globulin (A/G) ratio ± s.e.m. in plasma, Panel 
D. Mean hepatic total GSH contents ± SD (nmol/ml). Statistical significance is denoted as follows: *: 
p< 0.05; **:p< 0.01. 
Urine analysis and metabolomics 
Rats given TCE at 2000 mg/kg/day produced more urine, with a decreased density and 
decreased concentrations of creatinine, glucose, protein and enzymes (ALP, GGT, LDH)). 
When expressed per 24 h or related to the excretion of creatinine, the excretion of protein 
and GGT (n.s.) was lower, whereas the excretion of NAG was higher than in controls, after 
treatment with 2000 mg/kg/day of TCE. 
Urine samples were also analysed with NMR spectroscopy and PCDA, and results were 
shown in a score plot (figure VI.2). The plot indicated that metabolite profiles of urine from 
rats exposed to TCE differed from controls, in a dose-dependent manner. The profiles of 
samples from the same treatment group were more similar to each other than profiles 
between groups. The TCE treatment effect exceeded the interindividual and technical 
variation, even after exposure to low dose levels (50 mg/kg/day). The aim here was to obtain 
discriminative profiles, rather than to identify individual metabolites in urine. Nevertheless, 
the NMR spectra revealed at a glance that the differences were predominantly caused by 
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signals with a chemical shift of around 3.5 ppm, presumably corresponding to phase II 
conjugates of TCE biotransformation, such as N-acetylcysteine and glutathione conjugates of 
TCE. Also TCE and ethanol peaks were markedly elevated by the treatment. These NMR 
signals were part of a characteristic pattern of many signals that dose-dependently changed 
after TCE treatment, compared to controls. 
? 
o 
jo 
CM 
Q 
0.2" 
0.1fr 
0.1-
0.05-
o -
-0.05 
-0.1-
-0.15-
-0.2-
* 
* 
hig|-
* 
***** ** 
* 
: 2000 
* 
mg/kg/day 
+
 + 
+ * 
#J= 
mid: 500 mg/kg/day 
i i 1 
low: 50 mg/kg/day 
0 
Control Q0 
o °o\ft> 
— I 1 1 — ' 
-0.2 -0.15 •0.1 -0.05 0.05 0.1 0.15 
D1 (35.07%) 
Figure VI.2. Metabolomics - PCDA Score plot 
Score plot of principal component analysis with discriminant (PCDA) of NMR spectra, 
reflecting the metabolite profiles of urine. Each symbol in the score plot represents an 
individual NMR spectrum. Per group, samples of 5 rats were measured in triplicate. The 
symbols represent: 0: controls; x: exposure to low dose of TCE (50mg/kg/day); + : mid dose 
of TCE (500mg/kg/day); and *: high dose of TCE (2000 mg/kg/day). 
Hepatic transcriptome analysis 
Liver genes identified by DNA microarrays to change upon treatment with TCE were 
categorised and listed in the tables VI.2 A-E. For these tables, mean log(base2) transformed 
gene expression levels were calculated, corrected for the expression levels in the controls. 
Genes that altered expression upon treatment with TCE were categorised according to 
biological processes like drug metabolism, GSH metabolism and oxidative stress, fatty acid 
and cholesterol metabolism and protein synthesis & proteolysis. For a selection of genes, 
histograms show the mean gene expression levels and the statistical significance of the 
changes (figure VI .4). 
A dose-related increase was found in the number of genes that were differentially expressed 
upon exposure to TCE (figure VI.3). The high dose altered levels of 126 genes, the mid dose 
94 and the low dose 57 genes. Also the magnitude of the changes depended on the dose 
level. After exposure to TCE at the high dose, up to five-fold changes in mRNA levels were 
measured compared to control levels, the mid dose elicited changes up to three-fold, and at 
the low dose, changes were two-fold or less. 
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High 
61 up 
65 down 
Low 
30 up 
27 down 
Mid 
65 up 
29 down 
Figure VI.3. TCE-induced gene expression changes 
Diagram of hepatic gene expression changes, compared to controls, after 28-day exposure to TCE 
at dose levels of 50, 500 and 2000 mg/kg/day. Only genes were counted with changes with a p < 
0.01 in the statistical tests. If only changes were selected with a p < 0.001, treatment with 50, 500 
and 2000 mg/kg/day altered expression of 8, 21 and 34 genes, respectively. 
In parallel to ANOVA, multivariate statistical methods were applied to assess the effects of 
TCE on the individual hepatic gene expression profiles. Figure VI.5 shows a score plot of the 
PCDA of gene expression profiles. Even at 50 mg/kg/day, the treatment elicited effects larger 
than the technical variation. Along the horizontal axis, (D#1), the low and mid dose groups 
were distinct from controls and the high dose increased this distinction. The vertical axis, 
(D#2), was found to primarily explain the technical variation. The relative contribution of the 
individual genes to the TCE-induced differences in the profiles were shown by ranking the 
genes according to D#1. Most of the genes with a high contribution were also identified to 
change highly significantly in the ANOVA. To illustrate this overlap, genes that appeared in 
the top or bottom 100 of the ranking according to D#1 in the PCDA, were shown in boldface 
in the tables with ANOVA results (tables 2A-E). 
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Previous page Figure VI.5. Analysis of hepatic gene expression profiles 
Score plot of principal component analysis with discriminant (PCDA) of measurements of 
hepatic gene expression. Each symbol represents a DNA microarray measurement. Per 
group, pooled samples of 5 rats were measured in triplicate. The identification number of the 
DNA microarrays is provided (s#). CO: controls; low: TCE 50 mg/kg/day of TCE; mid: 500 
mg/kg/day of TCE and high 2000 mg/kg/day of TCE 
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Figure VI.4. Selection of gene expression changes induced by TCE. 
Group mean log(2) transformed gene expression levels as, measured by DNA microarrays, 
are shown for controls (CO) and samples exposed to TCE at dose levels of 50, 500 and 2000 
mg/kg/day. Error bars represent standard deviations. Statistical significance as determined by 
ANOVA is denoted as follows: **: p < 0.01, ***: p < 0.001. 
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VI.4 Discussion 
The effects of TCE on hepatic gene expression in rats exposed to TCE for 28 day were 
investigated with DNA microarrays. The results were related to (conventional) assessment of 
subacute toxicity. To delineate the specificity of hepatic transcriptome effects induced by 
TCE, a comparison was made with reported gene expression changes induced by 
hepatotoxicants that cause hepatic necrosis or peroxisome proliferation. 
Subacute toxicity of TCE 
The conventional toxicity endpoints demonstrated no TCE-related changes at 50 mg/kg/day. 
The effects observed at higher dose levels were comparable to those in earlier studies 
[187],[178]. TCE exposure resulted in lower terminal body weights at 2000 mg/kg/day. At this 
dose level, nephrotoxicity (karyomegaly), and increased excretion of NAG in urine were 
found. Plasma glucose was decreased and phospholipids and the A/G ratio increased, 
possibly associated to changes in the liver. Besides relative liver weight and GSH increases 
at 500 and 2000 mg/kg/day, no indications of TCE-induced hepatotoxicity were observed. 
Conventional toxicity markers did not reveal TCE-related effects at 50 mg/kg/day. 
Urine analysis and metabolomics 
The various routes of biotransformation and elimination of TCE result in characteristic 
metabolite contents in urine, which have been thoroughly studied [185];[180]. The current 
analytical methods to monitor TCE levels in human urine and blood have limited value, with 
low specificity and high variation between individuals and sexes [178]. These limitations 
might be overcome by measurement of profiles of hundreds of metabolites, that are likely 
more specific and robust markers than single metabolite levels. Without the aim to identify 
individual metabolites and resolve routes of biotransformation, we measured profiles of 
metabolites in urine as potential markers of TCE-exposure. While, conventional urine 
analysis showed some effects at high doses exposure (2000 mg/kg/day), metabolomics 
analysis demonstrated that the metabolite profiles of urine changed dose-dependently, from 
the lowest dose tested in this study (50 mg/kg/day). A characteristic pattern of multiple NMR 
signals was found, that dose-dependently changed. A few signals were identified, 
corresponding to TCE, ethanol and various N-acetylcysteine and glutathione conjugates of 
TCE. In conclusion, NMR profiling provided a sensitive, specific and robust method 
potentially useful to determine exposure to TCE in urine. 
Hepatic transcriptomics analysis 
This study demonstrated that TCE dose-dependently changed the expression of genes, both 
in the number and magnitude of changes. While conventional toxicity markers demonstrated 
effects in liver from 500 mg/kg/day (increase of relative liver weight and GSH), 
transcriptomics enabled to sensitively detect significant effects at the lowest dose level tested 
(50 mg/kg/day). Analysis of gene expression changes was performed with two different 
statistical methods, ANOVA and PCDA. While a large overlap was found, there were also 
genes with a significant change in only one of the methods. Nevertheless, both methods 
identified the same biological processes to be involved in the response to exposure to TCE. 
For instance, both methods identified ribosomal and proteasomal subunits to be induced, 
although some different subunits were significant in either ANOVA or PCDA. Thus, univariate 
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(ANOVA) and multivariate (PCDA) statistical methods were complementary to each other in 
the identification of relevant TCE-modulated genes. 
Gene expression changes related to processes that could be relevant in the response to 
TCE are described in more detail below. These processes were drug metabolism, GSH 
metabolism and oxidative stress, peroxisomal beta oxidation, fatty acid and cholesterol 
metabolism and protein synthesis & proteolysis. Other biological processes that were 
affected include the acute phase response, apoptosis, signal transduction, cell adhesion, cell 
structure and cytoskeleton, as listed in table VI.2E. 
Drug metabolism, oxidative stress and GSH metabolism 
Many enzymes involved in drug metabolism were induced by exposure to TCE (table VI.2A). 
Most pronouncedly changed were aldehyde dehydrogenases (Aldh), Afar, alcohol 
dehydrogenases (Adh), and GSH-S-transferases (Gst) (figure VI.4). Also UDP-
glucuronosyltransferases (Ugt) were induced, which convert TCE and its metabolites to 
more water-soluble conjugates. While in general, conjugation detoxifies hazardous 
metabolites in the liver, GSH-conjugates of TCE can induce toxicity in the kidneys upon 
bioactivation by y-glutamyltransferase and dipeptidases [186]. The induction of Cyp2e1 
(figure VI.4) has important implications for TCE biotransformation, being the most important 
enzyme for oxidation of TCE. 
Metabolites of TCE might be highly reactive and increase reactive oxygen species formation. 
Indeed, genes involved in oxidative stress like several metallothioneins (figure VI.4) and 
peroxiredoxinl were significantly induced. Oxidative stress is known to be accompanied by 
the induction of heme oxygenase and ferritins. However, after 28-days exposure to TCE, 
these genes were not found to be significantly upregulated. The induction of Nqo1 (figure 
VI.4) might enhance detoxification of reactive species, while protection is also provided by 
hepatic GSH. GSH levels may be elevated by induction of the rate-limiting enzyme for the 
biosynthesis of GSH: both the light chain (Gclc) (figure VI.4) and the regulatory chain (Gclm) 
of gamma glutamylcysteine synthetase were upregulated by TCE. The induced enzyme 
G6pd converts NADP+ to NADPH, used by GSH reductase to restore reduced GSH levels. 
Hepatic GSH levels were found dose-dependently elevated in rats exposed to TCE for 28 
days, indicating that more GSH was synthesised than consumed in conjugation reactions 
catalysed by Gsts. While Gstm3 gene expression was reduced at high dose exposure, 
Gstal, the most abundant GST in liver was dose-dependently induced by TCE. 
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Table VI.2A. Genes modulated by trichloroethylene, related to hepatic drug 
metabolism, GSH metabolism and oxidative stress. 
The level of statistical significance (Student's T-tests) is indicated next to the mean log(2) 
transformed fold changes, and listed in the last column for the ANOVA (A) (*: p < 0.02, **: p < 
0.01, ***: p<0.001). Genes in boldface appeared in the list of 100 most significantly up- or 
downregulated genes in the PCDA analysis. 
Acc# Symbol GeneName Low Mid High 
NM 022407 
M11794 
NM 013215 
NM 012695 
J00750 
NM 016999 
X89603 
M31363 
NM 031509 
M13506 
NM 017000 
NM 019286 
D30035 
NM 012844 
M15327 
NM 031543 
NM 017305 
NM 012709 
NM 031000 
NM 023025 
J05181 
NM 012541 
NM 031731 
BG668294 
NM 031154 
L26267 
NM 012661 
NM 019184 
Aldh1a1 
Afar 
Smp2a 
Mt1a 
Cyp4b1 
Mt3 
Sth2 
Gstal 
Udpgtr2 
Nqo1 
Adh1 
Prdxl 
Ephxl 
Adh1 
Cyp2e1 
Gclm 
Cyp2c12 
Akr1a1 
Cyp2j4 
Gclc 
Cyp1a2 
Aldh3a2 
Esd 
Gstm3 
Nfkbl 
Sts 
Cyp2c11 
Aldehyde dehydrogenase 1, A1 
sim. to SMRT2 metallothionein II 
Aflatoxin B1 aldehyde reductase 
senescence marker protein 2A, 
Metallothionein 
Cytochrome P450, subfamily IVB, 1 
Metallothionein 3 
Sulfotransferase hydroxysteroid 2 
Glutathione-S-transferase, alpha 
UDP-glucuronosyltransferase 
Diaphorase (NADH/NADPH) 
Alcohol dehydrogenase I alpha 
Peroxiredoxin 1 
Epoxide hydrolase 1 (microsomal) 
Alcohol dehydrogenase 
Cytochrome P450, 2e1 
Glutamate-cysteine ligase, regulatory 
Cytochrome P450 15-beta 
Aldo-keto reductase family 1, A1 
Cyp2J4 
Glutamylcysteine gamma synthetase 
light chain 
Cytochrome P450, 1a2 
Aldehyde dehydrogenase family 3, A2 
Esterase D/formylglutathione 
hydrolase 
Glutathione S-transferase, mu type 3 
Nuclear factor kappa B p105 subunit 
Steroid sulfatase 
Cytochrome P450, subfamily IIC 
0.80 * 
0.46 
0.59 
0.77 * 
0.32 
0.22 
0.45 
0.52 * 
0.42 ** 
0.42 
-0.08 
0.29 
0.55 ** 
0.29 
-0.23 
-0.04 
0.29 
0.17 
0.28 
0.01 
0.73 
0.06 
0.18 
0.39 
0.05 
-0.29 
-0.72 * 
0.17 
1.54 
0.51 
0.97 
1.20 
0.53 
1.11 
0.22 
1.13 
1.03 
0.79 
0.54 
0.21 
0.51 
0.23 
0.08 
0.32 
0.42 
0.15 
0.42 
0.27 
0.35 
-0.20 
-0.44 
0.44 
0.06 
-0.19 
-0.28 
-0.77 
*** 
** 
*** 
*** 
** 
*** 
* * • * 
** 
** 
* 
** 
** 
** 
2.28 
1.93 
1.85 
1.76 
1.72 
1.65 
1.63 
1.59 
1.44 
1.22 
1.22 
1.01 
0.87 
0.81 
0.70 
0.64 
0.62 
0.60 
0.59 
0.54 
0.53 
0.48 
0.37 
0.35 
-0.43 
-0.48 
-0.65 
-1.48 
*** *** 
*** *** 
*** *** 
*** *** 
*** *** 
*** *** 
*** *** 
*** *** 
*** *** 
*** *** 
** *** 
* ** 
** *** 
* ** 
* *** 
** *** 
** ** 
** ** 
** * 
* ** 
** * 
** 
** 
** 
** ** 
** * 
** ** 
** ** 
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Protein synthesis & proteolysis - The gene expression data suggest increased protein 
turnover, as ribosomal subunits and many subunits of the proteasome were significantly 
induced. Possibly, proteolysis and protein synthesis take place in different cells, or in 
different cellular compartments. 
Table VI.2C. Genes modulated by trichloroethylene, related to 
protein synthesis and proteolysis. 
The level of statistical significance (Student's T-tests) is indicated to the mean log(2) 
transformed fold changes, and listed in the last column for the ANOVA (A) (*: p < 0.02, **: p • 
0.01, ***: p<0.001). Genes in boldface appeared in the list of 100 most significantly up- or 
downregulated genes in the PCDA analysis. 
Acc# Symbol GeneName Low Mid High 
NM 022672 
X52783 
U53512 
BU671701 
D50695 
NM 017280 
NM 031838 
NM 017285 
NM 017282 
AF285103 
NM 031570 
NM 017281 
D50694 
AF146518 
Rps14 
Psmbl 
Mrpl17 
Psmc4 
Psma3 
Rps2 
Psmb3 
Psma5 
Psmb7 
Rps7 
Psma4 
Psmc2 
Enpep 
Ribosomal protein S14 
Proteasome subunit, beta type 1 
Mit. ribosomal protein L17 
sim. to eukar. translation initiation 
factor 3 sub6 interacting prot 
Proteasome 26S subunit, ATPase,' 
Proteasome subunit, alpha type 3 
Ribosomal protein S2 
Proteasome subunit, beta type 3 
Proteasome subunit, alpha type 5 
Proteasome subunit, beta type, 7 
Ribosomal protein S7 
Proteasome subunit, alpha type 4 
Proteasome 26S subunit, ATPase 
aminopeptidase A short variant 
0.63* 
0.57** 
0.55* 
0.85 
0.30 
0.35* 
0.04 
0.10 
0.44** 
0.19 
0.63** 
0.16 
0.26 
0.36 
0.56 
0.54** 
0.58* 
0.43 
0.37 
0.46** 
0.33 
0.42** 
0.22 
0.31 
0.29 
0.32* 
0.32 
0.04 
0.98* 
0.81 
0.75** 
0.66 
0.55** 
0.52** 
0.47* 
0.40*** 
0.38* 
0.36 
0.33 
0.31** 
0.22 
-0.35** 
Lipids, fatty acids and cholesterol metabolism 
Gene expression changes indicated that the metabolism of lipids, fatty acids and of sterols 
including cholesterol was affected by TCE. The peroxisomal beta oxidation of fatty acids was 
influenced at the gene expression level, bu induction of a.o. Acatl, Cyp4A, Dei, Echsl, 
Ehhadh. These results corroborate reported TCE-induced peroxisomal beta oxidation 
(increased relative liver weights and palmitoyl CoA oxidation activity) [182]. Proliferation of 
peroxisomes (PP) may be a response to perturbations in lipid metabolism [188] and is 
putatively associated with carcinogenesis [189]. A comparison was made of gene expression 
changes in rat livers upon exposure to TCE and model peroxisome proliferators such as 
Wy14,643, Clofibrate, gemfbrozil [190], [27];[27,191](table VI.3.). Several studies with 
peroxisome proliferators were performed in mice, not included in present comparison [192], 
[193], [194]. The comparison indicated that TCE altered the expression of hepatic genes 
characteristic for the response induced by peroxisome proliferating agents. This 
characteristic set of genes included enzymes involved in the beta oxidation of fatty acids. In 
agreement, TCE also increased relative liver weight. Alternatively, this relative liver weight 
could have been increased by the marked induction of biotransformation enzymes. 
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Table VI.2D. Genes modulated by trichloroethylene, related to fatty acids, cholesterol 
and lipids metabolism. 
The level of statistical significance (Student's T-tests) is indicated to the mean log(2) 
transformed fold changes, and listed in the last column for the ANOVA (A) (*: p < 0.02, **: p < 
0.01, ***: p < 0.001). Genes in boldface appeared in the list of 100 most significantly up- or 
downregulated genes in the PCDA analysis. 
Acc# 
NMJJ31561 
D00729 
NM_017306 
X55969 
X97831 
M57719 
NM_130433 
K03249 
NM_012930 
NM 031344 
D85189 
X15958 
NM_017075 
NM_138502 
NM 022389 
AF080568 
NM_013112 
AJ245707 
AF202887 
NM 017332 
NM 012737 
Symbo 
Cd36 
Dei 
Dei 
Apob 
Slc25 
GeneName 
Cd36 antigen 
delta3, delta2-enoyl-CoA isomerase 
Dodecenoyl-coenzyme A delta 
isomerase 
apolipoprotein B 
Solute carrier family 25 
(carnitine/acylcarnitine translocase) 
Cyp4A Cyp4a cytochrome P450 (IVA3) 
Acaa2 
Ehhadh 
Cpt2 
Fads2 
Facl4 
Ech1 
Acatl 
Mgll 
Dhcr7 
Pcyt2 
Apoa2 
Hpcl2 
Apoa5 
Fasn 
Apoa4 
acetyl-Coenzyme A acyltransferase 
2 (mit.3-oxoacyl-CoA thiolase) 
Enoyl-CoA, hydratase/3-hydroxyacyl 
CoA dehydrogenase 
Carnitine palmitoyltransferase 2 
Delta-6 fatty acid desaturase 
Fatty acid Coenzyme A ligase, 
long chain 4 
Enoyl CoA hydratase, short chain 1 
Acetyl-Co A acetyltransferase 1, 
mitochondrial 
monoglyceride lipase 
7-dehydrocholesterol reductase 
Phosphate cytidylyltransferase 2, 
ethanolamine 
Apolipoprotein A-ll 
2-hydroxyphytanoyl-CoA lyase 
Apolipoprotein A-V 
Fatty acid synthase 
Apolipoprotein A-IV 
Low 
0.35 
0.30 
0.73 
0.93 
0.83" 
0.05 
0.49 
0.15 
-0.08 
-0.14 
0.30 
0.44 
0.27 
-0.27 
-0.20 
-0.31 ** 
-0.42 
-0.33 
-0.13 
-0.87* 
-0.46 
Mid 
A >JA * * * 
0.70 
0.56 
0.92 
0.40 
0.67" 
0.21 
0.37 
0.24 
0.03 
0.33** 
0.21 
0.40" 
0.30 
-0.05 
0.06 
-0.41 *** 
-0.07 
-0.89** 
-0.82** 
-1.11** 
High A 
2.16*** *** 
1.98*** ** 
1.87" " 
1.07 
0 . 9 1 " " 
0 . 9 1 " *" 
0.87 
0.84"* " 
0.67" " 
0.59" *" 
0.57"* *** 
0.47* * 
0.42" * 
0.40 
0.27 *** 
-0.12 
-0.42 
-0.45" " 
-0.78" ** 
- 0 . 8 1 " ** 
-1.72"* "* 
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Table VI.3. Gene expression changes by TCE and. peroxisome proliferators 
A selection of genes is shown, of which the expression changed by TCE as well as by 
peroxisome proliferators, identified in studies by Cornwell ef a/. (PP1), Hamadeh ef 
a/.,(PP2) and McMillian ef a/.(PP3). 
Symbol 
Acs 
Cyp4A3 
Dei 
Cpt2 
Acatl 
Acaa 
Ehhadh / 
Echp 
Ech1 
Cd36 
Hsd11 
Apoa4 
ApoC3 
Fasn 
Mgll 
Atp 
Me1 
Pklr 
Idh 
-
Ces 
Nqo1 
Aldhl 
Gstal 
G6pc 
-
Aqp... 
Obp3 
Mt... 
Gene Name 
acyl-CoA oxidase 
cytochrome P450 4a3 
53, 62-enoyl CoA isomerase 
carnitine palmitoyltransferase 2 
acyl-CoA acetyltransferase 
acetyl-CoA acyltransferase 1 
peroxisomal bifunctional enzyme 
enoyl CoA hydratase, short chain 1 
cd36 antigen (fatty acid binding) 
hydroxysteroid dehydrogenase 11 beta 
apolipoprotein A IV 
apolipoprotein C-lll 
fatty acid synthase 
monoglyceride lipase 
div. ATPases 
malic enzyme 1 
pyruvate kinase 
isocitrate dehydrogenase 
(sim.to) Gadd45 
carboxylesterase (2) 
NAD(P)H dehydrogenase, quinone 1 
aldehyde dehydrogenase 1 
GSH-S-transferase A 
glucose-6-phosphatase 
div. complement components 
div. aquaporins 
alpha 2u-globulin 
metallothionein 
TCE 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
-
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
-
+ 
PP1 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
+ 
-
+ 
+ 
+ 
PP2 
+ 
+ 
+ 
-
-
+ 
+ 
+ 
+ 
+ 
-
-
PP3 
+ 
+ 
+ 
+ 
+ 
+? 
+ 
+ 
-
+ 
+ 
-
-
-
+ : induction of gene expression ; -: reduction of gene expression 
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Table VI.4. Gene expression changes by TCE vs. other compounds 
A selection of genes is shown of which the expression changed upon 28-day exposure to 
trichloroethylene (T), benzene (B) (Heijne et at, 2004), as well as by the model hepatotoxicants 
acetaminophen (A) (Heinloth et a/.,2004), or bromobenzene (BB) (Heijne et at, 2004). 
Symbol Gene Acc.#1 Acc.#2 RR A B T 
biotransformation 
Ephxl 
Afar 
Gsta 
Aldh 
Ugt 
Nqo1 
microsomal epoxide hydrolase 
Aflatoxin B1 aldehyde reductase 
Glutathione-S-transferase alpha 
Aldehyde dehydrogenases 
U DP-g lucuronosyltransferases 
NAD(P)H dehydrogenase, quinone 1 
Cyp2c12 Cytochrome P450 15-beta 
Cyp2e1 
Gclc 
Mt 
Timpl 
Prdxl 
Ho-1 
Ftl.Fth 
Rpn.. 
Psmb.. 
div. 
G6pc 
G6pd 
Orm 
Mug 
Bhmt 
Actb 
Hbb 
Hba 
Cytochrome P450, 2e1 
GSH metabolism and oxidative stress 
Glutamylcysteine gamma synthetase 
div. metallothioneins 
TIMP1 
peroxiredoxinl 
heme oxygenase 1 
ferritin light and heavy chain 
protein synthesis and oroteolvsis 
various ribosomal subunits 
various proteasome subunits 
fattv acid metabolism 
multiple genes 
alucose 
Glucose-6-phosphatase 
Glucose-6-phosphate dehydrogenase 
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Specificity of transcriptome changes related to hepatotoxicity 
Previous transcriptomics studies analysed effects in livers of rats exposed to model 
hepatotoxicants like acetaminophen (APAP) [69] and, in our laboratory, bromobenzene (BB) 
[2]. These compounds induced many hepatic gene expression changes in parallel to hepatic 
necrosis and increases in the relative liver weight. While TCE also induced the relative liver 
weight, no histopathological or other markers provided indications of hepatotoxicity. 
Nonetheless, various changes in hepatic gene expression were found, and it is yet unclear 
whether these should be considered as reversible or irreversible and adverse effects. The 
TCE-induced changes in hepatic gene expression were therefore compared to those induced 
by the well-known hepatotoxic compounds BB and APAP. The effects of TCE were also 
compared to those of benzene, which is not a recognised hepatotoxicant, but, like TCE, 
increased relative liver weights [5](table VI.4). 
TCE was found to modulate many genes in common with benzene. A few changes in gene 
expression were in common with the hepatotoxicants BB and APAP like induction of Ephxl, 
Nqo1, Aldh and reduction of G6pc. Some distinct effects were found between the model 
hepatotoxicants on the one hand, and benzene and TCE on the other. These include 
changes in genes related to fatty acid metabolism (eg. Ech1) and oxidative-stress response 
(HO-1). The induction of HO-1 and ferritins was found to be an early event in response to BB 
[3]. After 28 days of exposure to benzene and TCE, this effect could have vanished. Another 
study in our laboratory related changes in gene expressions to histopathological 
observations of necrosis [4]. In this way, induction of orosomucoid, actin beta, pervin and 
reduction of asialoglycoprotein 2 and lecithin-cholesterol acyltransferase (Lcat) were found to 
correlate to the degree of hepatic necrosis. These effects might be useful to differentiate 
between exposures to model hepatotoxicants and compounds like benzene and TCE, that 
did not induce histopathological effects in liver. TCE did not significantly alter the expression 
of any of those genes. Interestingly, a slight reduction of asialoglycoprotein 2 and Lcat was 
observed upon exposure to both B and TCE, though this decrease was not statistically 
significant. Possibly, this slight reduction is an early indication of adverse effects while larger 
decreases correlate with clear signs of necrosis. This hypothesis should be verified in further 
studies. 
One of the earliest toxicogenomics studies measured hepatic gene expression for 148 genes 
after exposure to TCE, Benzo(a)pyrene or Cadmium chloride [94]. Differential gene 
expression was found in mouse livers 6 hours after a single dose of these compounds. The 
only genes reported to change (only) by TCE were Hsp25, Hsp86 and Cyp2a. Our study did 
not reveal expression changes for those genes. The comparison of these results with present 
study is difficult because of the large differences in the studies (eg. species, duration and 
doses of exposure and microarray platforms). This emphasises that it is important to 
standardise toxicogenomics studies to be able to relate results to each other. 
Transcriptome changes and nephrotoxicity 
Several hepatic gene expression changes were observed that might relate to mechanisms 
suggested to mediate TCE-induced nephrotoxicity and/or nephrocarcinogenesis. A possible 
mechanism involves GSH conjugation of TCE and its metabolites, probably important when 
the Cyp-dependent pathway becomes saturated at high doses of TCE [195]. The induction of 
Gclc and Gclm and corresponding increased GSH levels could therefore increase the GSH 
conjugation, thereby leading to formation of more nephrotoxic metabolites. Induction of Gsta 
expression might enhance this process. On the other hand, the induction of Cyp2e1 could 
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prevent that the Cyp-dependent pathway becomes saturated, attenuating the role of the 
GSH-dependent route. 
This study revealed a 2.5-fold decrease in gene expression of alpha 2u-globulin in liver 
(figure VI.4). In male rats, alpha 2u-globulin accumulation in lysosomes causes hyalin protein 
droplet induction in the kidneys. This was associated to cell proliferation and raised as a 
possible explanation for chemical-induced carcinogenicity in male rats, though not in humans 
[196] [197], [198]. We suggest that the impaired hepatic gene expression of alpha 2u-globulin 
prevents accumulation of this protein in the kidneys, explaining the results of the kidney 
histopathology. Hyalin protein droplet induction was found in the controls and low dose 
animals and should be considered as a background effect, observed more often (Dr.B. Lina, 
personal communication). However, none of the animals treated with the mid and high dose 
of TCE showed hyalin droplet nephropathy. These findings may also explain why increase in 
renal alpha 2u-globulin concentration was not found upon exposure of male Fischer-344 rats 
to TCE [196]. 
Conclusions 
In summary, TCE changed expression of genes in rat liver, after 28-day repeated 
exposure to 50 mg/kg/day. The expression of genes changed in a dose-dependent 
manner, both in the number and the magnitude of the changes. The only hepatic 
effects found with conventional toxicology were increase of relative liver weight and 
glutathione contents, observed after exposure to 500 mg/kg/day. Metabolomics 
analysis enabled to assess exposure levels of TCE, in a robust and specific analysis 
of urine. The TCE induced gene expression changes were predominantly related to 
GSH biosynthesis and biotransformation. TCE induced characteristic changes in 
hepatic gene expression in common with agents inducing peroxisome proliferation. 
Comparison of the effects of TCE with model hepatotoxicants that induce liver 
necrosis, showed a few genes modulated in common. On the other hand, a 
considerable overlap in effects of TCE and benzene was found. Both benzene and 
TCE increased the liver weights but did not induce histopathological changes in liver. 
Moreover, the liver plays a central role in the biotransformation and activation, 
ultimately leading to target organ toxicity (benzene:blood and TCE:kidney). Besides 
the overlap, a characteristic pattern of TCE-induced gene expression changes was 
observed, which enabled to further delineate the specificity of gene expression 
changes in liver after exposure to (potentially) hepatotoxic compounds. 
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Abstract 
Benzene and trichloroethylene are widely used chemicals. They are toxic ard 
(suspected) carcinogenic, and frequently occur (as mixtures) in soil and 
water. In the present study, joint effects of repeated oral exposure to mixtures 
of benzene and trichloroethylene were investigated in a stepwise approach. 
First, joint effects of the mixtures were predicted from available data for the 
single compounds. Literature and range finding studies for subacute toxicity 
and hepatic gene expression profiling (transcriptomics) were used. 
Subsequently, the response to benzene and trichloroethylene (mixtures) was 
tested in an in vivo subacute toxicity study in male F344 rats. 
Benzene was hematotoxic while trichloroethylene affected the kidneys and 
liver. Most of the changes in routine toxicity end points caused by mixtures 
could be described by addition of effects of single compounds. The joint 
effects on relative lymphocyte and neutrophil counts, and, inexplicably, on red 
blood cell parameters were more pronounced than predicted. 
Investigative toxicological methods were used to explain mechanisms of joint 
action. Transcriptomics analysis (DNA microarrays) identified changes related 
to bioactivation and detoxification, fatty acid metabolism and peroxisome 
proliferation. The data suggested involvement of trancriptional regulators like 
the electrophile response element (EpRE), the peroxisome-proliferation 
activated receptor (PPARa) and hepatocyte nuclear factor (Hnf3). The 
response of most genes to the mixtures could be estimated by combining the 
effects of the individual compounds. 
Profile analysis with multivariate statistics exploited the large datasets to 
indicate that hepatic effects of trichloroethylene were enhanced in the 
presence of benzene. 
In vitro exposed hepatocytes had increased biotransformation enzyme activity 
According to in silico physiologically-based pharmacokinetic (PBPK) 
modelling, this enhanced bioactivation of trichloroethylene the metabolite 
presumably responsible for toxicity. This could explain how benzene 
enhanced the effects of trichloroethylene. 
Present study demonstrates how investigative methods (transcriptomics, in 
vitro exposures and PBPK modelling) could complement conventional 
toxicology to assess and explain the effects of mixtures of (potentially) toxic 
substances. 
132 
Mixtures 
VII.1 Introduction 
The present study demonstrates how transcriptomics, in vitro exposure and physiologically-
based pharmacokinetic (PBPK) modelling could complement conventional toxicological 
examinations to better assess and explain the effects of mixtures of the toxic chemicals B 
and TCE. 
Benzene (B) and trichloroethylene (TCE) are widely used chemicals that frequently occur (as 
mixtures) in soil and water. They are toxic and (suspected) carcinogenic environmental 
pollutants and therefore of high concern. The toxic effects of benzene and trichloroethylene 
are exerted by secondary metabolites of the compounds, after metabolism in the liver. 
Benzene (metabolites) primarily induce bone marrow and blood toxicity. Chronic exposure to 
benzene may increase the risk of acute myelogenous leukemia [128]. In hepatic 
biotransformation of TCE, glutathione conjugates are formed that, after bioactivation, are 
toxic predominantly in the kidneys. Whether TCE is also nephrocarcinogenic is still a subject 
of debate [178];[185-186].The exact toxic effects of exposure to mixtures of B and TCE are 
yet unclear. It is expected that the liver plays an important role, and forms a putative site of 
interaction. 
A stepwise approach was chosen to analyse mixture toxicity of B and TCE, as shown in 
figure VII.1. Initially, data were collected for the effects of the single compounds. Based on 
these data, the effects of mixtures were predicted. Subsequently, the hypotheses were 
tested in rats exposed to mixtures as described below. In the last step, new hypotheses were 
generated. 
The research programme started with 28-day range finding studies with either B or TCE in 
F344 rats [5-6];[199]. The conventional subacute toxicity data for the single compounds, in 
combination with published literature, were used to predict (interaction) effects of exposure to 
mixtures [200]. The conventional toxicology was also integrated with DNA microarray based 
measurements of hepatic gene expression (transcriptomics). This enabled detailed analysis 
of molecular mechanisms in response to exposure to B and TCE. Thus, the application of 
transcriptomics should also enable better understanding of the molecular mechanisms of 
joint action of B and TCE. And, as thousands of parameters are measured with a large 
dynamic range, transcriptomics may provide better means to distinguish and (more) 
quantitatively assess joint action compared to the conventional toxicity endpoints. 
Hypothesis generation and testing 
Based on conventional toxicology, trichloroethylene was proposed to influence effects of 
benzene on the liver and spleen and hematological parameters. Benzene was suggested to 
influence effects of TCE on the liver and kidneys [200]. Transcriptomics analyses in the 
range finding studies provided indications for several transcriptional regulation mechanisms 
that could be important in the response to mixtures of B and TCE. These mechanisms were 
related to a.o. glutathione metabolism, fatty acid metabolism and peroxisomal proliferation. 
Therefore, hepatic gene expression profiles of selected rats were analysed after exposure to 
mixtures. 
A putative mechanism of interaction upon exposure to mixtures that was investigated in more 
detail was the hepatic biotransformation of B and TCE. The mechanisms of hepatic 
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biotransformation of B and TCE share a number of enzymes, like the bioactivating enzyme 
cytochrome P450 2E (CYP2E) and conjugation enzymes like glutathione-S-transferases 
(GSTs) and UDP-glucuronyltransferases (UGTs) [207-208]. Therefore, toxicokinetic 
interactions may be expected after exposure to mixtures. These could determine toxicity in 
the liver, but also in kidney, bone marrow or other tissues. Both compounds are metabolised 
primarily by CYP2E, and were found to compete for the activation by CYP2E. It was reported 
that rats injected with mixtures of B and TCE showed reduced benzene metabolism as 
measured by conjugated phenol excretion [209]. This would imply that bioactivation of 
benzene is reduced after exposure to mixtures. Therefore, less than additive hematotoxic 
effects of benzene could be expected. Alternatively, if CYP activities would increase upon 
exposure to the mixtures, enhanced bioactivation and aggravated hematotoxic effects of 
benzene were considered more plausible. 
Recently, Gonzalez-Jasso et al. reported the induction of CYP2E gene (and protein) 
expression in rats exposed to benzene [159]. In our range finding studies, TCE and B were 
found to increase relative liver weight, which could be associated with biotransformation 
enzyme induction [5-6];[199]. However, the total CYP protein levels did not change 
significantly. On the other hand, hepatic transcriptomics analyses revealed that both B and 
TCE induced gene expression of many biotransformation enzymes including the CYP2E 
isozyme. Thus, the induction of CYP2E and other biotransformation enzymes is likely to play 
a pivotal role in the toxicity by benzene, TCE and mixtures. 
The present study with exposure of rats to mixtures aimed to shed more light on induction of 
biotransformation enzymes and other genes. In addition, F344 rat hepatocytes were exposed 
in vitro for specific measurements of CYP2E and GST activity. Moreover, literature-based 
PBPK modelling was applied to test the influence of enzyme induction. Especially the 
implications of benzene-induced oxidative metabolism of TCE were analysed in this in silico 
approach. 
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Figure VII.1 Integrated approach for toxicological analysis of mixtures effects 
Hypotheses were generated using data about the single compounds, from literature and the 
range finding studies. Hypotheses were tested in the main study, where rats were exposed to 
benzene (B), trichloroethylene (TCE) and mixtures. Gene expression was analysed with 
univariate and with multivariate statistical methods. In addition, hepatocytes were exposed in 
vitro, and important biotransformation enzyme activities were measured (GST and CYP2E). 
Physiologically based pharmacokinetic (PBPK) modelling with data from literature were used 
to determine the implications of enzyme activity changes. 
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VII.2 Materials and methods 
In vivo subacute toxicity study with (mixtures of) B and TCE 
The toxicity study were performed as reported earlier by Jonker et al. [199]. Benzene (> 99% purity) 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany), TCE (> 99% purity) (Aldrich Chemical Co., 
Milwaukee, USA), and corn oil (Remia, Den Dolder, The Netherlands) were administered orally to 
male F344 rats (CDFF® (F344)/CrlBR) (Charles River Wiga GmbH, Sulzfeld, Germany). The welfare of 
the animals was maintained in accordance with the general principles of the European Communities 
(Directive 86/609/EEC) and Dutch legislation. Throughout the study, feed (RM3 from Special Diets 
Services, Witham, England) and tap water were freely available. 
B and TCE were dissolved in corn oil and administered by daily oral gavage in a volume of 5 ml per 
kg body weight to groups of 5 rats. Fresh dosing solutions were prepared once and stored (at 2-10°C) 
in portions sufficient for one day. Prior to the corn oil dose, all animals received a similar volume of tap 
water (because tap water was the vehicle for another compound which was tested in this study though 
not included in present work) . The dose levels were based on previous range-finding studies [5-6]. 
TCE was given at 500 (Tl, low dose) or 1500 (Th, high dose) mg/kg body weight/day. B was given at a 
low dose (Bl) of 200 mg/kg/day, or at a high dose (Bh) of 600 (days 0-2) or 400 (from day 10) 
mg/kg/day. Four mixture groups received B plus TCE at combinations of these dose levels: BITI, BhTI, 
BITh or BhTh. Two control groups of 5 rats each (CO_1 and CO_2), were dosed with tap water and 
corn oil (5 ml/kg body weight of each) only. The dose volumes were adjusted twice per week for 
changes in body weight. The intended treatment period of 28 days was not achieved for several 
reasons. Initially, unexpectedly high toxicity of B necessitated discontinuation of treatment on day 3. 
Following a treatment-free period of 7 days, dosing was restarted on day 10 with reduced levels of B. 
Thereafter, it became increasingly difficult to administer the animals the second (corn oil) dose, 
several animals died from gavage trauma and treatment was terminated after the 14th/15th dose. The 
animals received their last dose on the day before sacrifice on days 23-24. Examinations and 
measurements to detect toxicity included daily clinical observations, body weight, food and water 
consumption, routine hematology and clinical chemistry, organ weights, and (histo)pathology (for 
details see Jonker et al. [199]. Statistical analyses were conducted by an initial F-test followed by t-
tests. In addition, the results for the mixture groups were analysed for departures from effect addition 
(interaction), by comparing the data with an additivity surface (as described by Jonker et al. [199], 
Animals showing evidence of gavage damage were excluded from the statistical analyses. 
Liver RNA extraction 
Liver samples were pulverised in liquid nitrogen before isolation of total RNA, using Trizol according to 
the manufacturer's protocol (Invitrogen, Breda, The Netherlands). RNA was further purified using the 
RNEasy purification kit, including a DNA digestion by RNAse-free DNAsel (Qiagen, Westburg B.V., 
Leusden, Netherlands). RNA was checked for purity and stability by gel electrophoresis and the 
concentration was calculated from the OD2eo as determined spectrophotometrically. 
DNA rnicroarray experiment design, quality criteria and data (pre)processing 
A referenced design was used for rnicroarray hybridisation, to account for dye-dependent effects. 
RNAs of individual rat livers were labelled with fluorescent Cy5, while reference material, previously 
obtained from RNA of the livers of control rats [5], was labelled with Cy3. The rat oligonucleotide 
microarrays used in this study were produced in collaboration with the UMC Utrecht genomics lab 
(Utrecht, The Netherlands), as described before [5]. Technical replicate hybridisations were performed 
to obtain, per animal, two microarrays, meeting stringent quality criteria described before [5]. After 
image analysis, the local background intensity value was subtracted from the signal intensity for each 
spot. The minimal signal intensity was set to 1.5 x background for the two channels. Flagged spots 
and controls were excluded from further interpretation. Genes for which less than 70 % of the 
microarrays delivered a significant signal were excluded from further interpretation. Ratios of the 
background-corrected intensities of tester over reference were calculated for each slide and, 
normalised using the lowess normalization algorithm [103] in the SAS statistical program. Data were 
log-transformed, with base 2, and excluded values were replaced by 0. Two-sided Student's T-tests 
were performed to assess the significance of the differences in gene expression in the test groups 
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compared to the controls. Changes were considered statistically significant if the p-value did not 
exceed 0.005. 
Transcriptomics - Confirmation of individual gene expression changes by B and TCE 
The response in the main study, of the genes found to change in the range finding studies, was 
assessed in samples exposed to either B or TCE. This was achieved by calculation of the average 
difference between relative gene expression levels (log(2)) in the samples treated with a high dose of 
benzene or TCE, and the controls. A (arbitrary) minimum increase or decrease of 0.3 on the log(2) 
scale (1.2-fold) was required for a gene to be designated as confirmed to change in accordance with 
previous findings. 
Transcriptomics - Multivariate statistical analysis of expression profiles with PLS models 
Partial least squares (PLS) regression analysis was carried out in Matlab (Version 6.5, The 
MathWorks Inc., Natick, MA, USA) using the PLS toolbox (Version 3.0, Eigenvector Research Inc., 
Manson, WA, USA). PLS models were generated to fit data from range finding studies. Log(2) 
transformed gene expression data were used as independent variables and exposure levels of TCE 
and B, respectively, as variables to be predicted. Full leave-one-out cross-validation was performed. 
Comparison of the predictions with the actual exposure levels, enabled to calculate the coefficient of 
correlation R2 as a measure of accuracy of the model. We required an arbitrary threshold of R2 > 0.7 to 
consider a model suitable for further analysis. Subsequently, the obtained PLS models were used to 
predict dose-equivalent levels based on gene expression data from the mixture study. Comparison of 
the predictions with the actual exposure dose levels enabled to calculate the coefficient of correlation 
R2 as a measure' of the accuracy of the predictions, and possibly as a measure to assess the 
occurrence of interaction effects, if gene expression changes would deviate from the expected effects. 
"In vitro" exposure of rat hepatocyte cultures and measurement of CYP2E and GST activity 
Primary rat hepatocytes were isolated from the liver of a male F344 rat, according to Seglen [201] and 
[202]. Collagen gel sandwich cultures of isolated rat hepatocytes were prepared, by coating the 
bottom of 75 cm culture flasks with collagen. Freshly isolated primary hepatocytes were plated at a 
density of approximately 7 x 104 cells/cm2 in Dulbecco's Modified Eagles Medium with 4.5 mg/ml 
glucose and L-glutamin supplemented with foetal calf serum (10% v/v), insulin (4 ug/ml), glucagon 
(0.007 ug/ml), hydrocortisone hemisuccinate (7.5 ug/ml), and gentamycin. Hepatocytes were attached 
to the collagen gels in 95% air and 5% C02 at 37°C for 4 hours. Culture medium was removed and 
cells were covered with collagen for a period of 45 - 60 minutes. Serum-free culture medium (12 ml) 
was added, and used throughout the experiment. Cells were exposed to benzene or TCE dissolved in 
DMSO (final concentration DMSO 0.1%). Fresh medium containing the test compounds was added 
daily. Hepatocytes were exposed to a concentration range of B or TCE of 0, 10, 100, 500, 1000, 5000 
and 10000 micromoles per liter. During the exposure, the flasks were sealed with parafilm to limit 
evaporation. After 4 days, cells were harvested by collagenase digestion and S9 fractions were 
prepared for enzyme activity measurements. Viability of the cells was assessed by measuring LDH 
levels in the medium. CYP2E activity was determined through the formation of 6-
hydroxychlorzoxazone from chlorzoxazone, assayed by HLPC UV analysis [203]. GST enzyme activity 
was determined in S9 fractions according to Habig et al. [82]. Protein concentrations in S9 mixtures 
were determined according to Bradford [82]. 
"In silico "physiologically based pharmacokinetic modelling 
A physiologically based pharmacokinetic (PBPK) model developed by Clewell et al [204] was used to 
investigate the effect of increased CYP2E activity on TCE metabolites like trichloroacetic acid (TCA). 
The rat PBPK model was run to determine effects of an oral dose of 2000 mg/kg/day of TCE using all 
parameters given in the original publication. A second run was performed to simulate the interaction 
with benzene, where the oxidative metabolism step (Vmax-ox) was increased by the factor found after 
treating hepatocytes with benzene. 
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VII.3 Results 
This study assessed the effects of (mixtures of) B and TCE, with conventional toxicological 
methods, hepatic gene expression profiling, in vitro exposures of hepatocytes and PBPK 
toxicokinetics modelling. For that purpose, F344 rats were exposed to benzene, 
trichloroethylene or mixtures. Two dose levels were chosen that previously showed effects 
with conventional toxicological methods and/or transcriptomics measurements [5-6]. 
In vivo subacute toxicity studies 
The results obtained for animals given B or TCE alone or as a mixture generally confirmed 
the organ-specific effects observed in the range-finding studies with the single compounds. A 
complete description is reported by Jonker et al. [199]. The main findings are summarized 
below. 
Growth was not affected by the low dose of B or TCE. The initial high dose of B (600 mg/kg) 
caused marked growth retardaton or even weight loss. Growth of animals given the reduced 
high dose of B (400 mg/kg), the high dose of TCE, or the mixtures was slightly to moderatly 
retarded (see Table VII.1 ). The rats with reduced growth also showed decreased food 
consumption. 
Hematology - TCE did not affect red blood cell, white blood cell or coagulation parameters. 
Both dose levels of B reduced, to about the same extent, total white blood cell count and the 
absolute numbers of lymphocytes and neutrophils. Similar changes in total or differential 
white blood cell counts were observed in the four mixture groups, most markedly in those 
given the high dose of B. In addition, the percentage of lymphocytes was decreased and that 
of neutrophils increased in the BhTh-group. 
Clinical chemistry - Animals given a high dose of B showed a decrease in plasma creatinine 
and urea. Animals given TCE at the high dose showed an increase in plasma albumin and a 
decrease in total cholesterol. Rats exposed to mixtures had increased plasma albumin and 
decreases in bilirubin, creatinine, urea, and cholesterol. 
Pathology - Spleen weights decreased dose-dependently in animals given B (Table VII. 1). 
Animals given the low (but not the high) dose of B showed increased weights of the liver and 
kidneys. TCE increased weights of the liver and kidneys at both dose levels. Animals given 
the mixtures showed increased liver and kidney weights and decreased spleen weight. 
Macroscopic examination at necropsy revealed no compound-related changes. 
Histopathological examination (no table presented) revealed karyomegaly, especially in the 
inner cortical region, in the kidneys of animals given TCE alone or in combination with B. The 
incidence and/or severity increased with dose. Compared with exposure to TCE alone, co-
exposure to B tended to aggravate the karyomegaly. Animals given B alone showed no 
compound-related histopathological changes. 
Analysis of the mixture data for departure from additivity revealed statistically significant 
interactions for some of the conventional endpoints, namely: percentages of lymphocytes 
and neutrophils, red blood cell count, hemoglobin and packed cell volume. The changes in 
these endpoints (decreases, except for neutrophils which were increased) were more 
pronounced than expected under the assumption of additivity. The interaction observed for 
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the red blood cell values was unexpected because neither B nor TCE affected red blood cell 
values when given alone. 
Table VII.1. Body and organ weights 
Terminal body weights, relative liver, kidneys and spleen weights of the rats treated with 
benzene, TCE, or mixtures. 
Group 
CO_l 
CO II 
Bl 
Bh 
Tl 
Th 
BITI 
BhTI 
BITh 
BhTh 
B TCE 
(mg/kg/day) 
0 
0 
200 
600 (400) 
0 
0 
200 
600 (400) 
200 
600 (400) 
0 
0 
0 
0 
500 
1500 
500 
500 
1500 
1500 
Body 
(g) 
200.4 ± 3.7 
199.0 ±8.5 
201.1 ±4.4 
184.4 ±8.8* 
202.3 ±1.0 
183.8 ±4.0 
183.8 ±5.6* 
169.1 ±5.5** 
167.5 ±7.5** 
162.7 ± 7.4** 
Rel. liver 
(g/kg BW) 
39.9 ± 1.4 
39.6 ±1.2 
45.4 ± 0.7** 
41.5 ±0.4 
47.1 ± 2.0** 
50.0 ± 1.8** 
45.4 ± 0.7** 
46.6 ± 0.9** 
49.2 ±1.1** 
51.8 ±1.4** 
Rel. kidney 
(g/kg BW) 
7.34 ±0.10 
7.28 ± 0.20 
8.18 ± 0.11* 
7.65 ± 0.07 
8.42 ±0.14* 
8.44 ± 0.23** 
7.99 ±0.15* 
8.28 ± 0.22** 
8.19 ±0 .13 " 
8.55 ± 0.20** 
Rel. spleen 
(g/kg BW) 
2.59 ± 0.04 
2.45 ± 0.05 
2.30 ± 0.09 
2.15 ±0.03* 
2.84 ± 0.53 
2.39 ± 0.06 
2.20 ± 0.04* 
1.98 ±0.12** 
2.24 ± 0.04 
2.17 ±0.05* 
n = 5 or all groups except Tl:n =2 and Bl: n =4 
Significance: One-way ANOVA + Dunnetts tests: *: p< 0.05; **: p< 0.01 
Hepatic gene expression profiling (transcriptomics) 
Gene expression was determined in livers of selected rats exposed to B, TCE or mixtures, 
using oligonucleotide DNA microarrays. The intention of this study was to highlight possible 
molecular mechanisms at the hepatic gene expression level for further studies. Because of 
this, and the availability of data from previous studies [5-6], the analysis was limited to two 
technical replicate measurements of two animals per group. Further, conclusive 
transcriptomics experiments would require a larger design, with replicated measurements of 
at least 3-5 rats per group. The average gene expression levels in two rats per treatment 
group were compared with controls, selected from both control groups, CO_l and COJI. The 
gene expression changes were analysed with two separate approaches. Univariate statistics 
were applied to analyse changes in expression of individual genes, while multivariate 
statistics were used to analyse profiles of hepatic gene expression, in response to the 
different treatments. 
Statistical significance of the changes was tested with univariate tests for 2437 genes left 
after quality filtering, and the number of changes was determined at two statistical confidence 
levels (Table VII.2 and figure VII.2). Both B and TCE altered expression of several genes at 
low doses, while higher doses affected more genes. Mixtures of B and TCE had the most 
pronounced effect on gene expression when TCE was included at high dose levels. 
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Figure VII.2 Numbers of gene expression changes 
Venn diagrams of numbers of genes of which expression significantly (p<0.005) changed in 
the different treatment groups. B:benzene; T:trichloroethylene, I: low dose, h: high dose 
Table VII.2. Numbers of genes differentially expressed after treatment 
Two-sided Student's T-tests were performed to identify the number of changes 
confidence: Bl Bh Tl Th Bl Tl Bl Th Bh Tl BhTh 
p< 0.001 
p < 0.005 
1 
10 
5 
27 
5 
18 
13 
54 
10 
32 
14 
60 
4 
15 
16 
47 
Benzene dose-dependently induced gene expression of Aflatoxin B1 aldehyde reductase 
(Afar), ribosomal subunits and cystathionine beta synthase (> two-fold and p < 0.005 at high 
dose). Tyrosine aminotransferase (Tat), aminolevulinic acid synthase 1 (Alasl) and the 
amino acid transporter A2 (solute carrier, Slc38a2) were dose-dependently reduced. TCE 
altered expression of more genes than benzene, and most pronouncedly induced were Afar, 
Aldhl, dodecenoyl-coenzyme A delta isomerase (Dei), cystathionine beta synthase, Gstm, 
and ferritin. Markedly reduced were cadherin 17 (Cdh17), carnitine palmitoyltransferase 1, 
ornithine aminotransferase (Oat), tryptophan 2,3-dioxygenase, hydroxyacid oxidase (Hao3) 
and the Abcc9 transporter. 
The confidence in the observed gene expression changes in the main study was increased 
by comparison with previously observed changes in the range finding studies with benzene 
[5] and TCE [6] , as described in the methods section. Confirmation was assessed for the 
400 genes most significantly affected in the range finding studies, by either B or TCE. The 
two sets of 400 genes contained 110 genes in common, affected by benzene as well as TCE 
treatment. For benzene, 33 genes out of the 400 were confirmed to change in the main 
study, after treatment with the high dose of benzene (17 up and 16 down). Most of these 
confirmed changes were slight (< 2-fold), and only two changes were established with 
statistical significance. These were the 2-fold induction of the "Myeloid differentiation primary 
response gene 116" (Myd116) and the 2.2-fold decrease of the "amino acid transporter A2" 
(solute carrier Slc38a2). Myd116 displayed increased expression during progression of 
transformation and in response to DNA damaging agents [205]. Slc38a2 is upregulated by a 
variety of hormones, growth factors, mitogens and altered levels of intracellular amino acids. 
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The expression in the skeletal muscle and liver is regulated by glucagon and insulin, for 
instance in association with diabetes [206]. 
For TCE, 106 out of the 400 genes were confirmed to change in the main study, after 
treatment with with the high dose of TCE (57 up and 49 down). Many genes for which the 
changes were not confirmed, were found to exhibit a large interanimal variation in response, 
for example metallothioneins, orosomucoid, hemoglobin, Hnf4 and apolipoprotein B. The 
marked induction by TCE of many ribosome (and proteasome) subunits in the range finding 
study was not confirmed in the main study. Out of the 106 confirmed genes, 39 were 
statistically significantly (p < 0.01) different from controls after treatment with TCE. A few of 
those were modulated in a similar manner by a high dose of benzene (Afar, ferritin, 
complement component 9, Hsp8, Tat, syndecan and Slc38a2). 
Mixtures of B and TCE (especially at high dose) modulated genes that were also modulated 
by benzene and/or TCE only (figure VII.2). At high dose levels, around one third of the TCE-
modulated genes was also changed by the mixtures. The overlap with benzene-induced 
changes was minimal. The genes most pronouncedly induced by TCE were also markedly 
induced by the mixtures, like the biotransformation enzymes Afar, Aldhl and the enzymes 
Cd36 and Dei, related to beta oxidation of fatty acids. Other genes significantly induced by 
the mixtures include epoxide hydrolases, GSH synthase, two DNA fragments representing a 
thyroid hormone responsive protein (NM_012703 and K01934), and the "kidney-specific 
protein" (AF062389). The mixtures significantly reduced expression of Cdh17, Oat, Hao3, 
alpha albumin, Cyp2c12, G6pc and transporters Slc38a2 and Abcc9. The oxidative stress 
responsive ferritin was induced by both TCE and the mixtures. Expression levels of genes 
with significant induction or reduction by TCE that were also modulated by the mixture at 
high dose levels, were listed in table VII.3 a and b. The genes with most pronouncedly 
changed expression were also displayed in figure VII.3. 
To assess the mode of joint action to change gene expression, we acquired the test 
hypothesis that the effects of B and TCE at the gene expression level could be summed to 
roughly predict the effect of mixtures. For simplicity, this hypothesis assumed that unlimited 
induction of expression of genes was possible, and that other steps in the mechanisms of 
action were not of influence (e.g. saturation of molecular receptors, transcription factors etc.) 
at the dose levels studied. Also, the fact that gene expression changes were expressed as 
log(2) ratios (test sample / reference) was neglected. Without aiming to exactly quantify the 
effects of the mixtures, expected gene expression levels were predicted by addition of the 
effects observed in samples exposed to either B or TCE at high doses. These predicted 
levels for the mixtures were compared to the actual effects measured upon exposure to a 
mixture of B and TCE at high doses. For the majority of the genes, the response to mixtures 
was similar to the response to TCE, regardless of the presence of benzene. However, for 
several genes the effect of TCE was enhanced by benzene, as expected based on the 
effects of benzene only on these genes. These included Afar, G6pc, Cdh17 and Oat. For a 
few genes, the effects of the mixtures deviated from expectations (departing from additivity). 
In the mixtures group, the enzyme Cd36 was clearly induced more than expected. Genes 
that were induced less than expected included ferritin, Gstm and ribosomal protein L15, 
Hsp8, Tat, complement component 9 and Slc38a2. 
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Figure VII.3 (previous page) 
The histograms display expression levels of genes significantly (p<0.005) modulated by 
trichloroethylene and modulated by mixtures of benzene and trichloroethylene. Bars represent mean 
log(2) expression levels of duplicate measurements of two rats per group (relative to reference), with 
error bars representing the standard deviations. In addition, gene expression changes in GSTa and 
CYP2E, important biotransformation enzymes for both compounds were displayed. Gstal gene 
expression was induced by the mixtures (p = 0.006 at BhTh, p < 0.005 at BITh and BhTI). For 
CYP2E1, gene expression changes could not be established with statistically significance. 
Multivariate statistical analysis of gene expression profiles 
The multivariate statistical technique PLS (partial least squares) was used to assess the 
relation between exposure and hepatic gene expression profiles. Profiles measured in the 
range finding studies were used to construct PLS models that calculated "predicted exposure 
levels" for B and TCE. Subsequently, these predictions were correlated to the actual 
exposure levels. The robustness of the models was determined by leave-one-out cross-
validation, and the accuracy of the models was shown by a coefficient of correlation, R2, of 
0.79 for benzene, and 0.85 for TCE. Based on these coefficients, both models were 
considered appropriate for subsequent analysis of hepatic gene expression in the main 
study. 
The B and TCE PLS models were tested with samples from the main study (see methods 
section). Valid models should be able to relate gene expression profiles to exposure levels 
also in the main study. The coefficient of correlation between the predicted and actual 
exposure levels provided an indication for the validity of the model. As an arbitrary criterion, 
an R2of 0.7 or larger was chosen to consider a model valid. The TCE model was tested with 
samples from the main study (Figure VI1.4a), and the predictions were in agreement with the 
actual exposure levels of TCE, as demonstrated by an R2 of 0.88. This model was 
considered suitable for analysis of effects of mixtures. The same testing with the benzene 
model (figure VII.4b) showed that this model was not suitable to relate benzene-induced 
gene expression changes to the actual exposure levels of benzene in the main study, as 
demonstrated by an R2of 0.01. Therefore, no further attempt was made to assess the effects 
of the mixtures with this model. 
The effects of mixtures of B and TCE on hepatic gene expression profiles were assessed 
with the PLS model for TCE. The gene expression changes were used to predict "exposure 
equivalents". These (on the y-axis) were correlated to the actual exposure levels of TCE (in 
the mixtures) (on the x-axis) (figure VII.5). The model calculated that the effects of mixtures 
were larger than the effects of TCE only. The analysis indicated that a mixture of low doses 
of TCE with B (Tl Bl and Tl Bh) affected gene expression more than low doses of TCE only. 
When the mixtures contained high levels of TCE, the effect of B in the mixtures got more 
pronounced. The low dose of B in the mixtures increased the predicted exposure equivalents 
by around 25%, while the high dose of B in the mixtures increased the effects by around 
50%, as compared to high doses of TCE only. In conclusion, when a mixture of B and TCE 
was given, the TCE-induced effects on gene expression in rat liver were enhanced. 
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Figure VII.4 a, b Testing ofPLS models to relate exposure to gene expression 
The models based on the range finding study related the actual exposure to the gene expression 
levels in the main study (which were used to calculate "predicted exposure"). 
Upper panel a) Trichloroethylene: R2 of 0.88 demonstrated that the TCE model could be used for 
further analysis of effects of mixtures. 
Lower panel b) Benzene: R2 of 0.01 demonstrated that the model was not suitable for further 
analysis Symbols: Range finding study: circles, Main study: triangles; CO: control; B: benzene; 
T:trichloroethylene; l:low, m:mid; h:high dose levels. 
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Figure VII.5 Assessment of mixtures effects with PLS model for TCE 
The PLS model based on the effects of TCE in the range finding study could relate the actual 
exposure to the gene expression levels in the main study (used to calculate "predicted exposure"). 
The effects in samples treated with mixtures were larger compared to effects of TCE alone, 
especially at high doses. CO: control; B: benzene; T:trichloroethylene; l:low, m:mid; h:high dose 
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Figure VII.6 a,b CYP2E and GST enzyme activity after benzene exposure, 
Figure VII.6 c,d CYP2E and GST enzyme activity after trichloroethylene exposure 
Activity of cytochrome P450 2e (CYP2E) or glutathione S-transferase (GST) was measured after a 
four day exposure of hepatocytes in vitro to benzene or trichloroethylene 
Data represent mean ± sd (n=3) 
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In vitro exposure of hepatocytes 
CYP2E is the most relevant enzyme for bioactivation of both B and TCE in liver 
(hepatocytes). GSTs conjugate (reactive) metabolites of both compounds to glutathione. 
Previous experiments identified changes in Cyp2e and Gst gene expression, and therefore, 
activities were analysed in detail after 4 days of exposure of hepatocytes to various 
concentrations of the compounds in vitro. Activities were determined after four days of 
exposure of the cells to concentrations that did not induce cytotoxicity. Benzene dose-
dependently elevated the levels of CYP2E activity to a maximum of 1.6 fold induction, and 
slightly decreased levels of GST activity. TCE increased GST activity, especially within the 
0.01 - 0.5 mM concentration range. At 10 mM, GST activity decreased while cytotoxicity 
(based on LDH release) was not overt. A dose-related effect of TCE on CYP2E activity was 
not found, (figure VII.6) 
In silico physiologically based pharmacokinetic modelling 
The effect on TCE metabolism of CYP2E induction due to benzene in the mixture was 
analysed with a PBPK model developed by Clewell et al. [204] (methods section). The rat 
PBPK model was used to determine effects of an oral dose of 2000 mg/kg/day of TCE using 
all parameters given in the original publication. Secondly, the model was used to simulate the 
interaction with benzene, where the oxidative metabolism step (Vmax-ox, see Methods 
section) was increased by a factor 1.6, as found in benzene-exposed hepatocytes. After 
induction of CYP2E activity, the TCA levels in blood were significantly increased (Figure 
VII.7), while TCE levels only marginally decreased. Both Cmax and AUC were predicted to 
increase by a factor of 1.3 as compared to the model for TCE only. The experimental results 
and the PBPK model simulations indicate that benzene in the mixtures is likely to increase 
the TCA formation from TCE. 
Without 
benzene 
With benzene 
20 30 
Time (h) 
Figure VII.7 PBPK model simulation for TCE at 2000 mg/kg/day 
Simulated formation of trichloro-acetic acid (TCA) from trichloroethylene (TCE) by hepatic 
biotransformation. This formation was simulated without, and with (dashed line) the presence of 
benzene in the exposure. Thus, the dashed line indicates the toxicokinetic interaction between TCE 
metabolism and benzene on TCE metabolism, which is caused by an increased activity of oxidative 
metabolism (CYP 2e1 protein activity) due to the presence of benzene in the mixture. 
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VII. 4 DISCUSSION 
The present study demonstrated how investigative toxicological methods enabled to acquire 
more insights in effects of mixtures of benzene and trichloroethylene. Hypothesised effects of 
mixtures based on single compound data were tested in the present study. 
In vivo subacute toxicity studies 
Statistical analysis of the conventional toxicological parameters to assess joint effects and 
interactions of B and TCE was described earlier by Jonker et al. [199]. In summary, the 
analysis showed no influence of benzene on nephrotoxicity that was dose-dependently 
induced by TCE. The mixtures increased the relative liver and kidney weight to about the 
same extent as TCE at the high dose. The benzene-induced hematotoxicity was more 
severe in the presence of TCE, though only benzene and not TCE was known to induce 
hematotoxicity [128]. It was proposed earlier [200] that benzene-induced hematotoxicity 
could be aggravated by TCE because of the ability to induce enzymes for bioactivation of 
benzene. Thus, the conventional toxicity parameters suggested joint additive effects of B and 
TCE in most cases, except for the hematotoxicity. However, these parameters could not 
provide explanations for the joint effects. For this purpose, investigative methods 
(transcriptomics, in vitro hepatocyte exposure and PBPK modelling) were applied that could 
provide insight in the effects at the molecular level. 
Hepatic gene expression profiling (transcriptomics) 
Transcriptomics measurements demonstrated effects of mixtures of B and TCE at the gene 
expression level, and provided insight in mechanisms putatively involved. The effects of TCE 
largely confirmed previous findings, both by individual gene expression changes, as well as 
by the entire profile changes, as demonstrated using the PLS models. The coefficient of 
correlation between the gene expression changes (used to calculate 'predicted exposure 
levels') and the actual levels of exposure was 0.88. Because the models were built on data 
of 28-day exposures, the correlations between the predictions and actual dose levels would 
probably have been higher if the rats in the main study had also been exposed for 28 days. 
However, the actual duration of the exposure was about 14 days. This could explain why the 
samples from the main study showed less pronounced gene expression changes than 
expected. The genes that were affected (table VII.2) were predominantly related to 
biotransformation, oxidative stress and to beta oxidation of fatty acids, as discussed below. B 
induced several gene expression changes in common with TCE. For benzene, gene 
expression changes (individual as well as the profiles analysed with the PLS model) were not 
very well reproducing the data of the range finding study. In both studies, many gene 
expression changes were subtle, and a pronounced dose-response was not observed. It is 
likely that the hematotoxic effects were critical and largely influenced the observations in 
liver. Other causes of the differences were the unexpectedly severe effects of benzene at the 
initial concentration of 600 mg/kg/day in the main study, and to differences in the duration of 
the exposure. 
For TCE, a PLS model could be used to predict dose levels based on the expression 
changes of 400 genes selected in a previous study. Many of the hepatic gene expression 
changes caused by TCE in the previous study were confirmed in this study. Analysis of gene 
expression profiles after exposure to mixtures indicated that effects of TCE were enhanced in 
the presence of benzene. Most of the individual genes that were significantly modulated by 
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TCE responded to the mixtures in a similar manner, regardless of the presence of benzene. 
In the cases where both compounds were found to affect the expression, the response to the 
mixtures could usually be explained roughly by addition of gene expression changes induced 
by the single compounds. Genes that were induced by both B and TCE indeed were more 
pronouncedly elevated by the mixtures (eg. Afar). Several genes that were reduced by both 
compounds showed a more pronounced reduction by the mixtures (e.g. G6pc, Cdh17 and 
Oat). For a few genes, the response to the mixture (at high doses) deviated from the 
expectations based on addition of the effects of the individual compounds. The induction of 
the Cd36 antigen enzyme was markedly higher than expected. This gene, encoding an 
enzyme related to fatty acid metabolism, was induced by TCE, though not by B. The 
mixtures of B and TCE at high doses strongly induced Cd36. However, rather than indicating 
an (synergistic) interaction, this effect could be explained by previous data. In the previous 
range finding study, B induced Cd36 more than two-fold. [5]. Several genes (incl. ferritin, 
Gstm and Slc38a2) responded less than expected to the mixtures. Further investigation 
should demonstrate whether these observations can be ascribed to interactive effects. The 
effect could for some genes also be ascribed to an upper bound in the increase of gene 
expression or other transcriptional regulatory mechanisms that affect the gene expression 
levels. 
The observed gene expression changes allowed to generate hypotheses on how B and TCE 
may elicit joint actions or interactions. Numerous genes differentially regulated in the range 
finding studies and the present, main study, suggested that biotransformation, fatty acid 
metabolism and peroxisomal proliferation were most importantly involved in the response to 
B and TCE (mixtures). 
Biotransformation 
Toxicokinetic interactions were expected because B and TCE are both metabolised primarily 
by the CYP2E enzyme. If CYP activities would increase, enhanced bioactivation and 
aggravated hematotoxic effects of B were considered plausible. In vivo gene expression 
induction for biotransformation enzymes CYP2E and GST were corroborated by exposure of 
hepatocytes in vitro. Exposure to TCE though not benzene increased total GST activity. The 
1.5-fold induction of Cyp2e gene expression by benzene found previously [5] was 
corroborated by increased activity of CYP2E in primary rat hepatocytes. Exact matches for 
comparison of in vivo gene expression and in vitro (total) enzyme activity were not expected, 
because many factors may determine whether transcriptional upregulation (in vivo) also 
leads to increased enzyme activity (in vitro). However, present findings were in agreement 
with each other. The concentrations at which induction occurred in vitro (from 0.5 -10 mM) 
were comparable to liver concentrations in vivo as predicted by PBPK models for benzene 
[210]. The induction of these biotransformation enzymes may be relevant for the 
toxicokinetics, upon exposure to mixtures of B and TCE. 
Although the induction of Cyp2e gene expression by benzene could not be confirmed in the 
present in vivo study, induction of CYP2E enzyme activity was observed after exposing rat 
hepatocytes in vitro to benzene. Moreover, a recent publication reported induction of CYP2E 
gene and protein expression in rats exposed to benzene [159]. The effect on TCE 
metabolism of CYP2E induction due to benzene in the mixture was analysed with a PBPK 
model (see methods section). The metabolism of TCE contains several interacting routes 
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[204], making it difficult to predict effects of CYP2E induction on the internal concentrations 
of TCE and its metabolites, e.g. trichloro-acetic acid (TCA). TCE is rapidly exhaled after an 
oral intake. An increase in CYP2E activity may directly increase the tissue levels of TCEOH 
and TCA, which are much less volatile. TCA has been shown to induce PPARa and 
peroxisome proliferation in rodent hepatocytes [211-214] . Because the GST mediated 
pathway only accounts for minor fraction of the total metabolism, changes in GST activity will 
probably not alter the disposition of TCE or of its oxidative metabolites. After 1.6-fold 
induction of CYP2E activity, the TCA levels in blood were found to increase, compared to the 
model for TCE only. Thus, the results of the PBPK model simulations indicate that benzene 
in the mixtures is likely to increase the TCA formation from TCE. In conclusion, exposure to 
mixtures of B and TCE were suggested to enhance levels of TCA, an active metabolite of 
TCE that most likely determines the toxic effects [213];[215]. 
Role of the electrophile response element 
B and TCE were found to alter expression of many biotransformation enzymes such as Afar, 
Nqo1, Ephxl, Adhs and Aldhs. The induction of genes like Nqo1, Afar, Gsta, Gclc, ferritin 
and peroxiredoxinl is commonly regulated by a mechanism under transcriptional control of 
the Electrophile Response Element (EpRE or ARE) [177];[[124]; [86-87], Present data 
indicate that both B and TCE induced expression of genes through this responsive element, 
which therefore might be a site for interaction upon simultaneous exposure to both 
compounds. 
Peroxisome proliferation and the role ofPPAR in response to TCE 
Another observation in the studies with individual components was that B and TCE 
modulated gene expression related to fatty acid metabolism. TCE pronouncedly modulated 
enzymes involved in beta oxidation of fatty acids. Most pronounced were the induction of 
enzymes like dodecenoyl CoA isomerase, Cyp4b, Enoyl-CoA, hydratase/3-hydroxyacyl Co A 
dehydrogenase and the trifunctional enzyme. In combination with the observed induction of 
relative liver weight, the gene expression changes provide indications for peroxisome 
proliferation, that could be mediated by the peroxisome proliferation activated receptor 
(PPAR alpha). This receptor, in combination with the retinoid X receptor mediates expression 
of many genes related to, a.o. fatty acid metabolism, including Acetyl CoA oxidase (Aox), 
Cd36, the bifunctional enzyme and Cyp4. Expression levels of PPAR itself were not 
determined in our studies. However, the range finding studies and the main study showed 
that B and TCE (mixtures) induced expression of a.o. Cd36 and Aox. We previously reported 
that TCE modulated expression of genes in common with reported compounds that induced 
peroxisome proliferation in rats, such as Wy14,643, Clofibrate and gemfbrozil [6]. Taken 
together, the effects of TCE on the induction of hepatic peroxisomal proliferation seem to 
play an important role also when TCE is administered in combination with benzene. The 
biotransformation of TCE to TCA might be crucial in the determination of hepatic toxicity, as 
the secondary metabolites of TCE, TCA (and DCA) were found to induce peroxisome 
proliferation in rodents (though not in humans) [212];[214]. The effects of benzene on 
bioactivation of TCE to TCA (with implications for peroxisomal proliferation) were further 
analysed using an "in silico" PBPK model, as described below. Further, dedicated studies 
could be designed to effectively demonstrate the role of PPAR alpha and induction of 
peroxisomal proliferation and putative interative effects upon exposure to mixtures of B and 
TCE. 
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Other cellular mechanisms 
Besides biotransformation and peroxisomal proliferation, B and TCE (mixtures) seemed to 
affect various cellular processes. These findings could not always be fully understood and 
incorporated in a coherent and conclusive description of the mechanism of combined action 
of B and TCE. Nevertheless, they may provide useful starting hypotheses for further 
investigations. Therefore, a selection of the findings is briefly presented. 
Both compounds in the range finding studies induced hepatic GSH levels, and gene 
expression of Gclc and Gclm, subunits of the key enzyme for biosynthesis of GSH. In 
response to mixtures, Gclc induction was not confirmed with statistical significance. 
However, GSH synthase, another important enzyme in GSH biosynthesis, was induced by 
the mixtures. 
Data both from clinical chemistry and transcriptomics analyses suggested changes in 
cholesterol metabolism upon exposure to B and/or TCE. In the range finding studies, B 
induced gene expression of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. 
B also slightly induced plasma cholesterol levels (n.s.) in the range finding studies, but the 
main study showed slightly reduced levels. At high doses, B and TCE induced expression of 
7-dehydrocholesterol (Dhcr7) reductase, which is involved in regulation of cholesterol 
biosynthesis [216-217]. 
Protein synthesis and degradation were affected at the transcriptional level by both 
compounds. TCE was found to markedly change expression of genes related to the hepatic 
acute phase response. Possibly associated to changes in glycolysis and/or gluconeogenesis, 
B modulated expression of the gene transcription regulator Hnf4 (and Hnf6), and both B and 
TCE reduced expression of G6pc. Another hepatocyte nuclear factor (Hnf3 gamma) was 
reduced in the liver samples of rats exposed to TCE and the mixtures with high TCE 
concentrations. Hnf3 has been associated with a.o. regulation of expression of tyrosine 
aminotransferase (Tat) [218], in the glucocorticoid response [219]. Tat was reduced by both 
TCE and benzene and slightly (n.s.) by the mixtures. Previosuly, elevation of Hnf3 gamma 
levels was found to attenuate the acute liver injury caused by administration of CCI4 [220]. 
Furthermore, Hnf 3 regulates human Cyp2c [221]. The rat Cyp2c12 expression was also 
associated to this transcription factor [222]. In agreement, our study showed reduced 
expression of Cyp2c12 by B, TCE and mixtures. The putative involvement of more processes 
was shown by expression changes of e.g. Cdh17 (cell adhesion), thyroid hormone 
responsive proteins, kidney-specific protein and alpha albumin. 
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Conclusions 
This subacute toxicity study analysed effects of mixtures of B and TCE in rats in a 
stepwise approach. Hypotheses were generated based on effects of the single 
compounds, and tested in rats exposed to mixtures. Profile analysis with multivariate 
statistics exploited the large transcriptomics datasets to provide indications for enhanced 
hepatic TCE-effects in the presence of benzene. Transcriptomics duta confirmed 
previously reported induction of genes related to biotransformation, but also highlighted 
changes in genes related to various other processes such as TCE-induced peroxisome 
proliferation. Putative roles of transcriptional regulation mechanisms involving EpRE. 
PPAR, Hnf and others were highlighted in the response to B and TCE und dedicated 
studies for this can now be designed. 
When hepatocytes were exposed in vitro of to benzene. CYP2E enzyme activity 
increased. According to in silica PBPK modelling, this induction enhanced oxidative 
bioactivation of TCE to TCA, which presumably is responsible for the toxic action. Thus, 
induction of CYP2E by benzene is one plausible explanation for the toxic effects of 
mixtures of B and TCE. Further studies could refine the PBPK models and the offects of 
changes in other biotransformation enzymes. For instance, more msnfiruh could clarify tho 
role of GSH conjugation by GST isozymes with subsequent toxicity and/or carcinogenicity 
in the kidneys. In addition, PBPK models for benzene could aid to identify the implications 
of the presence of trichloroethylene. 
In summary, this study demonstrates that an integrated approach with investigative 
toxicological methods including transcriptomics enabled better understanding of joint 
effects of chemicals upon exposure to mixtures. 
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VIII. Discussion and conclusions 
The studies described in this thesis were performed to explore applications of 
toxicogenomics. The studies primarily analysed the effects of chemicals in rat liver. The 
results of the studies will be briefly summarised. Potential applications of toxicogenomics 
will be discussed using results of the studies described in chapters II - VII. The technical 
aspects like sensitivity and reproducibility of the toxicogenomics methods are evaluated, 
as well as the relation between the different technologies. Challenges like the "linking of 
the layers" of gene, protein and metabolite measurements are mentioned. Lastly, the 
perspectives of toxicogenomics for hazard characterisation and human health risk 
assessment are discussed. 
VIII.1 Summary of the results 
Toxicogenomics methods were used to study the response in rat liver after exposure to 
bromobenzene, benzene and trichloroethylene and mixtures. Chapter II described 
transcriptomics and proteomics analyses in livers of rats exposed to bromobenzene. The 
protein and gene expression changes, 24 hours after single dosage of this well-known 
model hepatotoxicant, supported existing and raised new hypotheses about mechanisms 
of hepatotoxicity. The crucial role of hepatic glutathione levels and oxidative stress was 
apparent, and a cluster of genes was found to be co-ordinately induced by the electrophile 
response element (EpRE, also ARE). Gsta induction was confirmed by increased activity 
of this enzyme in cytosolic fractions. Induction of aldehyde dehydrogenases at both the 
gene and protein level might be related to lipid peroxidation by bromobenzene. Changes 
were related to metabolism of fatty acids and cholesterol, protein synthesis and 
proteolysis. Bromobenzene was found to elicit an acute phase response. The proteomics 
results corroborated findings like increased proteolysis. Proteomics and transcriptomics 
provided complementary results, and further development of proteomics methods could 
enhance analysis of correlations between gene expression and protein changes. 
Chapter III demonstrated the dose and time dependency of the gene expression changes 
by bromobenzene. Liver samples were measured at 6, 24 and 48 hours after dosage. 
With transcriptomics, effects were detected earlier and at lower dose levels compared to 
histopathology and clinical chemistry. Several gene expression changes were confirmed 
with the branched DNA assay. Markers for oxidative stress like heme oxygenase were 
induced already 6 hours after dosage. The suggestion that glutathione has a key role in 
the response to reactive metabolites of bromobenzene was supported by the finding of 
GSH synthesis and induction of enzymes responsible for this. 
In chapter IV, the transcriptomics data were analysed in combination with metabolomics 
analysis of urine and blood plasma of the same rats exposed to bromobenzene. The 
combined analysis of hepatic transcriptome and plasma metabolome data provided more 
insights in chemically induced hepatotoxicity, eg. in the involvement of apoptosis. The 
degree of hepatic necrosis in individual animals could be correlated to single metabolite 
signals and gene expression changes, using multivariate statistical techniques. 
Chapters II, III and IV described the effects of a model toxicant that induced obvious signs 
of liver damage within days. The question remained whether gene expression changes 
were characteristic for hepatotoxicity. Therefore, the next studies analysed hepatic gene 
expression changes in response to compounds which were not model hepatotoxicants. In 
chapter V and VI, effects at the liver gene expression level were reported after exposure 
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for 28 days to different concentrations of the widely used chemicals benzene and 
trichloroethylene (TCE). Transcriptomics analyses showed many hepatic gene expression 
changes, though histopathology and clinical chemistry did not reveal abnormalities in liver. 
Gene expression changes related to hepatic biotransformation of both TCE and benzene 
were found, which may influence the toxicity of benzene, in blood and bone marrow, and 
of TCE in the kidneys. 
Benzene-induced changes were compared to effects of the model hepatotoxicants 
bromobenzene and APAP, which induced hepatic necrosis. While results partly 
overlapped, the effects of benzene were more subtle, both in the magnitude and the 
number of the changes. In the next study, TCE was found to provoke changes similar to 
benzene, though also for TCE, a characteristic profile of gene expression was obtained. 
For instance, characteristic gene expression changes corroborated the peroxisome 
proliferating capacity of TCE. In conclusion, the studies enabled to delineate characteristic 
gene expression changes upon exposure to (potentially) hepatotoxic chemicals. 
Metabolomics analysis or urine (NMR and multivariate statistics) enabled to assess 
exposure to benzene and TCE, even low dose exposure. 
In chapter VII, toxic effects of mixtures of benzene and trichloroethylene in liver were 
analysed. To our knowledge, this was the first study to investigate combined action of 
mixtures of (toxic) compounds at the gene expression level. Livers of rats, exposed to 
benzene, trichloroethylene or to mixtures of these chemicals at different dose-levels were 
analysed with transcriptomics. Both individual gene expression changes and changes in 
the profiles of gene expression, analysed with multivariate statistical models, showed that 
benzene enhanced the effects of TCE. 
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VIII.2 Applications of toxicogenomics 
From the applications of toxicogenomics that were discussed in the introduction, this 
thesis primarily demonstrated the use of toxicogenomics to: 
d) investigate mechanisms of toxicity (see 1.2.1) 
e) obtain new markers of toxicity (see I.2.2) 
f) assess effects of mixtures of toxic compounds (see 1.2.4) 
In the following section, each of these applications is discussed in more detail in relation 
to the studies described in this thesis. 
a) mechanisms of toxicity 
Initial studies were performed to characterise mechanisms of toxicity at the protein and 
gene expression level in liver, in relation to pathological endpoints. Hepatic necrosis was 
induced by the well-studied compound bromobenzene, and many genes in the liver were 
found to be differentially expressed. The changes were related to biological processes like 
biotransformation, GSH metabolism, oxidative stress, acute phase response. 
Bromobenzene pronouncedly induced epoxide hydrolase (Ephxl) and Glutathione-S-
transferase alpha (Gsta), which could enhance detoxification of harmful metabolites of 
bromobenzene. The response to highly electrophilic metabolites of BB was suggestively 
mediated by the electrophile or antioxidant response element (EpRE or ARE). Also 
unexpected processes were affected, like cholesterol and fatty acid metabolism, protein 
synthesis and proteolysis. The combination of hepatic transcriptomics and metabolomics 
analysis of plasma (chapter IV) revealed more details in the mechanism of hepatotoxicity, 
and showed relationships between changes in expression of hepatic enzymes and 
metabolite levels in blood. In contrast to plasma, the profiling of urine did not contribute 
very much to the elucidation of mechanisms of biotransformation and toxicity of 
bromobenzene, nor of benzene or TCE, primarily because not enough signals could be 
identified. 
In the studies with benzene and TCE, transcriptomics enabled to identify effects relevant 
for the mechanism of toxicity, such as induction of bioactivating enzymes. Benzene and 
TCE were also found to affect the metabolism of fatty acids and sterols, including 
cholesterol. An interesting finding was that TCE reduced hepatic expression of alpha 2u-
globulin, which possibly explained why hyalin droplet nephropathy was not found with 
TCE, and could be refuted as a possible mechanism for nephrocarcinogenicity of TCE in 
rats. The known capacity of TCE to induce peroxisome proliferation was corroborated by 
relative liver weight increase and induction of gene characteristic for this effect. These 
genes were also found in studies with peroxisome proliferating agents. 
The toxicogenomics measurements revealed a multitude of effects. Adaptive responses, 
reversible effects and "normal" physiological effects like intraday variation should be 
distinguished from specific effects of the toxic stimuli. To delineate the significance and 
specificity of the effects, the gene expression changes induced by bromobenzene were 
compared with reported effects of high doses of acetaminophen (APAP, paracetamol) 
well-known to be hepatotoxic. An overlap in gene expression changes was observed, 
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especially in the pathways that were altered. Subsequently, gene expression changes 
were compared to effects of benzene and trichloroethylene. These widely used chemicals 
are not well-known hepatotoxicants. However, both compounds induced relative liver 
weights and GSH levels. Other effects in liver were not observed with histopathology and 
clinical chemistry. However, expression of many hepatic genes was modulated both by 
benzene and TCE. Several genes were modulated commonly by B and TCE, and a few 
effects were seen with benzene, TCE and with the model hepatotoxicants. Nevertheless, 
all compounds tested revealed many specific gene expression profiles changes, indicating 
that transcriptomics is useful to investigate and discriminate the effects of different 
(potentially) hepatotoxic compounds that lead to different (adverse) effects in the liver. In 
conclusion, the studies showed that toxicogenomics, especially transcriptomics, 
delineated crucial steps in the mechanisms of toxicity. Gene expression changes could be 
related to known effects of the compounds, while also many yet unknown effects were 
discovered. 
The transcriptomics studies in this thesis, as well as in other laboratories, showed that a 
fraction of the more than 30000 (rat) genes was differentially expressed in liver by many 
different treatments. As might have been expected, genes highly expressed in liver (e.g. 
biotransformation enzymes) were identified in many of the toxicogenomics studies. To this 
moment, studies predominantly analysed livers, and a large part of the important effects in 
the liver could be determined by measurement of a limited number (hundreds) of genes. 
The analysis of other tissues would probably require measurement of other genes. 
Identification of putatively interesting and/or unexpected effects would require 
measurements of as many genes as possible. 
b) new markers of toxicity 
Transcriptomics, proteomics and metabolomics were applied to obtain new markers of 
hepatotoxicity, for early identification of effects, at exposure to lower dose levels in 
comparison to the current markers. The methods identified gene, protein and metabolite 
changes in relation to the bromobenzene treatment (Chapter II - IV). Some effects at the 
gene expression level were identified early (6 hours) after treatment, when no other 
toxicity markers demonstrated effects. Many of the BB-induced effects were seen at a 
dose level 2,5 to 10 - fold below the level that induced effects observed with the 
conventional methods. The combined analysis of hepatic transcriptome and plasma 
metabolome yielded a ranked list of potential gene expression and metabolite markers of 
hepatic necrosis (Chapter IV). The potential, early and more sensitive markers of 
hepatotoxicity, should be further validated for use in assessment and quantification of 
hepatic necrosis. Metabolomics profiling revealed characteristic patterns of metabolites in 
urine. Because the identity of the individual signals was not established, individual 
metabolites as markers of benzene or TCE toxicity were not obtained. However, the entire 
profiles could be used to specifically and robustly assess exposure and/or effects of 
benzene and TCE (Chapter V and VI). In the study with mixtures of benzene and TCE 
(chapter VII), gene expression changes were found that could serve as markers to 
facilitate assessment of interaction effects upon exposure to mixtures. In conclusion, 
toxicogenomics methods yielded potential markers that discriminated treated from control 
samples, and markers that correlated with the degree of necrosis. Nevertheless, studies 
have to be performed to validate and establish these markers for use in routine practice. 
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c) effects of mixtures of toxic compounds 
The study described in chapter VII investigated effects of mixtures of benzene and TCE, 
at the gene expression level. Subacute toxicity and gene expression changes were 
analysed in samples exposed to benzene, TCE or mixtures. Effects of the previous range 
finding studies (chapter V and VI) were largely confirmed. The study demonstrated that 
various gene expression changes induced in liver by TCE were enhanced by benzene. 
Most of the genes responded as expected by combining the effects of the individual 
compounds. The measurements provided insights in biological pathways and regulatory 
mechanisms in the cell that were involved in the response to the exposures, such as the 
electrophile response element (EpRE.ARE), the peroxisome proliferation activated 
receptor (PPAR alpha) and a hepatic nuclear factor (Hnf3). The profiles of hepatic gene 
expression, used in multivariate statistical PLS models, proved also useful to assess the 
effects of the mixtures. The mathematical models also provided indications that benzene 
enhanced the TCE-induced changes at the hepatic gene expression level. 
A transcriptomics study was initiated in our laboratory to identify effects of mixtures of 
mildly hepatotoxic food additives [223], [224]. These additives were curcumin, propyl 
gallate, butylated hydroxytoluene and thiabendazole. These compounds induced relative 
liver weights, but no overt hepatotoxic effect. The first studies with 28-day exposure to the 
individual components provided new insights in the mechanisms of action at the gene 
expression level. The effects of combined intake of these food additives will be tested in 
further studies. 
The studies to assess mixture effects so far indicated that effects upon exposure to 
mixtures of toxicants might be subtly different from single compounds, and that 
experimental designs have to be chosen carefully to demonstrate interactions. Preferably, 
single compound, as well as mixture exposures at several dose levels should be included 
and performed in one integrated experiment. 
Taken together, transcriptomics may enhance the assessment of mixture toxicity, by 
analysis of individual gene expression changes, as well as by multivariate statistical 
analysis of profile changes. 
Other applications of toxicogenomics 
As explained in the introduction, toxicogenomics results could facilitate interspecies and 
intraspecies extrapolation. Studies in (especially chapter VII) have demonstrated 
interindividual variation in gene expression in response to toxic chemicals. Thus, 
toxicogenomics methods might enable to better characterise why individuals respond 
differently to treatments. Toxicogenetics studies the genetic basis for interindividual 
differences in response [225], and may be used together with transcriptomics, to studies 
the relation of genetic differences to expression of the genes. Only limited amounts of 
data are available, and more research is required to determine which genes show the 
largest interindividual variations (in composition and expression), and what the 
implications of these variations are for development of toxic effects. Toxicogenomics may 
build upon the extensive research that has already been performed to identify 
interindividual and interspecies differences in (mainly) drug metabolising enzymes and the 
consequences for the metabolism of xenobiotics. It is important to note that (routine) 
toxicity studies are performed with inbred strains of rats and mice, largely reducing the 
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differences in genetic background. The differences in response in humans might therefore 
be much larger than in animal experiments. 
The studies provided some indications that toxicogenomics could reduce, refine or replace 
the use of laboratory animals. It might support alternatives to animal testing, 
predominantly by providing detailed insights in mechanisms of toxic action in in vitro 
experiments. The insights may be used to refine in vivo toxicity testing. Because 
toxicogenomics can investigate many parameters in studies in vitro, this may increase the 
value of models to assess, explain and even predict toxicity in vivo. 
VIM. 3 Technical aspects of toxicogenomics methods 
Various technical aspects of the toxicogenomics methods (especially transcriptomics) 
were evaluated. The relation between transcriptomics, proteomics and metabolomics, and 
the strengths and limitations of each of these technologies was assessed. The sensitivity 
was evaluated in relation to conventional methods in toxicology, as described in the next 
section. The reproducibility of toxicogenomics studies was determined and efforts to 
standardise toxicogenomics measurements worldwide are discussed. 
Relation between functional genomics technologies 
The studies in this thesis applied transcriptomics, but also proteomics, and metabolomics 
in toxicolgical experiments. Measuring gene expression by mRNA levels using DNA 
microarrays has proven to provide useful information for toxicology. However, mRNA 
molecules have the indirect function to transfer information, rather than to directly act in 
cellular processes. In the first study described in this thesis ( chapter II) transcriptomics 
results were directly related to proteomics measurements of the same livers. Thus, the 
correlation between gene expression and protein levels was investigated. Technical 
limitations of the proteomics technolgies hampered the finding of many changes in protein 
levels to corroborate observed changes in gene expression. Especially the reproducibility 
of gelelectrophoresis and the identification of proteins with mass spectrometry limited the 
success of this approach. Nevertheless, complementary information was obtained from 
both techniques, for instance regarding the involvement of processes like increased 
protein synthesis and breakdown. With further developments and optimisations of 
proteomics technologies, these will prove to be of more importance for the elucidation of 
molecular mechanisms, because many cellular processes are influenced at the protein 
level. Subcellular redistribution, protein interactions and post-translational modifications 
such as phosphorylation may be crucial for correct functioning of cellular processes. 
Profiles of metabolite contents of tissue samples or body fluids such as blood plasma or 
urine could identify changes in biochemical processes in the samples, which may relate to 
effects in specific tissues or entire organisms. In contrast to transcriptomics and 
proteomics, metabolomics can provide evidence, rather than indications, of changes in 
biochemical pathways. Metabolomics was applied in studies described in chapter IV, V 
and VI. At present, the major shortcomings of metabolomics are the limitations to the 
identification of individual constituents of the metabolite profiles, and to the (mass) range 
of molecules that can be detected. A major strength of metabolomics, and of proteomics, 
is that samples (urine, saliva) can be used that are collected by non-invasive methods, 
while these samples are not useful for mRNA measurements with transcriptomics. 
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Sensitivity of toxicogenomics methods 
The sensitivity of toxicogenomics methods for the detection of effects was compared to 
that of conventional toxicity markers in several of the studies. Transcriptomics using DNA 
microarrays proved to be more sensitive than the conventional toxicity markers to detect 
effects. It is important to note that for most of the (gene expression) changes, it remains to 
be clarified whether these are irreversible and adverse effects. Some expression changes 
were identified early (6 hours) after treatment, when conventional toxicology could not 
demonstrate effects. Many of the BB-induced effects were seen at dose Ievels2,5 to 10 -
fold below the levels that induced effects observed with the conventional methods. Also 
after exposure to benzene or trichloroethylene, DNA microarrays were able to show many 
significant changes in gene expression at the lowest dose levels tested, while 
conventional toxicity markers detected effects on at 10 to 20-fold higher dose levels. 
Interindividual changes in gene expression within treatment groups were observed. After 
exposure to BB, animals exhibited different degrees of hepatocellular necrosis, which was 
also recognised at the gene expression level. Besides this, interindividual changes in 
gene expression were observed in the BB studies as well as in the mixtures study with 
benzene and TCE (in chapter VII). in the absence of overt physiological differences 
between the rats. 
Also, effects of corn oil (vehicle control)could be recognised with transcriptomics methods, 
as shown in table II.8. Furthermore, DNA microarrays enabled to demonstrate differences 
in liver mRNA levels of untreated rats, depending on the time of sacrifice. Liver samples 
isolated 24 or 48 hours after start of the study were more similar to each other than to 
samples isolated 6 hours after start of the study. Thus, this method may enable to 
characterise intra-day changes in healthy animals in detail. 
The sensitivity of proteomics methods for identification of single proteins was lower than 
current methods like immunohistochemistry (ELISA or Western blotting). However, in 
contrast to those methods, proteomics enable to detect changes in unexpected and 
unknown proteins. For identification with mass spectrometry, a minimal amount of protein 
has to be available (recovered from the gels), which is not always possible. With the 2D-
gel based proteomics method, typically only water-soluble proteins within a specified 
mass and pi range will be separated. Membrane-bound proteins will therefore not be 
identified. Furthermore, proteins that exactly co-migrate may mask each other on the gel. 
The analysis of whole proteome patterns with powerful image analysis software and 
multivariate statistical methods enhances the sensitivity, and the specificity of (2D-gel 
based) proteomics measurements. 
The metabolomics applications described in this thesis showed that methods with NMR 
analysis of urine and plasma, in combination with multivariate statistical methods proved 
more sensitive than the current toxicity markers. Using multivariate statistical tools for 
pattern recognition of the NMR spectra, nearly all samples exposed to the lowest dose 
levels tested in the different studies could be distinguished from control samples. 
Reproducibility of toxicogenomics methods 
The reproducibility of transcriptomics methods is illustrated by the studies described in this 
thesis. Within studies, stringent quality criteria proved indispensable to obtain reproducible 
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data. After application of these criteria, replicate DNA microarrays of identical samples 
and samples of the same treatment groups generated comparable results, with variation 
smaller than the treatment effects. 
Inter-study reproducibility was shown from results in chapters II and III. Both studies with 
exposure of rats to bromobenzene were performed independently. There were several 
differences in the protocols, such as the route of administration. Moreover, different 
batches of in-house produced cDNA microarrays, with partially different contents, were 
used for the two studies. Nonetheless, the effects measured 24 hours after dosage were 
largely overlapping. Especially the studies with trichloroethylene, reported in chapter VI 
and VII, showed reproducible gene expression changes. The results from the range 
finding studies with TCE in chapter VI proved suitable for the construction of a 
mathematical model that could describe and predict effects of TCE in the subsequent 
main study, described in chapter VII. Another confirmation comes from the comparison 
(chapter VI) between effects of TCE and agents that induce peroxisome proliferation, 
reported by several other laboratories. 
The studies with B and TCE made use of oligonucleotide DNA microarrays produced in 
collaboration with the Genomics lab at the Utrecht University Medical Centre (Utrecht, 
NL). Unpublished results with samples of the bromobenzene study showed good 
correlation of the results obtained with these oligonucleotide DNA microarrays when 
compared to the previously (chapter II, III) used cDNA microarrays. 
Inter-laboratory reproducibility was shown by comparison of results from our laboratory 
with results of the NIEHS laboratory (U.S.A. National Institute of Environmental Health 
Sciences) laboratory [69]. Expression of various genes changed in the same manner in rat 
livers after bromobenzene exposure in our laboratory, as compared to exposure to high 
doses of acetaminophen, at the NIEHS. The similarities were especially clear when the 
biological processes that were affected were compared. 
The International Life Science Institute consortium (ILSI) analysed the inter-laboratory 
variation in transcriptomics experiments, and reported that "despite some variability, 
robust gene expression changes were consistent between laboratory" [226]. 
Presently, large, worldwide efforts are undertaken to standardise the DNA microarray 
production technologies, the experimental protocols and data analysis to enhance inter-
study comparisons. MIAME was initiated to define the minimal information that should be 
provided with microarray experiments to enable interpretation and sharing of data 
between researchers (MIAME, www.mged.org). Databases are created to uniformly 
accommodate gene expression profiles gathered throughout the world, for instance at the 
European Bioinformatics Institute (TOX-Express) and at the US National Centre for 
Biotechnology Information (NCBI, GEO). The U.S. centre for toxicogenomics (NCT) 
established a database named (CEBS) to specifically accommodate toxicogenomics data. 
The Netherlands Toxicogenomics Centre (NTC) was founded to facilitate collaborative 
toxicogenomics efforts within the Netherlands (TNO, RIVM, Rikilt, University of 
Maastricht). It has become clear that global standardisation and collection of data into 
relational databases is required to enable further developments of toxicogenomics 
towards successful applications in toxicological hazard and risk assessment. 
In this thesis, the reproducibility of proteomics methods was only evaluated for the 2D-gel 
based method in the BB study described in chapter II. This demonstrated considerable 
technical variation between the three replicate gels per sample. Therefore, statistical 
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analysis could only confirm changes in protein levels for 24 proteins, while, even at a 
glance, many more protein spots seemed to be affected by BB treatment. The labour-
intensive methods using 2D-gels required improvements, because most applications 
required not only qualitative but also quantitative assessment of proteins in a sample. 
Studies with updated or alternative methods (eg. MS-MS) for proteomics research showed 
better reproducibility and more promising results [227-232]. 
The assessment of the reproducibility or metabolomics measurements in this thesis was 
restricted to technical and interindividual replications of the NMR spectra. By default, urine 
of plasma samples were recorded in triplicate with NMR spectroscopy, for all animals in 
the studies. In general, the technical variation between the spectra was smaller than the 
experimental, or interindividual variation. Comparisons of spectra between groups treated 
with different dose levels showed that the same signals recurred, though in different 
quantities, dependent on the dose levels. In conclusion, triplicate technical replicates for 
every individual sample in the study are sufficient to demonstrate experimental effects 
with NMR-based metabolomics methods. 
In conclusion, the toxicogenomics methods each provide a wealth of (detailed) 
information, and are largely complementary to each other. Currently, especially 
transcriptomics and metabolomics are sensitive and reproducible, while proteomics 
methods may become so after further developments. Initiatives are taken to standardise 
the methods to enable information exchange and comparisons of toxicogenomics studies. 
At this moment, transcriptomics is probably the most powerful and easy to apply of the 
functional genomics technologies. Proteomics and metabolomics will prove to be more 
relevant in the (near) future, given that some technical limitations are resolved. 
VIII.4 Challenges and perspectives in toxicogenomics 
Confirmation of hypotheses 
The functional genomics technologies produce vast amounts of data, typically with a 
somewhat lower level of confidence compared molecular biological measurements of 
single genes or proteins. Therefore, it is recommended that these technologies are used 
to test, but to generate hypotheses. These hypotheses should be confirmed and further 
investigated with dedicated methods by researchers with specific expertise and 
equipment. Changes in gene and protein expression or metabolite contents found with 
toxicogenomics methods can be designated as adverse effects only after correlation to 
physiological effects that confirm toxicity. 
Linking the layers 
The challenge for the coming years is to study interactions between genes, proteins and 
metabolites and to integrate the results of the different functional genomics methods 
("linking the layers"). Linking the measurements of genes, gene expressions, proteins and 
metabolites could provide the insights required to understand the processes within a cell. 
It is essential to apply multivariate statistical techniques to resolve the connections 
between the different data, and to be able to introduce the aspect of time to recognise and 
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explain dynamic effects in the processes. In toxicology, the influence of duration of 
exposure, time of recovery before analysis and the exposure dose levels are crucial 
determinants of the endpoints that may be observed. Better understanding of the 
sequence of events at the molecular level may enable to extrapolate from (limited) 
experimental conditions, to assess the toxicity of a compound after realistic exposure 
conditions (chronic exposure to low dose levels). 
Toxicogenomics for human health risk assessment 
Toxicogenomics methods may enhance human health risk assessment (see figure 1.1) in 
various ways. Detailed insights in mechanisms of action could be obtained, revealing the 
crucial steps and sequence of events at the molecular level. The methods enabled more 
sensitive and earlier detection of adverse effects in (animal) toxicity studies. Furthermore, 
the identification of effects after exposure to mixtures was enhanced. The value of 
toxicogenomics for risk assessment was recently analysed by our institute's department of 
toxicological risk assessment [233]. Also a U.S. society of toxicology taskforce evaluated 
the use of genomic data in risk assessment [234]. Toxicogenomics may be used for risk 
assessment given that the significance of the observed effects can be designated. The 
characteristics of changes in gene expression, protein or metabolite patterns have to be 
determined and related to conventional end points in toxicity. The effects of many different 
(model) compounds and treatment conditions have to be compared. For the identification 
of (no observed) adverse effect levels, it is essential to be able to differentiate adverse 
effects from reversible, adaptive responses and effects independent of the treatment (eg. 
intraday variation). Standardisation of the methods and the development of global 
databases is required to be able to compare toxicogenomics data, especially when 
patterns are compared to each other. In the absence of these databases, toxicogenomics 
methods are useful for the detailed investigation of mechanisms of action of particular 
compounds in dedicated studies. In this respect, toxicogenomics can be advantageously 
applied to simultaneously evaluate efficacy (e.g. of candidate drugs) and safety of a 
product (risk-benefit assessment). 
Many aspects will eventually determine whether toxicogenomics will be successfully 
applied in toxicological risk assessment. Regulations and guidelines, standardisation, a 
public opinion against animal testing and, of course, cost aspects. It was demonstrated in 
several applications described in this thesis that toxicogenomics can enhance 
identification and characterisation of toxicity. 
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Tables also avai lable onl ine at www.toxsci.org 
Table III. 2. Gene expression changes 24 h after bromobenzene dosage 
The subset of genes that were significantly ( p < 0.01) differentially expressed after 24 h in 
the high BB dosed rats compared to the controls. Genes were categorised according to 
biological mechanism or pathways. The log (base 2) average fold change and the p-value 
for the three dose levels are listed. A treshold was chosen for display reasons which was a 
log (base2) fold change > 0.7 or < -0.7 in any of the dose groups compared to the controls. 
Statistical level of significance: **: p < 0.01, ***: p < 0.001. ACC#: Genbank Accession 
number, metab: metabolism 
Category Gene name ACC # Low Mid High 
Acute phase 
Acute phase; 
ox.stress 
Acute phase; 
ox.stress 
Acute phase; 
ox.stress 
Acute phase 
Acute 
phase? 
Acute phase 
Acute 
phase? 
Acute phase 
Acute phase 
ox.stress 
Acute phase 
Ox.stress 
Ox.stress 
Ox.stress 
Ox.stress 
Ox.stress 
Amino acid 
Apoptosis 
Cholesterol 
Cysteine 
Cysteine 
Drug 
Drug;GSH 
Drug 
Drug;GSH 
Drug;GSH 
Drug 
Drug 
Drug 
Drug 
Drug 
Drug 
Orosomucoid 1 
ferritin, heavy polypeptide 1 
ferritin, heavy polypeptide 1 
ferritin light chain 1 
vitronectin 
sim to complement subcomponent C1s 
complement component 4a 
Fibrinogen, B beta polypeptide 
alpha(1)-inhibitor 3, variant I 
alpha(1)-inhibitor 3, variant I 
selenoprotein P, plasma, 1 
Serine protease inhibitor 
Heme oxygenase (HO-1) 
Heme oxygenase (HO-1) 
tissue inhibitor of metalloproteinase 1 
peroxiredoxin 1 
peroxiredoxin 1 
argininosuccinate lyase 
cytochrome c, somatic 
3-HMG-Co A synthase 2 
S-adenosylhomocysteine hydrolase 
cytosolic cysteine dioxygenase 1 
epoxide hydrolase 1 (mEH) 
glutathione S-transferase, alpha 1 (Gsta) 
aflatoxin B1 aldehyde reductase (Afar) 
glutathione S-transferase, alpha 1 (Gsta) 
GSTM, soluble.class Mu; (Gstm2) 
sulfotransferase, hydroxysteroid prefer. 2 
Mod. sim to NAD(P)H dehydrogenase 
(quinone)2 
Cytochrome P450 15-beta Cyp2C12 
sulfotransferase family 1 A, phenol-
preferring, member 1 
cytochrome P450, 2c39 (Cyp2C39) 
arachidonic acid epoxygenase 
AI029162 
AA817701 
AA818441 
AA817693 
AA956238 
AA900592 
AA965125 
AI071033 
AA817963 
AA817963 
AA963445 
AA901050 
AA874884 
AA874884 
AA957593 
AA875245 
AA875245 
AA818673 
AA866442 
AM 36048 
AA955402 
AA818579 
AA900551 
AA818339 
AA923966 
AA818339 
AA998734 
AA818024 
AI029553 
AA818124 
AA866493 
AA818043 
AA819756 
-0.09 
0.33 
0.25 
0.48 
-0.02 
-0.27 
-0.15 
0.20 
-0.47 
-0.54 " 
-0.11 
-0.01 
-0.02 
-0.09 
-0.17 
0.03 
-0.05 
0.06 
-0.11 
0.25 
-0.19 
0.03 
0.44 
0.82 
0.31 
0.62 
0.48 
-0.25 
-0.11 
-0.20 
-0.17 
-0.15 
-0.24 
0.57 
1.01 
0.97 
1.13 
-0.41 
-0.13 
-0.59 
-0.11 
-0.63 " 
-0.79 " 
-0.26 
-0.36 
0.14 
0.12 
-0.01 
0.92 " 
0.97 
-0.27 
0.50 
-0.17 
-0.35 
-0.29 " 
2.45 ** 
2.47 ** 
2.15 ** 
2.08 ** 
1.86 ** 
-0.57 ** 
0.22 
-0.25 
-0.28 
-0.28 
-0.29 
2.05 
1.71 
1.53 
1.21 
-0.73 
-1.01 
-1.19 
-1.20 
-1.21 
-1.42 
-1.67 
-1.75 
2.08 
1.81 
1.49 
1.29 
1.13 
-1.21 
1.00 
-1.80 
-0.90 
-1.07 
2.58 
2.27 
1.94 
1.67 
1.41 
-0.76 
-0.83 
-0.88 
-0.90 
-0.96 
-1.30 
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Drug 
Drug 
Drug 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Fatty acid 
Glucose 
Glucose 
Glycolysis 
Immuno. 
PKC; 
Prot.synth. 
Prot.synth. 
Proteolysis 
Proteolysis 
Proteolysis 
Proteolysis 
Proteolysis 
Ribosome 
Ribosome 
Ribosome 
Ribosome 
Structure 
Structure? 
Structure 
Structure 
Structure 
Structure 
Structure 
Sign.transd 
Sign.transd 
Sign.transd 
heme met 
heme 
Transport 
Other 
Other 
Other 
Other 
Other 
Other 
cytochrome P450, 2E1 (Cyp2E1) 
cytochrome P450 4A3 (Cyp4A3) 
cytochrome P450, 4a10 (Cyp4A10) 
Hadha; trifunctional protein 
2,4-dienoyl CoA reductase 1, mit. 
delta3, delta2-enoyl-CoA isomerase 
acetyl-coenzyme A dehydrogenase, 
medium chain 
peroxisomal multifunctional enzyme II 
acyl-coA oxidase 
enoyl coenzyme A hydratase 1 
Fatty acid binding protein 1, liver 
Fatty acid binding protein 1, liver 
carnitine palmitoyltransferase 1 
fatty acid Coenzyme A ligase, longchain 2 
glucose-6-phosphatase, (G6pc) 
alanine-glyoxylate aminotransferase 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
melanoma antigen, family D, 1 
14-3-3 Protein, Ywhaz 
High sim to elF-5A (elF-4D) [Mouse] 
High sim to eEF-1B gamma [Mouse] 
proteasome beta type 6 
plasma glutamate carboxypeptidase 
polyubiquitin 
complement component 1, s 
cathepsin S 
ribosomal protein L7 
ribosomal protein S2 
ribosomal protein L41 
ribosomal protein L21 
High sim to S11222 actin gamma 
Weak sim to pervin [Rat] 
High sim to alpha-tubulin [Rat] 
actin, beta 
keratin complex 1, acidic, gene 18 
alpha-tubulin 
cysteine-rich protein 3 
GTP-binding protein (ral A) 
asialoglycoprotein receptor 2 
synaptojanin 2 
hemoglobin beta chain complex 
hemoglobin, alpha 1 
sodium channel, voltage-gated, type 6, 
alpha polypeptide 
homer, neuronal immediate early gene, 2 
WeaksimtoY37E11B.5.p 
sim to apoptotic protease activ. factor 1 
DD6G4-2 
lumican 
dimethylglycine dehydrogenase 
AA818896 
AA924591 
AA956787 
AA900458 
AA875267 
AA997009 
AA925220 
AA874974 
AA924697 
AA926032 
AI072074 
AI072074 
AA875270 
AA926010 
AA964628 
AI029012 
AA924111 
AA925628 
AA858662 
AA874949 
AA818663 
AA925552 
AH 45442 
AA875068 
AA965204 
AA925933 
AA956776 
AA858477 
AI029242 
AA819765 
AA964496 
AA964725 
AI705683 
AA859846 
AI072634 
AA957078 
AA925907 
AA900726 
AA997920 
AA963164 
AA818084 
AA819784 
AA925248 
AI059976 
AI072198 
AA818945 
AA924781 
AA866389 
AA997856 
-0.24 
-0.11 
-0.01 
0.00 
0.11 
-0.16 
-0.09 
-0.07 
-0.10 
-0.04 
-0.25 
-0.05 
-0.13 
-0.03 
-0.60 
-0.16 
0.08 
-0.03 
-0.40 
0.07 
0.11 
0.39 " 
0.66 
-0.12 
-0.26 
-0.28 
0.25 
0.17 
0.28 
-0.34 
0.53 
0.48 
0.27 
0.24 
0.22 
-0.23 
-0.21 
0.06 
-0.32 
-0.09 
0.25 
0.38 
-0.05 
0.73 
0.01 
0.29 
-0.18 
-0.17 
-0.19 
-0.23 
-0.31 
-0.57 
-0.28 
0.22 
-0.49 
-0.55 
0.18 
-0.46 
-0.23 
-0.31 
-0.28 
-0.06 
-0.25 
-0.46 
-0.17 
0.48 
-0.26 
-0.68 " 
0.45 
0.45 
-0.17 
1.06 
0.12 
-0.56 
-0.34 
0.49 ** 
0.51 
0.41 
-0.37 
0.52 
0.43 
0.33 
0.34 
0.90 ** 
-0.17 
-0.53 
0.33 
-0.37 " 
-0.32 
-0.03 
0.10 
-0.32 
1.38 ** 
0.03 
0.29 
-0.21 
-0.17 
-0.28 
-1.36 
-1.37 
-1.63 
-0.74 
-0.85 
-0.86 
-0.89 
-0.95 
-1.06 
-1.07 
-1.16 
-1.19 
-1.25 
-1.56 
-1.58 
-0.88 
1.07 
-0.76 
-0.98 
0.95 
0.74 
1.68 
1.62 
0.91 
-1.32 
-1.33 
0.87 
0.82 
0.71 
-1.24 
2.73 
2.43 
1.48 
1.28 
1.19 
0.81 
-1.31 
0.81 
-1.11 
-1.60 
2.14 
2.06 
-0.89 
0.82 
0.79 
0.75 
-0.71 
-0.74 
-0.75 
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Other 
Other 
Other 
Other 
Other 
Other 
Weak sim to Arginase II, mitoch.[Rat] 
kynurenine aminotransferase 2 
ras-related GTP-binding protein 4b 
carboxylesterase 3 
DD6G4-2 
guanylate cyclase 1, soluble, beta 3 
AI028979 
AA998607 
AA818114 
AA955115 
AA923983 
AA955420 
0.02 
-0.07 
-0.13 
-0.22 
-0.10 
-0.30 
0.04 
-0.29 
-0.15 
-0.35 
-0.20 
-0.56 
Appendices 
-0.75 ** 
-0.75 " 
-0.77 ** 
-0.85 ** 
-0.88 *** 
-0.97 
Table III. 3. Gene expression changes 48 h after bromobenzene dosage 
The subset of genes that were significantly ( p < 0.01) differentially expressed after 48 h in the high BB 
dosed rats compared to the controls. Genes were categorised according to biological mechanism or 
pathways. The log (base 2) average fold change and the p-value for the three dose levels are listed. A 
threshold was chosen for display reasons which was a log (base2) fold change > 0.7 or < -0.7 in any of the 
dose groups compared to the controls. Statistical level of significance: **: p < 0.01, ***: p < 0.001. ACC#: 
Genbank Accession number, metab: metabolism 
Category Gene name ACC# low mid high 
Acute phase Orosomucoid 1 
Acute phase pancreatic secretory trypsin inhibitor type II 
Acute phase ferritin, heavy polypeptide 1 
Acute phase osteonectin 
Acute phase apolipoprotein A-l (apoA-l) 
Acute phase Weak sim to Ficolin 2 precursor 
Acute phase fibrinogen-like protein 1 
Acute phase pre-alpha-inhibitor, heavy chain 3 
Acute phase Weakly sim. to serum amyloid P-Component 
Acute phase alpha(1)-inhibitor 3, variant I 
Acute phase alpha(1)-inhibitor 3, variant I 
Acute phase Serine protease inhibitor 
Ox.stress Heme oxygenase (HO-1) 
Ox.stress peroxiredoxin 1 
Ox.stress peroxiredoxin 1 
Ox.stress Heme oxygenase (HO-1) 
Aminoacid ornithine aminotransferase 
Aminoacid argininosuccinate lyase 
Cysteine. cytosolic cysteine dioxygenase 1 
Drug;GSH glutathione S-transferase, alpha 1 (GSTA) 
Drug epoxide hydrolase 1 (mEH) 
Drug High sim to RAKb [Rat] (aldo-keto reductase) 
Drug;GSH glutathione S-transferase, alpha 1 (GSTA) 
Drug aflatoxin B1 aldehyde reductase (AFAR) 
Drug;GSH? High sim to GSTA 8 [Rat] 
Drug aldehyde dehydrogenase family 3, A1 
Drug aldo-keto reductase family 1, member A1 
Drug sulfotransferase family, cytosolic, 2A, 1 
Drug sulfotransferase, hydroxysteroid preferring 2 
Drug arachidonic acid epoxygenase;Cyp2C23 
Drug cytochrome P450 2d18 (Cyp2D18) 
Drug cytochrome P450 4A3 (Cyp4A3) 
Drug cytochrome P450, 4a10 (Cyp4A10) 
Drug cytochrome P450, subfamily 2E, (Cyp2E1) 
Fatty acid delta3, delta2-enoyl-CoA isomerase 
Fatty acid dodecenoyl-coenzyme A delta isomerase 
Fatty acid fatty acid binding protein 4 
AI029162 
AA858673 
AA818441 
AA957962 
AA964044 
AA859022 
AI044677 
AI030246 
AA819101 
AA817963 
AA817963 
AA901050 
AA874884 
AA875245 
AA875245 
AA874884 
AA818680 
AA818673 
AA818579 
AA818339 
AA900551 
AA817695 
AA818339 
AA923966 
AI059894 
AA866268 
AA875038 
AA819605 
AA818024 
AA819756 
AA997886 
AA924591 
AA956787 
AA818896 
AA997009 
AA965078 
AA925091 
0.33 
-0.16 
-0.33 
-0.05 
0.30 
0.14 
-0.38 
-0.19 
0.00 
-0.30 
-0.17 
0.12 
0.16 
0.08 
0.12 
-0.28 
0.00 
0.13 
-0.28 
0.16 
0.09 
0.02 
0.17 
0.14 
0.40 
-0.09 
-0.03 
-0.10 
0.06 
-0.16 
0.28 
-0.14 
-0.15 
-0.04 
-0.24 
-0.33 
0.27 
0.02 
0.15 
-0.01 
0.17 
0.49 
-0.22 
-0.43 
-0.47 
-0.21 
-0.31 
-0.38 
0.17 
0.13 
-0.02 
0.00 
-0.01 
-0.18 
-0.15 
-0.23 
0.53 
0.10 
0.20 
0.51 
0.13 
0.44 * 
0.03 
0.20 
-0.19 
-0.36 
0.15 
-0.19 
-0.01 
0.00 
0.19 
-0.07 
0.07 
0.20 
1.98 
1.84 
1.19 
0.91 
0.83 
-0.72 
-0.88 
-0.79 
-0.93 
-1.69 
-1.73 
-2.47 
1.07 
1.04 
1.02 
0.83 
-0.82 
-1.40 
-1.14 
2.31 
2.13 
1.87 
1.71 
1.46 
0.75 
0.74 
0.71 
-0.82 
-0.82 
-0.87 
-0.94 
-0.97 
-1.45 
-2.25 
-0.77 
-0.92 
0.79 
187 
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Glycolysis Glyceraldehyde-3-phosphate dehydrogenase 
signal transd. protein kinase C, delta 
signal transd. 14-3-3 protein, Ywhaz 
prot.synthesisHigh sim to eEF-1B gamma [Mouse] 
proteolysis carboxypeptidase A1 
proteolysis? polyubiquitin 
Ribosome ribosomal protein S2 
Ribosome ribosomal protein L41 
Ribosome ribosomal protein S27a 
Ribosome peptidyl arginine deiminase, type 2 
Ribosome High sim to 40S ribosomal protein S16 [Rat] 
Ribosome ribosomal protein L21 
Ribosome High sim to 60S ribosomal protein L37a [Rat] 
Ribosome ribosomal protein S23 
Ribosome High sim to 60S ribosomal protein L38 [Rat] 
Ribosome Mod.sim to human exonuclease 
Ribosome ribosomal protein L6 
Ribosome ribosomal protein L13 
Ribosome ribosomal protein S8 
Ribosome ribosomal protein L4 
Ribosome ribosomal protein S26 
Ribosome NADH dehydrogenase (ubiquinone) 1 alpha 5 
Ribosome DD6G4-2 
Ribosome ribosomal protein L7 mRNA, 5' end 
Ribosome ribosomal protein S2 
Ribosome ribosomal protein L35 
Ribosome ribosomal protein S11 
Ribosome ribosomal protein L21 
Structure actin, beta 
Structure alpha-tubulin 
Structure thymosin beta-4 
Structure smooth muscle alpha-actin 
Structure cortactin isoform B 
Structure dynein, cytoplasmic, light chain 1 
Structure calpactin I heavy chain 
Sign.transd. casein kinase II beta subunit 
Sign.transd. GTP-binding protein (ral A) 
Sign.transd. pyruvate kinase, muscle 
Sign.transd. guanine nucleotide binding protein 
Sign.transd.
 c o r e promoter element binding protein 
Sign.transd. asialoglycoprotein receptor 2 
Sign.transd. sim.to 3',5'-cyclic AMP phosphodiesterase 
Sign.transd. g a p junction membrane channel beta 5 
Sign.transd.
 EST, phosphatase? 
Transport ESTs 
Transport sim to myo-inositol 1-phosphate synthase A1 
Transport sodium channel, voltage-gated, type 6, alpha 
Transport ATPase, H+ transporting, lysosomal 
Transport solute carrier family 29, member 2 
Other secreted phosphoprotein 1 
Other vimentin 
AA924111 
AI044238 
AA858662 
AA818663 
AA956202 
AA875068 
AA819544 
AI029242 
AA899215 
AA818640 
AA860041 
AA819404 
AA900050 
AA900188 
AA858971 
AA899560 
AA924912 
AA859756 
AA874997 
AA817847 
AA900527 
AA874885 
AI711101 
AA956776 
AA858477 
AA925200 
AA818442 
AA819765 
AA859846 
AA957078 
AA819102 
AA819435 
AI069969 
AA962992 
AA859635 
AA997175 
AA900726 
AA818951 
AA859083 
AA900368 
AA997920 
AA858930 
AI044985 
AA926359 
AI043642 
AA933167 
AA925248 
AA858959 
AA859360 
AA964431 
AA859385 
0.17 
0.38 
0.23 
0.10 
1.20 
0.27 
0.01 
0.50 
0.38 
0.17 
0.17 
-0.08 
0.29 
0.22 
0.01 
0.01 
0.44 
0.22 
0.11 
0.19 
0.07 
0.26 
-0.20 
0.39 
0.06 
0.40 
-0.01 
-0.10 
0.11 
-0.11 
-0.01 
0.07 
-0.10 
0.13 
-0.41 
0.07 
0.04 
0.02 
0.02 
-0.36 
-0.01 
0.06 
0.20 
0.24 
0.06 
0.03 
-0.43 
-0.22 
-0.22 
0.18 
-0.04 
-0.21 
0.38 
0.07 
0.02 
0.74 
0.44 
0.27 
0.56 
0.38 
0.54 
0.05 
-0.04 
0.32 
0.19 
0.04 
0.23 
0.22 
0.24 
0.09 
0.21 
0.34 
0.12 
0.05 
0.22 
0.14 
0.37 
0.07 
-0.01 
0.04 
-0.14 
0.04 
0.13 
0.21 
0.01 
0.19 
-0.02 
0.13 
0.28 
0.39 
-0.26 
0.09 
-0.22 
0.13 
0.16 
0.26 
0.17 
0.05 
-0.27 
-0.21 
0.17 
0.03 
1.03 
0.85 
-0.92 
0.77 
1.08 
0.88 
1.26 
1.22 
1.04 
1.03 
0.99 
0.99 
0.96 
0.95 
0.93 
0.93 
0.90 
0.90 
0.86 
0.84 
0.84 
0.82 
0.81 
0.80 
0.79 
0.77 
0.74 
-1.06 
1.32 
1.30 
1.22 
0.81 
0.78 
0.73 
0.72 
2.05 
1.08 
0.87 
0.85 
-0.70 
-0.84 
-0.85 
-0.93 
-1.28 
0.80 
0.79 
-0.70 
-0.71 
-0.71 
1.24 
1.10 
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Other Weak sim to interferon,alpha-inducible prot. 
Other S100 calcium binding protein A10 (calpactin) 
Other clathrin light chain (LCB2) 
Other sim to HUMAN Small membrane protein 1 
Other serine (or cysteine) proteinase inhibitor, B5 
Other secretoglobin, family 1A, member 1 
Other stathmin 1 
Other Seminal vesicle protein, secretion 2 
Other retinol dehydrogenase type III 
Other lumican 
Other High sim to GENE 33 POLYPEPTIDE [Rat] 
Other retinol dehydrogenase type III 
Other sim to alcohol dehydrogenase 
Other carboxylesterase 3 
Other guanylate cyclase 1, soluble, beta 3 
AA819034 
AA900235 
AI579822 
AA818246 
AA899906 
AA817804 
AA957519 
AA900854 
AA866390 
AA866389 
AA997280 
AA866390 
AA818154 
AA955115 
AA955420 
-0.03 
0.04 
0.12 
-0.02 
0.15 
-0.06 
0.14 
0.01 
-0.24 
-0.23 
0.15 
-0.27 
-0.60 
-0.27 
0.04 
0.16 
0.21 
0.18 
-0.13 
0.00 
0.60 
0.11 
0.16 
-0.15 
-0.19 
0.16 
-0.27 
-0.34 
-0.22 
0.16 
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1.09 
1.04 
0.96 
0.91 
0.83 
0.79 
0.72 
0.70 
-0.74 
-0.76 
-0.82 
-0.85 
-0.87 
-0.95 
-1.13 
** 
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Appendix of Chapter VI 
Table VI.2E. Genes affected by trichloroethylene, related to various biological processes. The 
level of statistical significance (Student's T-tests) is indicated to the mean log(2) transformed 
fold changes, and listed in the last column for the ANOVA (A) (*: p < 0.02, **: p < 0.01, ***: 
p<0.001). Genes in boldface appeared in the list of 100 most significantly up- or downregulated 
genes in the PCDA analysis. 
Class 
acute phase 
acute phase 
acute phase 
acute phase 
acute phase 
acute phase 
acute phase 
amino acids 
amino acids 
amino acids 
amino acids 
amino acids 
amino acids 
amino acids 
amino acids 
amino acids 
amino acids 
Apoptosis 
apoptosis 
apoptosis 
cancer? 
cancer? 
cell_adhes 
cell adhes 
cell_adhes 
defense 
defense 
DNArepair 
Acc# 
NM 017096 
NM 012657 
NM 017170 
NM 019301 
NM 024157 
NM 017351 
NM_031531 
NM 017074 
NM 013078 
NM 017084 
NM 022403 
J05499 
NM 021750 
NM 019386 
NM 031012 
NM 012668 
NM_022521 
AI599423 
BG671464 
M15481 
X78606 
NM012646 
NM 012811 
NM 019375 
X78997 
NM_053469 
NM_012512 
X54862 
Symbo 
Crp 
Spin2b 
Sap 
Crry 
Cfi 
Paihc3 
GeneName 
C-reactive protein 
Serine protease inhibitor 
Serum amyloid P-component 
Complement receptor related 
Complement factor 1 
Pre-alpha-inhibitor, heavy chain 3 
Spin2c Serine protease inhibitor 
Cth 
Otc 
Gnmt 
Tdo2 
Ga 
Csad 
Tgm2 
CTL target antigen 
Ornithine carbamoyltransferase 
Glycine methyltransferase 
Tryptophan 2,3-dioxygenase 
Liver mitochondrial glutaminase 
Cysteine-sulfinate decarboxylase 
Tissue-type transglutaminase 
Anpep Alanyl aminopeptidase 
Tat 
Oat 
Igf1 
Rab28 
Rt1-n1 
Mfge8 
Cdh17 
Hamp 
B2m 
Mgmt 
Tyrosine aminotransferase 
Ornithine aminotransferase 
sim. to GADD45,. 
sim.to programmed cell death 10 
Insulin-like growth factor 1 
RAB28, member RAS oncogene 
RT1 class lb, H2-TL-like, grc region 
O-acetyltransferase Milk fat globule 
Septin 3 
Cadherin 17 
hepcidin antimicrobial peptide 
Beta-2-microglobulin 
06-methylguanine-DNA 
Low 
0.70 
0.32 
0.44* 
-0.1 
0.12 
-0.6" 
-0.7** 
0.33 
0.59* 
0.53** 
0 .53" 
-0.4" 
-0.2 
-0 .7" 
-0.5* 
0.20 
0.10 
0.82*** 
0.85" 
-0.0 
0.05 
-0.7 
-0.5" 
0.16 
-0.4" 
0.72* 
0.62 
0.12 
Mid 
0.37* 
0.35 
0 .66" 
-0.07 
-0 .28" 
-0 .42" 
-0 .46" 
0.07 
0.32"* 
0.39 
0.24* 
-0 .35" 
-0.08 
-0.22 
-0.44" 
-0.33 
-0.83*" 
0.31 
0.65" 
-0.09 
0.21 
-0.37* 
-0.06 
0.35 
-0.64*** 
-0.41 
0.48* 
0 .78" 
High 
0.87" 
0 .70" 
0.59* 
-0 .30" 
-0.56* 
-0.69" 
-0 .82" 
0 .70" 
0.26 
0.14 
-0.05 
-0.26 
-0.56" 
-0.56* 
- 0 . 8 1 " 
-0 .92" 
-1.53*** 
0.77"* 
0.70*** 
-0 .60" 
0 .32" 
-0.76" 
-0.56" 
-1 .00" 
-2.39*** 
-0.08 
0.55* 
0.67 
A 
** 
** 
** 
** 
*** 
*** 
*** 
** 
*** 
** 
*** 
* 
** 
** 
** 
*** 
*** 
*** 
*** 
* 
* 
** 
*** 
*** 
*** 
*** 
* 
** 
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DNA_repair NM_012699 Dnajb9 
methyltranferase 
DnaJ homolog, subfamily b, 0.32 0.03 -0.41 
e-_transp NM_012839 Cycs Cytochrome c, somatic 0.68* 0.32* 
sign_transd 
sign_transd 
sign_transd 
sign_transd 
sign_transd 
signtransd 
sign_transd 
sign_transd 
sign_transd 
signtransd 
signtransd 
signtransd 
AF057025 
NM_022392 
U61373 
NM_021764 
X73371 
AB027562 
NMJD12715 
NM_031822 
NM_021676 
M96548 
NM_016991 
NM 019249 
Tlr4 
F2rl1 
Fcgr2b 
Sh3bp5 
Adm 
Ncoa2 
Shank3 
Znf354a 
Adralb 
Ptprf 
signtransd AY014898 Ipmk 
signtransd AB030238 
signjransd NM_019232 Sgk 
0.34 
glucose? NM_022268 Pygl Liver glycogen phosphorylase -0.0 -0.48 -0.80* 
glycolysis M76591 Pgaml Phosphoglycerate mutase 1 0.08 0.31 0.51 * 
glycolysis NM013098 G6pc Glucose-6-phosphatase (G6pc) -1.0*** -0 .98" -1.59* 
glycolysis NM_012624 Pklr Pyruvate kinase, liver and RBC -0.5 -1.14* -1.35* 
glycolysis? NM031749 Gcs1 Glucosidase 1 -0.6* -0.14 -0.55* 
heme 
heme 
heme 
hemopoies. 
immunor. 
immunor. 
X05080 
NM_013096 
AF307840 
NM_024385 
X56596 
AF029240 
Hbb Hemoglobin, beta 
Hba1 Hemoglobin, alpha 1 
Ncb5or Flavohemoprotein b5+b5R 
Hhex Hematopoietically expressed 
homeobox 
MHC class II antigen RT1 .B-1 beta 
MHC class lb RT1.S3 (RT1.S3) 
0.81** 
-0.1 
0.19 
-0.7 
-0.7*** 
0.01 
0.88** 
0.31 ** 
0.34* 
0.01 
-0.41 * 
-0.47* 
0.53* *** 
-0.02 
0.36* 
-0.95" " 
-0.55 
-0 .78" *** 
Toll-like receptor 4 0.46 0.71 0.53 
Growth response protein (CL-6) 0.02 -0.66* 0.28 
Proteinase-activated receptor-2, 0.01 0.51 0.17 
Protein kinase C-binding Betal5 0.02 0.37* 0.11 
Fc gamma receptor 0.73*** 0.43 0.10 
SH3-domain binding protein 5 -0.0 0.17 -0.30 
Adrenomedullin -0.0 0.11 -0.35* 
Nuclear receptor coactivator 2 -0.6 -0.43 -0.42 
SH3/ankyrin domain 3 -0.5** -0.28 -0.46 
Zinc finger protein 354A 0.17 0 .44" -0.47 
Adrenergic, alpha 1B, receptor -0.6 -0.20 -0.52 
Protein tyrosine phosphatase, -0.4 -0.74"* -0.64* 
receptor type, F 
Inositol polyphosphate -0.5* -0.46" -0.67* 
multikinase 
Sim. to hepatocarcinogenesis- -0.3 -0.34 -1.01* 
related transc.factor 
Serum/glucocorticoid regulated -0.9 -0.86* -1.02* 
kinase 
steroid 
steroid 
NM 031682 
J05035 
Hsd17b Hydroxysteroid (17-beta) 
10 dehydrogenase 10 
Srd5a1 Steroid 5 alpha-reductase 1 
0.42* 
-0.3 
0.47* 
0.34 
transport NM_022388 Fxyd4 
transport 
transport 
transport 
transport 
transport 
transport 
transport 
transport 
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M13979 
NM_019158 
L19927 
Y12635 
AB006450 
NM_019186 
NM 145677 
Slc2a1 
Aqp8 
Atp5c1 
Atp6b2 
Timm17 
a 
Arl4 
Pcscl 
NM 031746 Slc13a2 
0.55* 
0.43 
stress BG668317 Hspca heat shock protein 1, alpha 0.77* 0.80"* 0.71 
stress NM_024351 Hspa8 Heat shock cognate protein 70 0.08 0.07 -0.61* 
structure M15883 Cltb Clathrin, light polypeptide (Lcb) 015 0.66" 0.62* 
structure NM_019167 Spnb3 Beta-spectrin 3 -0.6* -0.29 0.11 
structure X70369 Col3a1 Collagen, type III, alpha 1 -0.2 -0 .54" -0.54* 
structure NM_031136 Tmsb4x Thymosin beta-4 0.50 -0.19 -0.60 
FXYDdomain-containing ion 0.15 0.52* 0.60* 
transport regulator 4 
Solute carrier family 2,member 1 0 .60" 0.21 0.57* 
Aquaporin 8 -0.1 0.48* 0.50 
ATP synthase, H+ transporting, mit. 0.56* 0.26* 0.41 
F1 complex, gamma 1 
ATPase, H+transporting, lysosomal 0 .42" 0.14 0.19 
Translocator of inner mitoch -0.3 0.24 0.08 
membrane 17a 
ADP-ribosylation-like 4 0.17 0.48*" -0.26 
peroxisomal Ca-dependent solute 0.03 -0.24 -0.42 
carrier 
Solute carrier family 13, member 2 -0.6 ** -0.08 -0.42 * 
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transport 
transport 
transport 
transport 
unknown 
unknown 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
NM_012833 Abcc2 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 2 
NMJ331725 Scamp4 Secretory carrier membrane 
protein 4 
NM_022287 Slc26a1 Sulfate anion transporter 
AF019628 
BG666041 
BE112955 
NM_017132 
D00569 
NM_012600 
AF062389 
L46593 
D28560 
NM_022513 
NNM47138 
NM_144743 
D85435 
NM_130400 
BG671436 
NM_013010 
X72759 
NM_138839 
AF281632 
M22030 
NM_022629 
M22756 
AW141131 
X77236 
AF151784 
NM_013003 
AF526268 
NM_020082 
AJ301634 
M36708 
BG668391 
M83680 
M29295 
AF205717 
NM_019201 
X53003 
NM_021576 
NM_022532 
NM_021744 
NM_012976 
Y13413 
D50564 
D25233 
Abcc9 ABC transporter C (CFTR/MRP) 9 
Sim. to HSPC288 (LOC299207) 
sim. to MGC4614 (LOC294294) 
Rcn2 Reticulocalbin 2 
Decrl 2,4-dienoyl CoA reductase 1, mit. 
Me1 Malic enzyme 1, soluble 
Kidney-specific protein (KS) 
sim. to cornifin alpha (SPRR1) 
Enpp2 Ectonucleotide pyrophosphatase 
Dopa/tyrosine sulfotransferase 
Sip30 SNAP25 interacting protein 30 
carboxylesterase isoenzyme 
Prkcdbp PKC-delta binding protein 
Dhfr Dihydrofolate reductase 1 (active) 
sim. to Ubiquinol-cytochrome C 
reductase complex core protein 2 
Prkagl Protein kinase, AMP-activated, 
gamma 1 non-catalytic 
cox Via pseudogene (liver) 
Vmp1 vacuole Membrane Protein 1 
Sybil Synaptobrevin-like 1 
sim. to electron transfer 
flavoprotein alpha 
Bbox Gamma-butyrobetaine hydroxylase 
Ndufv2 24-kDa subunit of mitochondrial 
NADH dehydrogenase 
0.30 
-0.5 
-0.2* 
-0.1 
0.74** 
0.56 
0.19 
0.75" 
0.47* 
0.24 
0.56 
0.51 
0.78"* 
0.56 
0.93*" 
0.28 
0.77" 
0.92 
0.30 
0.32 
0.53 
0.49 
0 .68" 
0 .57" 
0.13 
sim. to CGI-35 protein (LOC299198) 0.01 
Protein phosphatase V 
Yme1l1 YME1 (S.cerevisiae)-like 1 
Pemt Phosphatidylethanolamine N-
methyltransferase 
Pgr1 T-cell activation protein-related 
protein 
Rnase4 Ribonuclease, RNase A family 4 
Sea 10 Spinocerebellar ataxia 10homolog 
(human) 
Ass Arginosuccinate synthetase 1 
sim. to NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 7 
Rab14 GTPaseRab14 
Snrpb Small nuclear ribonucleoprotein 
polypeptides B and B1 
Tm4sf4 Transmembrane 4 member 4 
Ctbpl C-terminal binding protein 1 
Acac acetyl-coenzyme A carboxylase 
Nt5 5 nucleotidase 
Arafl A-raf 
Cd14 CD14 antigen 
Lgals5 Lectin, galactose binding 5 
Apbb3 Amyloid beta (A4) precursor protein-
binding, family B, member 3 
Mpst Mercaptopyruvate sulfurtransferase 
Rb1 Retinoblastoma 1 
0 .43" 
0 .44" 
-0.2 
0.41 
0.77 
-0.3 
0.39 
-0 .4 " 
-0 .2 " 
-0.5*" 
0.17 
-0.3 
- 0 . 5 " 
0.13 
-0.4 
-0.5** 
-0.4 
-0.4 
- 0 .7 " 
-0.5 
-0.06 
0.07 
-0 .33" 
-0.17 
0.58* 
0 .64" 
0.91* 
0.92*" 
0 .70" 
0.54 
1.06* 
0.59*" 
0 .68" 
0.26 
0.09 
0.32 
0.35 
0.55" 
0 .62" 
0 .26" 
0.68* 
0.58 
0.27 
0.18 
0 .52" 
0 .67" 
0 .45" 
0 .56" 
0.32 
0.09 
-0.06 
0.26 
-0.42 
0.09 
0.26 
-0.03 
-0.29 
0.15 
-0 .39" 
-0.26 
-0.02 
-0.19 
-0.31 ** 
-0.14 
-0.20 
-0.35 
-0.43 
-0.58 
-0.63** *** 
-0.73* ** 
0.81 
0 .67" * 
1.55** *** 
1.27*" *** 
1 07 *** *** 
i n * * *** 
1.02* 
0 .90" " 
0.81 * *** 
0.79* ** 
0.79 
0 .76" " 
0.58 
0.48 
0.45 
0.45 
0.44 
0.36 
0.35 
0.33 
0.29 
0.27 
0.27 
0.26 
0.24 
0 .23" " 
0.13 
0.11 
0.07 
-0.02 
-0.07 
-0.12 
-0.18 
-0.28 
-0.33* " 
-0.38* ** 
-0 .38" " 
-0.46* ** 
-0 .47" " 
-0.50* " 
-0.52* *** 
-0.55 
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other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
other 
NMJ313086 
NM_024143 
AJ242926 
NM_019384 
Y17328 
X76456 
AF281635 
AF168795 
NM_032082 
NM_017343 
NM_021594 
NM_013069 
AF072439 
NM_019292 
NMJ47215 
Crem 
Fetub 
Crym 
Znf22 
Slfn4 
Hao3 
Mrlcb 
Cd74 
Zfp37 
Ca3 
Obp3 
CAMP responsive element 
modulator 
Bile acid CoA ligase 
Fetuin beta 
CTD-binding SR-like rA1 
Crystallin, mu 
alpha albumin 
Zinc finger protein 22 (KOX 15) 
Schlafen 4 
Hydroxyacid oxidase 3 
Myosin regulatory light chain 
ERM-binding phosphoprotein 
CD74 antigen 
Zinc finger protein 37 
Carbonic anhydrase 3 
alpha-2u globulin PGCL4 
0.22 
-0.0 
-0.6 
-0.4" 
0.04 
-0.0 
-0.6 
-0.6" 
0.33 
-0 .8" 
-0.4" 
-0.5 
-0.3 
0.09 
0.35 
0.05 
-0.39 
-0.51 *** 
-0.26 
0.15 
-0.24* 
-0.25 
-0.59 
0.08 
-0.29 
-0.30 
-0 .80" 
-0.19 
-0.38 
0.42 
-0 .55" *" 
-0.57* 
-0.58* ** 
-0 .59" " 
-0.60 
- 0 . 6 1 " " 
-0 .63" ** 
-0 .66" ** 
r\ f*J *** *** 
-0.74 
-0.87" * " 
-0 .97" " 
-1.00"* *** 
- 1 . 2 1 " " 
-1.30*** " * 
192 
Samenvatting 
Toxicogenomics 
Toepassingen van de nieuwe "functional genomics" 
technologieen in de toxicologie 
Toxicogenomics 
194 
Samenvatting 
De studies in dit proefschrift zijn uitgevoerd om te bepalen wat de waarde is van het 
toepassen van toxicogenomics methoden in de toxicologie. 
Wat is toxicogenomics ? 
Het woord toxicogenomics is een samentrekking van toxicologie en genomics, en beschrijft 
de toepassing in de toxicologie van nieuwe technologieen gebaseerd op kennis van het 
genoom (de genen). In de volgende paragrafen zal uitgelegd worden wat toxicologie is en 
waarvoor de nieuwe methoden kunnen dienen. 
Toxicologie 
De toxicologie bestudeert de effecten van giftige stoffen uit de omgeving op het lichaam. Er 
zijn methoden ontwikkeld om giftige eigenschappen van stoffen aan te tonen, bijvoorbeeld 
door gebruik van proefdieren, maar ook in vitro testen (in een reageerbuis). De routinematig 
toegepaste testen geven meestal aan dat er nadelige effecten van blootstelling optreden, 
maar niet hoe de toxiciteit van stoffen verklaard wordt. Er wordt bepaald bij welke 
blootstelling het geen-nadelig-effect-niveau van een stof wordt bereikt. Het onderliggende 
mechanisme van toxiciteit dat tot de schade leidt is echter vaak nog niet bekend. 
Om bovenstaande redenen, maar ook om dierproeven te voorkomen, zijn toxicologen op 
zoek naar nieuwe methoden om toxiciteit aan te tonen, te verklaren en liever nog, te 
voorspellen. Er wordt al steeds nauwkeuriger bestudeerd welke veranderingen er optreden in 
organen, weefsels, en cellen van blootgestelde dieren of in vitro modellen. De pathologie 
maakt veelvuldig gebruik van microscopie. Daamaast zijn er klinisch-chemische technieken 
om gehaltes van enzymen en metabolieten te bepalen (ook wel toxiciteitsmarkers genoemd). 
Deze kunnen een aanwijzing geven voor het optreden van schade. Verder behoren 
biochemische bepalingen en hematologie (bloedonderzoek) nog tot de conventionele 
technieken. 
Moleculair-biologische technieken maken metingen mogelijk aan cellulaire eiwitten, DNA 
(chromosomen en genen) en daaraan verwant RNA. De recent ontwikkelde 'functional 
genomics' technologieen passen de moleculaire technieken toe op veel grotere schaal. 
"Functional genomics" technologieen 
Een zeer belangrijke vooruitgang in de wetenschap was onlangs het ontcijferen van de 
samenstelling van het menselijk genoom, bestaande uit ongeveer 30000 verschillende 
genen. De genen bevatten de codes voor het produceren van de duizenden verschillende 
eiwitten in de cellen. Figuur 1.2 in hoofdstuk I geeft schematisch weer hoe functionele 
eiwitten gevormd worden met de genen als informatiebron. 
In elke eel van het lichaam zijn alle 30000 genen aanwezig, als DNA in de chromosomen. Ze 
bevatten de informatie nodig voor de aanmaak van eiwitten die dienen als enzymen en 
bouwstoffen in de eel. De genen zelf veranderen niet of nauwelijks. Wel kan de activiteit 
(expressie) van de genen veranderen. Die genexpressie bestaat uit het kopieren van de 
informatie van het gen naar informatiedragers, de boodschapper RNA's (mRNA's). De 
boodschappers vormen als het ware een mal voor de samenstelling van eiwitten uit 
afzonderlijke aminozuren. De eiwitten zijn uiteindelijk verantwoordelijk voor de structuur en 
de biochemische processen in de cellen, en daarmee ook voor de veranderingen in weefsels 
en uiteindelijk ook het lichaam. 
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De "functional genomics" technologies genomics, transcriptomics, proteomics en 
metabolomics bestuderen respectievelijk de samenstelling van het genoom, de expressie 
daarvan, de eiwitten en de metabolieten (zie tabel 1.1). Verschillende technieken zijn recent 
ontwikkeld om de verschillende onderdelen van de eel te meten. 
Transcriptomics - De uitvinding van de DNA microarray of DNA chip maakt het mogelijk van 
duizenden genen tegelijk de expressie of activiteit te meten. Een DNA microarray is een 
microscoopglaasje met daarop duizenden verschillende DNA codes die elk een ander gen 
vertegenwoordigen. Het mRNA gehalte is een maat voor de expressie van een gen en 
voorspelt veranderingen in gehaltes van eiwitten die een rol spelen in processen in een eel. 
Het mRNA wordt ge'isoleerd uit blootgesteld en uit onbehandeld weefsel. Door van beide 
monsters alle mRNA's samen op de DNA microarray te brengen kan per gen ineens 
uitgelezen worden wat de verhouding is in expressie van duizenden verschillende genen in 
blootgesteld t.o.v onbehandeld weefsel. Omdat mRNA moleculen ook wel transcripten van 
genen genoemd worden, heet deze methode transcriptomics. Het meten van genexpressie 
met DNA microarrays is schematisch weergegeven in Figuur 1.3a. 
Proteomics - Metingen aan eiwitten (proteinen vandaar proteomics) kunnen meer inzicht 
opleveren dan genexpressiemetingen. Het zijn nl. de eiwitten die de meeste functies in de 
eel vervullen. (zie ook figuur 1.1). Daarnaast kunnen de metingen bijvoorbeeld aantonen of 
de eiwitten actief of inactief zijn. Het meten van duizenden verschillende eiwitten wordt 
echter bemoeilijkt doordat eiwitten allemaal verschillende eigenschappen bezitten. Voorts is 
de identificatie van de gemeten eiwitten nog een beperkende factor. 
Metabolomics - Het meten van gehaltes van alle kleine moleculen (metabolieten) in een eel 
weefsel, of lichaamssappen is het doel van de metabolomics technologie. Deze gehaltes 
kunnen bevestigen dat eiwitten (enzymen) bepaalde omzettingen hebben verricht (zie ook 
figuur 1.1). Ophoping of juist tekorten aan bepaalde metabolieten kunnen duiden op 
veranderingen in het lichaam. 
Het is op dit moment nog lastig om van alle gemeten moleculen de identiteit vast te stellen. 
Een groot voordeel van metabolomics is dat ook monsters geanalyseerd kunnen worden die 
gemakkelijk verzameld kunnen worden zoals bloed en urine. 
Toxicologic op molecuulniveau 
Het lichaam beschikt over inventieve mechanismen om gifstoffen af te breken en uit te 
scheiden. Zo kunnen toxische stoffen (zoals alcohol, benzeen, broombenzeen) bepaalde 
genen stimuleren tot aanmaak van gif afbrekende enzymen. Een voorbeeld hiervan is de 
toename van de aanwezigheid van alcohol afbrekende enzymen na inname van alcohol. Dit 
is een respons die zijn oorsprong vindt in verhoogde expressie van genen die aanzetten tot 
aanmaak van alcohol dehydrogenase en Cyp2e1. 
Ook kan een gif processen in de eel zoals de celdeling of de aanmaak van cholesterol 
verstoren. Dat gebeurt onder andere als het gif ervoor zorgt dat genen betrokken bij die 
processen meer of minder actief worden. 
Blootstelling aan gifstoffen kan dus de genexpressie bemvloeden. Dit kan vervolgens leiden 
tot verandering in het functioneren van de eel, het orgaan of het lichaam. Hierdoor kunnen 
genexpressieveranderingen in een vroeg stadium een indicatie geven voor effecten die op 
196 
Samenvatting 
dat moment nog niet aantoonbaar zijn met pathologie, gebruik makend van microscopie. Ook 
kunnen de effecten wellicht al optreden bij lage blootstelling die nog geen uiterlijk 
veranderingen veroorzaken. Dat is belangrijk omdat in werkelijkheid vaak het risico van 
langdurige blootstelling aan lage concentraties beoordeeld moet worden. 
Transcriptomics bepalingen van de expressie van duizenden genen tegelijk (m.b.v. de DNA 
microarray) kunnen dus gevoeliger zijn in het aantonen van verstoringen door gifstoffen dan 
de gangbare technieken. Ook is aangetoond dat het op grote schaal meten van metabolieten 
in bloed of urine m.b.v. metabolomics al bij lage doseringen verschillen kan aantonen. 
Misschien wel het allerbelangrijkste is dat toxicogenomics de mogelijkheid biedt inzicht te 
krijgen hoe en waarom stoffen (of mengsels daarvan) toxisch zijn. De nieuwe methoden 
bieden de kans in kaart te brengen in welke biologische systemen de belangrijkste 
veranderingen optreden na blootstelling aan gif. Processen die verstoord worden, maar ook 
beschermende mechanismen kunnen zo geduid worden. Naast deze inzichten kan 
tegelijkertijd ook de normale gang van zaken in de eel op moleculair niveau bestudeerd 
worden. 
Na blootstelling aan een mengsel van giftige stoffen kunnen er effecten optreden die niet te 
verwachten waren op basis van de effecten van de afzonderlijke stoffen, zgn. interacties. 
Mengsels kunnen dus leiden tot onverwachte schadelijke effecten. Het vaststellen van 
interacties na blootstelling aan combinaties van stoffen vergt op dit moment zeer uitgebreide 
experimenten. Dit komt met name omdat er slechts zelden een goed begrip is van de 
werkingsmechanismen van de individuele componenten, laat staan van mogelijke 
be'i'nvloeding van stoffen van elkaar. Toxicogenomics kan helpen de werkingsmechanismen 
op te helderen. Bovendien biedt het meten van duizenden parameters meer kans op het 
vinden van effecten die de verschillend behandelde groepen onderscheiden dan het kleine 
aantal huidig beschikbare parameters. 
Doelen van dit onderzoek 
Van alle eerder beschreven mogelijke toepassingen is in dit proefschrift met name 
beschouwd of toxicogenomics kan bijdragen aan: 
a) het onderzoeken van mechanismen van toxiciteit 
b) een vroege herkenning van (toxische) effecten bij een blootstelling aan lage dosering, en 
de identificatie van nieuwe markers hiervoor 
c) het aantonen en verklaren van effecten van mengsels van toxische stoffen 
d) succesvolle toepassing van in vitro modellen en reductie van proefdiergebruik 
Daarnaast zijn technische aspecten van de toxicogenomics zoals reproduceerbaarheid en 
gevoeligheid bepaald. De relatie tussen de nieuwe technologieen onderling en de gangbare 
methoden is onderzocht. 
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Opbouw van net proefschrift en resultaten 
Hoofdstuk I bevat de Engelstalige introductie, die een uitgebreide beschrijving geeft van de 
mogelijke toepassingen van toxicogenomics methoden. Daamaast zijn de methoden in wat 
meer detail besproken. De feitelijke studies zijn beschreven in de hoofdstukken II tot en 
met VII, waarna in hoofdstuk VIII de resultaten bediscussieerd worden. 
Allereerst (hoofdstuk II) is bepaald of gen- en eiwitexpressie veranderingen na blootstelling 
aan de levertoxische stof broombenzeen (BB) aansluiten bij de bestaande inzichten. Verder 
is onderzocht welke nieuwe inzichten de technieken konden verschaffen met betrekking tot 
de moleculaire mechanismen van het ontstaan van celdood in de lever. 
Broombenzeen is een industrieel toegepaste organisch chemisch middel, en werd in deze 
studie gebruikt omdat het een stof is met welbekende levertoxische werking. Ratten werden 
eenmalig gedoseerd met BB, en na 24 uur werd de genexpressie bepaald voor meer dan 
3000 verschillende genen in de lever, gebruikmakend van DNA microarray's. Daarnaast zijn 
eiwitten in diezelfde levers geanalyseerd met geavanceerde proteomics technologieen. 
Onze studie bevestigde dat glutathion (GSH) in de lever een centrale rol speelt in het 
ontgiften van broombenzeen en bescherming tegen schade. Ook werden aanwijzingen 
gevonden voor de verstoring van processen als de aanmaak van cholesterol en vetzuren. 
Deze processen waren nog niet eerder gerelateerd aan deze vorm van levertoxiciteit. 
Diverse bewijzen werden gevonden voor een verhoogde aanmaak en afbraak van eiwitten, 
hetgeen duidelijk naar voren kwam met de proteomics technieken. 
Als vervolg op de eerste studie bepaalt de studie in hoofdstuk III of de veranderingen in 
genexpressie na blootstelling aan BB afhankelijk zijn van de dosering. Voorts is bepaald hoe 
de veranderingen optreden in de tijd, 6, 24 en 48 uur na een orale dosering. De DNA 
microarray's bleken in staat veranderingen aan te tonen bij 2,5 tot 5-voudig lagere 
doseringen dan de conventionele technieken. Enkele veranderingen, zoals expressie van 
heem oxygenase, werden al 6 uur na dosering gemeten. 
In hoofdstuk IV werd gebruik gemaakt van de genexpressie metingen uit de voorgaande 
studie met daaraan toegevoegd metabolomics analyses. Hiervoor werden bloed plasma en 
urine van dezelfde ratten geanalyseerd met NMR spectroscopic. Op een gevoelige manier 
zijn zo honderden metabolieten in deze monsters gemeten. De monsters uit de verschillende 
behandelgroepen waren te onderscheiden met wiskundige patroonherkenningstechnieken. 
Deze studie toonde aan dat een geintegreerde aanpak mogelijk maakte om de moleculaire 
profielen van individuele dieren met een verschillende graad van celdood in de lever van 
elkaar te onderscheiden. Zo werden moleculen geidentificeerd die typerend zouden kunnen 
zijn voor celdood in de lever (toxiciteitsmarkers). De betrokkenheid van enkele biochemische 
processen, zoals aminozuur metabolisme en glycolyse werd op moleculair niveau 
gerelateerd aan deze vorm van levertoxiciteit. 
Na de bestudering van effecten van broombenzeen, een industrieel toegepaste product en 
modelstof voor levertoxiciteit, werden de effecten van twee veelvuldig gebruikte chemicalien 
onderzocht op genexpressie niveau in de lever. Een van de doelen hiervan was te bepalen 
hoe specifiek de genexpressie veranderingen eigenlijk waren voor stoffen die schade in de 
lever veroorzaakten. 
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Hoofdstuk V beschrijft welke veranderingen er optraden nadat ratten gedurende 28 dagen 
blootgesteld werden aan benzeen. Benzeen wordt industrieel toegepast bij de productie van 
o.a. verf, inkt, en rubber, en komt voor in uitlaatgassen en sigarettenrook. Het is bekend dat 
de kritische effecten van benzeen gevonden worden in het bloed en beenmerg. Benzeen is 
carcinogeen en kan de kans op leukemie verhogen. Met de conventionele toxicologie werd 
bevestigd dat benzeen bloedvergiftiging veroorzaakt, gezien de reductie van het aantal witte 
bloedcellen en van het gewicht van de thymus en milt. In de lever daarentegen werden, 
behalve een kleine gewichtstoename, geen microscopische veranderingen geconstateerd. 
Desalniettemin werd met DNA microarray's gevonden dat de genexpressie in de lever 
veranderde, zelfs bij een lage dosering. Zo kon inzicht verkregen worden in welke processen 
betrokken zijn bij de reactie op blootstelling aan benzeen. Met name enzymen betrokken bij 
de omzetting van lichaamsvreemde stoffen (zoals benzeen zelf) werden geactiveerd. Meer 
onderzoek moet aantonen of dit de schadelijke effecten van benzeen verhoogt of juist 
verlaagt. Het profiel van genexpressie bleek gevoeliger effecten aan te tonen dan de 
gangbare methoden. Ook de profielen van metabolieten in de urine waren gevoelig te 
onderscheiden op basis van de blootstelling. 
Hoofdstuk VI beschrijft een onderzoek als in hoofdstuk V, waarbij nu de toxische effecten 
van trichloorethyleen (TCE) onderzocht werden. TCE is een industrieel veel toegepast 
chemisch product, ontvetter, oplosmiddel, maar ook toegepast in correctievloeistof (bijv. typ-
ex). Het kritische effect van TCE wordt gevonden in de nieren. Verder kan het ook schade in 
de lever veroorzaken. De dosisafhankelijke veranderingen in genexpressie die gevonden 
werden in de lever na blootstelling aan TCE gedurende 28 dagen, hebben gevolgen voor 
diverse processen in de lever, maar ook elders in het lichaam. Zowel enzymen die TCE 
activeren tot giftige metabolieten, als ook ontgiftende enzymen werden geactiveerd. 
Door benzeen en TCE veroorzaakte veranderingen in de expressie van levergenen werden 
vergeleken met effecten van BB en van een hoge dosering paracetamol (acetaminophen), 
beschreven door Heinloth et al., (2004). BB en paracetamol staan bekend als stoffen die 
specifieke schade (acute celdood) in de lever veroorzaken. De genexpressie veranderingen 
door benzeen en TCE overlapten gedeeltelijk met de effecten van BB en paracetamol. 
Echter, BB en paracetamol veroorzaakten meer en duidelijkere veranderingen in 
genexpressie. Voor alle onderzochte stoffen kon een karakteristiek patroon van 
veranderingen verkregen werden, hetgeen de bruikbaarheid van de toxicogenomics 
methoden bevestigt. 
In hoofdstuk VII is voor het eerst met DNA microarrays onderzoek gedaan naar effecten 
van mengsels van giftige stoffen. Ratten werden blootgesteld aan benzeen, trichloorethyleen 
of een combinatie daarvan in diverse doseringen, en de levers werden geanalyseerd met de 
DNA microarray's. De conventionele toxicologische bepalingen bleken slechts weinig 
effecten aan te tonen in de lever. De DNA microarray's daarentegen bewezen dat er veel 
genexpressie veranderingen optraden na blootstelling. De genen die het meest karakteristiek 
waren voor de effecten van benzeen en TCE uit de vorige studies werden opnieuw 
opgemerkt. Bestudering van de effecten van mengsels van benzeen en TCE gaf 
hoofdzakelijk aan dat genexpressie effecten van trichloorethyleen versterkt werden door 
toevoegen van benzeen. 
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Conciusies 
Uit dit proefschrift blijkt dat toximgcnomics mogelijkhedon hiodt om mechanismen 
van (lever)toxiciteit te vt-rhelderen. Duidelijk is gownrden d-it toxicogenomics op dit 
moment met name goschikt is om hypolhesen te genereren random 
werkingsmechanismen van toxiniluil. De7'» clienen dan met aanvullend onderzoek 
gestaafd te wordon {'m vivo en in vilmt. Er warden voorspelbare, maar ook 
onverwachte effecten van welbokende gifstoffen roals btoombeiizeen, benzeen en 
trichloorethyleen gevonden. Erjn voorbeeld daaivan vorrnt do bt-Tnvloeding van het 
vetzuur- en cholesterol metabolisme door de ondnrzochte chemicalien. 
Dit proefschrift toont aan dal hel is mogulijk om gevoeliger dan met de gangbare 
methoden in een vroog stadium effecten te identificeren. Zo kan hij meer realistische. 
lage doseringen in/icht verkregen worden in de processen die optreden na 
blootstelling aan toxische stoffe-n 
Het tweede deel van dit proefschrift laat zien hoe toxicogenomics gebruikt kan 
worden om de toxiciteit van mengsels van stoffen te onderzoeken. Met name door 
het verhelderen van werkingsmechanismen kunnen onderbouwde hypotheses over 
wederzijdse beinvloeding van stoffen gevormd worden. 
De studies laten een voorbode zien van hoe toxicogenomics het gebruik van 
proefdieren zou kunnen reduceren en verfijnen. Kennis en inzicht in de werking van 
giftige stoffen kunnen leiden tot vervanging van standaard experimenten door 
verfijnde en toegesneden proeven. Toxicogenomics kan mogelijk een alternatief voor 
proefdiergebruik bieden wanneer het toegepast wordt in combinatie met (in vitro) 
modellen. Op de wat langere termijn zijn aldus verkregen inzichten misschien 
voldoende om de volksgezondheid te waarborgen. 
De integratie van de nieuwe genomics technologieen zou diepgaande inzichten 
kunnen bieden in processen in de eel en verstoringen hiervan na blootstelling aan 
toxische stoffen. De uitdaging voor de toekomst is om inzicht te krijgen in alle 
stappen van de ingewikkelde werkingsmechanismen van toxiciteit. Door de 
schakelingen, communicatie en logistieke systemen te bestuderen en te beschrijven 
zou uiteindelijk een model opgesteld kunnen worden van het fijne raderwerk in een 
eel. Zo'n model zou dan gebruikt kunnen worden om te voorspellen wat de effecten 
zijn van invloeden van buitenaf, waaronder ook gifstoffen. 
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In het begin van dit millennium, in januari 2000, was dit nog slechts een leeg schrift. Blanco, 
zonder introductie, inhoud of zelfs maar een titel. Dankzij de inzet van velen kon ik dit schrift 
vullen tot een proefschrift. Ik wil iedereen bedanken die daaraan een bijdrage heeft geleverd! 
Enkele mensen verdienen een bijzondere vermelding! Allereerst wil ik mijn ouders bedanken 
dat ze mij als een nieuwsgierig en eigenwijs mannetje op de wereld hebben gezet! Samen 
met mijn broer en zussen werd ik altijd geholpen om groter en (eigen)wijzer te worden, ook 
nadat ik niet meer te houden was en uitvloog naar de universiteit. 
Eenmaal bij TNO Voeding was Ben van Ommen de grote gangmaker. Ben bood me een 
interessante baan aan en omdat toxicologie toch een soort 'gestoorde biologie' is, leek het 
mij als moleculair bioloog wel wat. Met baanbrekende technieken zouden we wel 'even' de 
expressie van enkele duizenden genen onderzoeken na blootstelling aan giftige stoffen. 
Massa's publicaties zouden volgen, dus kon ik het beste meteen ook maar promoveren! Nou 
Ben, het boek is gevuld! Het was niet altijd zo simpel, maar gelukkig blies je met je eeuwige 
optimisme alle vuiltjes uit de motor en hield de vaart erin! Ben, bedankt voor je enthousiasme 
en inspiratie! 
De eerste kennismaking met promotor Peter van Bladeren maakte me snel duidelijk dat hij 
naast mijn project nog wel wat meer zaken behartigde. Een mooie kamer, eigen 
secretaresse, sigaren en weinig tijd, hij leek de directeur van TNO wel! Ondanks al die 
andere zaken heb ik altijd tijd en belangstelling gekregen. Peter, bedankt dat je kritisch de 
juiste richting bewaakte en ook vanuit Zwitserland betrokken bleef. 
De betrokkenheid van John Groten, mijn afdelingshoofd bij TNO, werd nog groter door zijn 
aanstelling als hoogleraar in Wageningen. Vooral het tweede gedeelte van dit proefschrift en 
de combinatietoxicologie kregen volop aandacht. John, bedankt voor je inspanning om 
kritisch en nauwgezet de artikelen te helpen verfijnen. Leuk dat je bij mij voor het eerst als 
promotor optreedt. 
Het werk begon ruim vier jaar geleden met het vermenigvuldigen van duizenden 
rattengenen, en het glaasjes 'spotten' in het lab van Frank Schuren, samen met Annemiek, 
Evelyn en Ted. Er werden talloze technische euvels opgespoord en opgelost en de DNA 
microarray analyse ging echt werken. Het vertrek van de vrolijke pioniers van de array's bij 
TNO was steeds een aderlating. De hulp van o.a. Mieke en Alie maakte veel goed. Alle 
betrokken AMGT collega's hartelijk bedankt! 
Met name ons labhoofd Michele en ook Anja, Hester en Dionne verrichtten veel hak- en 
stampwerk en isoleerden RNA voor op de microarrays. Gelukkig bleken toxicogenomics 
proeven met relatief weinig monsters erg veel antwoorden te kunnen leveren. Hierdoor bleef 
het aantal ratten die in dit onderzoek een nog onmisbare rol vervulden, beperkt! Ik ben dan 
ook blij dat we veel monsters konden verzamelen uit al lopende studies. De grote 
hoeveelheid data bleek ook de grote uitdaging, namelijk om uit die miljoenen getalletjes 
zinnige informatie te halen. Het overgrote deel van mijn werk bestond dan ook uit data-
analyse in de computer. Dit was soms aanleiding voor collega's om te twijfelen of ik wel een 
echte AIO was, en of ik eigenlijk wel een labjas had! De ervaringsdeskundigen uit onze 
genomics groep konden hierover goed meepraten, maar gelukkig ook over vele andere 
onderwerpen. Bedankt allemaal voor een vrolijke werkomgeving. 
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Rob, bedankt voor het samen schrijven van artikelen, het delen van frustraties en de 
kritische beschouwingen tijdens het rondje! Het was ook leerzaam van dichtbij te zien hoe 
een net iets oudere en wijzere onderzoeker de wervelwind van projecten ingezogen werd. 
Fijn dat je mij als paranimf wilt bijstaan. Dat geldt ook voor Marjan. Het was geweldig om 
samen alles van het begin af mee te maken. Dat jij me op deze baan ooit attendeerde is ook 
niet geheel onbelangrijk. En omdat je wat eerder promoveerde kon ik mooi parasiteren op 
jouw en Miriam's ervaring in het produceren van een proefschrift. Je was altijd de bron van 
nuttige en betrouwbare informatie, toegang tot de vakgroep toxicologie in Wageningen en 
vele artikelen!. 
Marinus, enthousiaste whizz-kid, het is aan jou te danken dat ik me nu een oude, ingedutte 
en chagrijnige vent voel. Maar toch bedankt voor je energieke inzet en (on)gevraagde 
wetenswaardigheden. Robert-jan, bedankt voor jouw analyses voor onze gezamenlijke 
publicaties (te vernieuwend voor menig reviewer?) en veel succes met het afronden van je 
metabolomics proefschrift. 
De stagiaires wil ik bedanken voor hulp en appeltaarten, en met name Marieke Bart voor 
vele microarray hybridisaties. Diana Jonker, Andreas Freidig en Heleen Wortelboer, Joop 
van Nesselrooij en Monique Slijper (Utrecht) bedank ik hartelijk voor hun bijdragen aan 
publicaties. Talloze (oud) collega's hebben me op diverse manieren geholpen met het 
onderzoek, en met name noem ik Ana, Cyrille, Wilfred, Johan, Yvonne, Maria, Nicole, Han, 
Jan, Birol, Dimitri, Miriam, Rianne, Florence, Freek, Bert, Sonia, Marie-Jose, Nico, Truus, 
Paula, Richard, Michiel, Almira, Azz-Eddine, Lisette, Pol, Cor, Marco, Sabina, Bianca, 
Renger, Florian, Eric, Anne-Marie, Marloes, Jolanda, Karin en die ene collega wiens naam ik 
nu even ben vergeten! Het was fijn en nuttig ook andere TNO promovendi te kennen, 
waaronder Martijn, Micha, Kitty, Bart, Barry, Wendy, Joline. En in onze groep de aanwinsten 
Anne en Ashwin, de hoop op diepgaand onderzoek is nu op jullie gevestigd! I would also like 
to thank dr. Angela Slitt and dr. Curtis Klaassen from Kansas City for our valuable 
collaboration. 
Goed werk kan niet geleverd worden zonder ontspanning en plezier buiten werktijd. Omdat ik 
de afgelopen jaren zoveel moois heb meegemaakt, kan ik het belang van promoveren wel 
enigszins relativeren. Ik wil natuurlijk mijn ouders, Saskia, Maarten en Veerle en ook Helene 
en Han, Olivia, de oma's en andere familie hartelijk bedanken voor al hun aandacht. 
Gisela, jou kan ik eigenlijk op papier niet genoeg bedanken. Vooral het laatste jaar eiste dit 
proefschrift veel van onze aandacht en toch al schaarse tijd op. Gelukkig kon je me helpen 
om realistische doelen en prioriteiten te stellen. En, jouw 'g.a.a.p.-index' zou wel eens een 
nieuwe standaard kunnen worden bij het toetsen van de toegankelijkheid van artikelen. 
Onder de Nederlandse samenvatting zou ook jouw naam moeten staan. Je vakantie en veel 
vrije tijd werden dit jaar opgeofferd aan mijn werk en zonder jou had dit project vast veel 
langer geduurd! 
Tenslotte ons meisje, jij kwam vast ook wel eens aandacht tekort. Vanaf het eerste uur wist 
je echter zeer goed duidelijk te maken dat er meer is dan toxicogenomics! Ik hoop dat jij, en 
elk kind op deze wereld, net als ik de kans krijgt om te onderzoeken en ontdekken hoe het 
leven in elkaar zit, stap - voor - stap 
Wilbert 
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Wilbert H.M. Heijne werd geboren op 21 mei 1976 te Geneve (CH). Na verhuizing in 1984 
volgde hij basisonderwijs en middelbaar onderwijs in Nederland, en haalde in 1994 het 
Gymnasium diploma aan de Jansenius Scholengemeenschap te Hulst. 
Aansluitend studeerde Wilbert moleculaire wetenschappen aan de universiteit van 
Wageningen (biotechnologische specialisatie) met als afstudeeronderwerpen moleculaire 
biologie, virologie, genetica, biochemie en bioinformatica. In 1999 werkte hij 6 maanden bij 
dr. M.Saier aan de universiteit van San Diego (UCSD), U.S.A., aan de analyse van 
transporteiwitten met moleculaire biologie en bioinformatica. Zijn werk tijdens deze 
onderzoeken droeg bij aan enkele wetenschappelijke publicaties. 
Na het behalen van de bul in 1999, kreeg Wilbert een aanstelling bij TNO Voeding in Zeist. 
Hier werkte hij van januari 2000 tot September 2004 aan toxicogenomics studies, en voerde 
het onderzoek uit dat beschreven is in dit proefschrift. Allereerst werd een 
onderzoeksvoorstel opgesteld en vervolgens werden studies uitgevoerd om de nieuwe 
discipline Toxicogenomics te verkennen. Vanaf het eerste uur droeg Wilbert bij aan de 
ontwikkeling van de DNA microarray technologie bij TNO. De toepassing van deze nieuwe 
technologie in de toxicologie resulteerde in wetenschappelijke publicaties, overzichtsartikelen 
en presentaties op congressen als van de Amerikaanse Society of Toxicology (SOT). Wilbert 
participeerde in een aantal workshops over bioinformatica, data analyse en biostatistiek, en 
kreeg in 2003 een SOT reisbeurs en de prijs voor de beste presentatie op het jaarcongres 
van de Nederlandse Vereniging voor Toxicologie. 
Wilbert H.M. Heijne was born on May 21st in Geneve (Switzerland). He received primary and 
secondary education (gymnasium) in the Netherlands and graduated in 1994 at 
the"Jansenius" Secondary school in Hulst. He studied Molecular Sciences at Wageningen 
University (NL), ( specialisation biotechnology), with majors in molecular biology, virology, 
genetics, biochemistry and bioinformatics. In 1999, he worked for 6 months at the university 
of San Diego (UCSD), U.S.A. in the lab of dr. M.Saier, to analyse transport proteins with 
molecular biology and bioinformatics, resulting in several scientifical publications. 
After graduation in 1999, Wilbert joined the TNO Nutrition and Food Research institute in 
Zeist (NL). As a research fellow, he participate in toxicogenomics studies and performed the 
work described in this thesis. From the start at TNO, Wilbert was involved in the development 
of the DNA microarray technology. The applications of these methods in toxicology were 
described in peer-reviewed scientific publications, reviews and oral presentations at 
conferences like the annual meeting of the U.S. Society of Toxicology (SOT). Wilbert 
participated in various workshops about bioinformatics, data analysis and biostatistics, and in 
2003, he received a SOT travel award and the award for the best presentation at the annual 
meeting of the Dutch Society of Toxicology (NVT). 
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Glossary 
DNA Microarray: Tool to measure levels of gene expresssion (mRNA molecules); glass 
microscope slide with thousands of (arrayed) spots containing tiny amounts of DNA 
fragments. Each spot contain DNA fragments corresponding to a different gene. 
Functional genomics technologies: technologies that study the functions of the genome in 
relation to its structure and composition. These include genomics, transcriptomics, 
proteomics and metabolomics. 
Gene Functional part of the DNA (chromosomes) that retains the code for the synthesis of a 
protein 
Hepatotoxicity: Liver toxicity 
Hematology: analysis of blood 
Hematotoxicity: blood toxicity 
Metabolomics Studying levels of metabolites (small molecules) under different 
circumstances in biological samples such body fluids or tissue samples 
Messenger RNA (mRNA): molecule that transfers information from the DNA (gene) to the 
location in the cell where the proteins are assembled using this information 
Nephrotoxicity: kidney toxicity 
Proteomics: Studying protein contents in biological samples such as tissue or body fluids 
Toxicogenomics: Integration of functional genomics technologies in toxicology 
Toxicology: Studying harmful effects of poisonous substances in the (human) body 
Transcriptomics: Studying transcription (activity) of genes under different circumstances in 
biological tissue samples. This is achieved by measuring mRNA levels 
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Abbreviations 
Abbreviation Description 
AGT alanine-glyoxylate aminotransferase 
ALAT alanine aminotransferase 
ALP alkaline phosphatase 
APAP acetaminophen (paracetamol) 
APR acute phase response 
ASAT aspartate aminotransferase 
ATSDR Agency for Toxic Substances and Disease Registry 
B benzene 
BB bromobenzene 
bDNA branched DNA signal amplification (assay) 
cDNA complementary (copy) DNA 
CDNB 1-chloro-2,4-dinitrobenzene 
CGH comparative genome hybridization 
CO corn oil (vehicle control) 
CYP cytochrome P450 enzyme 
ELISA enzyme-linked immunosorbent assay 
FDA U.S. Food and Drug Administration 
FISH fluorescent in situ hybridisation 
GC gas chromatography 
GSH reduced glutathione 
GSH glutathione 
GSSG oxidised glutathione 
GST glutathione S-transferase 
i.p. intraperitoneal 
ICAT Isotope-coded affinity tagging 
LDH lactate dehydrogenase 
MALDI-TOF Matrix Assisted Laser Desorption lonisation - Time Of Flight 
mRNA messenger RNA 
MS mass spectrometry 
n.s. not statistically significant 
NMR Nuclear magnetic resonance spectroscopy 
OECD Organisation for Economic Co-operation and Development 
PC principal component 
PCA principal component analysis 
PCDA principal component discriminant analysis 
ROS reactive oxygen species 
RT-PCR real-time reverse transcriptase polymerase chain reaction 
SAGE serial analysis of gene expression 
SELDI Surfance-enhanced laser desorption/ionization 
SNP single nucleotide polymorphism 
TCA trichloroacetic acid 
TCE (T) trichloroethylene 
TNO Netherlands Organisation for Applied Scientific Research 
UT untreated 
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Genes 
Symbol Gene name 
Abcc ATB binding cassette containing transporter 
Acatl acyl-CoA acetyltransferase 
Actb Actin beta 
Adh Alcohol dehydrogenase (Adh1,....) 
Afar Aflatoxin aldehyde reductase 
Ahr Aryl hydrocarbon receptor 
Alas2 aminolevulinic acid synthase 2 
Aldh Aldehyde dehydrogenase (Aldhl, ...) 
Apo Apolipoprotein (ApoB, ApoE) 
Atpase ATP synthase 
Bhmt Betaine homocysteine methyltransferase 
Cd36 Cd36 antigen (enzyme) 
Cdh Cadherin 
Cps carbamoyl-phosphate synthase 
Cyp Cytochrome P450 enzyme (Cyp2a1, Cyp2e1, Cyp2c,...) 
Dei dodecenoyl CoA isomerase 
Dopa D-dopachrome tautomerase 
Ephxl epoxide hydrolase (microsomal) 
Feh, Fel ferritin heavy or light chain 
G6pc glucose-6-phosphatase 
G6pd glucose-6-phosphate dehydrogenase 
gadd45 Growth arrest and DNA damage protein 45 
Gapdh Glyceraldehyde 6-phosphate dehydrogenase 
Gel c gamma cysteine ligase (gamma-glutamylcysteine synthase) light chain 
Gst glutathione-S-transferase (Gsta, Gstm,...) 
Hao Hydroxy acid oxidase 
Hnf hepatic (hepatocyte) nuclear factor (Hnf3, Hnf4,Hnf6) 
Ho-1 heme oxygenase 
Hpd hydroxyphenylpyruvate dioxygenase 
Hsp Heat shock protein (Hsp60, Hsp70,..) 
Lcat Lecithin-cholesterol acyltransferase 
L-Fabp liver fatty acid binding protein 
Lisch7 liver-specific transcription factor 
Me1 Malic enzymel 
Mpo myeloperoxidase 
Mrp Multi-drug resistant protein (Mrp1, Mrp2, Mrp3,...) 
Mt Metallothionein (Mt1, Mt2, Mt3,...) 
Myd116 Myeloid differentiation primary response gene 116 
Nqo1 NAD(P)H dehydrogenase, quinone 1 
Oat Ornithine aminotransferase 
PPAR Peroxisome-proliferation activated receptor (alpha, gamma,..) 
RXR Retinoid - X- receptor 
Sic Solute carrier protein 
Tat Tyrosine aminotransferase 
Timpl Tissue inhibitor of metalloproteinase 
Ugt UDP-glucuronosyltransferases 
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A 
Omslagillustratie 
Dit proefschrift illustreert hoe aan de hand van metingen van activiteit van genen de 
giftigheid van stoffen onderzocht kan worden. Het toont ook dat er nog een hele weg 
te gaan is tot alle vragen opgelost zijn, stap voor stap! 
Cover illustration 
This thesis demonstrates how the toxicity of substances can be determined with the 
aid of gene expression measurements. It also shows that we are a long way from 
solving all the questions, step-by-step. 
The research described in this thesis was performed at TNO Nutrition and Food 
Research, Zeist, The Netherlands . 
This work was supported by TNO Nutrition and Food Research 
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